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The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or 
Superfund) for hazardous substances found at Department of Energy (DOE) waste sites.  CERCLA 
directs ATSDR to prepare toxicological profiles for hazardous substances most commonly found at 
facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat 
to human health, as determined by ATSDR and the EPA.  ATSDR and DOE entered into a Memorandum 
of Understanding on November 4, 1992 which provided that ATSDR would prepare toxicological profiles 
for hazardous substances based upon ATSDR=s or DOE=s identification of need. The current ATSDR 
priority list of hazardous substances at DOE NPL sites was announced in the Federal Register on July 24, 
1996 (61 FR 38451). 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement:  The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects 
observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.9 Biomarkers of Exposure and Effect 
Section 3.12 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail:  atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341­
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. 
Department of Energy, the World Health Organization, and the International Atomic Energy Agency in 
the medical management of radiation accidents.  A 24-hour emergency response program at the Oak 
Ridge Institute for Science and Education (ORISE), REAC/TS trains, consults, or assists in the response 
to all kinds of radiation accidents. Contact: Oak Ridge Institute for Science and Education, REAC/TS, 
PO Box 117, MS 39, Oak Ridge, TN 37831-0117 • Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour 
Emergency Phone 865-576-1005 (ask for REAC/TS) • e-mail: cooleyp@orau.gov • website (including 
emergency medical guidance): http://www.orau.gov/reacts/default.htm 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 • 
FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
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The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. 	 Data Needs Review.  The Research Implementation Branch reviews data needs sections to assure 
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1 STRONTIUM 
1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about strontium and the effects of exposure.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Strontium and strontium-90 have been found in at least 
102 and 12 of the 1,636 current or former NPL sites, respectively.  However, the total number of 
NPL sites evaluated for strontium and strontium-90 are not known.  As more sites are evaluated, 
the sites at which strontium and strontium-90 are found may increase.  This information is 
important because exposure to strontium and strontium-90 may harm you and because these sites 
may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact.  External exposure to 
radiation may occur from natural or man-made sources.  Naturally occurring sources of radiation 
are cosmic radiation from space or radioactive materials in soil or building materials.  Man-made 
sources of radioactive materials are found in consumer products, industrial equipment, atom 
bomb fallout, and to a smaller extent from hospital waste and nuclear reactors. 
If you are exposed to strontium, many factors determine whether you’ll be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider the other chemicals you’re exposed to and your age, sex, diet, family 
traits, lifestyle, and state of health. 
1.1 WHAT IS STRONTIUM? 
Strontium is a natural and commonly occurring element.  Strontium can exist in two oxidation 
states: 0 and +2. Under normal environmental conditions, only the +2 oxidation state is stable 
2 STRONTIUM 
1. PUBLIC HEALTH STATEMENT 
enough to be important.  Pure strontium is a hard, white-colored metal, but this form is not found 
in the environment.  Rather, strontium is usually found in nature in the form of minerals.  
Strontium can form a variety of compounds.  Strontium compounds do not have any particular 
smell.  There are two types of strontium compounds, those that dissolve in water and those that 
do not. Natural strontium is not radioactive and exists in four stable types (or isotopes), each of 
which can be written as 84Sr, 86Sr, 87Sr, and 88Sr, and read as strontium eighty-four, strontium 
eighty-six, etc. All four isotopes behave the same chemically, so any combination of the four 
would have the same chemical effect on your body. 
Rocks, soil, dust, coal, oil, surface and underground water, air, plants, and animals all contain 
varying amounts of strontium.  Typical concentrations in most materials are a few parts per 
million (ppm).  Strontium ore is found in nature as the minerals celestite (SrSO4) and strontianite 
(SrCO3). After the strontium is extracted from strontium ore, it is concentrated into strontium 
carbonate or other chemical forms by a series of chemical processes.  Strontium compounds, 
such as strontium carbonate, are used in making ceramics and glass products, pyrotechnics, paint 
pigments, fluorescent lights, medicines, and other products.  For more information, see 
Chapter 5. 
Strontium can also exist as radioactive isotopes (see Chapter 4).  90Sr, or strontium ninety, is the 
most hazardous of the radioactive isotopes of the chemical element strontium. 90Sr is formed in 
nuclear reactors or during the explosion of nuclear weapons.  Each radioactive element, 
including strontium, constantly gives off radiation, and this process changes it into an isotope of 
another element or a different isotope of the same element.  This process is called radioactive 
decay. 90Sr gives off beta particles (sometimes referred to as beta radiation) and turns into 
yttrium ninety (90Y); 90Y is also radioactive and gives off radiation to form zirconium ninety 
(90Zr), which is a stable isotope. The radioactive half-life is the time that it takes for half of a 
radioactive strontium isotope to give off its radiation and change into a different element.  90Sr 
has a half-life of 29 years. 
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90Sr has limited use and is considered a waste product.  The radioactive isotope 89Sr is used as a 
cancer therapeutic to alleviate bone pain. 85Sr has also been used in medical applications.  For 
more information about the properties and use of radioactive strontium, see Chapters 4 and 5. 
Quantities of radioactive strontium, as well as other radioactive elements, are measured in units 
of mass (grams) or radioactivity (curies or becquerels).  Both the curie (Ci) and the becquerel 
(Bq) tell us how much a radioactive material decays every second.  The becquerel is a new 
international unit known as the SI unit, and the curie is an older unit; both are used currently.  A 
becquerel is the amount of radioactive material in which 1 atom transforms every second.  
One curie is the amount of radioactive material in which 37 billion atoms transform every 
second; this is approximately the radioactivity of 1 gram of radium.  For more information on 
radiation, see Appendix D and the glossary, Chapter 10, at the end of this profile or the ATSDR 
Toxicological Profile for Ionizing Radiation. 
1.2 WHAT HAPPENS TO STRONTIUM WHEN IT ENTERS THE ENVIRONMENT?  
Stable and radioactive strontium compounds in the air are present as dust.  Emissions from 
burning coal and oil increase stable strontium levels in air.  The average amount of strontium that 
has been measured in air from different parts of the United States is 20 nanograms per cubic 
meter (a nanogram is a trillion times smaller than a gram).  Most of the strontium in air is in the 
form of stable strontium.  Very small dust particles of stable and radioactive strontium in the air 
fall out of the air onto surface water, plant surfaces, and soil either by themselves or when rain or 
snow falls. These particles of strontium eventually end up back in the soil or in the bottoms of 
lakes, rivers, and ponds, where they stay and mix with stable and radioactive strontium that is 
already there. 
In water, most forms of stable and radioactive strontium are dissolved.  Stable strontium that is 
dissolved in water comes from strontium in rocks and soil that water runs over and through.  
Only a very small part of the strontium found in water is from the settling of strontium dust out 
of the air. Some strontium is suspended in water.  Typically, the amount of strontium that has 
been measured in drinking water in different parts of the United States by the EPA is less than 
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1 milligram for every liter of water (1 mg/L).  90Sr in water comes primarily from the settling of 
90Sr dust out of the air. Some 90Sr is suspended in water.  In general, the amount of 90Sr that has 
been measured in drinking water in different parts of the United States by EPA is less than 
one-tenth of a picocurie for every liter of water (0.1 pCi/L or 0.004 Bq/L). 
Strontium is found naturally in soil in amounts that vary over a wide range, but the typical 
concentration is 0.2 milligrams per kilogram (kg) of soil (or 0.2 mg/kg).  The disposal of coal 
ash, incinerator ash, and industrial wastes may increase the concentration of strontium in soil.  
Generally, the amount of 90Sr in soil is very small and is only a fraction of the total concentration 
of strontium in soil.  Higher concentrations of 90Sr in soil may be found near hazardous waste 
sites, radioactive waste sites, and Department of Energy facilities located around the United 
States. A major portion of stable and radioactive strontium in soil dissolves in water, so it is 
likely to move deeper into the ground and enter groundwater.  However, strontium compounds 
may stay in the soil for years without moving downward into groundwater.  In the environment, 
chemical reactions can change the water-soluble stable and radioactive strontium compounds 
into insoluble forms.  In some cases, water-insoluble strontium compounds can change to soluble 
forms.  For more information about the transport properties of stable and radioactive strontium in 
the environment, see Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO STRONTIUM? 
Strontium is found nearly everywhere in small amounts, and you can be exposed to low levels of 
strontium by breathing air, eating food, drinking water, or accidentally eating soil or dust that 
contains strontium.  Food and drinking water are the largest sources of exposure to strontium.  
Because of the nature of strontium, some of it gets into fish, vegetables, and livestock.  Grain, 
leafy vegetables, and dairy products contribute the greatest percentage of dietary strontium to 
humans.  The concentration of strontium in leafy vegetables, such as cabbage, grown in the 
United States is less than 64 mg in a kg of the fresh vegetables (i.e., 64 ppm).  For most people, 
the intake of strontium will be moderate.  More information about strontium exposure can be 
found in Chapter 6. 
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90Sr is found nearly everywhere in small amounts from past nuclear accidents and fallout from 
nuclear explosions. You can be exposed to low levels of 90Sr by eating food, drinking water, or 
accidentally eating soil or dust that contains 90Sr. Food and drinking water are the largest 
sources of exposure to 90Sr. Because of the nature of 90Sr, some of it gets into fish, vegetables, 
and livestock. Grain, leafy vegetables, and dairy products contribute the greatest percentage of 
dietary 90Sr to humans.  The concentration of 90Sr in fresh vegetables grown in the United States 
is less than 9 pCi (or 0.3 Bq) in 1 kg of dried vegetables (in a hot oven).  The intake of 
radioactive strontium for most people will be small.  You can take in more 90Sr if you eat food 
that was grown on a radioactive strontium-contaminated hazardous waste site.  More information 
about radioactive strontium exposure can be found in Chapter 6. 
1.4 HOW CAN STRONTIUM ENTER AND LEAVE MY BODY? 
Both stable strontium and radioactive strontium enter and leave the body in the same way.   
If a person breathes in vapors or dust containing a chemical form of strontium that is soluble in 
water, then the chemical will dissolve in the moist surface inside the lungs and strontium will 
enter the bloodstream relatively quickly.  If the chemical form of strontium does not dissolve in 
water easily, then particles may remain in the lung for a time.  When you eat food or drink water 
that contains strontium, only a small portion leaves the intestines and enters the bloodstream.  
Studies in animals suggest that infants may absorb more strontium from the intestines than 
adults. If a fluid mixture of a strontium salt is placed on the skin, the strontium will pass through 
the skin very slowly and then enter the bloodstream.  If the skin has scratches or cuts, strontium 
will pass through the skin much more quickly. 
Once strontium enters the bloodstream, it is distributed throughout the body, where it can enter 
and leave cells quite easily. In the body, strontium behaves very much like calcium.  A large 
portion of the strontium will accumulate in bone. In adults, strontium mostly attaches to the 
surfaces of bones. In children, whose bones are still growing, strontium may be used by the 
body to create the hard bone mineral itself.  As a result the strontium will be stored in the bone 
for a long time (years).  Because of the way bone grows, strontium will be locally dissolved from 
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bone and recirculate through the bloodstream, where it may be reused by growing bone, or be 
eliminated.  This process accounts for the slow removal of strontium from the body. 
Strontium is eliminated from the body through urine, feces, and sweat.  Elimination through 
urine may occur over long periods, when small amounts of strontium are released from bone and 
do not get recaptured by bone. When strontium is taken in by mouth, the portion that does not 
pass through the intestinal wall to enter the bloodstream is eliminated through feces during the 
first day or so after exposure. 
See Chapter 3 for further information. 
1.5 HOW CAN STRONTIUM AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.   
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body. In the case of a radioactive chemical, it is also important to gather 
information concerning the radiation dose and dose rate to the body.  For some chemicals, 
animal testing may be necessary.  Animal testing may also be used to identify health effects such 
as cancer or birth defects. Without laboratory animals, scientists would lose a basic method to 
get information needed to make wise decisions to protect public health.  Scientists have the 
responsibility to treat research animals with care and compassion.  Laws today protect the 
welfare of research animals, and scientists must comply with strict animal care guidelines. 
There are no harmful effects of stable strontium in humans at the levels typically found in the 
environment.  The only chemical form of stable strontium that is very harmful by inhalation is 
strontium chromate, but this is because of toxic chromium and not strontium itself.  Problems 
with bone growth may occur in children eating or drinking unusually high levels of strontium, 
especially if the diet is low in calcium and protein.  Ordinary strontium salts are not harmful 
when inhaled or placed on the skin. 
7 STRONTIUM 
1. PUBLIC HEALTH STATEMENT 
Animal studies showed that eating or drinking very large amounts of stable strontium can be 
lethal, but the public is not likely to encounter such high levels of strontium.  In these unusually 
high amounts, so much strontium was taken into bone instead of calcium that growing bones 
were weakened. Strontium had more severe effects on bone growth in young animals than in 
adults. 
It is not known whether stable strontium affects reproduction in people.  The effect of stable 
strontium on reproduction in animals is not known.  The Department of Health and Human 
Services has determined that strontium chromate is expected to be a carcinogen, but this is 
because of chromium.  There is no information that any other form of stable strontium causes 
cancer in humans or animals.   
The harmful effects of radioactive strontium are caused by the high energy effects of radiation.  
Since radioactive strontium is taken up into bone, bone itself and the soft tissues nearby may be 
damaged by radiation released over time.  Because bone marrow is the essential source of blood 
cells, blood cell counts may be reduced if the dose is too high.  This has been seen in humans 
who received injections of radioactive strontium (89Sr) to destroy cancer tissue that had spread to 
the bone marrow.  Lowered blood cell counts were also seen in animals that breathed or 
swallowed radioactive strontium.  Numerous problems occur when the number of blood cells is 
too low. A loss of red blood cells, anemia, prevents the body from getting sufficient oxygen, 
resulting in tiredness. A loss of platelets may prevent the blood from clotting properly, and may 
result in abnormal bleeding, especially in the intestines.  A loss in white blood cells harms the 
body’s ability to fight infectious disease.  
Radiation damage may also occur from exposure to the skin.  Medically, radioactive strontium 
probes have been used intentionally to destroy unwanted tissue on the surface of the eye or skin.  
The eye tissues sometimes become inflamed or abnormally thin after a long time.  Thinning of 
the lower layer of the skin (dermis) has also been reported in animal studies as a delayed effect.   
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It is not known whether exposure to radioactive strontium would affect human reproduction.  
Harmful effects on animal reproduction occurred at doses that were more than a million times 
higher than typical exposure levels for the general population.   
Radioactive strontium may cause cancer as a result of damage to the genetic material (DNA) in 
cells. An increase in leukemia over time was reported in individuals in one foreign population 
who swallowed relatively large amounts of 90Sr (and other radioactive materials) in river water 
contaminated by a nuclear weapons plant.  Cancers of the bone, nose, and lung (in the case of a 
breathing exposure), and leukemia were reported in animal studies.  In addition, skin and bone 
cancer were reported in animals that received radiation at high doses to the skin.  The 
International Agency for Research on Cancer (IARC) has determined that radioactive strontium 
is carcinogenic to humans, because it is deposited inside the body and emits beta radiation.  The 
EPA has determined that radioactive strontium is a human carcinogen.  
To learn more about the health effects of exposure to stable or radioactive strontium, see  
Chapter 3. 
1.6 HOW CAN STRONTIUM AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans.  
Children are exposed to stable strontium in the same manner as adults:  usually in small amounts 
in drinking water and food. Young children who have more hand-to-mouth activity or who eat 
soil may accidentally eat more strontium.  Infants and children with active bone growth absorb 
more strontium from the gut than adults. 
Excess stable strontium causes problems with growing bone.  For this reason, children are more 
susceptible to the effects of stable strontium than adults who have mature bone.  Children who 
eat or drink unusually high levels of stable strontium may have problems with bone growth, but 
only if the diet is low in calcium and protein.  Children who drink milk, especially milk fortified 
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with vitamin D, are not likely to have bone problems from exposure to excess stable strontium.  
The amount of stable strontium that is usually taken in from food or water or by breathing is too 
low to cause bone problems in children.  No developmental studies in humans or animals 
examined the effect on the fetus when the mother takes in excess strontium.  However, no 
problems are expected with fetal bone growth because only small amounts of strontium are 
transferred from the mother across the placenta to the fetus.  Evidence suggests that stable 
strontium can be transferred from the mother to nursing infants through breast milk, but the 
presence of calcium and protein in milk protects against bone problems during nursing. 
Children take in, use, and get rid of radioactive strontium in the same ways as stable strontium.  
Children are likely to be more vulnerable than adults to the effects of radioactive strontium 
because relatively more goes into bone when it is growing.  Also, children are potentially more 
vulnerable than adults to radiation damage because they keep radioactive strontium in bone for a 
longer time. 
Children would be expected to have the same types of effects from exposure to radioactive 
strontium as exposed adults.  Children can be exposed to radioactive strontium at levels higher 
than background without showing increases in cancer rates.  Evidence from one foreign 
population showed that children who drank water containing unusually high levels of radioactive 
strontium for 7 years showed an increase in leukemia.  High levels of radioactive strontium cause 
more bone damage and higher bone cancer rates when animals are exposed before birth or as 
juveniles rather than as adults. In humans and animals, radioactive strontium can be transferred 
into milk or across the placenta into the fetus. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO STRONTIUM? 
If your doctor finds that you have been exposed to significant amounts of strontium, ask whether 
your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate.  Public health officials may publish guidelines for reducing exposure 
to strontium when necessary. 
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It is possible that higher-than-normal levels of stable strontium may occur naturally in soil in 
some places or that higher levels of radioactive strontium may be found in soil near hazardous 
waste sites. Some children eat a lot of dirt.  You should prevent your children from eating dirt.  
Make sure they wash their hands frequently, and before eating.  If you live near a hazardous 
waste site, discourage your children from putting their hands in their mouths or from engaging in 
other hand-to-mouth activities. 
Since strontium is so common in the environment, and is naturally present in food and water, we 
cannot avoid being exposed to it. For several reasons, having a balanced diet with sufficient 
vitamin D, calcium, and protein will be protective by reducing the amount of ingested strontium 
that is absorbed. 
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO STRONTIUM? 
All people have small amounts of stable strontium in their bodies, mostly in bone.  It can be 
measured in the blood, hair, feces, or urine.  The amount is usually measured by its mass 
(grams).  Measurements in urine can show whether you have been exposed recently to larger­
than-normal amounts of strontium.  Measurements in hair can reveal whether you were exposed 
to high amounts of strontium in the past.  Most physicians do not test for strontium in their 
offices, but can collect samples and send them to a special laboratory.  X-rays can show changes 
in bone that may occur from exposure to high amounts of strontium, but these changes may have 
other causes (a diet low in vitamin D or a high exposure to some other trace metal). 
If a person has been exposed to radioactive strontium, special tests can be used to measure 
radioactive strontium in blood, feces, or urine.  These tests are most useful when done soon after 
exposure, since radioactive strontium quickly enters into bone and takes many years to be 
completely removed from bone.  Radioactive strontium can be measured by its mass (in grams) 
or by its radiation emissions.  These emissions, which differ for the various isotopes of 
strontium, are used to tell the amount of radioactive strontium (in curies or bequerels) and the 
radiation dose that it gives to your body (in sieverts or rem).  In a procedure that is similar to 
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being x-rayed, specialized equipment can measure radioactive strontium that has been 
incorporated into bone. 
For more information, please read Chapters 3 and 7. 
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), the Food and Drug Administration (FDA), and the U.S. Nuclear 
Regulatory Commission (USNRC).   
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR), the National Institute for 
Occupational Safety and Health (NIOSH), and the FDA. 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; they are then adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for strontium include the following: 
EPA recommends that drinking water levels of stable strontium should not be more than 
4 milligrams per liter of water (4 mg/L). 
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The Department of Energy (DOE) established derived air concentrations (DAC) for workplace 
exposure to radiation at DOE facilities.  The DAC ranges from 0.000000002 microcuries per 
milliliter (µCi/mL) (2x10-9 µCi/mL of air = 70 µBq/mL of air) for radioactive particles remaining 
in the lung for 100 days to 0.000000008 µCi/mL (8x10-9 µCi/mL of air = 300 µBq/mL of air) for 
radioactive particles remaining in the lung for less than 10 days.  The USNRC established an 
annual intake limit of 20 µCi (7 MBq) for on-the-job exposure to 90Sr in air. 
EPA set standards for the concentration of 90Sr in community water supplies. The average 
annual concentration of 90Sr in water supplies should not exceed 8 pCi/L (0.3 Bq/L).  EPA also 
established maximum contaminant levels (MCLs) in drinking water for radionuclide activities to 
protect against harmful effects of 90Sr. For beta particles like strontium, the MCL is 4 mrem per 
year (4x10-5 Sv per year). The USNRC set a workplace value of 31 µCi (1.1 MBq) for the 
amount of 90Sr that can be taken in by mouth in a year without any harmful effects.  
More information on regulations and guidelines is available in Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, your regional Nuclear Regulatory Commission office, or 
contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You 
may request a copy of the ATSDR ToxProfiles CD-ROM by calling the information and 
technical assistance toll-free number at 1-888-42ATSDR (1-888-422-8737), by email at 
atsdric@cdc.gov, or by writing to: 
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Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road NE 
Mailstop F-32 
Atlanta, GA 30333 
Fax: 1-770-488-4178 
For-profit organizations may request a copy of final profiles from the following: 
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/ 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO STRONTIUM IN THE 
UNITED STATES 
Stable Strontium.  Elemental strontium (atomic number 38) occurs naturally in the earth's mantle as a 
mixture of four stable isotopes, 88Sr, 86Sr, 87Sr, and 84Sr, and is present everywhere in very dilute 
concentrations. It is very similar to calcium in its environmental and physiological behavior.  Strontium 
is generally found in molecular compounds with other elements.  Commercially important strontium 
minerals include celestite (SrSO4) and strontianite (SrCO3). Strontium is used in the manufacture of 
ceramics and glass products, primarily in the faceplate glass of televisions and other cathode-ray-tube 
devices, where it serves to block x-ray emissions.  
The general population is exposed to stable strontium primarily by ingestion of food and water, and to a 
lesser degree, by inhalation.  The strontium content in air averages 20 ng/m3, with higher concentrations 
resulting from stack emissions from coal-burning plants.  Strontium is present in nearly all fresh waters in 
amounts generally ranging between 0.5 and 1.5 mg/L, with higher levels occurring where there are 
celestite-rich limestone deposits.  The average concentration of stable strontium in soil is approximately 
240 mg Sr/kg, but agricultural soils may be treated with phosphate fertilizer or limestone, which contain 
~610 mg Sr/kg.  Because strontium is chemically similar to calcium, it is taken up from the soil by fruits 
and vegetables. The average concentration of strontium in fruit produce ranged from 0.0416 to 
2.232 µg/L. The total estimated daily exposure to stable strontium is approximately 3.3 mg/day 
(0.046 mg/kg/day):  400 ng/day from inhalation, 2 mg/day from drinking water, and 1.3 mg/day from the 
diet (see Chapter 6). Assuming a reference body weight of 70 kg, the typical daily strontium exposure is 
46 µg/kg body weight.  The strontium content of the human body is approximately 4.6 ppm by weight, 
99% of which is localized in bones and teeth.  Blood concentrations of strontium are in the range of  
20–31 µg/L. 
Radioactive Strontium. The radioactive isotopes of strontium do not occur naturally but are produced as 
a by-product of nuclear fission of 235U, 238U, or 239Pu.  The most significant isotopes are 90Sr (half-life of 
29 years), 89Sr (half-life of 51 days), and 85Sr (half-life of 65 days), which decay by the emission of beta 
particles. 90Sr is currently found in spent fuel rods in nuclear reactors and is considered a waste product.  
Other radioactive strontium isotopes have been employed for medical uses: 89Sr (as Metastron™) as a 
cancer therapeutic for the relief of bone pain and 85Sr in the radiologic imaging of bone.  85Sr also has 
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minor commercial applications in thermoelectric power generation, as a beta particle standard source, and 
in instruments that measure the thickness and density of materials.  Disposal and handling of radioactive 
strontium isotopes are regulated by the U.S. Nuclear Regulatory Commission. 
The general population is exposed to very small amounts of radioactive strontium from the ingestion of 
contaminated water and food; inhalation exposure is negligible.  The average concentration of 90Sr in 
drinking water in 1994 was estimated as 0.1 pCi/L; after 1994, estimates were based on gross beta activity 
and not reported by individual elements since the amounts were so small.  Fresh vegetables contribute 
more than one third of the yearly dietary intake of 90Sr, followed by grains and dairy products.  The 
current total daily exposure levels to radioactive strontium are estimated to be approximately 5.2 pCi/day 
(0.16 Bq/day; 0.074 pCi/kg/day):  5 pCi/day from food and 0.2 pCi/day from drinking water. 
See Chapter 6 for more detailed information regarding concentrations of stable and radioactive strontium 
in environmental media. 
2.2 SUMMARY OF HEALTH EFFECTS 
Stable Strontium.  There is no direct evidence that stable strontium is toxic to humans under normal 
environmental exposures.  The primary toxicological effect of absorbed excess strontium in laboratory 
animals is abnormal skeletal development (rickets), which occurs only at relatively high oral doses.  The 
inhalation toxicity of pure stable strontium has not been evaluated.  At levels normally encountered in the 
environment, strontium appears to have low toxicity to adults or to juveniles with adequate nutrition.  
Juveniles, especially those with poor nutrition, are vulnerable because strontium, as an imperfect 
surrogate for calcium, interferes with bone mineralization in the developing skeleton.  The data for 
adverse health effects of stable strontium in humans are sparse, but indicate a possibility of skeletal 
effects under special circumstances: an epidemiological study of strontium-related rickets in Turkish 
children and a few studies of hemodialysis patients who developed osteomalacia because of strontium in 
dialysis water.  Numerous animal studies demonstrated adverse effects on skeletal development in 
juveniles following ingestion of excess stable strontium (discussed below under Skeletal Effects).  No 
developmental or reproductive studies have been conducted involving exposure to stable strontium during 
gestation. No studies examined whether stable strontium is carcinogenic to humans or animals.  One 
strontium compound, strontium chromate, is a genotoxic human carcinogen by the inhalation route, but 
the hazard is caused by hexavalent chromium and not strontium. 
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Other effects have been observed sporadically and are of unclear physiological significance.  Paralysis of 
the hindlimbs was observed in orally-exposed rats, but it is uncertain whether the cause was 
neurophysiological or the result of local neuronal damage secondary to deformation of the femora.  Minor 
unspecified changes in hepatic histology and glycogen content were observed in orally-exposed rats.  The 
following section discusses effects in the primary target of stable strontium, the skeleton, in greater detail. 
Skeletal Effects. Although strontium, as a molecular surrogate for calcium, can be distributed 
throughout the body, its main target for deposition is the skeleton.  One suggestive epidemiological study 
found that increased strontium ingestion contributed to an increase in the prevalence of signs of rickets 
(craniomalacia, rachitic rosary, bulging at the wrist, bony deformities of the leg, and delayed closure of 
the fontanelles) in children in a region of Turkey.  A significantly increased incidence of rickets was 
associated with a diet restricted to water and cereals grown locally in soils with strontium concentrations 
in excess of 350 mg/kg.  Other contributing factors included probable deficiencies in vitamin D, protein, 
and calcium after weaning; breast feeding for >2 years appeared to be a protective factor against the 
development of rickets in this population.  The only reports of strontium-related skeletal problems in 
adults concerned osteomalacia in hemodialysis patients exposed to strontium in dialysis water.  Dialysis 
patients may be unusually susceptible because of their impaired handling of strontium.  Stable strontium 
compounds have been used for the treatment of osteoporosis (see Section 2.3). 
Animal studies strongly support the identification of bone as the most sensitive target of strontium 
toxicity.  Relatively high doses of strontium (≥500 mg/kg/day) caused a reduction in bone mineralization 
(ash weight) and an alteration in the chemical composition of organic bone matrix.  In addition, the 
hypertrophic zones of the epiphyseal growth plates of long bones became abnormally deep and wide, as 
calcification failed to occur. Severe weakening of the bones resulted from rickets, in which the skeleton 
could not support the body adequately; deformity of the head of the femur may have contributed to 
paralysis of the hind limbs in some cases.  Young animals were more sensitive to the effect of excess 
strontium than older animals, possibly because the absorption and retention of strontium were higher in 
the young.  In addition, inadequate calcium and vitamin D in the diet increased the severity of skeletal 
effects. The chemical form of strontium may influence toxicity by affecting gastrointestinal absorption. 
One intermediate oral animal study that tested strontium phosphate reported a much higher no-effect level 
than studies that tested strontium chloride or carbonate.  However, cation effects on strontium toxicity 
have not been studied systematically. 
18 STRONTIUM 
2. RELEVANCE TO PUBLIC HEALTH 
Evidence from the few human studies and numerous animal toxicity studies suggest that healthy adults 
living near hazardous waste sites are unlikely to be exposed to levels of stable strontium sufficiently high 
to cause adverse skeletal effects.  Children living in areas where the soil and drinking water contain 
relatively high amounts of strontium may be vulnerable to skeletal effects if their nutritional status is poor 
(deficient in calcium, vitamin D, and/or protein) and if the diet is restricted to foods grown locally.  All 
these conditions are not likely to be common in the United States, since the food supply generally comes 
from a wide geographic area.   
Radioactive Strontium. Exposure to radioactive strontium can result in health consequences that vary 
depending on the dose, the route of exposure, and the chemical form.  Both 90Sr and 89Sr emit beta 
particles, which, in tissue, may ionize cellular molecules within a range of 1 cm, resulting in tissue 
damage and disruption of cellular function if the capacity of natural repair mechanisms is exceeded.  
Adverse health effects occur at high levels of exposure that significantly exceed background levels 
encountered by the general population. It should be noted that no discernable adverse health effects were 
detected in the general population from chronic low-level exposure to 90Sr in fallout during the period of 
aboveground weapons testing. 
90Sr represents the most significant isotope of concern because of its relatively long half-life (29 years) 
and because of the bone-seeking properties of strontium.  The most serious effects of oral exposure to 
absorbed radioactive strontium are necrotic lesions and cancers of bone and the adjacent tissues.  High 
level acute exposures can destroy hematopoietic bone marrow, leading to acute radiation syndrome (see 
below), the primary cause of mortality in the short term.  At lower doses, irradiation of bone marrow may 
lead to chronic suppression of immune function. 
The consequences of inhalation exposures in animals vary depending on the solubility of the form of 
radiostrontium.  Insoluble particles tend to be retained in the lung, resulting in pneumonitis; necrosis of 
the pulmonary, vascular, and adjacent myocardial tissues; pulmonary fibrosis; and, later, pulmonary and 
vascular cancers.  Inhalation of soluble radiostrontium does not have these local effects because the 
material is absorbed and distributed in the skeleton.  The effects of inhalation of soluble strontium are, 
therefore, similar to those described for the oral route:  acute radiation syndrome and other hematopoietic 
effects, osteosarcoma, and immunosuppression. 
External exposure to solid strontium sources placed near the skin or eye can cause local lesions when 
doses are significantly higher than background.  Effects observed in clinical studies on the eye included 
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keratitis or scarring of the cornea, telangiectasis or scarring of the conjunctiva, iritis, conjunctivitis, mild 
irritation, and scleral thinning. Dermal effects in clinical studies range from erythema and pigmentation 
changes, dry and moist desquamation (which involves destruction of the basal epithelial cells), and 
telangiectasis and increased vascular permeability, to long-term responses such as epithelial and dermal 
hyperplasia, chronic fibrosis, and dermal atrophy. 
There is inconclusive evidence in humans and definitive evidence in laboratory animals that exposure to 
radioactive strontium at very high doses in utero can lead to adverse developmental effects.  Slight 
increases in developmental effects were noted in a population of the former Soviet Union whose drinking 
water (the Techa River) was contaminated with multiple radioactive elements released from a plutonium 
production plant between 1949 and 1956.  These effects included slight increases in child mortality from 
chromosomal defects and from congenital anomalies of the nervous system, circulatory system, and other 
unspecified anomalies in the progeny of exposed individuals.  However, the specific contribution of 
radiostrontium to these effects is not known.  Developmental effects in laboratory animals were noted at 
extremely high doses, as if, on a kilogram body weight basis, individual pregnant females were receiving 
daily the entire amount of 90Sr currently released from one nuclear power plant into the environment 
during a year (see Table 6-1).  There is evidence that maternal oral exposure to radioactive strontium can 
lead to reduced fetal and postnatal survival in the offspring, but there is no evidence for birth defects.  At 
the very highest doses of radioactive strontium injected into pregnant females, the offpsring exhibit 
increases in birth defects (skeletal anomalies and partial atelectasis of the lungs), and cancers of soft 
tissues near bone (meningeal and pituitary tumors), as well as hyperplasia of lymph nodes and spleen and 
deficient hematopoiesis. Exposure to radioactive strontium in milk from dams injected at very high doses 
reduces the numbers of early-stage oocytes in the ovary of neonatal mice, but the effect is less severe than 
when offspring are exposed only in utero. 
There is no evidence in humans that radioactive strontium leads to reproductive effects, but there is some 
evidence in laboratory animals.  Although the Techa River populations received the highest known 
extended oral exposure to radioactive strontium (and other radionuclides) of any human group, there were 
no significant effects on reproductive parameters (birth rate, fertility, incidence of spontaneous abortion). 
An increase in fetal deaths was noted in some studies in rats, but no reproductive effects were noted in 
larger laboratory animals at equivalent oral doses.  This difference appears to be related to the fact that in 
small animals, the bone marrow cavity diameters are not wide enough to leave the central hematopoetic 
tissues untouched by beta-irradiation emitted by radioactive strontium bound to bone.  Exposure to high 
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doses of radioactive strontium by injection led to significant reproductive effects (reduced fertility, 
reduced gonadal cellularity, suppressed spermatocyte maturation) in mice.  
Other effects of radioactive strontium have been observed sporadically in animal studies and are of 
unclear physiological significance.  Anorexia, reduced body weight, and liver effects that were possibly 
secondary to radiation pneumonitis (chronic passive congestion of the liver and mild centrilobular hepatic 
fibrosis) were observed in beagles following a single inhalation exposure of insoluble 90Sr particles at an 
initial lung burden of 25 :Ci/kg. 
The populations potentially most sensitive to radiostrontium exposure include the young and individuals 
that have poor nutrition or deficiencies in vitamin D.  Infants and children are more vulnerable than adults 
because they absorb strontium through the gastrointestinal tract at slightly higher rates and because they 
have actively growing bones that incorporate more strontium than mature bones.  Very high prenatal 
exposure levels may cause major developmental anomalies in the skeleton and adjacent areas if critical 
tissues are destroyed.  In addition, since children have a higher proportion of mitotic cells than adults, 
their rates of genotoxic damage are higher.  This is because genetic lesions become fixed mutations when 
mitosis occurs before genetic damage is repaired.  Genetic lesions in genes controlling the cell cycle can 
lead to the development of cancer and may be the basis of excess cancer cases attributed to exposure to 
radioactive strontium.  Individuals with poor nutrition or deficiencies in vitamin D, such as those with 
osteomalacia, are theoretically more vulnerable to radioactive strontium because their lower absorption of 
calcium results in relatively higher rates of strontium incorporation into bone during the remodeling 
process that continues throughout life.  The level of incorporation of radiostrontium into bone can be 
somewhat reduced by ingestion of alginates soon after exposure.  Removal from bone after incorporation 
is not feasible. 
The major adverse effects of exposure to radioactive strontium, non-cancerous lesions of hematopoietic 
bone marrow tissue, cancer, and dystrophic lesions of the skeleton, are discussed below in greater detail.  
It should be noted that the large animal studies are more relevant than rodent studies to humans because 
the severity of bone marrow effects is inversely proportional to the diameter of the bone marrow cavity. 
Non-Cancerous Bone Marrow Effects (Including Acute Radiation Syndrome).    Bone 
marrow effects are the most serious immediate consequences of exposure to high levels of radioactive 
strontium by either the inhalation or oral route.  When absorbed radioactive strontium incorporates into 
bone, irradiation of the bone marrow results in hypoplasia of the hemopoietic tissue and pancytopenia, 
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with the severity depending on the dose.  At the highest doses, acute radiation syndrome (anorexia, 
bloody diarrhea) would be expected because of the virtual destruction of the bone marrow.  Acute 
radiation syndrome was not observed in the orally-exposed Techa River population, but was observed in 
dogs several weeks after receiving long-term retained body burdens of ≥47 :Ci 90Sr/kg (≥1.74 MBq/kg) 
following a single exposure to soluble 90SrCl2 by inhalation.  Hemorrhaging is caused by the drastic 
depression in platelet counts; a severe drop in neutrophil counts precedes death.  At lower exposure 
levels, pancytopenia is detectable, but is not immediately life-threatening.  This was observed in dogs that 
received long-term retained burdens >10 :Ci 90Sr/kg (>0.37 MBq/kg) following a single inhalation 
exposure of soluble 90SrCl2 
At lower levels of exposure, not all types of hematopoietic cells within bone marrow are affected, 
possibly because of differences in intrinsic rates of replacement.  In the orally-exposed Techa River 
populations, milder chronic effects of bone marrow irradiation were reported in a small percentage of 
exposed individuals:  leukopenia, thrombocytopenia, and granulocytopenia, as well as lymphopenia 
involving T lymphocytes and large granulocytic lymphocytes.  Reduced lymphocyte counts, indicators of 
weakened immune function, in some individuals who received radiation to the bone marrow in excess of 
30 rem (0.3 Sv) per year, were implicated as the cause of the higher incidences of infectious disease in 
those who developed radiation-induced cancers.  Suppression of the immune system is also supported by 
studies in pigs exposed to 625 :Ci 90Sr/day (23.13 MBq/day) in feed for 4–9 months or in dogs receiving 
single inhalation exposures of soluble (long-term retained burden >10 :Ci 90Sr/kg [>370 kBq/kg]) or 
insoluble (initial lung burden ≥5 :Ci 90Sr/kg [≥185 kBq/kg]) radioactive strontium.  
mice indicate that natural killer cells were preferentially eliminated.  Chronic myeloid metaplasia, 
possibly related to genotoxicity, was another effect of bone marrow irradiation in orally-exposed pigs that 
received cumulative doses in excess of 40 rad (0.4 Gy) and in a small percentage of dogs that received 
≥0.4 :Ci 90Sr/kg/day (44.4 kBq/kg/day) from mid-gestation to 1.5 years.   
Injection studies in 
Cancer. Radioactive strontium, like other radionuclides, is a genotoxic carcinogen.  Mutations in 
genes controlling the cell cycle can lead to cancer if the damage is not repaired before the next cell 
division; rapidly dividing cells, such as the hematopoietic cells in bone marrow, are especially vulnerable.  
Incorporation of radioactive strontium into bone places bone and the adjacent soft tissues at risk for 
cancer. Chronic consumption of radioactive strontium (and other radionuclides), leading to estimated 
doses to bone marrow in excess of 10 rem (0.1 Sv), significantly increased the incidence of leukemia in 
the Techa River population, but this effect was not observed in offspring exposed in utero who received 
lower doses. Leukemia has also been observed in animals exposed orally or by inhalation to soluble 
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radioactive strontium.  Other cancers observed in animal studies include osteosarcomas, 
hemangiosarcomas, cancers of other soft tissues near bone, and, in feeding studies, nasal, oral, and 
periodontal carcinomas.  In dogs that inhaled insoluble 90Sr, the particles lodged in the respiratory tract, 
causing cancers of the immediately surrounding tissues:  hemangiosarcomas of the lung and heart and 
carcinomas of the respiratory tract.  External exposure to 90Sr (solid source) in mice induced skin cancers 
(squamous cell carcinoma, basal cell carcinoma, fibrosarcoma) and, in one study, osteosarcomas.  
Immature organisms are potentially more vulnerable than adults to radioactive strontium partly because 
they have a higher proportion of cells in mitotic phase and partly because they incorporate relatively more 
radiostrontium into bone.  In a multigenerational swine study, doses that were not carcinogenic in the 
females exposed as adults induced osteosarcomas in the F1 or F2 generations exposed from conception. 
National Council on Radiation Protection and Measurements concluded that uncertainties remain 
regarding extrapolation from the high doses of 90Sr known to cause cancer in animals to the lower doses 
that might increase the incidence of leukemia in humans.  The Council suggested that more basic 
knowledge on the mechanism of cancer induction by ionizing radiation would be required to understand 
the risk of internal exposure to 90Sr. EPA has determined that radioactive strontium is a known human 
carcinogen (Group A). EPA estimated that the risk of developing cancer following exposure to 8 pCi/L in 
drinking water is 1 in 100,000.  The International Agency for Research on Cancer has determined that 
internally deposited radionuclides, such as radioactive strontium, are carcinogenic to humans (Group 1). 
Skeletal Effects. Dystrophic lesions of the skeleton occur when the level of oral exposure of soluble 
radioactive strontium is high enough that the amount incorporated into bone results in irradiation of the 
bone at levels exceeding natural repair mechanisms.  The effect could occur by acute exposure to a very 
high dose, by intermediate-duration exposure at a moderate dose, or by chronic-duration exposure at a 
lower dose. Such lesions, primarily affecting articular and periarticular tissues, were reported in the 
Techa River populations that received mean radiation doses to the surface of bone in excess of 200 rem 
(2 Sv) following chronic oral exposure to radiostrontium, but not at the lower doses. 
Animal oral exposure studies support the findings in humans.  Skeletal or dental effects in adults are less 
severe than in developing animals because in adults, incorporation of radioactive strontium is mainly 
restricted to the surfaces of bone or teeth.  Incorporation throughout the developing bone renders it 
vulnerable to weakening as a result of focal necrosis from long-term irradiation.  Intermediate-exposure at 
6 µCi/kg/day for 1–10 months reduced numbers of osteocytes and damaged blood vessels in the bone of 
adult rabbits.  More severe effects damaging the bone structure (necrosis of vasculature, impaired 
transformation into cortical bone, and fracturing) were observed in dogs exposed in utero and chronically 
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into adulthood at 0.4 µCi/kg/day.  Damage to developing teeth (disordered tooth structure and increased 
cell death of differentiating odontoblasts and pulp cells) has been reported in rabbits following injection 
of a very high dose (600 µCi 90Sr/kg), but effects were less severe in mature teeth.  
2.3 MINIMAL RISK LEVELS 
Inhalation MRLs 
Stable Strontium.  Data on the toxicity of inhaled stable strontium are not suitable for derivation of an 
inhalation MRL: one case report of a woman exposed to an undetermined concentration of strontium 
mixed with other chemicals in smoke from an ignited flare (Federman and Sachter 1997).  
Radioactive Strontium. The main sources on the toxicity of inhaled radioactive strontium are two acute-
duration studies in dogs reporting severe hematological and immunological effects following a single 
nose-only exposure to 90Sr as fused clay particles for several minutes (Jones et al. 1976) or strontium 
chloride (Gillett et al. 1987a). Inhalation of 90Sr fused-clay particles leading to initial lung burdens of 
5 µCi 90Sr/kg (185 kBq/kg) resulted in chronic significant depression of lymphocyte counts and 
suppression of immune function (Jones et al. 1976). Chronic thrombocytopenia and neutropenia, which 
persisted for 1,000 days in dogs at all tested exposure levels (long-term retained burdens at or above 
1 µCi 90Sr/kg; 0.04 MBq/kg), was observed in dogs exposed to soluble 90SrCl2 (Gillett et al. 1987a).  
These data were not considered adequate for derivation of an acute-duration inhalation MRL because the 
observed hematological and immunological effects were considered severe adverse effects. 
Oral MRLs 
Stable Strontium. 
•	 An MRL of 2.0 mg/kg/day has been derived for intermediate-duration oral exposure  

(15–364 days) to stable strontium and its compounds.
 
The most consistent effects of oral exposure to excess stable strontium are rickets (impaired cartilage 
calcification) and osteomalacia (impaired bone mineralization), especially in the young.  One Turkish 
epidemiological study provided indirect evidence that excess oral exposure to strontium (in the presence 
of other predisposing factors) may contribute to the development of rickets in children (Ögzür et al. 
1996).  Overall, animal studies on strontium have concentrated on the evaluation of skeletal effects, with 
24 STRONTIUM 
2. RELEVANCE TO PUBLIC HEALTH 
occasional consideration to body weight and serum chemistry.  In young rodents, typical effects of excess 
strontium included an abnormal widening of the cartilaginous epiphyseal plates of the long bones, a lack 
of bone calcification, and abnormal deposition of unmineralized bone matrix or osteoid (Johnson et al. 
1968; Kshirsagar 1976; Marie and Hott 1986; Morohashi et al. 1994; Neufeld and Boskey 1994; Storey 
1962).  The skeletal effects of strontium are known to be related to its chemical similarity to calcium and 
its suppression of vitamin D metabolism and intestinal calcium absorption (Armbrecht et al. 1998).  
Effects are more severe in young rats than in adults because the rate of skeletal incorporation of strontium 
is higher in young animals (see Section 3.5.2.2). 
A lowest-observed-adverse-effect level (LOAEL) of 550 mg strontium/kg/day is identified for bone 
mineralization abnormalities in weanling rats that were exposed to dietary strontium carbonate for 
20 days (Storey 1961).  The epiphyseal plates of long bones were irregular and abnormally thick.  
Furthermore, areas of uncalcified bone matrix were deposited in the distal ends of the metaphyseal 
trabeculae and proximal end of the diaphyses.  Irregularities in the organization of the cells of the 
hypertrophic zone, in the pattern of calcification, and in the deposition of osteoid were more conspicuous 
with increasing dose.  In tibias, the dry weight, ash weight, ash percentage, and calcium in ash were 
significantly reduced with increased strontium intake.  No effects on bone mineralization occurred in 
weanling rats ingesting 140 mg strontium/kg/day, the NOAEL for intemediate-duration exposure.  In 
adult rats examined in this study, the effects of strontium ingestion were less severe in that higher doses 
were required to produce the same effect.  The no-effect level in adults was 690 mg strontium/kg/day, 
which was higher than the LOAEL for weanlings.  In adults, changes in tibial histology, such as abnormal 
thickening of the epiphyseal cartilages and abnormally widened metaphyseal osteoid seams, were noted at 
or above 1,370 mg strontium/kg/day.  At 2,750 mg strontium/kg/day, osteoid tissue was deposited near 
vascular canals and the areas of bone resorption were reduced.  In adult rat tibias, the dry weight, ash 
weight, ash percentage, and calcium in ash were only significantly affected at the highest dose.  This 
study demonstrates the difference in sensitivity to strontium between young and old animals, which is 
caused by the higher rate of strontium incorporation into the developing skeleton in young animals.  
The critical dose levels identified in the Storey (1961) study are supported by other studies in rodents.  
Similar LOAELs (500–565 mg strontium/kg/day) for abnormal bone mineralization are identified in 
several studies on weanling rats exposed to strontium carbonate (Morohashi et al. 1994; Neufeld and 
Boskey 1994) or an unspecified form of strontium (Johnson et al. 1968).  Slight skeletal effects were 
noted in mice exposed to 350 mg strontium/kg/day as strontium chloride (Marie and Hott 1986).  In 
addition, similar no-observed-adverse-effect levels (NOAELs) in the range of 110–168 mg 
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strontium/kg/day for skeletal effects were identified from studies in weanling rats exposed to an 
unspecified form of strontium (Grynpas et al. 1996), strontium chloride hexahydrate (Kroes et al. 1977), 
or strontium carbonate (Morohashi et al. 1994).  The study by Storey (1961) is preferred as the basis for 
the intermediate MRL because both young and adult animals were tested, the administered doses included 
NOAELs and LOAELs for both age groups, and the evaluation of skeletal effects included 
histopathological analysis.  Some of the other studies have serious deficiencies that render them 
unsuitable for deriving an MRL.  Two studies administered single doses of 166–168 mg/kg, but reported 
no adverse effects (Grynpas et al. 1996; Kroes et al. 1977); although the results support the NOAEL by 
Storey (1961), the lack of higher doses causing positive results raises uncertainty about the experiments.  
The study by Johnson et al. (1968) administered a single dose of 565 mg/kg that was a serious LOAEL 
for increased mortality.  Three of the other studies had deficiencies that rendered them less suitable than 
Storey (1961).  The study by Morohashi et al. (1994) did not analyze bone histopathology.  Studies by 
Marie and Hott (1986) and Neufield and Boskey (1994) administered single doses of 350 and 500 mg/kg, 
respectively, which were LOAELs for skeletal effects, but the studies provided no information on no-
effect levels or effects at higher doses.  Therefore, the NOAEL of 140 mg strontium/kg/day for skeletal 
effects in weanling rats (Storey 1961) would appear to be the most appropriate basis for calculating an 
intermediate MRL.  The NOAEL of 140 mg strontium/kg/day was divided by an uncertainty factor of 
30 (10 for extrapolation from animal to human and 3 for human variability) and a modifying factor of 
3 (for short study duration and limited end point examination).  A partial uncertainty factor was used to 
account for human variability because the selected NOAEL was based on the response of juveniles, which 
is also the most sensitive human group. The resulting MRL is calculated to be 2.0 mg strontium/kg/day, 
which is approximately 40 times higher than the total estimated daily exposure to stable strontium of 
0.047 mg/kg/day.  The MRL represents an estimate of daily human exposure that is likely to be without 
an appreciable risk of adverse health effects. Since the MRL is based on effects in young rats, it is 
considered to be protective of children, who are similar with respect to immaturity of the skeleton and 
high intestinal rates of strontium absorption.   
MRLs were not derived for acute- or chronic-duration oral exposures to stable strontium.  The relevant 
acute data are limited to two lethality studies in mice (Ghosh et al. 1990; Llobet et al. 1991a) and two 
toxicity studies in rats (Kshirsagar 1976; Kroes et al. 1977).  The rat studies were not considered suitable 
for MRL derivation. In the Kshirsagar (1976) study, the only administered dose, 3,000 mg strontium per 
kg/day as strontium phosphate, resulted in severe body weight effects (62% reduction in body weight 
gain) and was higher than the LD50 values reported for mice (Ghosh et al. 1990; Llobet et al. 1991a).  The 
Kroes et al. (1977) study did not identify an adverse effect level.  Limited data on the chronic toxicity of 
26 STRONTIUM 
2. RELEVANCE TO PUBLIC HEALTH 
stable strontium are available for humans and no data are available for animals.  The available data 
involve patients with osteoporosis or other disorders of bone mineralization who were treated for several 
years with low doses of strontium in the form of strontium salts:  strontium lactate (Shorr and Carter 
1952), strontium gluconate or strontium carbonate (Skoryna 1981a, 1984), and strontium ranelate 
(Meunier et al. 2002, 2004; Reginster 2002, 2003, Reginster et al. 2002).  None of the studies reported 
adverse effects on bone or significant increases in side-effects related to treatment, but reporting was poor 
in some of the studies (Shorr and Carter 1952; Skoryna 1981a, 1984).  These data are not suitable for 
MRL derivation for several reasons. All subjects in these studies were co-administered calcium and some 
were given vitamin D, both of which are known to interfere with strontium toxicity.  In addition, all of the 
subjects were adults, the majority being postmenopausal women with osteoporosis.  Considering that the 
intermediate oral MRL is based upon bone effects in juvenile rats, there is reason to suspect that a chronic 
oral MRL based on these data would not be protective of the most sensitive population (juveniles). 
Radioactive Strontium. No MRLs were derived for oral exposure to radioactive strontium, although the 
database includes chronic-duration human studies and acute-, intermediate-, and chronic-duration animal 
studies in several species. Strontium dosimetry information is available for the populations affected by 
contamination of the Techa River, but these exposures included simultaneous external gamma radiation 
from 137Cs, 106Ru, and 95Z and internal radiation from 137Cs, in addition to 89Sr and 90Sr (Kossenko et al. 
1994). The combined exposure studies are not suitable for the derivation of MRLs.  An increase in the 
incidence of leukemia was reported for Techa River individuals receiving estimated bone marrow doses, 
attributed to radioactive strontium, in excess of 10 rem (0.1 Sv) (Kossenko 1996; Kossenko et al. 1997, 
2000, 2002).  Dystrophic lesions of the skeleton were observed in individuals with mean radiation doses 
to the surface of bone in excess of 200 rem (2 Sv) (Akleyev et al. 1995).  Studies on rodents are not 
suitable models for establishing MRL levels for human exposure to radioactive strontium because of their 
relatively smaller bone diameter which places their bone marrow tissues at greater risk of radiation 
damage.  Most of the large animal studies reported serious hematological effects at all dose levels.  
Immunosuppression was observed in pigs fed 625 :Ci 90Sr/day (23.13 MBq/day) for 4–9 months 
(Howard 1970; Howard and Clarke 1970).  Chronic myeloid metaplasia was another effect of bone 
marrow irradiation in orally-exposed pigs that received cumulative doses in excess of 40 rad (0.4 Gy) and 
a small percentage of dogs that received ≥0.4 :Ci 90Sr/kg/day (44.4 kBq/kg/day) from mid-gestation to 
1.5 years (Dungworth et al. 1969; Howard 1970; Howard and Clarke 1970).  These serious effects are not 
suitable bases for determining MRL levels. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of strontium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.  
Appendix D contains background information on radiation physics, chemistry, and biology. 
Naturally occurring strontium is a mixture of four stable (nonradioactive) isotopes, 84Sr, 86Sr, 87Sr, and 
88Sr, the last being the most abundant.  Section 3.2 contains a discussion of the chemical toxicity of stable 
strontium; radiation toxicity associated with exposure to radiostrontium (primarily 90Sr and 89Sr) is 
discussed in Section 3.3. The chemical properties of stable and radioactive strontium isotopes are 
identical and are described in Chapter 4. 
Strontium is fairly reactive and therefore is rarely found in its pure form in the earth’s crust.  Examples of 
common strontium compounds include strontium carbonate, strontium chloride, strontium hydroxide, 
strontium nitrate, strontium oxide, and strontium titanate.  The most toxic strontium compound is 
strontium chromate, which is used in the production of pigments and can cause cancer by the inhalation 
route. Strontium chromate is not included in the Levels of Significant Exposure (LSE) tables for 
strontium since the carcinogenic effects of the compound are a function of the concentration of 
hexavalent chromium, and strontium only contributes to solubility.  The Toxicological Profile for 
Chromium (Agency for Toxic Substances and Disease Registry 2000) should be consulted for additional 
information on the health effects of strontium chromate. 
There is no direct evidence that strontium is toxic to humans, but there is suggestive epidemiological 
evidence that the oral toxicity observed at high doses in juvenile laboratory animals may pertain to 
humans under special circumstances.  Stable strontium is of relatively low toxicity.  It comprises about 
4.6 ppm by weight of the human body, but does not have any recognized essential biological role.  
Human exposure to strontium is primarily by the oral route (via fruits, vegetables, and drinking water), 
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although inhalation exposures are also possible.  No toxic effects of stable strontium have been reported 
for the exposure levels normally encountered in the environment.  Strontium is not readily absorbed 
through intact skin, but is absorbed through abraded skin and through puncture wounds.  The biological 
effects of strontium are related to its chemical similarity to calcium, with both elements being found in 
Group 2 of the periodic table and forming divalent cations.  However, since strontium is not the same size 
as calcium, it does not substitute precisely for calcium in biological processes.  At different stages of the 
life cycle, organisms vary in their ability to discriminate between strontium and calcium, which may 
cause age-related differences in gastrointestinal absorption, and therefore in health effects.  Because of its 
similarity to calcium, strontium accumulates to a high degree in bone, and, in high concentrations, may 
seriously interfere with the normal process of bone development.  The young are particularly vulnerable 
because a lack of discrimination between calcium and strontium occurs during a dynamic period of bone 
formation and growth.  For this reason, body burdens of strontium will be higher in children than in 
adults, and the health effects associated with high exposure levels would be more severe.  As suggested in 
one human study and demonstrated in several animal studies, strontium ‘rickets’ is one potential 
consequence of childhood exposure to excess stable strontium. 
Beta emissions from 90Sr have a limited ability to penetrate through tissue (see Appendix D 
Section D.2.3). For that reason, radiostrontium must be internalized or placed in close contact with skin 
before adverse health effects will occur. The ‘bone-seeking’ behavior of strontium is the basis for 
concern regarding oral or inhalation exposures to the radioactive isotopes, particularly 90Sr, with its long 
half-life of 29 years and highly energetic 0.546 MeV beta particles, plus the 2.2 MeV beta particles of its 
short-lived 90Y decay product isotope.  Radioactive strontium isotopes incorporate into bone and irradiate 
the bone cells, the hemopoietic bone marrow, and potentially, the soft tissues surrounding bone, 
especially in the skull.  Human populations accidentally exposed to high levels of radiation from 
radiostrontium (and other radionuclides and external radiation) experienced chronic radiation sickness 
(postirradiation changes in hematological parameters) and increased leukemia and cancer mortality in the 
decades following exposure.  In animal studies, high-level exposures to 90Sr led to death within weeks 
because of radiation damage to hemopoietic tissues. Longer-term lower level exposures that overcome 
genetic repair mechanisms may lead to myeloid leukemia, osteosarcoma, and lymphoma (only observed 
in some rodent studies).  It should be understood that because strontium is retained for a long time in the 
skeleton, acute- or intermediate-duration uptakes (i.e., absorption events occurring within a period of 
<2 weeks or <1 year, respectively) can result in decade-long (i.e., chronic) effects from internal exposure 
to the radiation emitted from the retained isotopes.  Children would appear to have a higher lifetime risk 
for cancer effects per unit uptake, because of their relatively higher rate of skeletal incorporation of 
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strontium and potentially longer radiation exposure period.  Immediately nonlethal exposures to high 
levels of radioactive strontium may contribute to suppression of the immune system. 
Limited human data are available regarding health effects that can be exclusively associated with 
exposure to radioactive strontium sources such as 90Sr and 89Sr. These radionuclides are products of 
nuclear fission and may, therefore, be released from sites where nuclear fission occurs, from radioactive 
material removed from such sites, or from leakage of radioactive strontium sources.  Both 90Sr and 89Sr 
emit beta radiation that travels short distances and can penetrate the skin and superficial body tissues.  
The radiation dose from these radionuclides can be classified as either external (if the source is outside 
the body) or internal (if the source is inside the body). 
The external dose from strontium radionuclides emitting beta radiation outside the body is normally of 
little health concern unless the radioactive material contacts the skin.  Skin contact can allow the beta 
radiation to pass through the epidermis to live dermal tissue where it becomes a major contributor to a 
radiostrontium-generated radiation dose to the skin.  At very high doses, the beta radiation can cause such 
adverse effects as erythema, ulceration, or even tissue necrosis. 
Once radioactive strontium is internalized, it is absorbed, distributed, and excreted in the same manner as 
stable strontium; the chemical similarity of strontium to calcium results in deposition of radioactive 
strontium in bone.  The internal radiation dose from strontium is actually a measure of the amount of 
energy that the beta emissions deposit in tissue.  The short-range beta radiation produces a localized dose, 
generally to bone and the soft tissues adjacent to bone; hemopoietic bone marrow is the most biologically 
significant target of radioactive strontium emissions.  Molecular damage results from the direct ionization 
of atoms that are encountered by beta radiation and by interactions of resulting free radicals with nearby 
atoms.  Tissue damage results when the molecular damage is extensive and exceeds the capacity of 
natural repair mechanisms. 
In radiation biology, the term absorbed dose is the amount of energy deposited by radiation over time per 
unit mass of tissue, expressed in units of rad or gray (Gy) (see Appendix D for a detailed description of 
principles of ionizing radiation).  The term dose equivalent refers to the biologically significant dose, 
which is determined by multiplying the absorbed dose by a quality factor for the type and energy of the 
radiations involved. Dose equivalent is expressed in units of rem or sievert (Sv).  The quality factor is 
considered to be unity for the beta radiation emitted from 90Sr and 89Sr, so for these radionuclides, the 
absorbed dose (in rad or gray) is numerically identical to the dose equivalent (in rem or sievert).  The dose 
30 STRONTIUM 
3. HEALTH EFFECTS 
equivalent from internalized strontium radionuclides is estimated using the quantity of material entering 
the body (via ingestion or inhalation), the biokinetic parameters for strontium (retention, distribution, and 
excretion), the energies and intensities of the beta radiation emitted, and the parameters describing the 
profile of absorbed radiation energy within the body.  If, for example, a person ingests a given activity of 
radiostrontium (measured in curies [Ci] or becquerels [Bq]), the tissues of the body will absorb some of 
the energy of the emitted beta radiation in a pattern reflecting the kinetics of distribution and elimination 
of the ingested radiostrontium, the rate at which the radioactive isotope decays to a stable form, and the 
age of the person at the time of ingestion (which affects both the biokinetics of the radiostrontium and the 
potential length of time over which the tissues can be exposed to the radiation).  Each tissue, therefore, 
can receive a different dose equivalent.  The total dose equivalent for the body will reflect the integration 
of the dose equivalents for the various tissues using a weighting scheme for the relative sensitivities of 
tissues and organs. 
The EPA has published a set of internal dose conversion factors for standard persons of various ages 
(newborn; 1, 5, 10, or 15 years of age; and adult) in its Federal Guidance Report No. 13 supplemental CD 
(EPA 2000e).  For example, the EPA has estimated that the dose equivalents following ingestion of 1 Bq 
of 90Sr are 2.77x10-8 and 2.77x10-7 Sv, respectively, for the adult and infant (assuming an integration time 
of 50 years for an adult following the initial exposure).  For 89Sr, these values are 2.57x10-9 Sv and 
3.59x10-8 Sv, respectively.  Age-specific dose coefficients for inhalation and ingestion of any of the 
radioactive isotopes of strontium by the general public can be found in ICRP publications 71 (ICRP 1995) 
and 72 (ICRP 1996), respectively.  Dose coefficients for inhalation and ingestion of strontium 
radionuclides can be found in U.S. EPA Federal Guidance Report No. 11 (EPA 1988).  Dose coefficients 
for external exposure to radioisotopes of strontium in air, surface water, or soil contaminated to various 
depths can be found in U.S. EPA Federal Guidance Report No. 12 (EPA 1993b). 
Unless otherwise stated, exposure levels in the text are presented per kg of body weight.  In Appendix D, 
standard and SI units of radiation activity (curies, becquerels) and absorbed dose (rad, gray) are compared 
in Table D-5 and are discussed in Sections D.2.2 Half-Life and Activity and D.3.1.2 Absorbed Dose and 
Absorbed Dose-Rate. 
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3.2 	 DISCUSSION OF HEALTH EFFECTS OF STABLE STRONTIUM BY ROUTE OF 
EXPOSURE 
Section 3.2 discusses the chemical toxicity of strontium.  Radiation toxicity resulting from exposure to 

radiostrontium is discussed in Section 3.3. 

To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
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adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of strontium are 
indicated in Tables 3-2, 3-3, and 3-4 and Figures 3-2 and 3-3.  Because cancer effects could occur at 
lower exposure levels, Figures 3-2 and 3-3 also show a range for the upper bound of estimated excess 
risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for strontium.  An MRL is defined as an estimate of daily human exposure to a substance that is 
likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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3.2.1 Inhalation Exposure 
3.2.1.1 Death 
The only studies located regarding death in humans following inhalation exposure to stable strontium are 
related to strontium chromate.  Strontium chromate has been implicated as a cause of increased deaths 
from lung cancer in occupational studies (Davies 1979, 1984) (see Section 3.2.1.7).  The toxicity of 
strontium chromate is attributed to hexavalent chromium ion, which enters lung cells and is metabolized 
to a genotoxic agent. Strontium itself contributes to solubility of strontium chromate, but any associated 
health effect is expected to be masked by that of the chromate.  No studies were located regarding death 
in animals following inhalation exposure to stable strontium. 
3.2.1.2 Systemic Effects 
No data are available regarding systemic effects following inhalation exposure to stable strontium for 
which the exposure levels are known. For that reason, no LSE table has been created for stable strontium. 
No studies were located that described gastrointestinal, hematological, hepatic, renal, body weight, 
metabolic, endocrine, dermal, or ocular effects in humans or animals following inhalation exposure to 
stable strontium. 
Respiratory Effects. The only report of adverse respiratory effects in humans resulting from the 
inhalation of stable strontium is a case report of an anaphylactic reaction to smoke from an ignited 
roadside flare (Federman and Sachter 1997).  The flare contained approximately 75% strontium nitrate 
(31% strontium), among other known irritating ingredients, and the exact contribution of strontium to the 
effect is uncertain. The anaphylactic reaction to the smoke included coughing, wheezing, and severe 
respiratory difficulties.  This case report is discussed in Section 3.2.1.3 Immunological and 
Lymphoreticular Effects.  No other reports were located describing longer-term respiratory effects 
following inhalation of stable strontium compounds by humans or animals. 
Cardiovascular Effects. A single study documented adverse cardiovascular effects in humans 
resulting from the inhalation of stable strontium in smoke from an ignited roadside flare (Federman and 
Sachter 1997).  Extreme tachycardia resulted as part of an anaphylactic reaction to the smoke, which 
contained ~31% strontium as strontium nitrate, in addition to other known irritants.  The role of strontium 
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in this reaction is not established. No other reports were located describing longer-term cardiovascular 
effects following inhalation of stable strontium compounds by humans or animals. 
3.2.1.3 Immunological and Lymphoreticular Effects 
The single located study of immunological effects in humans following inhalation exposure to stable 
strontium is a case report of an anaphylactic reaction to smoke from an emergency roadside flare 
(Federman and Sachter 1997).  A 35-year-old female paramedic developed a sudden, severe reaction upon 
inhaling fumes from a flare that contained approximately 31% strontium as strontium nitrate.  Initial 
symptoms included coughing, wheezing, and shortness of breath that was not responsive to albuterol, 
epinephrine, or steroids; recovery ultimately required sedation, intubation, and intensive care for several 
days.  Although the paramedic had been unsymptomatic before the incident, her medical history included 
several significant contributory factors: rheumatic fever requiring penicillin prophylaxis until age 12, a 
severe anaphylactic reaction to a bee sting at age 23, and adult-onset asthma at age 32.  The ingredients of 
the flare (Road Fusee®; Standard Fusee Corporation, Easton, Maryland) included ±75% strontium nitrate 
(~31% strontium), ±10% potassium perchlorate, ±10% sulfur, and ±10% sawdust/oil binder.  Upon 
combustion, each of these would yield products known to be irritating to the respiratory tract: strontium 
oxide, nitrous oxide, potassium oxide, chlorine gas, sulfur dioxide, and particulates.  Thus, the exact 
contribution of strontium to the development of anaphylaxis in this case is uncertain.  However, see 
Section 3.6.2 for a possible mechanism by which strontium could contribute to an immunological effect.  
No studies were located regarding immunological effects in animals following inhalation exposure to 
stable forms of strontium. 
No studies were located regarding the following effects in humans or animals following inhalation 
exposure to stable strontium: 
3.2.1.4 Neurological Effects 
3.2.1.5 Reproductive Effects 
3.2.1.6 Developmental Effects 
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3.2.1.7 Cancer 
There were no reports regarding cancer in humans or animals resulting from inhalation exposure to stable 
strontium compounds except for strontium chromate.  In an epidemiological study, no excess risk for lung 
cancer was found among workers in two Japanese factories who were involved in the production of 
strontium chromate pigment (Kano et al. 1993).  However, exposures to strontium chromate in the 
factories may have been low because of suitable industrial hygiene procedures.  Another epidemiological 
study examined workers in British chromate pigment manufacturing plants (Davies 1979, 1984).  In one 
factory, both lead and zinc chromate were produced until 1976, and strontium chromate was produced 
from 1950 to 1968.  For lung cancer deaths in workers exposed to ‘high’ and ‘medium’ levels of 
chromates before 1961, when industrial hygiene improvements were introduced, the observed/expected 
ratio (O/E) was 6/1.61, with a standard mortality ratio (SMR) of 373 (p<0.01).  For workers exposed to 
‘high’ and medium’ levels from 1961 to 1967, the values were O/E=5/089, SMR=562 (p<0.01).  The 
contribution of strontium to toxicity in these studies was not addressed. 
No standard inhalation study of strontium chromate in animals was located.  However, Levy et al. (1986) 
used an intrabronchial pellet implantation technique to evaluate the carcinogenicity of 23 different 
commercially available chromates, including two batches of strontium chromate.  Metal pellets were 
coated with a mixture of cholesterol and strontium chromate and implanted into the left bronchus of male 
and female young rats (100 per group).  Of 198 lungs treated with strontium chromate, 105 (53%) had a 
primary keratinizing squamous carcinoma of the bronchial epithelium.  The authors indicated that 
carcinogenicity was associated with sparingly soluble hexavalent chromium compounds such as 
strontium, calcium, or zinc chromates. 
3.2.2 Oral Exposure  
There are no direct dose-response data for adverse effects of exposure to stable strontium in humans, but 
one epidemiological study suggests that the skeletal toxicity observed at high oral doses in juvenile 
animals may be relevant to humans (see Musculoskeletal Effects).  At low exposure levels, ingestion of 
stable strontium poses no harm to organisms with access to adequate calcium, phosphorus, and vitamin D.  
At higher exposure levels, especially under conditions of inadequate calcium, phosphorus, and vitamin D, 
stable strontium will interfere with normal bone development, causing ‘strontium rickets’ of variable 
severity. 
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3.2.2.1 Death 
No deaths in healthy humans have been reported after oral exposure to stable strontium.  Stable strontium 
caused death in laboratory animals only at doses that are very high compared to normal human exposure.  
In acute exposure studies in mice, the oral LD50 for strontium nitrate was reported to be 2,350 mg 
strontium/kg in males (Llobet et al. 1991a).  For strontium chloride administered by gavage, the acute oral 
LD50 in albino mice was reported to be 2,900 mg strontium/kg for males and 2,700 mg strontium/kg for 
females (Ghosh et al. 1990). 
In intermediate-duration animal studies, ingestion of excess stable strontium resulted in increased 
mortality.  The premature death rate was 40% among weanling male Sprague-Dawley rats fed stable 
strontium (form not specified) at a dose level of 565 mg strontium/kg/day for 43 days (Johnson et al. 
1968).  Weanling male Wistar rats exposed to strontium phosphate in the diet at a dose level of 2,820 mg 
strontium/kg/day for 4–6 weeks had a mortality rate of 30%, but no mortality occurred at 580 or 1,270 mg 
strontium/kg/day (Kshirsagar 1976).  From an analysis of a pair-fed group (food intake matched to the 
high-dose group), the author concluded that the increased mortality in the high-dose group was not related 
to reduced food intake, but rather to the ingestion of strontium.  No studies were located regarding death 
in animals following chronic-duration oral administration of stable strontium. 
All reliable LOAEL values for death from stable strontium in each species and duration category are 
recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.2 Systemic Effects 
No studies were located regarding dermal or ocular effects in humans or animals following oral exposure 
to stable strontium.  The highest reliable NOAEL and all LOAEL values for the systemic effects from 
oral exposure to stable strontium in each species and duration category are shown in Table 3-1 and plotted 
in Figure 3-1. 
Respiratory Effects. No studies were located regarding respiratory effects in humans following oral 
exposure to stable strontium.  No studies were located regarding acute or chronic respiratory effects in 
animals following exposure to stable forms of strontium.  In one intermediate-duration study, respiratory 
difficulties were noted in rats following lethal ingestion of 565 mg strontium/kg/day of stable strontium 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
ACUTE EXPOSURE 
Death 
1 Mouse once Ghosh et al. 19902900 M (LD50) 
 (albino) (GW) Strontium chloride
 
c 
2700 F (LD50) 
2 Mouse NR Llobet et al. 1991a2350 M (LD50) 
 (NS) (NS) Strontium nitrate
 
Systemic 
3 Rat 2 wks Kroes et al. 1977 
ad lib Hemato 110 






Bd Wt 110 
Table 3-1 Levels of Significant Exposure to Strontium - Chemical Toxicity - Oral (continued) 
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Rat PND 21-64 
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3000 M (small intestine: decr acid & 
alkaline phosphatase; 
reversible) 
3000 M (bone: incr alkaline
phosphatase; reversible)






3000 M (bd wt gain decr 62%) 
565 M (40% mortality) 



































Rat 8 wks 
ad lib 
(W) 
Musc/skel 168 M 
Grynpas et al. 1996 
(NS) 
Bd Wt 168 M 




Rat PND 21-64 
ad lib 
(F) 
Resp 565 M (unspecified difficulties) 
Johnson et al. 1968 
NS 
Musc/skel 565 M (rickets) 
9 
(Wistar) 
Rat 90 d 
ad lib 
(F) 
Hemato 166 F 
Kroes et al. 1977 
Strontium chloride 6H2O 
Musc/skel 166 F 
Hepatic 166 F 
Renal 166 F 
Bd Wt 166 F 






















Rat 4-6 wks 
ad lib 
(F) 
Cardio 2820 M (hemorrhage) 
Kshirsagar 1976 
Strontium phosphate 
Gastro 580 M 1270 M (small intestine: reversible decr 
alkaline phosphatase) 
Musc/skel 580 M 1270 M (bone: incr alkaline 
phosphatase, reversible) 
Hepatic 1270 M 2820 M (reversible decr alkaline 
phosphatase) 




Rat 9 wks 
ad lib 
(W) 
Musc/skel 524 M 633 M (bone calcification rate decr by 
17%) 
Marie et al. 1985 
Strontium chloride 
Bd Wt 633 M 
Metab 633 M 





a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route)figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
12 Rat 4 wk Matsumoto 1976 
Musc/skel 1970 M (tibiae: length decr 33%, ad lib(Wistar) epiphyseal plates 5 x wider, Strontium carbonate 
(F) decr mineralization) 
Bd Wt 1970 M (bd wt gain decr by 60%) 
13 Rat 27 d Morohashi et al. 1994 
Gastro ad lib 102 510 F (20% decr net intestinal Ca2+ (Wistar) Strontium carbonateabsorption)
(F) 
Musc/skel 102 510 F (decr bone formation, 





Bd Wt 510 F 
Metab 102 F 510 F (hypocalcemia) 
14 Rat 3 wk Neufeld and Boskey 1994 
Musc/skel ad lib 500 M (abnormal bone mineralization) (Sprague- Strontium carbonate
Dawley) (F)
Bd Wt 500 M 



































Rat PND 21-41 
ad lib 
(F) 
Musc/skel 1850 M (epiphyseal cartilage 
histopathology) 
Reinholt et al. 1984 
(NS) 
Bd Wt 
Metab 1850 M 
1850 M (28% decr bd wt gain) 
16 
(NS) 
Rat 20 d 
ad lib 
(F) 
Musc/skel 140 F 
b  








2220 F (24% decr bd wt gain) 
17 
(NS) 
Rat 20 d 
ad lib 
(F) 
Musc/skel 690 F 1370 F (tibial epiphyseal cartilage 




Bd Wt 2750 F 






















Rat up to 7 months 
ad lib 
(F) 
Musc/skel 2160 (rickets) 
Storey 1962 
Strontium carbonate 
Bd Wt 2160 (30% decr bd wt gain) 
19 
(NS) 
Rat >7 mo 
ad lib 
(F) 







Rat 26 d 
ad lib 
(F) 
Musc/skel 1520 M (rickets) 
Svensson et al. 1987 
Strontium chloride 
Endocr 1520 M 
Bd Wt 1520 M (16% decr bd wt gain) 
Metab 1520 M 
21 
(C57BL/6J) 
Mouse 29 d 
ad lib 
(W) 
Musc/skel 350 M (11% decr number of 
osteoclasts; decr bone 
resorption; 10% incr osteoid 
surface) 
Marie and Hott 1986 
Strontium chloride 
Bd Wt 350 M 
Metab 350 M 

























565 M (paralysis of hindlimbs) 
Johnson et al. 1968 
NS 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate oral MRL of 2.0 mg/kg/day. The MRL was derived by dividing the NOAEL by an uncertainty factor of 30(10 for extrapolation from animals to 
humans, and 3 for human variability), and by a modifying factor of 3(for limited endpoint examination and short duration). 
c Differences in levels of health effects and cancer effects between males and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
Ad lib - ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); decr = decreased; (F) = food; Gastro = gastrointestinal; (GW) = gavage in water; Hemato = 
hematological; hr = hour(s); incr = increased; LD50 = lethal does, 50% kill; LOAEL = lowest-observed-adverse-effect level; Metab = metabolic; Musc/skel = musculoskeletal; NOAEL 






































Figure 3-1 Levels of Significant Exposure to Strontium - Chemical Toxicity - Oral 
Acute (≤14 days) 
Systemic 
mg/kg/day 
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Figure 3-1 Levels of Significant Exposure to Strontium - Chemical Toxicity - Oral (Continued) 
Intermediate (15-364 days) 
Systemic 
mg/kg/day 
6r 10r 10r 
18r12r 15r 
19r 20r 20r 
17r10r 10r 10r 
1000 
17r11r 10r 10r5r 8r 8r 16r11r 13r 14r13r 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50
d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Level
r-Rat m-Mouse e-Gerbil 
LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans
   for effects
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans



















Figure 3-1 Levels of Significant Exposure to Strontium - Chemical Toxicity - Oral (Continued) 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50
d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Level
r-Rat m-Mouse e-Gerbil 
LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans
   for effects
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans
 other thanq-Cow a-Sheep g-Guinea Pig 
Cancer 
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(form unspecified) for 4–6 weeks (Johnson et al. 1968).  No description of the respiratory effects or 
incidence data were reported. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans 
following acute- or intermediate-duration oral exposure to stable strontium. 
One epidemiological study examined the relationship between trace metals, including strontium, in 
drinking water and the rates of various kinds of vascular disease in 24 communities in the lowest quartile 
of the economic scale in Texas (Dawson et al. 1978).  The concentration of strontium was measured in 
samples of drinking water and 2,187 urine samples from subjects (aged 5–97 years) in families that had 
resided within their respective communities for at least 10 years.  There was a significant correlation 
between mean strontium levels in drinking water and in the urine. However, the only statistically 
significant product-moment correlationship for strontium (in urine and in drinking water) was for a 
decreased community mortality rate (in people over 45 years old) for hypertension with heart disease.  
There was no correlation found between strontium and mortality from arteriosclerotic and degenerative 
heart disease, other heart diseases, hypertension, general arteriosclerosis, or vascular diseases of the 
central nervous system. 
No studies were located regarding cardiovascular effects after acute- or chronic-duration oral exposure in 
animals.  In male weanling Wistar rats (5–6 per group) given strontium as strontium phosphate in the diet 
for 4–6 weeks, hemorrhage (unspecified) occurred at 2,820 mg strontium/kg/day, possibly related to the 
increased mortality at this dose level, but not at or ≤1,270 mg strontium/kg/day (Kshirsagar 1976). 
Gastrointestinal Effects.    No studies were located regarding gastrointestinal effects in humans 
following oral exposure to stable strontium. 
No studies were located regarding gastrointestinal effects in animals following chronic-duration oral 
exposure to various forms of stable strontium.  Acute- and intermediate-duration oral studies in animals 
have examined gastrointestinal effects that would be likely to influence calcium and phosphorus 
metabolism. Decreases in acid and alkaline phosphatase activities were observed in the small intestine of 
5–6 male weanling (21 days old) Wistar rats given 3,000 mg strontium/kg/day as strontium phosphate for 
2 weeks (Kshirsagar 1976).  These effects were reversed by giving the rats a normal low-strontium diet 
for 2 weeks. The biological significance of the decreased phosphatase activities is not known.  Studies in 
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chickens first demonstrated the relationship between strontium toxicity, calcium, and vitamin D.  In male 
white Leghorn chickens raised on a diet deficient in vitamin D for the first 2 weeks of life, ingestion of 
>2,300 mg strontium/kg/day as strontium carbonate in a low-calcium, low-vitamin D diet for 11–14 days, 
affected calcium transport in the duodenum (Omdahl and DeLuca 1972).  Strontium ingestion reduced the 
duodenal activation of vitamin D3 (conversion of 25-hydroxycholecalciferol to 1,25-dihydroxy­
cholecalciferol), reduced the activity of calcium binding protein, and reduced the absorption of calcium 
by the duodenum.  Similar effects were observed in chickens given excess strontium in a diet with 
adequate vitamin D, but deficient in calcium (0.01%) (Corradino and Wasserman 1970; Corradino et al. 
1971a, 1971b).  In addition, excess strontium ingestion significantly reduced the absorption of glucose, 
histidine, and alanine by the duodenum to levels typical of rachitic (vitamin D-deprived) chickens 
(Corradino et al. 1971b).  The effects of strontium on calcium transport by the duodenum were reversed 
by transferring chickens to a normal low-strontium diet containing adequate amounts of vitamin D3 and 
calcium.  The chicken data are not included in Table 3-2, because the physiological rates are likely to be 
very different from mammals, and also because health risk assessment methodology is currently limited 
to mammals.  However, these phenomena were confirmed in a recent study in rats (Armbrecht et al. 
1998). Six days on a diet low in calcium, but containing 0.8% strontium, was sufficient to suppress the 
serum levels of activated vitamin D, the concentrations of calbindin D protein (two calcium-binding 
protein induced by vitamin D; see Sections 3.6.1 and 3.6.2), and the rates of calcium transport in the 
duodenum of young, adult, and old rats. 
In male weanling (3 weeks old) Wistar rats (5–6 per group) given strontium phosphate in the diet for 
6 weeks, a decrease in alkaline phosphatase activity in the small intestine occurred at 1,270 mg 
strontium/kg/day, but not at 580 mg strontium/kg/day (Kshirsagar 1976).  This decrease in enzyme 
activity was partly reversed by feeding the rats a normal low-strontium diet for 2 weeks.  As mentioned 
above, the biological significance of these changes in phosphatase activity is not known.  In slightly older 
female juvenile Wistar rats (36 days old, 6–8 per group) that ingested 510 mg strontium/kg/day as 
strontium carbonate for 27 days, the net intestinal absorption of calcium was reduced by 20%, but no 
effects occurred at 100 mg strontium/kg/day (Morohashi et al. 1994).  In male white Leghorn chickens 
fed 255 mg strontium/kg/day (probably as carbonate) in a diet low in vitamin D3 for the first 16 days after 
hatching, the conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol and the transport 
of calcium were suppressed in the duodenum (Omhdahl and DeLuca 1971).  This study is omitted from 
Table 3-1 because of probable differences in physiology. 
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Hematological Effects. No studies were located regarding hematological effects in humans 
following oral exposure to stable strontium. 
No studies were located regarding hematological effects in animals following chronic-duration oral 
exposure to stable strontium.  In adult Wistar rats given up to 110 mg strontium/kg/day as strontium 
chloride in the diet for 2 weeks, the total number of erythrocytes was slightly elevated in both sexes, and 
the leucocyte count was slightly elevated in males at the highest dose level at termination (Kroes et al. 
1977).  However, since the results were not reported quantitatively, the significance of this information is 
uncertain. No hematological changes were observed among weanling Wistar rats fed up to 166 mg 
strontium/kg/day as strontium chloride in the diet for 90 days (Kroes et al. 1977).  However, the relatively 
high level of calcium (0.85%) in the diet given to these animals may have reduced absorption and 
therefore the effect of strontium. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after 
acute-duration oral exposure to stable strontium.  The only long-term human exposure study is an 
epidemiological study that was carried out in the Ulaş Health Region of Sivas, Turkey (Özgür et al. 
1996).  This region has a high prevalence of childhood rickets, 32% compared to 4.4% nationally among 
children aged up to 5 years, and the study sought to determine whether higher levels of strontium in the 
soil might be a contributing factor.  Soils surrounding 55 villages were characterized as to strontium 
concentration (Group 1, >350 ppm; Group 2, <350 ppm).  A total of 2,140 children (ages 6–60 months) 
from these localities (613 in Group 1 and 1,527 in Group 2) were examined for one or more signs of 
rickets: craniotabes (localized craniomalacia or thinning of cranium), rachitic rosary (beadlike growths at 
the ends of ribs where they join cartilage), conspicuous bulging at the wrist, bony deformities of the legs 
(bowleg, knock-knee), and delayed closure of the fontanelles.  A significantly higher proportion of 
Group 1 children had one or more rachitic signs than those in Group 2: 37.5 vs 19.5%.  In addition, the 
severity of disease (number of rachitic signs per child) was proportionally higher in Group 1 (p<0.001). 
For each cohort, the incidence of rickets was higher in Group 1 than in Group 2 and the differences were 
statistically significant for ages 6–12, 13–18, 25–36, and 37–48 months (odds ratios 1.66–2.55).  When 
the duration of breast feeding was considered, the incidence of rickets within the two groups did not differ 
for children breast fed for 24 months or longer.  However, for shorter periods of breast feeding, between 0 
and 24 months, the incidence of rickets was significantly higher in Group 1 (odds ratios 1.79–3.14).  The 
implication of this study is that breast feeding may be protective against strontium toxicity in nursing 
infants, probably by providing both calcium and protein, both of which tend to reduce the incorporation of 
strontium into bone (see Sections 3.10, 3.11, and 3.12.2).  The authors attributed the higher incidence of 
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rickets in Group 1 children to their diet, which, after weaning, is mainly based on grains grown in 
strontium-rich soil. 
No studies were located regarding musculoskeletal effects in animals after chronic-duration oral exposure 
to stable strontium.  Acute- and intermediate-duration studies in animals documented significant adverse 
effects of strontium on bone that were especially severe in the young.  In an acute-duration study, there 
was no effect on bone in groups of adult SPF Wistar rats that ingested up to 110 mg strontium/kg/day as 
strontium chloride in the diet for 2 weeks (Kroes et al. 1977).  Strontium was detected in bone following 
ingestion of 11 or 110 mg/kg/day, but not at lower doses (0.1 or 1.0 mg/kg/day).  Among male weanling 
(21 days old) Wistar rats that ingested 3,000 mg strontium/kg/day as strontium phosphate in the diet for 
2 weeks, alkaline phosphatase activity was significantly increased in bone compared to controls 
(Kshirsagar 1976).  The author speculated that the observed increase in alkaline phosphatase activity may 
have been related to a stimulation of osteoblasts, which secrete osteoid and have a high alkaline 
phosphatase content. In acute studies on young chickens fed 2,300–2,400 mg/kg/day of strontium, and an 
inadequate level of calcium, severe defects in bone organization and decreased mineralization were 
observed within 1 or 2 weeks (Corradino and Wasserman 1970; Corradino et al. 1971a, 1971b; Omdahl 
and DeLuca 1972): abnormally wide hypertrophic cartilaginous zone and impaired endochondral 
ossification (the removal of hypertrophic cartilage and its replacement by bone). As noted above, the 
chicken data are omitted from Table 3-1. 
Numerous abnormalities of bone structure and bone mineralization were observed in weanling male 
Sprague-Dawley rats (100–125 g) that ingested 500 mg strontium/kg/day as strontium carbonate in the 
diet for 3 weeks (Neufeld and Boskey 1994).  In strontium-fed rats, the ash weight (mineral content) of 
metaphyseal bone was reduced and the complexed acidic phospholipid content (lipid nucleator of bone 
mineral) was significantly higher than in controls.  Large areas of nonmineralized bone (osteoid) were 
observed in epiphyseal bone and secondary spongiosa.  The epiphyseal plates were abnormally wide and 
the metaphyses were abnormally long and dense.  The diaphyses contained localized areas of decreased 
bone density.  The primary spongiosa of the proximal tibia was longer and the trabeculae was 
disorganized and apparently disconnected from the overlying calcified cartilage.  The authors suggested 
that since the levels of complexed acidic phospholipids were high and vitamin D deficiency is known to 
increase complexed acidic phospholipid levels, that the effect of strontium was probably not mediated 
through its effect on vitamin D.  They suggested the binding of strontium to the surface of initial 
hydroxyapatite crystallites reduced their further proliferation, resulting in a smaller crystal size. 
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Similarly, significant abnormalities of bone organization occurred in five weanling (21 days old) male 
England Wright Y rats that ingested 1,850 mg strontium/kg/day (form unspecified) for 20 days in a diet 
sufficient in calcium, phosphorus, and vitamin D (Reinholt et al. 1984).  In treated rats, the mean 
thickness of the epiphyseal growth plate was 70% larger than normal.  In the epiphyseal regions of long 
bones, the volume of each zone was larger than its normal counterpart, and in addition, the relative sizes 
were altered; the proportional volumes of the resting, proliferative, and calcifying zones were 
significantly smaller and that of the hypertrophic zone was significantly larger than normal.  There was an 
increase in the volume of extracellular matrix in bone, suggested to be associated with a reduced rate of 
extracellular matrix vesicle degradation.  Another study from this laboratory examined the biochemistry 
of epiphyseal cartilage in rats treated as above (Reinholt et al. 1985).  In strontium-treated rats, alterations 
were observed in the proteoglycan composition (slightly higher galactosamine content), chondroitin 
sulfate chain lengths (larger), regional distributions of large and small chondroitin sulfate peptides, and 
regional distributions of both non-sulfated chondroitin sulfate disaccharides and hyaluronic acid-
disaccharides. The authors suggested that these strontium-induced alterations in cartilage matrix might 
affect the process of mineralization. 
No effects on bone histology were observed in young female rats (40–60 g) that were fed 140 mg 
strontium/kg/day as strontium carbonate for 20 days, but histological abnormalities were detected at doses 
between 550 and 4,975 mg/kg/day (Storey 1961).  Alterations in the appearance of the cartilage plate 
(irregular, thicker, with areas of uncalcified bone matrix in the distal ends of the metaphyseal trabeculae 
and proximal end of the diaphysis) were observed at 550 mg strontium/kg/day.  Irregularities in the 
organization of the cells of hypertrophic zone (distorting the usual parallel arrangement of intercellular 
matrix columns), in the pattern of calcification, and in deposition of osteoid were more conspicuous with 
increasing dose. At higher doses, bands of uncalcified cartilage matrix were isolated between areas of 
osteoid tissue. In tibias, the dry weight, ash weight, ash percentage, and calcium in ash were significantly 
reduced with increased strontium intake.  In the same study, adult female rats given doses of 170– 
2,750 mg strontium/kg/day exhibited milder effects in bone.  Histological changes in the tibia (thicker 
epiphyseal cartilage, increased width of metaphyseal osteoid seams) were noted at 1,370 or 2,750 mg 
strontium/kg/day only.  Other significant effects seen only at 2,750 mg strontium/kg/day included the 
deposition of osteoid tissue near vascular canals, a reduction in the area of bone resorption, and reductions 
in the dry weight, ash weight, ash percentage, and calcium in ash of bone (Storey 1961). 
A 24% reduction in bone formation rate, 28% reduction in bone resorption rate (based on 45Ca uptake), 
and a significantly reduced calcium content in ashed femurs, but no change in ash weight were observed 
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after female juvenile Wistar rats (36 days old) ingested 510 mg strontium/kg/day as strontium carbonate 
in the diet for 27 days (Morohashi et al. 1994).  These rats were also significantly hypocalcemic.  No 
effects were observed at 50 or 100 mg strontium/kg/day other than an unexplained increase in calcium 
content of bone at 50 mg strontium/kg/day (Morohashi et al. 1994).  Minor bone effects occurred in 
21-day-old male C57BL/6J mice after ingesting 350 mg strontium/kg/day as strontium chloride in the 
drinking water for 29 days (Marie and Hott 1986).  Strontium had no significant effect on tibial length or 
bone mineral content (percent ash, calcium, or phosphorus).  In vertebrae, strontium had no effect on the 
osteoblastic surface (percent endosteal surface showing plump osteoblasts), bone matrix apposition rate, 
osteoid seam thickness (average width of all endosteal osteoid seams), or calcified bone volume.  
However, exposure to strontium resulted in a 10% increase in osteoid surface (percent endosteal surface 
covered by an osteoid seam) and an 11% reduction in the number of active osteoclasts. 
There was radiographic evidence of abnormally thickened epiphyseal cartilage plates in the long bones of 
weanling male Wistar rats exposed to strontium phosphate in the diet at a dose level of 2,820 mg 
strontium/kg/day for 4–6 weeks, but no effect at 580 mg strontium/kg/day and little effect at 1,270 mg 
strontium/kg/day (Kshirsagar 1976).  Ingestion of 565 mg strontium/kg/day for 43 days resulted in several 
bone abnormalities in young Sprague-Dawley rats (Johnson et al. 1968).  The level of sodium in bone was 
significantly lowered, and the level of potassium was significantly increased, and the overall index of 
bone mineralization (percent bone ash) was decreased.  Unmineralized osteoid was visible in histological 
sections of vertebrae. Rats became rachitic and osteomalacic and exhibited paralysis of the hindlimbs. 
Beneficial effects of a low dose of strontium were noted on bone mineralization, such as a 17% increase 
in mineral bone volume and a 70% increase in the number of bone forming sites, with no adverse effect 
on the hydroxyapatite mineral particle size in 28-day-old male Sprague-Dawley rats ingesting 168 mg 
strontium/kg/day in an unspecified form for 8 weeks (Grynpas et al. 1996) or in young SPF Wistar rats 
fed doses up to 166 mg strontium/kg/day as strontium chloride in the diet for 90 days (Kroes et al. 1977).  
Stimulation of calcified bone growth was noted among male weanling Sprague-Dawley rats ingesting 
between 316 and 524 mg strontium/kg/day as strontium chloride for 9 weeks, but reduced bone 
calcification was observed at 633 mg/kg/day (Marie et al. 1985).  In male weanling Sprague-Dawley rats 
ingesting 1,520 mg strontium/kg/day for 26 days, epiphyseal growth plates had abnormally thick 
hypertrophic zones and impaired calcification and resorption at the metaphyseal side (Svensson et al. 
1985, 1987).  In addition, cartilage from strontium-treated rats contained 75% less calcium and had a 60% 
lower rate of synthesis of glycosaminoglycans and collagen.  When 4-week-old male Wistar rats (50– 
60 kg body weight) were fed 1,970 mg strontium/kg/day as strontium carbonate in a diet low in calcium 
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(0.04%), bone mineralization was significantly affected (Matsumoto 1976).  This study is presented in 
detail in Section 3.2.2.6 Developmental Effects, as an example of skeletal anomalies in young animals 
resulting from strontium ingestion. 
In another intermediate-duration animal study, young (50–70 g) rats ingested 2,160 mg strontium/kg/day 
and adult rats ingested 1,570 mg strontium/kg/day as strontium carbonate for 7 months (Storey 1962).  At 
3 weeks, young rats developed a rachitic gait, and subsequently, some rats (numbers not specified) 
developed spinal kyphosis, bent tibiae, and irregular discolored enamel on anterior teeth.  Histological 
abnormalities in long bone differentiation included reduced calcification, excess growth of epiphyseal 
cartilage, abnormal deposition of osteoid (unmineralized bone) in the metaphysis, fragmentation of the 
epiphyseal plates, and isolated nodules of cartilage.  Osteoid accumulation was observed in the skull.  
Adult rats were affected by strontium ingestion in the same way, but to a lesser degree than young 
animals.  Abnormal depositions of osteoid in long bones and skull were not as extensive as in young rats.  
The epiphyseal plate did not become fragmented.  Tooth enamel was abnormally white and pitted. 
Hepatic Effects. No studies were located regarding hepatic effects in humans following oral exposure 
to stable strontium. 
No studies were located regarding hepatic effects in animals after chronic-duration oral exposure to stable 
strontium.  In acute- and intermediate-duration studies, in which the diet contained adequate amounts of 
calcium and vitamin D, few hepatic effects were reported.  No histological changes were observed in the 
livers of adult Wistar rats given up to 110 mg strontium/kg/day as strontium chloride in the diet for 
2 weeks (Kroes et al. 1977).  Acid phosphatase activity decreased by about 8% in the livers of 5–6 male 
weanling (21 days old) Wistar rats given 3,000 mg strontium/kg/day as strontium phosphate for 2 weeks 
(Kshirsagar 1976).  However, this effect was reversible by feeding the rats a normal, low-strontium diet 
for 2 weeks. In male weanling Wistar rats, ingestion of strontium phosphate in the diet for 4–6 weeks 
resulted in a >26% decrease in hepatic alkaline phosphatase activity at 2,820 mg strontium/kg/day, but no 
decrease at 1,270 mg strontium/kg/day (Kshirsagar 1976).  The biological significance of these small, but 
statistically significant, changes in hepatic phosphatase activity is not known. Among weanling male and 
female Wistar rats fed strontium chloride in the diet for 90 days, the only hepatic effects were ‘slight 
histological changes’ (not described) and an ‘increase in peripheral glycogen’ in females at the highest 
dose (166 mg strontium/kg/day); no other hepatic effects were observed in either sex ≤146 mg 
strontium/kg/day (Kroes et al. 1977). 
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Renal Effects. No studies were located regarding renal effects in humans after oral exposure to stable 
strontium. 
No studies were located regarding renal effects in animals after chronic-duration oral exposure to stable 
strontium.  In acute- and intermediate-duration studies, in which the diet contained adequate amounts of 
calcium and vitamin D, no renal effects were reported.  No organ weight or histological changes were 
observed in the kidneys of adult Wistar rats given up to 110 mg strontium/kg/day as strontium chloride in 
the diet for 2 weeks (Kroes et al. 1977).  Similarly, no such changes were observed among weanling 
Wistar rats fed up to 166 mg strontium/kg/day as strontium chloride in the diet for 90 days (Kroes et al. 
1977).  In male white Leghorn chickens raised on a diet deficient in vitamin D for the first 2 weeks of life, 
ingestion of 2,350 mg strontium/kg/day in a low-calcium, low-vitamin D diet for 7 additional days, 
reduced the activation of vitamin D3 in mitochondria of the kidney (Omdahl and DeLuca 1972).  Because 
of physiological differences between birds and mammals, this study is omitted from Table 3-1. 
Endocrine Effects. Few studies were located regarding endocrine effects in humans after oral 
exposure to stable strontium.  Vezzoli et al. (1998) reported that strontium absorption was inversely 
correlated with parathyroid hormone levels. 
No studies were located regarding endocrine effects in animals of acute- or chronic-duration oral 
exposure to stable forms of strontium.  There were no histological changes in the parathyroid gland or 
alterations in parathyroid hormone levels observed in male weanling Sprague-Dawley rats given 
1,520 mg strontium/kg/day in the diet for 26 days (Svensson et al. 1987).  The authors cautioned that their 
biochemical methods could not distinguish between active and inactive forms of the hormone.  A few 
organ weight changes were observed among weanling Wistar rats fed up to 166 mg strontium/kg/day as 
strontium chloride in the diet for 90 days (Kroes et al. 1977).  The relative thyroid weight was 
significantly heavier in males at 36 and 146 mg strontium/kg/day and the relative pituitary weight was 
significantly decreased in females at 10 and 166 mg strontium/kg/day, but in neither case was there a 
clear dose-response. Slight histological changes in the thyroid were reported. 
Body Weight Effects.    No studies were located regarding body weight effects in humans after oral 
exposure to stable strontium. 
No studies were located regarding body weight effects in animals after chronic-duration oral exposure to 
stable strontium.  In acute- and intermediate-duration animal studies, the effective dose levels for body 
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weight effects were relatively high and young animals were more sensitive than adults.  In an acute-
duration study, there was no effect on body weight in groups of adult SPF Wistar rats that ingested up to 
110 mg strontium/kg/day as strontium chloride in the diet for 2 weeks (Kroes et al. 1977).  Body weight 
gain was reduced by 62% among male weanling (21-day-old) Wistar rats that ingested 2,820 mg 
strontium/kg/day as strontium phosphate in the diet for 2 weeks, but this effect was reversible by feeding 
rats a diet low in strontium for 2 weeks (Kshirsagar 1976).  From an analysis of a pair-fed control group 
(food intake matched to this high-dose group), the author concluded that the severe effects were a result 
of excess strontium, and not the reduced diet.  Ingestion of 1,090 or 1,630 mg strontium/kg/day as 
strontium lactate reduced body weight gain in 5-week-old albino rats within several days (Teree et al. 
1965).  However, it seems likely that the reduced body weight gains resulted from an observed (but not 
measured) reduction in food intake, possibly because of reduced palatibility at the higher dose levels.  
Since the reduction appears not to be a systemic effect of strontium ingestion, this study is omitted from 
Table 3-1. 
Most of the intermediate-duration oral exposure studies in weanling rodents have reported no effect on 
body weight for exposures <633 mg strontium/kg/day (rats: Grynpas et al. 1996; Kroes et al. 1977; Marie 
et al. 1985; Morohashi et al. 1994; Neufeld and Boskey 1994; Skoryna 1981a; and mice: Marie and Hott 
1986).  Intermediate-duration exposures to stable strontium at levels above 1,000 mg/kg/day adversely 
affected body weight.  A 15% reduction in body weight gain was observed among weanling (21-day-old) 
male Wistar rats that ingested 1,270 mg strontium/kg/day as strontium phosphate for 4–6 weeks, but no 
reduction was observed at 580 mg strontium/kg/day (Kshirsagar 1976).  The body weight gain was 28% 
lower than controls in weanling (21-day-old) male England Wright Y rats that ingested 1,850 mg 
strontium/kg/day (form unspecified) for 20 days (Reinholt et al. 1985).  The terminal body weight was 
16% lower than normal in male weanling Sprague-Dawley rats that ingested 1,520 mg strontium/kg/day 
(form not specified in this paper, but other publications from this lab used strontium chloride) for 26 days 
(Svensson et al. 1987). 
A >30% loss in body weight occurred in young female rats (40–60 g) that were fed 4,975 mg 
strontium/kg/day as strontium carbonate for 20 days (Storey 1961); body weight gain was reduced by 
24% at 2,220 mg, but was unaffected at 1,460 mg strontium/kg/day.  Food intake was not reported, so it is 
uncertain to what extent these results are attributable to unpalatability.  Similarly treated adult female rats 
exhibited no significant body weight changes at 2,750 mg strontium/kg/day (Storey 1961).  Body weight 
gain was about a third lower than controls in young (50–70 g) rats that ingested 2,160 mg 
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strontium/kg/day as strontium carbonate for 7 months (Storey 1962); no quantitative body weight data 
were reported for young or adult animals. 
In acute- and intermediate-duration studies, strontium effects on body weight were more severe in 
animals on diets low in calcium.  Reduced body weight gain was reported in young white Leghorn chicks 
following ingestion of a high strontium/low calcium diet for 1 or 2 weeks (Corradino and Wasserman 
1970; Corradino et al. 1971a, 1971b).  The body weight gain of male weanling Wistar rats was reduced 
by 60% after ingestion of strontium carbonate (1,960 mg strontium/kg/day) in a diet low in calcium 
(0.04%) for 4 weeks (Matsumoto 1976). 
Metabolic Effects. No studies were located regarding metabolic effects in humans after oral exposure 
to stable strontium. 
No studies were located regarding metabolic effects in animals after chronic-duration oral exposure to 
stable strontium.  In animal studies, few metabolic effects resulted from acute- or intermediate-duration 
oral exposure to stable strontium.  In chicks given a normal Vitamin D3-containing diet for 2 weeks after 
hatching, ingestion of a diet containing excess strontium reduced the plasma concentration of calcium, 
probably a consequence of reduced calcium absorption by the duodenum (Corradino et al. 1971a).  
Intermediate-duration exposures to 150–1,850 mg strontium/kg/day as strontium carbonate or strontium 
chloride had no effects on the serum levels of calcium, phosphorus, or magnesium in young or adult 
rodents given adequate dietary calcium, phosphorus, and vitamin D (rats: Grynpas et al. 1996; Kroes et al. 
1977; Marie et al. 1985; Neufeld and Boskey 1994; Svensson et al. 1985, 1987; Reinholt et al. 1984; 
Skoryna 1981a; and mice: Marie and Hott 1986).  No effects on serum calcium levels were observed in 
young female rats (40–60 g) that were fed 4,975 mg strontium/kg/day as strontium carbonate for 20 days 
or in adult female rats similarly fed 2,750 mg strontium/kg/day (Storey 1961).  At 4,975 mg 
strontium/kg/day in the young rats, the calcium/strontium ratio was 1, whereas the ratio at 2,750 mg 
strontium/kg/day in adult rats was 1.4.  A 13% reduction in serum calcium was observed in female 
juvenile Wistar rats (36-day-old, 6–8 per group) that ingested 510 mg strontium/kg/day as strontium 
carbonate in the diet for 27 days, but no effect was observed at 100 mg strontium/kg/day (Morohashi et al. 
1994). 
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3.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located that reported immunological or lymphoreticular effects in humans or animals 
following oral exposure to stable strontium. 
3.2.2.4 Neurological Effects 
No studies were located that reported neurological effects in humans following oral exposure to stable 
strontium.  No behavioral effects were observed in rats that ingested strontium chloride at levels up to 
110 mg strontium/kg/day for 2 weeks or 166 mg strontium/kg/day for 90 days (Kroes et al. 1977).  
Johnson et al. (1968) reported paralysis of the hindlimbs in weanling male Sprague-Dawley rats that were 
fed 565 mg/kg/day of stable strontium (form not specified) for 43 days.  It is not clear whether the 
observed paralysis was neurological or muscular, but it could have been related to abnormal calcium 
signaling in muscle or nerve.  It is unlikely that the paralysis was due to the deformation of the femora as 
severely rachitic and osteomalacic rodents are not generally paralyzed.  The NOAEL and LOAEL are 
recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals following oral exposure to 
stable strontium. 
3.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans following acute- or intermediate-
duration oral exposure to stable forms of strontium.  The only chronic-duration study is the Turkish 
epidemiological analysis that found a relationship between the concentration of strontium in the local soil 
and the prevalence of rickets in children between the ages of 6 months and 5 years (Ögzur et al. 1996).  A 
relatively short period of breast feeding, which presumably affected calcium intake, and soil levels of 
strontium higher than 350 ppm, which probably determined the level of strontium in dietary grains 
consumed after weaning, were associated with an increase in the prevalence and severity of rickets.  This 
study is discussed above in Section 3.2.2.2 Musculoskeletal Effects. 
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No studies were located that examined the effect of exposure to stable strontium in utero following oral 
maternal exposure in animals.  However, the studies discussed in Section 3.2.2.2 Musculoskeletal Effects 
address the effects of strontium on bone organogenesis, in particular, endochondral ossification, a 
developmental process that continues long after birth.  For example, in a study in which 4-week-old male 
Wistar rats (50–60 g body weight) were fed 1,970 mg strontium/kg/day as strontium carbonate in a diet 
low in calcium (0.04%), bone mineralization was significantly affected (Matsumoto 1976).  Tibial length 
was reduced by 33% and the tibial proximal and distal epiphyseal plates were both about 5 times wider 
than normal.  Microradiographic and histological analyses of tibial proximal heads revealed that no 
mineralization was detectable, that the organization of chondroblasts was irregular, and that osteoid rather 
than mineralized bone was deposited.  Other studies on weanlings were conducted for acute durations 
(rat: Kshirsagar 1976) and intermediate durations (rat: Grynpas et al. 1996; Kroes et al. 1977; Morohashi 
et al. 1994; Neufeld and Boskey 1994; Reinholt et al. 1984, 1985; Svensson et al. 1985, 1987; and mice: 
Marie and Hott 1986).  Intermediate-duration studies on rats demonstrated that ingestion of strontium 
resulted in more severe skeletal effects in young animals than in adults (Storey 1961, 1962). These 
studies are described in Section 3.2.2.2 Musculoskeletal Effects and are listed in Table 3-1 and Figure 3-1 
under that category. 
3.2.2.7 Cancer 
No studies were located that demonstrated cancer effects of stable strontium following oral exposure in 
humans or animals.  In one case-control study, no association was found between the incidence of liver 
cancer in 1984 on Chongming Island in China and the levels of stable strontium detected in hair (Wang et 
al. 1990). 
3.2.3 Dermal Exposure  
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to stable strontium: 
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3.2.3.1 Death 
3.2.3.2 Systemic Effects  
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.2.4 Other Routes of Exposure 
This section includes injection and in vitro studies that provide evidence for the biological basis of 
toxicity of stable strontium in humans and animals.  Since these studies are not directly relevant to general 
population exposure conditions, no LSE tables have been created for this section. 
Cardiovascular Effects. Cardiovascular effects of strontium have been investigated by intravenous 
infusion studies in dogs.  Infusions of strontium (as chloride or gluconate) averaging 172 mg strontium/kg 
under conditions of lowered potassium induced accelerated ventricular escape beats, ventricular 
tachycardia, or atrial fibrillation (Foster et al. 1977). High levels of strontium also induced oscillatory 
potentials and prolonged depolarization (precursors to arrhythmia) in Purkinje fibers of isolated sheep 
hearts (Gonzalez and Vassalle 1990). Whereas intravenous infusions at 4 mg strontium/kg had no effect 
on cardiac physiology, infusions at ~15 mg strontium/kg that brought the strontium/Ca ratio above 1 had 
a temporary negative chronotropic effect, reduced cardiac output, increased pulmonary vascular 
resistance, and systemic vascular resistance, but had no effect on pulmonary or systemic arterial pressure 
or pulmonary wedge pressure (Barry et al. 1972; Skoryna et al. 1986).  The concentrations of strontium 
used in these studies are very high relative to the mean concentration of strontium in human blood, 27 µg 
strontium/L (see Table 6-9). 
Hematological Effects. Because of its molecular similarity to calcium, the association of stable 
strontium with several kinds of blood cells has been investigated in a number of in vitro experiments.  
Strontium ions were found to be transported across the cell membrane of human erythrocytes by means of 
an ATP-dependent calcium pump (de la Sierra et al. 1990; Olson 1979; Olson and Cazort 1969; Porzig 
1973). In washed platelets from human and rabbit, strontium stimulated the secretion of 
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5-hydroxytryptamine (Best et al. 1981; Bone et al. 1980; Togna et al. 1989).  Best et al. (1981) concluded 
that strontium activates the release of arachidonate from platelet membrane phospholipid, with the 
subsequent synthesis of thromboxane A2, a reaction that was antagonized by aspirin.  These authors also 
suggested that strontium, because of its smaller hydrated ionic radius compared to calcium, is able to 
enter the platelet and mimic the rise in cytosolic calcium concentration that normally serves to activate 
secretion of 5-hydroxytryptamine (Best et al. 1981).  Strontium was also found to stimulate degranulation 
of human large granular lymphocytes, which resulted in the inhibition of natural killer (NK) cells 
(Neighbour et al. 1982).  The content of strontium (and calcium) was found to be significantly elevated 
above healthy control levels in granulocytes isolated from Swedish patients with active rheumatoid 
arthritis or seronegative spondarthritis (Hällgren et al. 1984).  The strontium overload was thought to be 
linked to the degree of inflammation, and was positively related to serum levels of the acute-phase protein 
haptoglobin; corticosteroid therapy differentially reduced the strontium content of granulocytes compared 
to calcium.  The authors suggested that leukocyte endogenous mediator (LEM) regulated the 
accumulation of strontium in granulocytes. 
Immunological and Lymphoreticular Effects.    Several in vitro experiments have demonstrated 
that strontium, although less efficient than calcium, is able to stimulate histamine release from rat mast 
cells (Alm and Bloom 1981a, 1981b; Atkinson et al. 1979; Foreman 1977; Foreman and Mongar 1972a, 
1972b; Foreman et al. 1977).  This is probably relevant to humans, since strontium has been shown to 
degranulate human lymphocytes (Neighbor et al. 1982) and stimulate the release of 5-hydroxytryptamine 
by human platelets (Best et al. 1981) (see Hematological Effects above).  In rabbit blood treated with 
strontium chloride in vitro, the bacterocidal properties of serum were reduced (Toshioka et al. 1974); this 
effect was attributed to the inhibition of complement. 
Neurological Effects. In vitro studies have demonstrated subtle differences between strontium and 
calcium with respect to neurological function at the cellular level.  In a calcium-free medium, strontium 
ion weakly supported the generation of excitatory postsynaptic potentials following stimulation of guinea 
pig superior cervical ganglia (i.e., the release of acetylcholine was less efficient than when calcium was 
present) (McLachlan 1977). Calcium is sequestered in mitochondria and smooth endoplasmic reticulum 
of isolated presynaptic nerve terminals in preference to strontium (Rasgado-Flores et al. 1987).  Strontium 
ion inhibits the uptake of calcium by synaptic vesicles in vitro, thereby blocking the antiport-regulated 
release of H+ (Gonçalves et al. 1999).  Strontium ion was slightly more efficient than calcium ion in 
supporting the release of neurotransmitter from synaptosomes induced by leptinotoxin-h (Madeddu et al. 
1985).  Strontium ion was found to support the asynchronous mode of transmitter release in isolated layer 
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V pyramidal cells of the prefrontal cortex (Aghajanian and Marek 1999).  This is apparently mediated 
through calcium-binding protein synaptotagmin III, as strontium does not support the function of 
calcium-binding synaptotagmins I and II (Li et al. 1995). 
Reproductive Effects.    The results of one in vitro study suggest that stable strontium is not directly 
harmful to human spermatozoa.  In developing an improved method to be used by fertility clinics for 
testing the functional capacity of human spermatozoa, it was found that inclusion of strontium chloride in 
the testing medium improved the rate of penetration compared to calcium chloride (Mortimer 1986; 
Mortimer et al. 1986). 
Developmental Effects. Subcutaneous injection of up to 82 mg strontium/kg/day as strontium 
nitrate into female Wistar rats between days 9 and 19 of gestation had no teratogenic effect, no adverse 
effect on the ossification of the skeleton, and no effect on the number of resorptions (Lansdown et al. 
1972). 
3.3 	 DISCUSSION OF HEALTH EFFECTS OF RADIOACTIVE STRONTIUM BY ROUTE OF 
EXPOSURE 
Section 3.3 discusses radiation toxicity associated with exposure to radionuclides of strontium and is 
organized in the same manner as that of Section 3.2, first by route of exposure (inhalation, oral, and 
external) and then by health effect  (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing NOAELs or LOAELs reflect the actual dose (levels of 
exposure) used in the studies.  Refer to Section 3.2 for detailed discussion of the classification of 
endpoints as a NOAEL, less serious LOAEL, or serious LOAEL. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of radiostrontium 
are indicated in Tables 3-2, 3-3, and 3-4 and Figures 3-2 and 3-3.  Because cancer effects could occur at 
lower exposure levels, Figures 3-2 and 3-3 also show a range for the upper bound of estimated excess 
risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
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Refer to Appendix B for a User's Guide, which should aid in the interpretation of the tables and figures 
for Levels of Significant Exposure. 
3.3.1 Inhalation Exposure 
The two major sources of data regarding health effects of inhaled radioactive strontium are long-term 
studies using beagles at the Lovelace Foundation, Albuquerque, New Mexico (now known as the 
Lovelace Respiratory Research Institute).  One study examined the acute inhalation effects of a relatively 
soluble aerosol of 90SrCl2, and the other examined the acute inhalation effects of relatively insoluble 
particles of 90Sr fused to aluminum silicate (‘90Sr fused-clay particles’).   
In the soluble aerosol study, beagles were exposed by nose breathing for varying exposure durations  
(2–22 minutes) to graded concentrations (2.16–419 µCi 90Sr/L; 0.08–15.5 MBq/L) of 90SrCl2 to produce 
graded levels of initial body burdens.  Individual variations in the degree to which aerosol was cleared 
from the respiratory tract and swallowed contributed to variability in the initial rapid rate of clearance 
during the first few days.  Therefore, exposures were expressed in terms of the long-term retained burden 
(LTRB), which ranged from 1.08 to 119 µCi (0.04–4.4 MBq) 90Sr/kg of body weight.  Radiostrontium 
quickly passed through the lungs and was overwhelmingly retained in the skeleton, where initial skeletal 
dose rates were calculated to be 0.43–55 rad/day (0.0043–0.55 Gy/day).  Clearance of radiostrontium 
from the skeleton was gradual.  For that reason, the initial and long-term health effects were primarily 
related to hemopoietic bone marrow and osteogenic tissues.  Reports relating to the 90SrCl2 aerosol study 
include Benjamin et al. (1974b, 1975, 1976a, 1976c, 1979), Boecker et al. (1969, 1991), Fission Product 
Inhalation Project (1967a), Gillett et al. (1987a, 1987b), Hahn et al. (1991), McClellan et al. (1973, 
1983a), and Muggenburg et al. (1977, 1978, 1979). 
In the other study, beagles were exposed by nose-only inhalation to 90Sr fused-clay particles for initial 
lung burdens ranging from 0.21 to 94 µCi 90Sr/kg (0.008–3.5 MBq/kg) of body weight.  Control animals 
were exposed to similar aluminosilicate clay particles fused to stable strontium.  Early and late-occurring 
health effects of inhaled particulate radiostrontium were primarily associated with the lung.  Some 
particles were cleared into the lung-associated lymph nodes, where radiation damage led to their entry 
into the circulatory system, leading to distribution to spleen, liver, and possibly other tissues.  Trapping of 
radioactive particles by these tissues created possible sites for radiation damage and tumor development.  
The biological retention half-time for 90Sr in fused-clay particles was approximately 490 (±320 days 
standard deviation). Reports relating to 90Sr fused clay particles include Benjamin et al. (1974a, 1975), 
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Griffith et al. (1992), Hahn et al. (1983a), Hobbs et al. (1972), Jones et al. (1972, 1976), Scott (1980), and 
Snipes et al. (1974a, 1974b, 1976, 1977, 1978, 1979).  A similar study with a smaller group of dogs was 
carried out by Benjamin et al. (1976c). 
3.3.1.1 Death 
No studies were located regarding death in humans following inhalation exposure to radioactive 
strontium.  Information on the lethality of inhaled radioactive strontium is limited to acute exposure 
studies. Because of the bone-seeking behavior of strontium, an acute exposure to airborne 90Sr results in 
chronic exposure to radiation from 90Sr incorporated into bone.  If insoluble radiostrontium compounds 
are inhaled, there could be long-term lung exposure (see discussion of the study by Willard and Snyder 
(1966) in Section 3.5.1.1). 
In two different experiments briefly described in a report by the Lovelace Foundation (now known as the 
Lovelace Respiratory Research Institute), young male and female Holtzman rats were exposed once to 
90Sr by whole body inhalation for initial body burdens ranging from 170 to 1,660 µCi 90Sr/kg (0.63– 
61.4 MBq/kg) of body weight and average skeletal radiation doses ranging from 12,600 to 19,000 rad 
(126–190 Gy) (Fission Product Inhalation Project 1967b).  Survival was inversely proportional to dose, 
with rats receiving the lowest dose living for more than 700 days, and those receiving the highest dose 
living less than 200 days.  In the two experiments, 77% of the rats that died and 47% of the rats that were 
killed in a moribund state were found to have osteosarcoma.  Among rats dying with tumors, the average 
skeletal dose was 81 rad/day, compared to 62 rad/day for rats without tumors (0.81 vs 0.62 Gy/day).  The 
small sample sizes in this study do not permit its inclusion in the LSE Table 3-2. 
In acute inhalation studies in beagle dogs, high-dose radiation effects of inhaled 90SrCl2 on bone marrow 
resulted in death within days or weeks of exposure, whereas lower doses reduced long-term survival 
through carcinogenetic effects.  For all exposed dogs, the mean survival time was 3,000 days, compared 
to 4,500 days for the controls (Gillett et al. 1987b).  Among dogs receiving high or medium doses (long­
term retained body burdens between 47 and 120 µCi 90Sr/kg (1.74 and 4.44 MBq/kg), 6/22 died within 
32 days from severe hypoplasia of the bone marrow (Gillett et al. 1987a; Muggenburg et al. 1979).  
Individual neutrophil counts were the most reliable predictors of lethality.  Death from primary bone 
tumors occurred from 2 to 10 years after exposure to inhaled 90SrCl2 (Gillett et al. 1987b). Fibrosarcomas 
and metastasizing hemangiosarcomas occurred somewhat earlier than osteosarcomas and were the major 
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contributors to shortened mean survival times for the dogs exposed to inhaled 90SrCl2 (Gillett et al. 
1987b).  Deaths from myelomonocytic leukemia and from bone-associated soft tissues of the skull were 
also concluded to be associated with radiostrontium; the long-term retained burdens were 9.2–27 µCi 
90Sr/kg (0.34–1.0 MBq/kg) and 21–35 µCi 90Sr/kg (0.081–1.3 MBq/kg), respectively.  These are extreme 
doses. 
In beagle dogs exposed by acute inhalation to 90Sr fused-clay particles, the pattern of mortality was 
different since the radioactive particles were initially embedded in the lung.  No deaths occurred until the 
5th month postexposure.  Of 36 dogs with initial lung burdens ≥25 µCi 90Sr/kg (925 kBq/kg) of body 
weight, 35 died within the first 2 years, primarily of radiation pneumonitis and/or pulmonary fibrosis 
(Snipes et al. 1979).  Subsequently, within the 2nd to 7th years after exposure, deaths from 
hemangiosarcoma and carcinoma of the lung were common.  None of the control dogs died during the 
9 years following exposure (Snipes et al. 1979), indicating that the observed mortality was not caused by 
inhalation of nonradioactive aluminum silicate particles alone.  Among dogs dying prematurely from 
neoplasms of the lung, the initial lung burdens were between 3.7 and 94 µCi/kg (0.14–3.5 MBq/kg) and 
the doses to the lungs ranged from 43,000 to 67,000 rad (430–670 Gy) (Benjamin et al. 1975). 
The percent mortality values for dogs from exposure to radioactive strontium by the inhalation route are 
presented in Table 3-2 and plotted in Figure 3-2. 
3.3.1.2 Systemic Effects 
No studies were located that described endocrine, dermal, or ocular effects in humans or animals 
following inhalation exposure to radioactive strontium.  The highest NOAEL values and all reliable 
LOAEL values in each species and duration category for systemic effects from radiation exposure to 
strontium by the inhalation route are presented in Table 3-2 and plotted in Figure 3-2. 
Respiratory Effects. The only respiratory effects reported for the study in which beagle dogs were 
exposed to soluble aerosols of 90SrCl2 (Boecker et al. 1969; Gillett et al. 1987b) were late primary cancers 
of the respiratory tract or tumors metastasizing to the lung.  These effects are discussed in Section 3.2.1.7 
Cancer. 
Table 3-2 Levels of Significant Exposure to Strontium - Radiation Toxicity - Inhalation 
Exposure/ LOAEL 
Duration/
a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route) figure (Strain) System (µCi/kg) (µCi/kg) (µCi/kg) Chemical Form
ACUTE EXPOSURE 
Death 
1 Dog 2-22 min Gillett et al. 1987a47 [LTRB] (6/24 died from boneonce(Beagle) marrow hypoplasia) Strontium-90 (chloride) 
Systemic 
2 Dog once Benjamin et al. 1976c 
Cardio 25 [ILB] (damaged pulmonary 
(Beagle) vasculature; hypertrophic right Sr-90 (fused-clay particles) 
ventricle; congestive heart 
failure) 





congestion; one with mild 
centrilobular fibrosis) 
Bd Wt 25 [ILB] (emaciation) 
3 Dog 2-22 min Gillett et al. 1987a 
Gastro 47 [LTRB] (anorexia, bloodyonce(Beagle) diarrhea from acute radiation Strontium-90 (chloride) 
syndrome) 
	 
Hemato 1.5 [LTRB] (60% decr platelet 
count) 
Renal 47 [LTRB] (incr blood urea 
nitrogen, decr urine output from 











Table 3-2 Levels of Significant Exposure to Strontium - Radiation Toxicity - Inhalation (continued) 
Exposure/ LOAEL
Duration/
a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route)figure (Strain) System (µCi/kg) (µCi/kg) (µCi/kg) Chemical Form 
4 Dog 2-22 min Muggenburg et al. 1977










Bd Wt 1.9 [LTRB] (decr bd wt) 
5 Dog once Snipes et al. 1979
Resp 25 [ILB] (pulmonary pneumonitis,
(Beagle) fibrosis) Sr-90 (fused-clay particles)
	 




once Benjamin et al. 1976c

 
6 Dog 25 [ILB] (50% decr lymphocytes
(Beagle) for 28 weeks) Sr-90 (fused-clay particles)
7 Dog 2-22 min Gillett et al. 1987a10 [LTRB] (22% decr lymphocyteonce(Beagle) count lasting 3 years) Strontium-90 (chloride) 
	 
8 Dog once Jones et al. 19765 [ILB] (lymphocyte counts decr

















a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route)figure (Strain) System (µCi/kg) (µCi/kg) (µCi/kg) Chemical Form 
Cancer 






10 Dog once Benjamin et al. 19753.7 [ILB] (CEL: hemangiosarcoma
(Beagle) of lung, heart) Sr-90 (fused-clay particles)
11 Dog 2-22 min Gillett et al. 1987b7 [LTRB] (CEL: osteosarcoma)once(Beagle) Strontium-90 (chloride) 
	 
9 [LTRB] (CEL: leukemia) 
	 
27 [LTRB] (one premature death 
after 585 days from leukemia) 

 
2 [LTRB] (CEL: nasal carcinoma) 
a The number corresponds to entries in Figure 3-2. 
	 
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; decr = decreased; Gastro = gastrointestinal; (GW) = gavage in water; Hemato = hematological; hr = hour(s); 
[ILB] = initial lung burden; incr = increased; LOAEL = lowest-observed-adverse-effect level; [LTRB] = long-term retained burden; min = minute(s); NOAEL = 






























































Figure 3-2 Levels of Significant Exposure to Strontium - Radiation Toxicity - Inhalation 
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*Doses represent the lowest dose tested per study that produced a tumorigenic 
response and do not imply the existence of a threshold for the cancer endpoint. 
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Respiratory effects were more pronounced in beagle dogs that were exposed to 90Sr fused-clay particles 
by inhalation (Benjamin et al. 1976c; Snipes et al. 1979).  The primary cause of early death among dogs 
exposed to initial lung burdens ≥25 µCi 90Sr/kg (925 kBq/kg) was radiation pneumonitis and/or 
pulmonary fibrosis (Snipes et al. 1979).  No such effects were reported in control dogs exposed to 
nonradioactive aluminosilicate-fused clay particles (Snipes et al. 1979).  Clinical signs included an 
increased respiratory rate, dyspnea, cyanosis, and dry and moist rales (Benjamin et al. 1976c).  
Radiographically, the dogs showed increased focal or diffuse lung-field densities.  The pneumonitis was 
characterized by acute and chronic inflammation with increased numbers of alveolar macrophages, 
hypertrophy and hyperplasia of alveolar lining cells, degeneration of the bronchiolar epithelium and 
alveolar ducts, focal emphysema, and edema.  The fibrosis involved the alveolar septa, pleura, and 
perivascular regions, with substantial scarring.  Vascular damage in the lungs was characterized by 
congestion, hemorrhage (possibly related to thrombocytopenia), fibrin exudation, and occasional vessels 
with fibrinoid necrosis or intimal proliferation. 
Cardiovascular Effects. Acute inhalation of radiostrontium was reported to lead to adverse 
cardiovascular effects in dogs. Among beagles that died within 5–15 months following inhalation 
exposure to 90Sr fused-clay particles, most exhibited myocardial necrosis or degeneration, and fibrosis, 
primarily of the right atrium (Hobbs et al. 1972); these animals had initial lung burdens between 33 and 
100 µCi/kg (1.2–3.7 MBq/kg) and cumulative beta radiation doses to the lung of 34,000 to 82,000 rad 
(340–820 Gy).  In a later report of the same study, acute and chronic vascular lesions, characterized as 
inflammatory or degenerative, affected the elastic and muscular pulmonary arteries in dogs with initial 
lung burdens between 16 and 94 µCi/kg (0.6–3.5 MBq/kg) and doses to the lung between 40,000 and 
96,000 rad (400–960 Gy) at the time of death (Snipes et al. 1977).  Vascular damage in the lungs was 
characterized by congestion, hemorrhage, fibrin exudation, and occasional vessels with fibrinoid necrosis 
or intimal proliferation (Benjamin et al. 1976c).  These effects were attributed to the direct effect of beta 
radiation (from radiostrontium particles embedded in the lung) on adjacent tissue.  In addition, 
presumably as a consequence of radiation damage to the pulmonary vasculature, the right ventricle 
became dilated and hypertrophic with congestive heart failure.  Hemangiosarcomas resulting from 
radiostrontium exposure in this study are discussed in Section 3.3.1.7 Cancer. 
Gastrointestinal Effects.    Gastrointestinal effects were observed in beagle dogs receiving single 
high doses (long-term retained body burdens between 47 and 83 µCi/kg; 1.74 and 3.07 MBq/kg) of 
soluble aerosols containing 90SrCl2 (Gillett et al. 1987a).  Anorexia and, 2 days before death, bloody 
diarrhea, developed in six dogs that died between 18 and 32 days after the extreme radiation dose rate 
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induced acute radiation syndrome (Gillett et al. 1987a).  It is likely that severe thrombopenia, one of the 
features of radiation-induced bone marrow hypoplasia, contributed to hemorrhage in the gastrointestinal 
tract as elsewhere in the body.  In addition, some effects could have been due to inhaled 90SrCl2 droplets 
being transported from the mucoid, ciliated nasopharyngeal and tracheobronchial epithelia to the pharynx 
and then swallowed. The gastrointestinal epithelium then would have been exposed directly to beta 
emissions from radiostrontium for a day or two.  Another report of the same study described three 
exposed dogs that died at age >11 years with a malabsorption syndrome (Muggenburg et al. 1977).  All of 
the dogs exhibited chronic diarrhea with anorexia, and at necropsy, contained chronic degenerative and 
inflammatory lesions of the small intestines.  Their long-term retained burdens were 1.9–9.6 µCi/kg 
(70.3–355.2 kBq/kg) and the absorbed doses to the skeleton were calculated to be 530–5,600 rad (5.3– 
56 Gy).  Although the authors could not firmly establish whether the syndrome was a consequence of 
exposure or of age, the cumulative radiation dose to the digestive tract was likely to have been very low 
and this argues against 90Sr as the cause.   
One beagle dog that was exposed to 90Sr fused-clay particles and had an initial lung burden of 4.1 µCi/kg 
(151.7 kBq/kg) and a cumulative radiation dose to the lung of 20,000 rad (200 Gy) died 9 years after 
exposure with anorexia and an ulcerative lesion to the pharynx (Snipes et al. 1979).  Whether the 
pharyngeal lesion was related to exposure is uncertain, since the report was preliminary and no other 
response to radiation had been observed in this animal. 
Hematological Effects.  Profound hematological effects were observed in beagle dogs that were 
exposed once by inhalation either to soluble aerosols containing 90SrCl2, or to 90Sr fused to 
aluminosilicate particles that produced extremely large radiation dose rates and doses in the affected 
tissues sufficient to induce acute radiation syndrome. 
Significant dose-related pancytopenia developed in dogs that were exposed to 90SrCl2 aerosols and had 
long-term retained burdens >10 µCi (370 kBq) 90Sr/kg (Gillett et al. 1987a).  Profound decreases in 
platelet numbers were evident by 7 days and were maximal by 28 days.  Drastic thrombocytopenia 
(platelets reduced >90%) probably contributed to widespread hemorrhaging and premature death in dogs 
with long-term retained burdens ≥47 µCi/kg (≥1.7 MBq/kg).  Significant immediate reductions in platelet 
counts (>60%) occurred in surviving dogs with long-term retained burdens of ≥1.5 µCi/kg 
(≥0.56 MBq/kg).  However, even dogs with the lowest long-term retained burdens (1–10 µCi/kg; 0.04– 
0.36 MBq/kg), which otherwise showed little immediate effect, exhibited long-term (>3 years) depression 
in platelet counts compared to controls.  The pattern of neutropenia followed a similar exposure-response, 
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and profound neutropenia was the most accurate predictor of death.  In surviving dogs that were 
immediately affected by exposure, neutrophil counts recovered, but in these dogs, as well as those 
immediately unaffected, significant long-term (>3 years) suppression was observed compared to controls.  
Similarly, lymphocyte counts were drastically reduced (by 75%) in dogs dying within weeks of exposure 
with long-term retained burdens ≥47 µCi/kg (≥1.7 MBq/kg).  Surviving dogs with long-term retained 
burdens >10 µCi (370 kBq) 90Sr/kg exhibited a long-term (>3 years) suppression of lymphocyte counts 
(>30%).  Dogs with long-term retained burdens between 6 and 10 µCi/kg (0.26–0.36 MBq/kg) exhibited 
normal lymphocyte counts that were normal over 1,400 days except for periods of significant depression 
at 60–120 and 900–1,000 days.  Dogs with long-term retained burdens between 1 and 3 µCi/kg (0.04– 
0.12 MBq/kg) had lymphocyte counts that were not significantly different from controls.  Reduced 
erythrocyte mass, as exemplified by decreases in hematocrit, red blood cell counts, and hemoglobin 
levels, occurred between 2 and 3 weeks after exposure (slightly later than the depression in platelet and 
white cell counts).  In the most severely affected dogs, red blood cell counts fell to 70–80% of pre-
exposure values, with maximal depression at 32 days.  Prolonged depression of erythrocyte counts was 
observed in surviving dogs with long-term retained burdens ≥27 µCi/kg (≥1 MBq/kg). 
Significant suppression of peripheral lymphocyte counts was observed in beagle dogs that were exposed 
by inhalation to 90Sr fused-clay particles (Jones et al. 1976).  Lymphocytes declined gradually over time 
in all exposed groups (initial lung burdens ≥5 µCi/kg; ≥185 kBq/kg), and remained more than 50% lower 
than controls after 2 years. 
Hepatic Effects. No studies were located that described hepatic effects in humans following 
inhalation exposure to radioactive strontium.  All beagle dogs that died from radiation pneumonitis 
following a single inhalation exposure to high concentrations of 90Sr fused-clay particles (25 µCi 90Sr/kg 
of body weight; 925 kBq/kg) exhibited chronic passive congestion of the liver, and one had mild 
centrilobular fibrosis (Benjamin et al. 1976c). 
Renal Effects. No studies were located that described renal effects in humans following inhalation 
exposure to radioactive strontium isotopes.  Some beagle dogs in the terminal stages of acute radiation 
syndrome following inhalation exposure to aerosols of 90SrCl2 (long-term retained burden  
47–83 µCi 90Sr/kg; 1.74–3.07 MBq/kg) had low urine output and elevated blood urea nitrogen (Gillett et 
al. 1987a). 
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Body Weight Effects    No studies were located that described body weight effects in humans 
following inhalation of radiostrontium.  Anorexia and reduced body weight were observed among beagle 
dogs with long-term retained burdens between 45 and 119 µCi/kg (1.7–4.4 MBq/kg) following inhalation 
of 90SrCl2 aerosols (Gillett et al. 1987a; Muggenburg et al. 1977) or initial lung burdens between 25 and 
32 µCi/kg (0.93–1.2 MBq/kg) following inhalation of 90Sr fused-clay particles (Benjamin et al. 1976c). 
3.3.1.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans following inhalation exposure to 
radioactive strontium isotopes.  However, profound effects on the immune system were a consequence of 
acute inhalation exposure to radiostrontium in dog studies.  Effects in dogs exposed to soluble aerosols of 
90SrCl2 were sequelae of general irradiation of the bone marrow from 90Sr incorporated into bone. 
Significant dose-related lymphopenia was observed in young adult beagle dogs (12–14 months old) after 
a single inhalation exposure to 90SrCl2 at long-term retained burdens >10 µCi 90Sr/kg (370 kBq/kg; Gillett 
et al. 1987a).  Furthermore, there was some evidence of immunosuppression in dogs with average initial 
body burdens of 35 µCi 90Sr/kg (1.3 MBq/kg) (Fission Product Inhalation Project 1967a); titers for 
infectious canine hepatitis and leptospira vaccines were depressed more than 30% following exposure to 
90SrCl2 aerosols. Effects in dogs exposed to relatively insoluble 90Sr fused-clay particles were primarily a 
consequence of irradiation of the blood as it circulated through the lungs, although some damage to 
thoracic lymph nodes was observed.  Among beagle dogs (17–20 months old) exposed by nose-only 
inhalation to 90Sr fused clay particles (initial lung burdens 25–32 µCi 90Sr/kg; 0.925–1.18 MBq/kg), the 
numbers of peripheral lymphocytes were depressed by more than 50% during the 12th through 28th weeks 
after exposure, although recovery was observed by week 44 (Benjamin et al. 1976c).  The cumulative 
radiation dose to the lungs ranged from 35,000 to 43,000 rad (350–430 Gy).  During the period of 
lymphocyte suppression, the immune response to phytohemagglutinin antigen tested in vitro was 
depressed 10-fold in the dog that had the highest initial lung burden (32 µCi/kg; 1.18 MBq/kg) and was 
the first to die.  In this animal, the tracheobronchial and sternal lymph nodes, which received a significant 
radiation dose from 90Sr, were depleted of lymphocytes, although peripheral nodes, which received much 
lower doses, were nearly normal.  In the main study that employed 1-year-old beagles, the highest initial 
lung burdens of 90Sr fused-clay particles resulted in severe atrophy and fibrosis of the tracheobronchial 
lymph nodes (Snipes et al. 1977).  In other dogs, which had initial lung burdens averaging between 5 and 
19 µCi/kg (185 and 703 kBq/kg), fluctuations in the peripheral lymphocyte numbers were observed, but 
the values remained depressed by 40% for 2 years following inhalation exposure (Jones et al. 1976).  
74 STRONTIUM 
3. HEALTH EFFECTS 
Cumulative doses in these dogs ranged from 1,055 to 4,005 rad (10.5–40 Gy).  None of the dog studies 
reported whether there was a NOAEL identified for immunological effects.  Significant chronic 
suppression of the immune system is considered a serious effect because of the impaired resistance to 
infectious disease. 
3.3.1.4 Neurological Effects 
No studies were located that described neurological effects in humans following inhalation exposure to 
radioactive strontium.  A beagle dog that was exposed to the highest concentration of 90SrCl2 aerosol 
(long-term retained burden of 119 µCi/kg or 4.4 MBq/kg) succumbed with epileptic seizures, but the 
authors deemed these to be unrelated to exposure (Gillett et al. 1987b).  Serious neurological effects 
(convulsions, paralysis) were observed in several dogs that were in the terminal stages of cancer 
following inhalation of 90Sr fused clay particles (Snipes et al. 1977, 1978).  No other studies addressed 
neurological effects in animals following inhalation exposure to radioactive strontium isotopes. 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
neurological effects from exposure to radioactive strontium by the inhalation route are presented in 
Table 3-2 and plotted in Figure 3-2. 
No studies were located regarding the following effects in humans or animals following inhalation 
exposure to radioactive strontium: 
3.3.1.5 Reproductive Effects 
3.3.1.6 Developmental Effects 
3.3.1.7 Cancer 
No studies were located regarding cancer in humans following inhalation exposure to radioactive 
strontium isotopes, but several studies reported carcinogenetic effects in animals.  The types of cancers 
produced varied with the form of strontium administered.  In studies using soluble forms of radioactive 
strontium, (e.g., 90SrCl2), bone-associated cancers were the predominant types, because absorbed 
strontium primarily incorporates into bone.  Studies using relatively insoluble 90Sr fused-clay particles 
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reported lung-related cancers as the major initial types, since the particles were initially embedded in the 
lungs. As particles slowly dissolved (releasing 90Sr) or were cleared from the lungs, tumors were induced 
in other tissues. 
In two different experiments described in a report by the Lovelace Foundation (now known as the 
Lovelace Respiratory Research Institute), young male and female Holtzman rats were exposed once to an 
aerosol of 90Sr in cesium chloride by whole body inhalation for initial body burdens ranging from 170 to 
1,660 µCi 90Sr/kg (6.3–61.4 MBq/kg) of body weight (Fission Product Inhalation Project 1967b).  The 
average skeletal radiation doses over their remaining lifespans averaged from 12,600 to 25,900 rad (126– 
259 Gy).  In the two experiments, 77 or 47% of the rats that died or were euthanized in a moribund state 
were found to have bone tumors (osteosarcomas).  Among rats dying with tumors, the average skeletal 
dose rate was 81 rad/day, compared to 62 rad/day for rats without tumors (0.81 vs 0.62 Gy/day). 
Primary bone cancer was the most frequent cause of death in beagle dogs (30/66) given a single 
inhalation exposure to 90SrCl2 aerosol and then observed for their lifespans (Benjamin et al. 1974a, 1976a, 
1979; Gillett et al. 1987b; McClellan et al. 1973; Muggenburg et al. 1977, 1978, 1979).  The cumulative 
absorbed doses of beta radiation to bone ranged from 12 to 1,200 rad (0.012–12 Gy) at 30 days and from 
200 to 170,000 rad (2–1,700 Gy) at 1,000 days after exposure.  In dogs with bone-related tumors, the 
long-term retained burdens ranged from 2 to 119 µCi 90Sr/kg (0.081–4.4 MBq/kg ) of body weight.  
Bone-tumor-related deaths occurred 759–3,472 days after exposure (median survival time of 1,702 days, 
compared to 4,500 days for controls).  Twenty-seven tumors were classified as different subtypes of 
osteosarcoma, 14 as hemangiosarcomas, 3 as fibrosarcomas, and 1 as a myxosarcoma.  Four additional 
animals developed carcinomas in soft tissues adjacent to the bones of the skull: invasive baso-squamous 
carcinoma, transitional carcinomas of the nasal cavity, and an adenocarcinoma in the maxilloturbinate 
region (Benjamin et al. 1979). In addition, two dogs died from myelomonocytic leukemia resulting from 
irradiation of bone marrow.  Metastasis occurred from 21 tumors, in particular the hemangiosarcomas, 
with the lungs being the most frequent site of metastasis (76%). 
Among 127 beagle dogs exposed by inhalation to 90Sr fused-clay particles, deaths from primary 
pulmonary tumors were common: 19 dogs with hemangiosarcomas (one each also with bronchioalveolar 
carcinoma, nasal squamous cell carcinoma, or pulmonary epidermoid carcinoma), and one with 
pulmonary squamous cell carcinoma (Snipes et al. 1979).  All 34 dogs exposed to 90Sr fused clay particles 
with cumulative exposures of >29,000 rad (290 Gy) developed pulmonary hemangiosarcoma.  The heart 
wall was the other primary location of hemangiosarcoma (11 dogs), the others being the mediastinum, 
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spleen, rib, lung-associated lymph nodes, and liver (Snipes et al. 1979).  Hemangiosarcomas were 
metastatic in all but one affected dog.  Among dogs dying prematurely from neoplasms of the lung, the 
initial lung burdens were 3.7–94 µCi/kg (0.14–3.5 MBq/kg) and the estimated cumulative doses to the 
lungs ranged from 43,000 to 67,000 rad (430–670 Gy) (Benjamin et al. 1975).  Considering all dogs with 
tumors, pulmonary carcinomas or sarcomas occurred in 3/12 dogs that received cumulative radiation 
doses of 17,000–25,000 rad (170–250 Gy), but no pulmonary tumors were reported for three dogs with 
cumulative exposure levels of 11,000–15,000 rad (110–150 Gy; Hahn et al. 1983a). 
The highest NOAEL values and all reliable LOAEL values in each species and duration category for 
cancer effects from exposure to radioactive strontium by the inhalation route are presented in Table 3-2 
and plotted in Figure 3-2. 
3.3.2 Oral Exposure  
Upon ingestion, radioactive strontium isotopes become incorporated into bone, and irradiate the 
surrounding hard and soft tissues, resulting in hypoplasia of the bone marrow or various forms of cancer 
(osteosarcoma, leukemia).  Adverse effects are associated with higher skeletal burdens of radioactive 
strontium.  Younger organisms are more vulnerable to adverse effects of both stable and radioactive 
strontium.  Maternal oral exposure to sufficient radioactive strontium can adversely affect the fetus. 
The database for oral exposures to radioactive strontium is substantial.  Human health effect data are 
derived primarily from long-term and ongoing studies of a population that was exposed to contaminated 
drinking water and food following the release of large quantities of radioactive materials into the Techa 
River from a Soviet nuclear weapons facility between 1949 and 1956.  This population received a mixed 
exposure to external gamma radiation and to internal radiation from 89Sr, 90Sr, and 137Cs (Akleyev et al. 
1995; Kossenko et al. 2000).  Animal data include several large, long-term studies in dogs, miniature 
pigs, and rodents. In addition to the papers cited below, interim reports and analyses for the beagle 
lifetime study (Laboratory for Energy-Related Health Research at the University of California at Davis) 
were published by Nilsson and Book (1987), Nilsson et al. (1985), Pool et al. (1972, 1973b), and Raabe et 
al. (1981a, 1981b, 1983, 1994). 
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3.3.2.1 Death 
In the Techa River population that was exposed to radiostrontium and radiocesium in drinking water and 
food between 1949 and 1956, an increase in the number of deaths from leukemia and solid cancers was 
reported (Kossenko 1996).  In the exposed group, the standardized mortality rate was 140 (95% CI: 131– 
150) per 100,000 compared to 105 (95% CI: 101–109) per 100,000 in the control group during the 
followup period (1950–1982).  Absorbed doses to the red bone marrow in the study group were between 
17.6 and 164 rad (0.176 and 1.64 Gy).  No increase in cancer mortality was observed among offspring of 
exposed individuals.  These data are omitted from Table 3-3 because the exposures were to multiple 
sources of radiation. 
Oral exposure to radioactive strontium caused dose-related increases in mortality in animal studies.  In 
general, younger animals were more sensitive to the effects of radiation than older animals.  There was an 
increase in deaths in a small number (6 out of 7) of Rhesus monkeys given 100 µCi of 90Sr per day 
(3.7 MBq/day) by gavage for 5 or 10 days (Casarett et al. 1962).  One monkey given 11 µCi/kg/day 
(0.42 MBq/kg/day) for 5 days died 4 years after treatment from leukemia with a total skeletal dose of 
4,300 rad (43 Gy).  One monkey given a dose of 28 µCi/kg/day (1.0 MBq/kg/day) for 10 days died within 
4 months of treatment from pancytopenia with an estimated skeletal dose of 4,500 rad (45 Gy).  Two 
others exposed to an average of 18 µCi/kg/day (0.67 MBq/kg/day) for 10 days died from bone associated 
cancers within 36 months of treatment, and with estimated skeletal doses of 4,700–9,500 rad (47–95 Gy).  
Because of the small sample size and the fact that the animals were of different ages, this study serves as 
an indicator, but not as proof of dose-response effects of ingested radiostrontium. 
In experiments in which weanling (30 days old) and adult Long-Evans rats were given 90Sr in drinking 
water for 10 days, survival at 5 months was reduced by 80% in the weanlings consuming at least 297– 
386 µCi 90Sr/kg/day (11 MBq/kg/day; total 464 µCi or 17 MBq), but was unaffected in adults consuming 
64–194 µCi 90Sr/kg/day (7.2 MBq/kg/day; total 650 µCi or 24.1 MBq; Casarett et al. 1962).  The reduced 
survival of the weanlings was consistent with their higher skeletal burden at 5 months: >20 times higher 
than in the adults.  In another acute study, six young female dairy cattle (three sets of twins from three 
different strains, ages 398 and 479 days and weighing 145–349 kg at the start of treatment) were given 
44 µCi 90Sr/kg/day (1.63 MBq/kg/day) ‘orally’ for 5 days (Cragle et al. 1969). The four youngest 
(398 days) and lightest heifers (145–212 kg), which were administered a total of 32–46 mCi (1.18– 
1.70 GBq), died of radiation sickness between 93 and 132 days after treatment was started, whereas the 
older and heavier animals (342–349 kg), which had received a total of 75–77 mCi of 90Sr (2.78– 
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2.85 GBq), were still alive 3 years after treatment.  In addition to age-related differences, strain 
differences may have contributed to the results; the older cows were Holsteins, which have more massive 
skeletons than the Brown Swiss and Jersey strains.  The authors suggested that the larger animals 
survived because of the wider diameter of the marrow cavity, which possibly shielded the central marrow 
from beta radiation released from 90Sr (and its 90Y decay product) deposited at the periphery of the bone 
shaft. 
In an intermediate-duration experiment, young (87-day-old) Long-Evans rats were treated with up to 
104 µCi of 90Sr per kg of body weight per day (3.8 MBq/kg/day) for 30 days over a period of 37 days 
(Casarett et al. 1962; Hopkins et al. 1966); the total amount administered was 790 µCi (29.2 MBq).  In 
these rats, the estimated skeletal activity of 90Sr at 5 months was 11 µCi (407 kBq) and survival was 
reduced by about 36%.  In the young rats treated for 30 days, skeletal activity was higher and survival 
was reduced accordingly compared to the adult rats treated for 10 days (see previous paragraph), but the 
differences were out of proportion to the total amounts of 90Sr administered to the two sets of rats.  The 
total amount given to adults was 18% less than to the juveniles, but the skeletal doses in the adults were 
82% less, suggesting age-related differences in incorporation. 
In a lifetime study, adult CF-1 mice that were exposed to 90Sr beginning at ages 110–250 days were less 
vulnerable to continuous exposure than mice that had been exposed since conception (Finkel et al. 1960). 
The adult lifespan was shortened by 17% in mice given 31 µCi 90Sr/kg/day (1.15 MBq/kg/day), but was 
unaffected by administration of up to 16 µCi 90Sr/kg/day (592 kBq/kg/day).  In mice exposed from 
conception, the lifetime was shortened by 40% when given 36 µCi 90Sr/kg/day (1.33 MBq/kg/day), and 
by 26% when given between 4 and 19 µCi 90Sr/kg/day (148 and 703 kBq/kg/day), but was unaffected by 
0.05–0.4 µCi 90Sr/kg/day (1.85–14.8 kBq/kg/day).  In albino rats that were fed 0.5 or 2 µCi 90Sr/kg/day 
(18.5 or 74 kBq/kg/day) for their postweaning lifetime, the lifespan was shortened, by about 18 or 30%, 
respectively, compared to controls (Zapol’skaya et al. 1974).  The authors calculated that the lifespan was 
shortened by 0.09 day per rad.  A plot of mortality against absorbed dose showed maximum mortality 
(40%) against a skeletal absorbed dose of 4,000 rad (40 Gy).  In a study in which eight weanling Dutch 
rabbits were fed approximately 6 µCi/kg/day (218 kBq/kg/day) in pellets once a day for 31–280 days, 
some died within a few weeks with bone marrow that was slightly hypoplastic (Downie et al. 1959).  The 
bone marrow was entirely atrophic in rabbits dying several months later with osteogenic sarcoma. 
Two related long-term oral exposure studies demonstrated dose-related effects of 90SrCl2 on survival in 
beagle dogs. In the main study, groups of pregnant beagles were fed 0.002–3.6 µCi 90Sr/kg/day (0.074– 
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133.2 kBq/kg/day) from gestational day 21 through lactation to postnatal day 44, and the pups were fed 
the same doses from weaning at day 42 through day 540 (Raabe et al. 1983; White et al. 1993).  Survival 
of the pups was reduced by 18, 64, and 85% at the three highest levels (0.4, 1.2, and 3.6 µCi/kg/day or 
14.8, 44.4, and 133.2 kBq/kg/day, respectively).  Survival was not significantly different from the 
controls for exposures of 0.002–0.13 µCi/kg/day (0.074–4.8 kBq/kg/day).  Mean absorbed skeletal 
absorbed doses at or below 2,250 rad (22.5 Gy) had no effect on mortality, whereas increased mortality 
was observed at or above 5,040 rad (50.4 Gy).  The secondary study had a similar protocol, except that 
the dogs were given doses of 0.13–1.2 µCi/day (4.81–44.4 kBq/day) from gestational day 21 throughout 
their entire lifetime (Book et al. 1982).  The mean lifetime absorbed skeletal doses were 2,840–11,190 rad 
(28.4–111.9 Gy).  The median lifespans were reduced by 11–65%, which was similar to the results of the 
main study. This implies that irradiation after day 540 did not significantly change the survival rate and 
that survival was shortened because of exposure at a young age.  The two main radiation-related causes of 
death in these studies were myeloproliferative syndrome and skeletal sarcomas (see Section 3.3.2.7 
Cancer). 
In a multigenerational study of female Pitman-Moore miniature swine, there were dose-related effects on 
mortality following chronic ingestion of 90Sr in the form of strontium chloride (Clarke et al. 1970; 
McClellan et al. 1963; Ragan et al. 1973).  Sows ingesting 3,100 µCi 90Sr/day (114.7 MBq/day) from age 
9 months did not survive their first pregnancy, succumbing from the destruction of hemopoietic tissue in 
the bone marrow.  The sows developed anemia, leukopenia, thrombocytopenia, and terminal hemorrhagic 
syndrome (Clarke et al. 1972).  Exposure to 25, 125, or 625 µCi 90Sr/day (0.925, 4.625, or 
23.13 MBq/day) significantly increased mortality after 11, 5, and 1 year(s), respectively, whereas 
exposure to 1 or 5 µCi 90Sr/day (37 or 185 kBq/day) had no effect on survival.  Effects on the F1 females 
exposed from the time of conception were more severe, even though, after weaning, their administered 
dose level was only a fraction of the maternal level until the age of 6 months.  None of the F1 females 
exposed to 625 µCi 90Sr/day (23.13 MBq/day) survived to the age of 9 months, whereas that dose was not 
immediately fatal to the parental generation of sows.  Furthermore, the F1 females receiving 25 µCi 
90Sr/day (925 kBq/day) showed a significant increase in cumulative mortality after 7 years, rather than 11.  
However, the 1 and 5 µCi 90Sr/day levels (37 and 185 kBq/day), as in the parental generation, had no 
effect on survival. In this study, the average attained body burden was 10, 50, 250, 1,250, and 4,700 µCi 
(0.37, 1.85, 9.25, 46.25, and 173.9 MBq) for the 1, 5, 25, 125, and 625 µCi 90Sr/day (0.037, 0.185, 0.925, 
4.625, and 23.13 MBq/day) levels, respectively. 
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All reliable LOAEL values for death from oral exposure to radioactive strontium in each species and 
duration category are recorded in Table 3-3 and plotted in Figure 3-3. 
3.3.2.2 Systemic Effects 
No studies were located regarding endocrine, dermal, or metabolic effects in humans or animals after oral 
exposure to radioactive strontium.  The highest reliable NOAEL and all LOAEL values for the systemic 
effects from oral exposure to radioactive strontium are shown in Table 3-3 and plotted in Figure 3-3. 
Respiratory Effects. No studies were located regarding respiratory effects in humans following oral 
exposure to radioactive strontium isotopes.  No studies were located regarding respiratory effects in 
animals following acute- or intermediate-duration exposure to radioactive strontium.  In a chronic-
duration beagle study, animals exposed to 0.4 or 1.2 µCi/kg/day (14.8 or 44.4 kBq/kg/day) of  90Sr in 
utero from gestational day 21, throughout lactation, and from weaning on day 42 to day 540 exhibited 
only secondary respiratory effects (Dungworth et al. 1969); lungs showed varying degrees of myeloid 
infiltration (see Section 3.3.2.7 Cancer).  Since this effect is not the direct result of the action of 
radiostrontium on lung tissue, but rather a secondary effect of myeloid proliferation induced by irradiation 
of bone marrow, it is not categorized under Systemic: Respiratory Effects in Table 3-3. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after 
oral exposure to radioactive strontium isotopes.  No studies were located regarding cardiovascular effects 
in animals after acute- or intermediate-duration oral exposure to radioactive strontium isotopes. 
Petechiae, ecchymoses, and gastrointestinal bleeding were found postmortem in some beagles in a 
chronic-duration study, in which animals were exposed to 0.002–1.2 µCi 90Sr/kg/day (0.074– 
44.4 kBq/kg/day) in utero from gestational day 21, throughout lactation, and from weaning on day 42 to 
day 540 (Dungworth et al. 1969).  These findings, observed in high dose animals (0.4 and 1.2 µCi/kg/day; 
14.8 and 44.4 kBq/kg/day), indicated the presence of a hemorrhagic disorder related to thrombocytopenia 
(see Hematological Effects below).  
The highest reliable NOAEL and all LOAEL values for cardiovascular effects from oral exposure to 
radioactive strontium in each species and duration category are shown in Table 3-3 and plotted in 
Figure 3-3. 
Table 3-3 Levels of Significant Exposure to Strontium - Radiation Toxicity - Oral 
Exposure/ LOAEL
Duration/
a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route)figure (Strain) System (uCi/kg/day) (uCi/kg/day) (uCi/kg/day) Chemical Form 
ACUTE EXPOSURE 
Death 
1 Monkey 5-10 d Casarett et al. 196228 M (1/1 dead within 4 months
(Rhesus) (GW) from pancytopenia; est Strontium-90 


skeletal dose at death 
=4,500 rad) 
2 Rat 10 d Casarett et al. 1962297 M (lifespan decr 80%)
(Long- Evans) ad lib Strontium-90 
(W) 




4 Rat 10 d Casarett et al. 1962 
Hemato 297 M (hypoplasia of bone marrow)




Musc/skel 297 M (failure of osteogenesis) 
5 Rat 10 d Casarett et al. 1962 
ad lib Hemato 64 M (slight hypoplasia of bone(Long- Evans) marrow) Strontium-90 
(W) 
6 Cow 5 d Cragle et al. 1969
Gastro 44 F (intestinal hemorrhage)1 x/d 
Strontium-90 
Hemato 44 F (severe leukopenia, 
thrombocytopenia) 
Reproductive 




















































(Long- Evans) ad lib
(W) 
Rat 10 d











Rat 30 d 




























11 (CEL: leukemia in 1/1)
300 M (CEL: osteosarcoma)
135 M (CEL: 2 x incr in incidence of
malignancies) 
	 
74 M (35% decr survival)
6 (premature death from bone
marrow hypoplasia) 
74 M (moderate bone marrow
hypoplasia) 
74 M (damaged epiphyseal cartilage) 
6 (bone marrow hypoplasia;
anemia, reduced platelets) 
6 (decr osteocytes, decr blood 
vessels of bone) 

 
Casarett et al. 1962
Strontium-90
Casarett et al. 1962
Strontium-90 
Casarett et al. 1962
Strontium-90 
Casarett et al. 1962
Strontium-90 
Downie et al. 1959
Strontium-90 
Casarett et al. 1962 
Strontium-90 
Downie et al. 1959 
Strontium-90 

































74 (CEL: 28% osteosarcoma, 
11% skin carcinoma, 6% 
leukemia compared to 
none in control group) 
M 
Finkel et al. 1960 
Strontium-90 





1 x 30 d 
ad lib 
Rat 
74 F (CEL: osteosarcoma) 

















6 (CEL: osteosarcoma; 
multiple myeloma) 
0.5 (18% mortality) 
Downie et al. 1959 
Strontium-90 








ad lib 31 F (survival decr 17%) 







ad lib 4 F (survival decr 36%) 
Finkel et al. 1960 
Strontium-90 


































































0.5 (~21% leukopenia lasting 2
yrs) 
0.4 M (osteodystrophy)
0.4 M (petechiae, ecchymoses,
gastrointestinal bleeding) 





0.4 M (periacinar lipidosis; 
terminal necrosis) 
0.4 M (progressive weight loss 
in anemic dogs) 




Zapol’skaya et al. 1974
Strontium-90
Finkel et al. 1960 
Strontium-90 
Book et al. 1982 
Strontium-90 
Dungworth et al. 1969
Strontium-90
Momeni et al. 1976 
Strontium-90







































Rat 372-620 d 
daily(albino) ad lib 
(F) 
Mouse 600 d 
ad lib(CF-1) 
(F) 







PND540(Beagle) ad lib 
(F) 
0.4 M (splenic myeloid metaplasia)




0.03 F (CEL: reticular tumors)
36 F (CEL: 4x incr reticulocyte
tumors; osteosarcoma) 
0.4 M (premature death from
cancer) 
1.3 M (CEL: osteosarcoma)
0.4 M (incr death from cancer)
Dungworth et al. 1969
Strontium-90 
Finkel et al. 1960
Strontium-90 
Zapol’skaya et al. 1974
Strontium-90
Finkel et al. 1960
Strontium-90 
Finkel et al. 1960
Strontium-90 
Book et al. 1982
Strontium-90 
White et al. 1993
Strontium-90
a The number corresponds to entries in Figure 3-3. 
Ad lib - ad libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); decr = decreased; (F) = food; (G) = gavage; Gastro = gastrointestinal; GD = 
gestational day; (GW) = gavage in water; Hemato = hematological; incr = increased; LOAEL = lowest-observed-adverse-effect level; min = minute(s); mo = month(s); Musc/skel = 



































Figure 3-3 Levels of Significant Exposure to Strontium - Radiation Toxicity - Oral 
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Figure 3-3 Levels of Significant Exposure to Strontium - Radiation Toxicity - Oral (Continued) 
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Figure 3-3 Levels of Significant Exposure to Strontium - Radiation Toxicity - Oral (Continued) 
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Gastrointestinal Effects.    No studies were located regarding gastrointestinal effects in humans after 
oral exposure to radioactive strontium.  Intestinal hemorrhage occurred in cows succumbing to radiation 
sickness 3 months after ingesting 44 µCi 90Sr/kg/day (1.63 MBq/kg/day) for 5 days (Cragle et al. 1969). 
It is likely that other reports of terminal hemorrhagic effects (see Hematological Effects below) following 
high doses of radiostrontium encompassed intestinal hemorrhage whether or not it was specifically 
mentioned. 
Hematological Effects. In human and animal studies, adverse hematological affects were associated 
with beta radiation of bone marrow following incorporation of radiostrontium into bone. 
The Techa River population exposed to chronic combined external gamma radiation and internal radiation 
due to 90Sr and 137Cs exhibited alterations in hematological parameters, including leukopenia, 
thrombocytopenia, and granulocytopenia (Akleyev et al. 1995).  These effects were observed in a portion 
of the exposed population that received radiation doses to the bone marrow at rates in excess of 30– 
50 rem (0.3–0.5 Sv) per year.  These data are omitted from Table 3-3 because exposures were to multiple 
sources of radiation. 
Among Rhesus monkeys given 1,000 µCi (37 MBq) of 90Sr over 10 days, the one with the highest dose on 
a kg body weight basis (28 µCi/kg/day; 1.0 MBq/kg/day) died from pancytopenia within 4 months of 
treatment (Casarett et al. 1962).  Among young (30 days old) Long-Evans rats that were given >300 µCi 
90Sr/kg/day (11 MBq/kg/day) in drinking water for 10 days (total 460 µCi; 17 MBq), the bone marrow 
was extremely hypoplastic.  Hypoplastic effects were slight among adult males given doses of 64 or 
135 µCi/kg/day or adult females given 92 or 194 µCi/kg/day (total 330 or 650 µCi; total 12.2 or 
24.1 MBq; Casarett et al. 1962).  Skeletal radiation doses were about 15 times higher in the younger rats.  
In another acute study, six young female dairy cattle (three sets of twins, ages 398 and 479 days and 
weighing 145–349 kg at the start of treatment) were given 44 µCi 90Sr/kg/day (1.63 MBq/kg/day) for 
5 days (Cragle et al. 1969).  All six heifers exhibited decreases in leukocyte and platelet counts by the 
first month.  In surviving animals, the counts plateaued at about 60% of the normal value.  In four 
animals, the youngest (398 days old) and lightest (145–212 kg) at the time of dosing, leukocyte and 
platelet counts dropped severely after 80 days, shortly before the onset of the terminal stages of radiation 
sickness. 
In an intermediate-duration study in young Long-Evans rats, moderate hypoplasia of the bone marrow 
occurred among males (87 days old) given 74 µCi/kg/day and females given 104 µCi/kg/day (2.7 and 
90 STRONTIUM 
3. HEALTH EFFECTS 
3.8 MBq/kg/day, respectively) of 90Sr in drinking water for 30 days (total 790 µCi; 29.2 MBq) (Casarett 
et al. 1962). Hypoplasia of the bone marrow leading to anemia and thrombocytopenia developed in 
Dutch rabbits that were fed approximately 6 µCi 90Sr/kg/day (218 kBq/kg/day) in pellets for 31–280 days 
(Downie et al. 1959). 
Chronic-duration studies in several species reported suppression of hematopoiesis.  In albino rats fed 
≥0.5 µCi 90Sr/kg/day (18.5 kBq/kg/day) for their post-weaning lifetime, hematopoiesis was significantly 
depressed (Zapol’skaya et al. 1974).  Lymphocytes were the first cells affected, then neutrophils, 
thrombocytes, and after 1 year, erythrocytes.  Morphological abnormalities included binucleation.  At 
0.5 µCi 90Sr/kg/day (18.5 kBq/kg/day), leukocyte numbers remained 20% depressed by the end of the 
second year.  The authors calculated that the minimal dose to induce leukopenia was 150–200 rad.  The 
reduction in leucocytes plateaued at about 30–35% for absorbed doses between 400 and 2,000 rad.  
Hematological effects were reported in a chronic-duration beagle study, in which animals were exposed 
to 0.002–1.2 µCi/kg/day (0.074–44.4 kBq/kg/day) of 90Sr in utero from gestational day 21, throughout 
lactation, and from weaning on day 42 to day 540 (Dungworth et al. 1969).  Six years after exposure 
began, the following effects were observed at doses of 0.44 or 1.2 µCi/kg/day (14.8 or 44.4 kBq/kg/day): 
abnormal erythrocyte morphology (primarily poikilocytosis, anisocytosis, and hypochromasia, with some 
instances of macrocytosis), dose-related, radiation-induced leukopenia, an abnormal number of immature 
granulocytes, one case of unusual giant neutophils, a reduction in the number of platelets, anemia, and 
splenomegaly. Similarly, female Pitman-Moore miniature swine exposed to 3,100 µCi 90Sr/day 
(114.7 MBq/day) as strontium chloride died within 3–4 months from destruction of hematopoietic tissue 
in bone marrow, which resulted in anemia, leukopenia, thrombocytopenia, and terminal hemorrhagic 
syndrome (Clarke et al. 1972).  In addition, two animals in this group developed myeloid metaplasia. 
Musculoskeletal Effects. Skeletal effects following oral exposure to radioactive strontium have 
been reported in humans and animals.  Dystrophic lesions of the skeleton, primarily affecting articular 
and periarticular tissues, were observed in the Techa River populations that were chronically exposed to 
radiostrontium and other radionuclides in contaminated food and water (Akleyev et al. 1995).  The 
incidence of skeletal lesions was significantly higher for mean radiation doses to the surface of bone in 
excess of 200 rem (2 Sv). 
In an acute uptake, chronic radiation study, male and female 30-day-old Long-Evans rats that were given 
300 or 390 µCi 90Sr/kg/day, respectively (11 or 14.4 MBq/kg/day) in drinking water for 5–10 days (total 
460 µCi; 17 MBq) exhibited signs of abnormal osteogenesis more than 10 months after administration 
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(Casarett et al. 1962).  As marrow failed to invade into metaphyseal cartilage, the cartilage resumed active 
proliferation.  Resorption failed to occur in metaphyseal cartilage and metaphyseal spongiosa failed to 
transform to lamellar bone.  Often, cartilage and fibrous marrow were incorporated into cortical bone, 
sometimes causing fracture and deformation. 
In an intermediate uptake, chronic radiation study on young (87 days old) Long-Evans rats, ingestion of 
74 (males) or 104 (females) µCi 90Sr /kg/day (2.7 or 3.8 MBq/kg/day) in drinking water for 30 days (total 
790 µCi; 28.9 MBq) adversely affected the vasculature of the bone, which interfered with the normal 
transformation of cartilage into bone (Casarett et al. 1962).  At the end of the long bones, the cartilage 
discs were damaged, with detachment of primary spongiosa and failure of resorption. In another 
intermediate-duration study, numbers of osteocytes (bone cells surrounded by a mineralized matrix and 
connected by a mesh-work of processes) were reduced in Dutch rabbits that ingested approximately 6 µCi 
90Sr/kg/day (218 kBq/kg/day) in pellets for 48 days (Downie et al. 1959). 
Bone damage was a notable effect of chronic-duration oral exposure to radioactive strontium in dogs 
(Momeni et al. 1976).  Groups of pregnant beagles were fed 0.002–3.6 µCi 90Sr/kg/day (0.074– 
133.2 kBq/kg/day) from gestational day 21 through lactation to PND 44, and the pups were fed the same 
doses from weaning at day 42 through day 540 (Raabe et al. 1983; White et al. 1993).  Ten years from the 
start of the study, dose-related skeletal effects included mild trabecular osteopenia, endosteal and 
periosteal cortical changes (sclerosis and thickening), and mottling or focal osteolytic lesions (Momeni et 
al. 1976).  These occurred in all the dogs in the 3.6 µCi/kg/day group and also in the 1.2 and 
0.4 µCi/kg/day groups (133.2, 44.4, and 14.8 kBq/kg/day, respectively).  Radiation-induced 
osteodystrophy was noted in three out of four beagle dogs that received 1.2 µCi 90Sr/kg/day 
(44.4 kBq/kg/day) for life beginning at midgestion (Book et al. 1982); the average dose rate (cumulative 
dose divided by lifespan) for these dogs was 4 rad/day (0.04 Gy/day).  Radiation osteonecrosis was said 
to be a common finding among female Pitman-Moore miniature swine that died with hematopoietic 
disorders or bone marrow hypoplasia after ingesting 90SrCl2 at levels between 1 and 3,100 µCi/day (0.37– 
114.7 MBq/day) until death (Clarke et al. 1972).  The incidence of osteonecrosis at each dose level was 
not reported.  Bone cancers that were reported in these chronic studies are discussed below in 
Section 3.3.2.7. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure to 
radioactive strontium isotopes.  No studies were located regarding hepatic effects in animals after acute- 
or intermediate-duration oral exposure to radioactive strontium isotopes.  In a chronic-duration beagle 
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study, animals exposed to 0.4 or 1.2 µCi 90Sr/kg/day (14.8 or 44.4 kBq/kg/day) in utero from gestational 
day 21, throughout lactation, and from weaning on day 42 to day 540 exhibited only secondary hepatic 
effects (Dungworth et al. 1969). Livers were sometimes enlarged from myeloid infiltration and periacinar 
lipidosis, sometimes with terminal necrosis, in dogs with severe anemia.  Since the observed myeloid 
infilitration was a secondary effect resulting from irradiation of the bone marrow, it is not categorized 
under Systemic: Hepatic Effects in Table 3-3. 
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to 
radioactive strontium isotopes.  Approximately 19% of adult Long-Evans rats ingesting 65 µCi 90Sr/day 
(2.41 MBq/day; 135 or 194 µCi/kg/day, 5 or 7.2 MBq/kg/day for males and females, respectively) of in 
drinking water for 10 days developed chronic interstitial nephritis, a common disease in older rats, during 
their remaining lifespan (Casarett et al. 1962).  It is very unlikely that the ingestion of radiostrontium was 
related to the occurrence of nephritis. 
Ocular Effects.    No studies were located regarding ocular effects in humans after oral exposure to 
radioactive strontium isotopes. 
No studies were located regarding ocular effects in animals after acute- or intermediate-duration oral 
exposure to radioactive strontium isotopes.  In one chronic-duration study, 2 out of 403 beagles that had 
been exposed to 90Sr in utero from gestational day 21, during lactation, and from weaning on day 42 to 
day 540, developed a benign melanoma of the eye, but the dose-level was not reported (Raabe et al. 
1994). Statistical analysis showed that these tumors (not found in controls, but also found in dogs 
irradiated through other exposure routes, or with other radionuclides) were significantly related to 
exposure to ionizing radiation.  According to a 6-year report from the same chronic-duration beagle study, 
animals exposed to 0.4 or 1.2 µCi 90Sr/kg/day (14.8 or 44.4 kBq/kg/day) in utero from gestational day 21, 
throughout lactation, and from weaning on day 42 to day 540 exhibited only indirect ocular effects 
(Dungworth et al. 1969).  The eyes of dogs with a myeloproliferative disorder exhibited some slight 
degree of myeloid infiltration (see Section 3.3.2.7 Cancer).  Since this was a secondary effect resulting 
from irradiation of bone marrow and not the direct response of the eye tissues to radiostrontium, it is not 
categorized under Ocular Effects in Table 3-3. 
Body Weight Effects.    No studies were located regarding body weight effects in humans after oral 
exposure to radioactive strontium isotopes.  No studies were located regarding body weight effects in 
animals after acute- or intermediate oral exposure to radioactive strontium.  No effect on body weight was 
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observed among female CF-1 mice that had been exposed to 90Sr in utero, during lactation, and up to day 
414 at doses of up to 36 µCi of 90Sr/kg/day (1.33 MBq/day) (Finkel et al. 1960).  Progressive weight loss 
was observed among beagle dogs that developed anemia after having been exposed to 0.4–1.2 µCi of 
90Sr/kg/day (148–444 kBq/kg/day) from mid-gestation to age 1.5 years (Dungworth et al. 1969). 
3.3.2.3 Immunological and Lymphoreticular Effects 
Immunological changes were reported in the Techa River population that was exposed to chronic 
combined external gamma radiation and internal radiation from 90Sr and 137Cs between 1949 and 1956 
(Akleyev et al. 1995).  Immunological disorders persisted for 30 years and included decreased expression 
of antigens of differentiating T-lymphocytes, decreased T-lymphoblast transformation, and reduced 
counts of large granulocytic lymphocytes.  Granulocytopenia developed in a portion of the exposed 
population that received radiation to the bone marrow at rates in excess of 30–50 rem (0.3–0.5 Sv) per 
year.  Akleyev et al. (1995) suggested that radiation-induced immunodeficiency may have contributed to 
the higher incidence of leukemia in the exposed population (see Section 3.3.2.7 Cancer).  Clinical 
manifestations of immune insufficiency in exposed cancer patients included 3-fold increases in the 
incidences of infectious diseases (chronic pneumonia, chronic bronchitis, pulmonary tuberculosis, and 
osteomyelitis) compared to a nontumor-bearing group.  These data are omitted from Table 3-3 because of 
the mixed exposures. 
No animal studies were located that described immunological effects following acute oral uptake of 
radiostrontium.  Intermediate-to-chronic-duration exposures to radiostrontium resulted in impaired 
immune function in animals.  In Pitman-Moore miniature pigs that were fed 625 µCi 90Sr/day 
(23.13 MBq/day) as strontium chloride for 9 months, the antibody response to inoculated Brucella 
abortus (strain 19) antigen was determined by the plate agglutination test to be less than half that of 
controls (Howard 1970). In another test, peripheral leukocyte cultures were prepared from these same 
animals at monthly intervals, in medium containing phytohemagglutinin (PHA).  In pigs that were fed 
625 µCi 90Sr/day (23.13 MBq/day) for 4–5 months, peripheral lymphocytes lost the ability to respond to 
PHA stimulation; this adverse effect was sustained for at least 6 months.  The author attributed these 
immunological effects to exposure to 90Sr. Myeloid metaplasia also afflicted female Pitman-Moore 
miniature swine that were fed 3,100 µCi 90Sr/day (114.7 MBq/day) until the end of life at age 3–4 months 
(Howard and Clarke 1970). The cumulative doses at the time of death ranged from 40 to 10,000 rad (0.4– 
100 Gy). 
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In a 6-year status report of a chronic uptake study in which beagle dogs were exposed to 90Sr from 
midgestion to age 1.5 years, 1.3% of dogs receiving 0.4 µCi 90Sr/kg/day (14.8 kBq/kg/day) and 3.7% of 
dogs receiving 1.2 µCi 90Sr/kg/day (44.4 kBq/kg/day) developed myeloid metaplasia of the spleen 
(Dungworth et al. 1969). 
The highest reliable NOAEL values and all LOAEL values for immunological and lymphoreticular 
effects from oral exposure to radioactive strontium in each species and duration category are recorded in 
Table 3-3 and plotted in Figure 3-3. 
3.3.2.4 Neurological Effects 
Nervous system disorders (weakness, apathy, fatigue) were reported in the Techa River population that 
was chronically exposed to combined external gamma radiation and internal radiation from 90Sr and 137Cs 
(Akleyev et al. 1995).  Neurological effects were observed at chronic dose rates in excess of 40–50 rad 
(0.4–0.5 Gy) per year and persisted for 14–20 years in the exposed population. However, it is not clear to 
what extent strontium-derived radiation contributed to neurological effects, compared to external gamma 
radiation. These data are omitted from Table 3-3 because of the mixed exposures. 
No studies were located that reported neurological effects in animals following oral exposure to 
radioactive strontium isotopes. 
3.3.2.5 Reproductive Effects 
No significant reproductive effects were reported in the Techa River population that was exposed to 
combined external gamma radiation and internal radiation from 90Sr and 137Cs between 1949 and 1956 
(Kossenko et al. 1994).  Exposure had no effect on birth rate, fertility, or the incidence of spontaneous 
abortions in the study group that had received average doses to the gonads of up to 74 rem (0.74 Sv), 
primarily from external gamma radiation (Akleyev et al. 1995).  An increase in the incidence of ectopic 
pregnancies was not dose-associated.  These data are omitted from Table 3-3 because exposures were to 
multiple sources and it is probable that radiostrontium had a minor effect on the gonadal radiation dose. 
In one acute study, female rats were given a single dose of 400 µCi 90Sr/kg by gavage 1–10 days before 
impregnation (Moskalev et al. 1969).  At the time of conception, the maternal skeletal dose was 800 rad 
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(8 Gy) and soft tissue dose was 10 rad (0.1 Gy).  Fetuses received skeletal doses of 20 rad (0.2 Gy). 
Under these conditions, 22% of fetuses died.  In an intermediate-duration study, groups of 230– 
339 female CF-1 mice were fed 90Sr in the diet at doses between 0.03 and 31 µCi/kg/day (1.11 and 
1,147 kBq/day; Finkel et al. 1960).  Dams and males bred while on the radiostrontium diet, and dams 
were maintained on diet throughout gestation and lactation.  Radiostrontium feeding had no effect on 
fertility, the number of live offspring, or the number of female offspring surviving at PND 35. 
In a multigenerational study, 9-month-old female Pitman-Moore miniature swine were fed a diet 
containing between 1 and 3,100 µCi 90Sr/day (0.037 and 114.7 MBq/day) and then were bred with males 
that were only exposed to 90Sr during the period of mating (Clarke et al. 1970, 1972; McClellan et al. 
1963).  Ingestion of radioactive strontium had no effect on fertility or fecundity. Pregnant sows receiving 
3,100 µCi 90Sr/day (114.7 MBq/day) did not survive to the end of the period of gestation because of bone 
marrow hypoplasia, but their fetuses were apparently normal (McClellan et al. 1963).  For doses between 
1 and 625 µCi 90Sr/day (0.037 and 23.13 MBq/day), there was no significant effect on litter size, 
percentage of stillborn, or birth weight.  Exposure had no effect on frequency and duration of the estrus 
cycle or in the number of repeat breedings.  However, the F1 offspring of the sows ingesting 625 µCi 
90Sr/day (23.13 MBq/day) did not survive to adulthood.  Survival of the F2 offspring was apparently 
similar to the F1 generation, but their reproductive capacity was not reported, since later studies focused 
on cancer effects. 
The highest reliable NOAEL values and all LOAEL values for reproductive effects from oral exposure to 
radioactive strontium in each species and duration category are recorded in Table 3-3 and plotted in 
Figure 3-3. 
3.3.2.6 Developmental Effects 
Few developmental effects were reported in the progeny of the Techa River population that was exposed 
to combined external gamma radiation and internal radiation from 90Sr and 137Cs between 1949 and 1956 
(Kossenko et al. 1994).  The cohort of women in the study received radiation doses to the gonads of up to 
74 rem (0.74 Sv), primarily from external gamma radiation (Akleyev et al. 1995); the proportion of the 
dose attributable to radiostrontium was not specified, but is likely to have been relatively small.  No 
increase in the incidences of spontaneous abortion, miscarriages, or stillbirths was observed.  However, 
there were slight increases in child mortality from chromosomal defects and from congenital anomalies of 
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the nervous system, circulatory system, and other unspecified anomalies in the progeny of the exposed 
group compared to controls.  Considering deaths from these anomalies, from labor complications, or from 
unspecified perinatal causes, the mortality coefficient of the offspring of parents with gonadal doses of 
11 rem (0.11 Sv) was double that of the unexposed control group.  Kossenko et al. (1994) calculated that 
the gonadal doses required to double the incidences of stillbirths, miscarriages, early neonatal mortality, 
or lethal developmental effects were rather high, ranging from 20 to 480 rem (0.2–4.8 Sv) for the different 
end points. These data are omitted from Table 3-3 because of the combined internal and external 
radiation exposures. 
In one animal study, CF-1 mice were exposed to 90Sr from the time of conception; breeding adults were 
fed a diet containing 0.03–31 µCi 90Sr/kg/day (1.11–1,147 kBq/kg/day), and the dams were fed the same 
diet throughout gestation and lactation (Finkel et al. 1960).  The offspring were fed the same diet 
throughout their lifetimes.  Gestational exposure to radiostrontium did not affect litter size or early 
survival of offspring, and no teratogenic effects were noted.  However, survival of the offspring was 
shortened at doses of 3 µCi 90Sr/kg/day (111 kBq/kg/day) or higher, which was related to the higher 
incidence of bone-related cancer (see Section 3.3.2.7 Cancer).  Autoradiographs demonstrated the 
uniform distribution of 90Sr in the skeleton, which probably contributed to these effects. 
In a large multigenerational study, 9-month-old female Pitman-Moore miniature swine were fed a diet 
containing between 1 and 3,100 µCi 90Sr/day (0.037 and 114.7 MBq/day) and then were bred with males 
that were only exposed to 90Sr during the period of mating (Clarke et al. 1970, 1972; McClellan et al. 
1963). Ingestion of radioactive strontium had no effect on fertility or fecundity.  Fetuses were apparently 
unaffected, even those of sows that died during pregnancy from bone marrow hypoplasia after ingesting 
3,100 µCi 90Sr/day (114.7 MBq/day; McClellan et al. 1963).  For doses between 1 and 625 µCi 90Sr/day 
(0.037 and 23.13 MBq/day), there was no significant effect on litter size, percentage of stillborn, or birth 
weight. In offspring of sows ingesting 625 µCi 90Sr/day (23.13 MBq/day), the weaning weight was 
reduced because radiation-induced hematopoietic effects reduced the output of milk (Clarke et al. 1970).  
After weaning, the F1 offspring were fed 90Sr in the diet at graded levels that, by 6 months, equaled the 
maternal level, 1–625 µCi 90Sr/day (0.037–23.13 MBq/day).  The 625 µCi 90Sr/day (23.13 MBq/day) F1 
females did not survive to be bred at 9 months.  These results indicate an age-related vulnerability to 90Sr, 
since the 625 µCi 90Sr/day (23.13 MBq/day) dosage was not lethal to the parental generation (pigs 
exposed from age 9 months).  
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The highest reliable NOAEL values and all LOAEL values for developmental effects from oral exposure 
to radioactive strontium in each species and duration category are recorded in Table 3-3 and plotted in 
Figure 3-3. 
3.3.2.7 Cancer 
Epidemiological studies have found little or no association between oral exposure to radioactive strontium 
from fallout and cancer effects in humans.  In an epidemiological study using the Danish cancer registry, 
no association was found between the incidence of thyroid cancer in Denmark between 1943 and 1988 
and the levels of skeletal incorporation of 90Sr from fallout (Sala and Olsen 1993).  In another 
epidemiological study, data collected between 1959 and 1970 in a 90Sr monitoring program in Glasgow, 
Scotland, were used to identify three cohorts with respect to the hypothetical risk for leukemia and non­
Hodgkin’s lymphoma, acute myeloid leukemia, all childhood cancers combined, and bone tumors (Hole 
et al. 1993). The three cohorts were a high risk group born in 1963–1966 (exposed to high levels of 
fallout, i.e., 90Sr, at a young age), a medium risk group born in 1959–1962 (exposed to high levels at an 
older age), and a low risk group born after 1966. Cumulative incidences for all cancers, leukemia and 
non-Hodgkin’s lymphoma, and acute myeloid leukemia all showed a secular (progressive, noncyclical) 
increasing trend for children born before 1982.  However, the study found no evidence for increased risks 
of total cancers, leukemia and Non-Hodgkin’s lymphoma, or acute myeloid leukemia for cohorts born 
during the period of highest fallout (radiostrontium) exposure.  The few cases of bone tumors showed a 
statistically nonsignificant increase for children born during the ‘high risk’ period. 
In contrast, the Techa River population that was exposed to contaminated water and food as a result of 
releases from a nuclear weapons facility exhibited a significant increase in the incidence of leukemia 
(Kossenko 1996; Kossenko et al. 1997, 2000, 2002).  An excess of leukemia cases (0.85 excess cases per 
10,000 person-year Gy (95% CI: 0.2; 1.5) was observed in groups of individuals with estimated bone 
marrow doses in excess of 10 rem (0.1 Sv), and the risk of mortality from leukemia increased with 
increasing dose (Kossenko, 1997, 2002).  This finding can be related to the body burdens of 90Sr, which in 
the Techa River cohort, have been >100 times higher than fallout-related exposures during the same 
period (Shagina et al. 2000).  No increase in cancer rates has been observed in the progeny of the Techa 
River cohort (Kossenko 1996). 
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As shown in numerous animal studies, oral exposure to radioactive strontium may increase the incidence 
of cancers of bone and bone marrow.  In a small study in which young monkeys were given 90Sr by 
gavage, one given 11.2 µCi 90Sr/kg/day (0.42 MBq/kg/day) for 5 days died of leukemia, with a final 
skeletal dose of 4,300 rad (43 Gy) 4 years after treatment (Casarett et al. 1962).  Two others exposed to an 
average of 18 µCi 90Sr/kg/day (0.67 MBq/kg/day) for 10 days died from bone-associated cancers 
(chondrosarcoma, osteosarcoma) within 36 months of treatment, with estimated skeletal doses of 4,700– 
9,500 rad (47–95 Gy). 
Acute-duration experiments using Long-Evans rats demonstrated that weanlings, with their relatively 
higher rate of incorporation of strontium into the skeleton, were more vulnerable than adults to the 
carcinogenetic effects of 90Sr (Casarett et al. 1962).  Weanlings (30 days old) were given 46 µCi 90Sr/day 
(1.7 MBq/day) and adults were given 33 or 65 µCi 90Sr/day (1.2 or 2.4 MBq/day) in drinking water for 
10 days; on a body weight basis, the amounts given were >300 µCi/kg/day (11 MBq/kg/day) for 
weanlings, 64 or 135 µCi/kg/day for adult males, or 92 or 194 µCi/kg/day for adult females.  After 
5 months, 33 µCi (1.2 MBq) of radioisotope were detected in the skeletons of weanlings that received 
460 µCi (17 MBq), but only 1 or 2 µCi (37 or 74 kBq) were detected in the skeletons of adults that 
received 330 or 650 µCi (12.2 or 24.1 MBq), respectively.  The differences in incorporation of 90Sr 
probably accounted for the age-related differences in the incidence of osteosarcoma; 17.5% of weanlings 
developed osteosarcoma compared to none of the adults.  However, in the high dose adults, the overall 
incidence of malignancy (leukemia, squamous cell carcinoma of the skin, various other carcinomas) was 
more than doubled, compared to controls.  At the lower dose, the overall rate of malignancies in adults 
was lower than in controls (6.25% compared to 16.2%).  In an intermediate-duration experiment, in which 
male 87-day-old Long-Evans rats were given 74 µCi 90Sr/kg/day (2.7 MBq/kg/day) and females were 
given 104 µCi 90Sr/kg/day (3.8 MBq/kg/day) in drinking water for 30 days (total 790 µCi; 29.2 MBq), the 
incidence of osteosarcomas was 27.5% compared to none in the controls.  Overall, the incidence of 
malignancy in the treated group was more than double that of controls; other neoplasms included 11.25% 
skin carcinoma (facial) and 6.25% leukemia.  The 87-day-old rats treated for 30 days had a 5-month 
skeletal burden of about 11µCi (407 kBq), which, on a kg body weight basis, was less than one quarter 
that of weanlings treated for 10 days.  This discrepancy reflects differences in rates of absorption and 
osteogenesis, which are higher in the younger rats.  The older rats had a higher incidence of osteosarcoma 
than the weanlings because they survived beyond the latency period for the cancer.  In another 
intermediate-duration rat study, oral exposure to 90Sr for 37 days (total dose of 790 µCi; 29.2 MBq) 
increased the incidence of osteolysis and osteogenic sarcoma by 21% (Hopkins et al. 1966).  The 
radiation dose to the skeleton after 150 days was 4,000 rad (40 Gy).  Young rabbits (~52 days old) that 
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were fed an average of 6 µCi 90Sr/kg/day (218 kBq/kg/day) 90Sr in pellets for 224–280 days developed 
multiple osteogenic sarcomas in the skull and at the rapidly growing ends of the long bones within 6– 
8 months (Downie et al. 1959). 
Relatively large studies in rats, mice, dogs, and pigs demonstrated increased tumor induction following 
chronic ingestion of 90Sr. In the rat study, albino rats were fed between 0.05 and 2 µCi 90Sr/kg/day for 
their post-weaning lifetime, resulting in exposures between 0.01 and 0.4 µCi/day (Zapol’skaya et al. 
1974).  In rats consuming 2 µCi 90Sr/kg/day, the number of rats with malignant tumors was 18.7%, 
compared to 1.3% for controls.  At 0.5 90Sr/kg/day, the tumor incidence was 3–6 times lower (not 
specified numerically), but the outcome at 0.05 90Sr/kg/day was not reported.  The most common 
malignancies were lymphosarcoma (8%), osteosarcoma (6.7%), and “leukosis” (4%).  The latency periods 
were 300–540 days for lymphosarcomas and 450–660 days for “leukosis” and osteosarcoma.  The 
cumulative absorbed doses averaged 1,350 rad (13.5 Gy) just before the onset of lymphosarcoma, 
2,200 rad (22 Gy) just before the onset of ‘leukosis’, and 2,400 rad (24 Gy) just before the onset of 
osteosarcoma. 
In the mouse study, mice were exposed either as adults (beginning at age 110–250 days) or from 
conception to 0.05–36 µCi 90Sr/kg/day (Finkel et al. 1960).  There was a higher incidence of reticular 
tumors in blood-forming tissues, but no evidence of osteogenic sarcoma in all adult exposed groups.  
Possibly because of the experimental design-groups were not exposed simultaneously and were subjected 
to environmental differences-tumor incidence in adults did not show a clear dose-response.  However, the 
tumor incidence was significantly elevated in mice exposed to 90Sr from conception.  The highest dose 
level resulted in the early appearance of reticular tumors, especially lymphomas; 24% of mice at this level 
died with reticular-tissue tumors by 525 days, compared to 6% in controls.  Other tumors unique to the 
high-dose level included six osteogenic sarcomas, four osteolytic tumors, and two epidermoid carcinomas 
of the oral cavity.  Radiography demonstrated that radioactive strontium was ubiquitously distributed 
throughout the skeleton of mice exposed from conception. 
In the dog study, groups of pregnant beagles were fed between 0.002 and 3.6 µCi 90Sr/kg/day (0.074 and 
133.2 kBq/kg/day) from day 21 of gestation to postnatal day 42 (White et al. 1993).  The pups were 
weaned and then fed a diet containing the same 90Sr/calcium ratio as the dam until day 540.  Bone 
sarcoma deaths occurred in dogs ingesting between 0.13 and 3.6 µCi 90Sr/kg/day (4.8–133.2 kBq/kg/day) 
resulting in bone doses at death of 5,000–10,700 rad (50–107 Gy), but not at 0.002–0.043 µCi 90Sr/kg/day 
(0.1–1.6 kBq/kg/day) with doses to death of 100–2,300 rad (1–23 Gy).  The higher the amount of 90Sr 
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given, the earlier the age of onset of sarcomas and the more likely they were to be osteosarcomas.  Of 
66 sarcomas, 75% were osteosarcomas; other types were chondrosarcoma, hemangiosarcoma, 
fibrosarcoma, and undifferentiated sarcoma.  Multiple tumors occurred only at the two highest doses.  
Other cancer deaths occurred at high doses: radiation-induced myeloid leukemia (43 deaths), oral or nasal 
carcinoma (29 deaths), and periodontal carcinoma (16 deaths).  The leukemic animals (average age at 
death 1,156 days) were not at risk for osteosarcoma, which had an average age of onset of 2,864 days.  
The mean cumulative skeletal doses at the time of onset in the four highest exposure groups for dogs with 
tumors were between 3,100 and 11,600 rad (31–116 Gy).  The authors indicated that of the exposures that 
did not give rise to tumors, the lowest exposure (8 mrad/day; 0.08 mGy/day) was 25 times higher than 
background and the highest (146 mrad/day; 1.46 mGy/day) was 500 times higher than background.  
Therefore, lifetime chronic exposure to low linear energy transfer (LET) beta particle radiation up to 
500 times background showed no apparent carcinogenic potential in dogs. 
Stage-specific differences in carcinogenetic effects were reported in a large multigenerational study of 
female Pitman-Moore miniature swine that were fed between 1 and 3,100 µCi 90Sr/day 
(0.037–114.7 MBq/day) for life (Clarke et al. 1972; Howard 1970; Howard and Clarke 1970).  In the 
parental generation, which was started on the regimen at age 9 months of age, myeloid metaplasia was 
observed at nearly all levels, and lymphoid or myeloid neoplasms were observed when between 1 and 
125 µCi 90Sr/day were ingested.  The average doses to the skeleton for the parental females were between 
40 and 10,000 rad.  No bone cancer occurred in the parental generation, whereas osteosarcomas occurred 
in F1 or F2 offspring exposed from conception to 125 or 625 µCi/day with average skeletal doses higher 
than 9,000 rad (90 Gy).  Osteosarcoma had a longer latency period and occurred at higher exposure 
levels. Myeloid metaplasia and myeloid and lymphoid neoplasms developed sooner and more frequently 
in the F1 and F2 generations than in the parental generation. 
The cancer effect levels (CELs) resulting from oral exposure to radioactive strontium in each species and 
duration category are recorded in Table 3-3 and plotted in Figure 3-3. 
3.3.3 External Exposure 
Cardiovascular, dermal, ocular, and cancer effects have been reported following acute- or intermediate-
duration external exposure to beta radiation from a solid radioactive strontium source apposed to the skin 
or eye.  In these studies, 90Sr was considered to be in equilibrium with 90Y; that is, following decay of 90Sr, 
some radiation emissions could be expected from decay of its transformation product, 90Y. 
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3.3.3.1 Death 
No studies were located regarding death in humans or animals after external exposure to radioactive 
strontium. 
3.3.3.2 Systemic Effects 
No studies were located regarding respiratory, gastrointestinal, hematological, musculoskeletal, hepatic, 
renal, or endocrine effects in humans or animals after external exposure to radioactive strontium isotopes. 
Cardiovascular Effects.    Exposure to excessive ionizing radiation is known to affect the integrity of 
the vasculature of the skin, increasing the permeability of the vasculature to plasma protein.  A study by 
Song et al. (1968) examined the ability of several anti-inflammatory agents to suppress this radiation-
induced increase in vascular permeability.  Albino male guinea pigs were exposed to 3,000 rep (Roentgen 
equivalent, physical) (3,230 rad; 1 rep.0.93 rad) of particles (800 rad/min; 8.0 Gy/min) from a 90Sr/90Y 
source. Immediately after irradiation, 125I-labeled guinea pig serum albumin was injected into the heart as 
a tracer. The peak increase in vascular permeability, as measured by the ratio of accumulation of labeled 
plasma protein in the nonirradiated control and beta-irradiated skin, was determined to occur at 18 hours.  
In the group receiving no anti-inflammatory drug, the irradiated epidermis and dermis exhibited 
approximately 3- and 1.6-fold increases in the peak accumulation of plasma protein, respectively. 
The highest reliable NOAEL values and all LOAEL values for cardiovascular effects from external 
exposure to radioactive strontium in each species and duration category are recorded in Table 3-4. 
Dermal Effects.    Several studies in humans and animals have reported damage to the skin following 
external exposure to radioactive strontium.  Beta radiation from 90strontium has been used to treat 
hemangiomas in children and adults.  One study described some delayed effects of this radiation 
treatment within patients in one medical practice in Belgrad, Yugoslavia (now Serbia; Bekerus 1970).  
The beta source was a 50 mCi 90Sr plate with a diameter of 9.9 mm.  Adults were treated with an initial 




















1 Human once 
<1 min Ocular 1700 (scleral thinning in diabetic 
patient) 
Wesberry and Wesberry 1993 
Strontium-90 
Table 3-4 Levels of Significant Exposure to Strontium - Radiation Toxicity - External Radiation 
2 Mouse 	 1-60 min Hopewell et al. 1986 
once Dermal 2200 M (50% incr moist desquamation)(SAS/4) Strontium-90/yttrium-90 
3 Mouse 	 9 min Hoshino and Tanooka 1975 Dermal	 2700 F (acute injury, scarring)once(ICR) 	 Strontium-90/yttrium-90 
4 Mouse 	 once Randall and Coggle 1995Dermal 5000 M (late chronic fibrosis)
(CD-1) Strontium-90/yttrium-90 
5 Mouse	 once Randall and Coggle 1995Dermal 5000 M (late chronic fibrosis)
(CBA/ca Strontium-90/yttrium-90
agouti) 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) (rad) Chemical Form 
6 Gn Pig 	 1.4 to 8.3 min Etoh et al. 1977 
once Dermal	 1000 M (reversible 25% loss of basal(albino) cells; erythema; hair loss) 	 Strontium-90/yttrium-90 
7 Gn Pig 	 4 min Song et al. 1968 
once Cardio 3230 M (incr vascular permeability in 
(albino) dermis) Strontium-90/yttrium-90
 
8 Pig	 1-60 min Hamlet et al. 1986 Dermal	 2000 F (late 35% dermal atrophy)once(Large White) 	 Strontium-90/yttrium-90 
9 Pig once Hopewell et al. 1985 
3 to 12 min Dermal 2340 F (moist desquamation)Large White Strontium-90 
10 Pig 	 1-60 min Hopewell et al. 1986 
once Dermal 3000 F (50% incr moist desquamation) 
(Large White) Strontium-90/yttrium-90
 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) 	 (rad) Chemical Form 
11 Pig	 1-60 min Peel et al. 1984. 




12 Mouse 1 hr Hoshino and Tanooka 197517800 F (CEL: 1/5 fibrosarcomaonce(ICR)	 of skin) Strontium-90/yttrium-90 
INTERMEDIATE EXPOSURE 
Systemic 
13 Human	 1 yr Bekerus 1970 
~1 x/mo Dermal 220 (delayed telangiectasis, slight 
~min/d atrophy) Strontium-90 






Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain) System (rad) (rad) (rad) Chemical Form 
14 Human 3 wk Tong et al. 1969 
1 x/wk Ocular 1075 (conjunctival telangiectasis, 
<1 min/d scarring; abnormal nuclei of Strontium-90 
conjunctival epithelium) 
Cancer 
15 Mouse 43 wks Hoshino and Tanooka 197517800 F (CEL: 1/5 reticulocyte1 x/wk(ICR) sarcoma) Strontium-90/yttrium-901 hr 
16 Mouse 177-300 d Ootsuyama and Tanooka 1988150 F (CEL: fibrosarcoma;3 x/wk(ICR) squamous cell Strontium-90/yttrium-90~min/d 
carcinoma; basal 
cell carcinoma) 
17 Mouse 177-300 d Ootsuyama and Tanooka 1989150 F (CEL: osteosarcoma)3 x/wk(ICR) Strontium-90/yttrium-90~min/d 
a There is no corresponding LSE figure. 
1 In these studies, a solid radioactive source was placed adjacent to the eye or skin. 
~ = approximately; CEL = cancer effect level; d = day(s); Gn pig = guinea pig; hr = hour(s); incr = increased; LOAEL = lowest-observed-adverse-effect level; min = minute(s); NOAEL 
= no-observed-adverse-effect level 
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not exceeding a total of 7,530 rad (75.3 Gy).  Children were treated with an initial dose of 200–300 rad 
(2–3 Gy) and additional treatments over 6–16 months, for a total exposure of 2,420–6,130 rad (24.2– 
61.3 Gy) in some cases.  Eight or 10 years after treatment, about a third of the patients developed delayed 
reactions to radiation: achromia, excess pigmentation, slight atrophy, and telangiectasis.  The author did 
not specify the exposure levels that resulted in these effects. 
Acute dermal reactions to 90Sr have been described for depilated skin in mice, guinea pigs, and pigs.  In 
mice, skin exposed to a single 2,000–5,000 rad (20–50 Gy) dose of beta radiation from a 90Sr-90Y source 
sustained an acute reaction (Hoshino and Tanooka 1975; Randall and Coggle 1995).  For example, all 
mice exposed once to 5,000 rad (50 Gy) from a 1 mm diameter source developed an acute skin reaction 
with the following characteristics (Randall and Coggle 1995).  After an asymptomatic period of 3 or 
4 days, the skin exhibited increasing erythema and pigmentation changes, leading to dry desquamation by 
day 10.  Within a few days, exposed skin entered a period of moist desquamation, during which a serum 
scab was formed that was prevalent between days 15 and 25.  Re-growth of the epithelium commenced at 
the edges of the irradiated field and from surviving hair follicles.  By 1 month postirradiation, the 
epidermis was overtly normal, although histologically hyperplastic.  Chronic fibrosis was a delayed skin 
reaction that was not apparent until 3–6 months postirradiation. 
Dose-related effects were noted in guinea pig skin that was treated with a 25x25 mm square 90Sr source 
(Etoh et al. 1977). At 1,000 rad, there was a transient 25% reduction in the number of basal epithelial 
cells by day 10, which approached normality by day 15.  At 2,200 rad, the epithelial basal cell population 
dropped by about 60% at day 12, but was slightly above normal by day 20.  At 3,000 and 5,000 rad, the 
basal epithelial cell population was reduced 75%, but hyperplasia was also detected at the margin of the 
field. Hyperplasia was maintained for the 50-day observation period following exposure to 2,200– 
5,000 rad.  At 3,000 rad, erythema was noted by day 14, followed by dry desquamation and complete hair 
loss by day 21.  A similar pattern, with ulceration at 1 month, was seen at 5,000 rad. 
Within certain ranges, field-size effects for acute, localized external exposures to radioactive strontium 
have been demonstrated in mice and pigs.  Hopewell et al. (1986) exposed young SAS/4 male mice to 
different levels of radiation from 90Sr sources varying in diameter between 1 and 22.5 mm.  The ED50 
values for moist desquamation were 2,200–2,750 rad (22–27.5 Gy) for the 22.5-mm source and 7,500– 
9,000 rad for the 5-mm source.  Acute tissue breakdown was only achieved in mouse skin by very high 
doses (ED50 ≥14,000 rad) when the smallest sources were employed (≤2 mm in diameter).  In a parallel 
study in pigs, moist desquamation occurred at 2,250–7,500 rad (22.5–75 Gy) and acute tissue necrosis 
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occurred at doses of ≥14,000 rad (140 Gy) (Hopewell et al. 1985, 1986).  Peel et al. (1984) compared the 
effect on pigskin of acute exposure to 90Sr sources with diameters between 1 and 40 mm.  The effects of 
acute beta radiation included epithelial cell death within the first 16 weeks, and subsequently, dermal 
necrosis that was attributed to vascular damage.  The rate of repair was dependent on the size of the 
exposed area, since repair was dependent upon the migration of healthy cells into the wound. Transient 
moist desquamation associated with bright red erythema was observed between 4 and 6 weeks.  At ‘high’ 
doses, this intensified and the dermis became ulcerated, but healed with scarring.  After doses ≥4,000 rad 
(22.5-mm source), 6,600 rad (11-mm source), or 12,500 rad (5-mm source), a dusky red or mauve 
erythema followed by dermal necrosis occurred between weeks 10 and 16.  In pigs that were acutely 
exposed to the same range of 90Sr sources at the age of 3 months, dose-dependent dermal atrophy was 
detected in the irradiated field 2 years later, reaching a maximal 55% reduction in dermal thickness for all 
doses above 4,500 rad (45 Gy; Hamlet et al. 1986). Dermal atrophy was produced by doses below the 
threshold required to induce moist desquamation.  The threshold dose for moist desquamation following 
irradiation by the 22.5 mm source (2,250 rad) produced a 38% thinning of the dermis.  Irradiation from 
the 1-mm source produced 30% dermal thinning at the threshold (7,250 rad).  Irradiation from the 5-mm 
source (2,000 rad) reduced the thickness of the dermis by 35%.  For the 11–22.5-mm sources, above 
doses that caused maximal thinning (in the range of 12,000–6,250 rad, respectively), the relative dermal 
thickness increased slightly, but remained 30–40% thinner than normal. 
The highest reliable NOAEL values and all LOAEL values for dermal effects from external exposure to 
radioactive strontium in each species and duration category are recorded in Table 3-4.  
Ocular Effects.    Beta radiation has been employed medically to treat pterygium, an alteration in the 
conjunctival connective tissue that results in the penetration of the superficial corneal stroma by vascular 
connective tissue (Tong et al. 1969; Wesberry and Wesberry 1993).  As an adjunct to surgical removal of 
the pterygium, a solid 90Sr source is apposed to the site in order to reduce neovascularization.  Several 
clinical studies reported complications resulting from this procedure.  Serious effects (radiation cataracts, 
keratinization and telangiectasis of the conjunctiva) resulted from the high dose levels used when the 
technique was first employed using other beta-emitting radionuclides (Merriam 1955).  Atrophy of the 
sclera occurred after a dose of 1,600 rad from 90Sr. In a later study, 78 eyes in 62 patients were treated 
with 1,080 rad (10.8 Gy) of beta radiation from a 90Sr source repeated at weekly intervals (total dose 
3,200 rad; 32 Gy; Tong et al. 1969).  Because pterygia recurred within 2–18 months, six patients were re­
treated as before, two were given a single dose of 2,100 rad (21 Gy), and one of these two received a third 
dose of 2,100 rad (21 Gy).  One eye, which had received treatments of 5,380 rad (53.8 Gy) each to two 
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adjacent fields, developed keratitis of the cornea.  Other complications noted were telangiectasis of the 
conjunctiva (27%), scarring of the conjunctiva (14%), and scarring of the cornea (3%); the authors did not 
specify the exposure levels at which these side effects occurred.  A more recent study described results for 
171 eyes that had been treated with single doses of 1,700–1,800 rad (17–18 Gy) (Wesberry and Wesberry 
1993).  During follow-up periods lasting between 1 and 19 years, the only complications noted were one 
case each of corneal scarring, iritis, conjunctivitis, mild irritation, and, in a diabetic patient, scleral 
thinning.  A complication rate of 1.8% was reported for a study of 490 eyes (399 patients) that received 
doses between 31 and 42 Gy (3,100–4,200 rad) in four or five fractions over 29 days (Nishimura et al. 
2000).  Scleral thinning, not severe enough to require treatment, was reported for four eyes in three 
patients 0.5, 2, and 9 years after treatment.  Infectious scleral ulcer occurred within weeks of treatment in 
one male.  Ischemic necrosis of the sclera in one male and adhesion of the eyelid and eyeball in one 
female occurred several years after repeat treatments for recurring pterygia; adhesive scarring of the 
eyelid occurred in one female 7 years after treatment. 
No studies were located regarding ocular effects in animals after external exposure to radioactive 
strontium isotopes. 
The highest reliable NOAEL values and all LOAEL values for ocular effects in humans from external 
exposure to radioactive strontium in each duration category are recorded in Table 3-4. 
No studies were located regarding the following effects in humans or animals after external exposure to 
radioactive strontium isotopes: 
3.3.3.3 Immunological and Lymphoreticular Effects 
3.3.3.4 Neurological Effects 
3.3.3.5 Reproductive Effects 
3.3.3.6 Developmental Effects 
3.3.3.7 Cancer 
Development of skin cancers in mice following localized exposure to beta radiation from a solid 90Sr-90Y 
source depended on the dose and on strain susceptibilities (Hoshino and Tanooka 1975).  In experiments 
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using a 40 mCi (1.48x109 Bq) 90Sr-90Y source that delivered doses of 290 rad/min (2.9 Gy/min) to the 
skin, ICR mice exposed to a single localized dose of 2,700 rad (27 Gy) developed an acute skin reaction 
within the first month (see Section 3.3.4.2 Dermal Effects), but did not develop skin cancer during a 
23-month observation period (Hoshino and Tanooka 1975).  When the exposure was repeated 7 times for 
a total dose of 17,800 rad (178 Gy), one fibrosarcoma of the skin appeared after 10 months among five 
mice. Even extending the duration of the repeated 17,800 rad treatment for 43 weeks did not increase the 
incidence of malignant skin tumor; a single reticulocyte sarcoma developed in one out of five mice.  Mice 
from a different strain, Japanese ddN, exposed to single doses of up to 17,400 rad (174 Gy) did not 
develop skin tumors during a 1-year observation period (Hoshino and Tanooka 1975).  In the acute 
dermal toxicity experiments described above, Randall and Coggle (1995) selected the exposure level of 
5,000 rad (50 Gy) for their mouse studies since it is known to be a critical dose for carcinogenetic effects 
in humans exposed to ionizing radiation. 
Ootsuyama and Tanooka (1988, 1989) exposed the backs of female ICR mice to beta radiation from a 
40,000 µCi (1,500 MBq) source of 90Sr–90Y, which delivered a surface dose rate of 228 rad/minute 
(2.28 Gy/minute) and a 20–80% lower dose rate to the top of the vertebrae.  Mice were irradiated 3 times 
weekly at skin entrance doses per exposure of 135–1,180 rad (1.35–11.8 Gy), and irradiation was 
continued until a palpable tumor appeared (up to 86 weeks).  Tumors arising included squamous cell 
carcinomas, basal cell carcinomas, fibrosarcomas, and osteosarcomas.  No skin tumors arose in mice 
receiving 135 rad/day (1.35 Gy/day).  The total number of irradiations (and total dose) needed to induce 
50% incidence of skin tumors ranged from 252 sessions for a total of 37,800 rad (378 Gy) for the 
150 rad/day level and 156 sessions for a total of 192,300 rad (1,923 Gy) for the 1,180 rad/day level.  
Osteosarcomas were induced at lower doses, most frequently with skin surface doses of 250–350 rad 
(2.5–3.5 Gy) per exposure.  In time, 100% of mice developed tumors in groups receiving 250–1,180 rad 
per exposure. Ootsuyama and Tanooka (1988) suggested that the 135 rad/day dose might represent a 
threshold dose, since no tumors formed.  However, in their experimental design, they arbitrarily 
terminated exposures at this dose level on day 300, which conceivably could be shorter than the latency 
period for tumor development at that dose. 
The CELs resulting from external exposure to radioactive strontium in each species and duration category 
are recorded in Table 3-4. 
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3.3.4 Other Routes of Exposure 
This section includes injection and in vitro studies that provide evidence for the biological basis of 
toxicity of stable and radioactive strontium in humans and animals.  Since these studies are not directly 
relevant to general population exposure conditions, no LSE tables have been created for this section. 
Hematological Effects Hematological effects have been observed in several clinical studies in 
which 89Sr, one of the shorter-lived radioactive isotopes of strontium, has been used in cancer therapy for 
the relief of pain by irradiating and destroying tumors that have metastasized to the bone marrow 
(Baziotis et al. 1998; Ben-Josef et al. 1995b; Blake et al. 1987c; Breen et al. 1992; Kan 1995; Lee et al. 
1996; Piffanelli et al. 2001; Sciuto et al. 2001).  Significant reductions in platelet and white blood cell 
counts (averaging 70 and 30%, respectively) were seen 3 months after patients were injected with a single 
therapeutic dose (40 µCi 89Sr/kg; 1.5 MBq/kg) (Lee et al. 1996).  In two patients who received two doses 
of 60 µCi 89Sr/kg (2.2 MBq/kg) 6 months apart, platelet counts were significantly reduced (>30%) for at 
least 1 year.  Similar effects have been observed in animals.  Hypoplasia of the bone marrow has been 
observed in mice injected with 90Sr (Ito et al. 1976; Nilsson 1970) or 89Sr, the latter of which has been 
used intentionally to create mice with aplastic bone marrow (Bennett et al. 1976; Haller and Wigzell 
1977; Levy et al. 1981; Merluzzi et al. 1978; Oghiso et al. 1988; Sawyer et al. 1982).  CBA/J mice 
injected with fixed doses of 89Sr that differed in the specific activity of the preparation, showed 
quantitative differences in the degree of bone marrow suppression (Shibata et al. 1985).  Acute 
hematological symptoms (depression of hemopoiesis leading to anemia or hemorrhage) were observed in 
beagles beginning several weeks after injection of 64 or 98 µCi 90Sr/kg (Dougherty et al. 1972).  Transient 
neutropenia occurred at the 10.8 µCi 90Sr/kg level, and prolonged (36-month) depression of all types of 
leukocytes was reported at 32.7–98 µCi 90Sr/kg.  No hematological effects were noted at levels between 
0.57 and 3.46 µCi 90Sr/kg. 
Musculoskeletal Effects. Osteonecrosis was reported after 2 days for 2-day-old rats that were 
injected intraperitoneally with 2 mCi 90Sr/kg of body weight (Hopkins and Casarett 1972).  In weanling 
rabbits, injection of 600 µCi 90Sr/kg resulted in increasing cell death of differentiating odontoblasts and 
pulp cells of immature teeth and disordered tooth structure (Rushton 1963).  Mature teeth in the same 
animal, or teeth in adults injected at the age of 3 years or older, were not affected as severely. 
Immunological and Lymphoreticular Effects.    Evidence from injection studies in animals 
corroborates the sensitivity of the immune system to radioactive strontium.  In mice that have been 
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injected with 89Sr or 90Sr to deplete bone marrow, NK cells are preferentially eliminated (Emmanuel et al. 
1981; Gidlund et al. 1990; Haller and Wigzell 1977; Wiltrout et al. 1989).  The loss of this cell population 
results in a reduced ability to defend against lymphoid tumors (Haller and Wigzell 1977; Luevano et al. 
1981) or a transplanted methylcholanthrene-induced sarcoma (Scuderi and Rosse 1981b).  In CBA/SU 
mice injected with 90Sr(NO3)2, the responsiveness of spleen cells to activation by B-cell mitogen 
lipopolysaccharide was reduced, which was attributed to the cytotoxic effect of 90Sr on bone marrow, a 
source of precursor cells for the spleen (Bierke 1990).  In mice injected with 400–800 µCi 90Sr/kg to 
deplete bone marrow, the thymus went through two phases of weight loss and regeneration within 50 days 
(Järplid 1973). 
Reproductive Effects.    Numerous animal studies demonstrated adverse reproductive effects of 
injected radioactive strontium.  For the first 4 weeks after male CBA mice were injected intraperitoneally 
with 18 µCi of 90Sr and mated with untreated females, fetal deaths were 5–10% higher than controls 
(Lüning et al. 1963a). The increase in fetal mortality was much less (only ~2%) when the same males 
were mated 11–15 weeks postinjection (Lüning et al. 1963b).  In a similar study using male C3H/He mice, 
a single injection of 1,160 µCi 90SrCl2/kg resulted in fetal death rates 7–8% higher than normal for 
matings conducted 10–40 weeks after injection (Reddi 1971).  Autoradiography demonstrated that 90Sr 
selectively accumulated in testicular stem cells. 
When female CBA mice were injected with 90Sr(NO3)2 on the 19th day of pregnancy, a dose of ≥43 µCi 
90Sr(NO3)2/kg (≥1,600 kBq/kg) transiently suppressed spermatocyte maturation of the male offspring, but 
the spermatid numbers had recovered by day 56 (De Rooij and Rönnbäck 1989).  After the recovery 
period, the reproductive capacity (number of litters, litter size) of male offspring at the highest dose level 
(86 µCi 90Sr(NO3)2/kg; 3,200 kBq/kg) was unaffected.  No testicular effects were observed at doses of 
11 or 21 µCi 90Sr(NO3)2/kg (400 or 800 kBq/kg).  Compared to the effect on male offspring, reproductive 
effects were more severe in female offspring of dams exposed to 90Sr(NO3)2 on the 19th day of pregnancy 
(Rönnbäck 1980). Dose-related decreases in the number of differentiating oocytes in the ovary were 
observed up to day 84 at all dose levels ranging from 5.5 to 43 µCi 90Sr(NO3)2/kg (200–1,600 kBq/kg).  
Injection on the 16–19th day was found to have more severe effects than injection earlier in gestation 
(Nilsson and Henricson 1969; Rönnbäck 1979).  A longer-term study demonstrated that the radioactive­
strontium-induced decrease in the number of oocytes in the ovary persisted for at least 10 months 
(Rönnbäck 1981b).  Furthermore, the reproductive capacity (number of fertile females, number of litters, 
number of young per litter) of females treated in utero was significantly reduced at the two highest 
maternal dose levels (43 and 86 µCi 90Sr(NO3)2/kg; 1,600 and 3,200 kBq/kg).  Rönnbäck (1981a) also 
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examined the effect of exposure via lactation using CBA mice receiving 21 µCi 90Sr(NO3)2/kg 
(800 kBq/kg).  Ovarian cellularity, especially the earliest stages of oogenesis, was reduced in females 
exposed in utero, whether or not they suckled milk contaminated with 90Sr. However, early stage oocyte 
numbers were somewhat improved by sucking uncontaminated milk.  When unexposed newborn females 
were exposed to contaminated milk, the numbers of early stage oocytes was significantly reduced, but not 
as severely as in females exposed in utero. These studies suggest that reproductive capacity, particularly 
in females, may be adversely affected by gestational exposure to high levels of radioactive strontium.  
These levels are high compared to reported releases of 90Sr from nuclear power facilities (see Table 6-1). 
Developmental Effects. Injection of relatively high doses of radioactive strontium into pregnant 
animals resulted in severe developmental effects.  A single dose of ≥764 µCi 90Sr/kg into female Long-
Evans rats had no effect on fetal mortality when administered on gestational day 10, but significantly 
increased fetal mortality when administered on gestational day 2 (Hopkins et al. 1967).  In addition, there 
were dose-related increases in the incidence of fetuses with skeletal abnormalities (general stunting, lack 
of ossification, fusion of ribs, vertebral anomalies, missing tail).  The incidence of micropthalmia was 
also significantly increased at the higher activity level (1,488 µCi 90Sr/kg). The offspring of female 
Wistar rats injected with ≥100 µCi 90Sr(NO3)2 at gestational day 18 showed no gross malformations, but 
there was a significant increase in the incidence of meningeal and pituitary tumors (Schmahl and Kollmer 
1981; Schmahl et al. 1979).  This was shown to be connected with a late gestational increase in the 
transfer of transplacental strontium to the basioccipital and sphenoid bones of the skull.  Tumor 
development was probably assisted by the position of the pituitary gland within the sella turcica, which 
resulted in the gland being irradiated from the ventral and lateral surfaces.  The total radiation dose rate at 
that position was calculated to be between 60 and 120 rad for the lifespan of 30 months.  After pregnant 
dogs were injected with 1 mCi of radiostrontium per kg (80–99% 89Sr and 1–20% 90Sr) 6 days prior to 
delivery, the puppies dying within 11 weeks exhibited abnormalities of the skeleton (underdevelopment 
of the jaws, incomplete and abnormal ossification, abnormal epiphyseal cartilage), partial atelectasis of 
the lungs, hyperplasia of lymph nodes and spleen, or deficient hematopoiesis (Finkel and Biskis 1969; 
Finkel et al. 1972). Puppies injected subcutaneously 12 days after birth showed some skull abnormalities 
and developed osteosarcomas.  Effects on the reproductive system following in utero exposure to 
radioactive strontium are discussed in the preceding paragraphs.  Cancer effects in animals exposed to 
radioactive strontium in utero are discussed in the next paragraph. 
Cancer. Numerous studies in several species reported the induction of malignant tumors in response to 
injection of radioactive strontium (mice: Ash and Loutit 1977; Bierke and Nilsson 1990; Ito et al. 1976; 
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Loutit 1976; Nilsson 1971, 1972; Nilsson et al. 1980a; Reif and Triest 1982; Chinese hamsters: Benjamin 
et al. 1976b; Brooks et al. 1974; rabbits: Kshirsagar et al. 1965; Vaughan and Williamson 1969; mongrel 
dogs: Finkel and Biskis 1969; Finkel et al. 1971; beagle dogs: Lloyd et al. 1995; Taylor et al. 1966).  In 
general, osteosarcomas and bone hemangiosarcomas developed at higher dose levels, and lymphomas and 
leukemias developed at lower levels.  Carcinomas of soft tissues adjacent to bone also developed.  The 
offspring of pregnant rats that were injected on gestational day 18 had a higher incidence of pituitary 
adenoma and meningeal sarcoma (Schmahl and Kollmer 1981; Schmahl et al. 1979).  These findings 
were attributed to the higher incorporation of 90Sr to the skull at that developmental period and to the 
anatomical position of the pituitary within the sella turcica, which subjected it to radiation from all but the 
dorsal surface. The female offspring of pregnant mice that were injected intravenously with 90Sr on 
gestational day 19 developed a higher incidence of tubular adenoma of the ovaries (Rönnbäck and 
Nilsson 1982). 
3.4 GENOTOXICITY  
There is little evidence for genotoxicity of stable strontium.  However, radioactive strontium isotopes 
release ionizing radiation that, within an effective radius, is known to damage DNA (see Appendix D 
Section D.4.1 Radiation Effects at the Cellular Level).  Summaries of in vivo and in vitro genotoxicity 
data are presented in Tables 3-5 and 3-6, respectively. 
In Vivo Exposure 
Stable Strontium.  No studies were located regarding genotoxic effects in humans following exposure to 
stable strontium.  The only in vivo genotoxicity study for stable strontium in animals involved acute oral 
exposure. Oral administration of 130 mg strontium/kg body weight as strontium chloride to Swiss albino 
female mice increased the incidence of chromosomal aberrations (gaps, breaks, nondisjunction, and 
polyploidy) in bone marrow cells 5-fold after 6 hours (Ghosh et al. 1990).  Genotoxicity in male mice 
administered a similar dose (140 mg/kg) was only doubled, and therefore, was less severe than in females.  
At higher doses (440–1,400 mg/kg), the incidence of chromosomal aberrations was similar in both sexes 
after 6, 12, or 24 hours. 
Radioactive Strontium. Human in vivo genotoxicity data are available from studies of the Techa River 
populations exposed to combined external gamma radiation and internal radiation from 90Sr and 137Cs 
between 1949 and 1956 and from studies on patients exposed to 89Sr as a radiopharmaceutical.  The stable 
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Table 3-5. Genotoxicity of Stable and Radioactive Strontium In Vivo 
Species (test system) End point Results Reference 
Stable Strontium 
Strontium chloride: 
Mouse (bone marrow) Chromosomal gaps, breaks, + Ghosh et al. 1990 
polyploidy, centric fusion 
Radioactive Strontium 
89Strontium chloride: 
Human (lymphocytes) Transient increase in + Watanabe et al. 1998 
micronuclei 
90Strontium: 
Human (lymphocytes) Chromosomal aberrations + Ilynskikh et al. 1999 
(rings, dicentric, tricentric) 
Mouse (skin) Unscheduled DNA synthesis + Ootsuyama and Tanooka 
1986 
Mouse (thymus, lymph Aneuploidy + Ito et al. 1976 
nodes, bone marrow) 
Chinese hamster (bone Chromosomal breaks, + Brooks and McClellan 
marrow) exchanges, rings 1969 
Miniature swine Chromosomal breaks in + Clarke et al. 1972; 
(leukocytes) leukemic cells Howard 1970 
+ = positive results; – = negative results; DNA = deoxyribonucleic acid 
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Table 3-6. Genotoxicity of Stable and Radioactive Strontium In Vitro 
Results 
With Without 
Species (test system) End point activation activation Reference 
Stable Strontium 
Strontium chloride: 
In vitro DNA synthesis reaction	 Lack of fidelity in DNA – – Loeb et al. 1977 
synthesis 
Prokaryotic organisms: 
Bacillus subtilis Rec- Growth inhibition – – Kanematsu et al. 
1980 
Eukaryotic cells: 




Human (blood) 	 Chromosomal rings, + de Oliveira et al. 
dicentrics, acentrics 2001 
DNA damage in + 
electrophoretic assay 
Human (lymphocytes) 	 Micronucleus formation + Mills et al. 1996 
Human (lymphocytes) Micronucleus formation + 	 Hall and Wells 
1988 
– = negative result; + = positive result; (+) = weakly positive result; DNA = deoxyribonucleic acid 
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chromosomal translocation frequency in peripheral lymphocytes was evaluated in 73 radiation-exposed 
individuals from the Techa River area and 39 unexposed individuals from noncontaminated areas 
(Bauchinger et al. 1998). The mean genomic frequency of translocations per cell in the exposed group 
(12.8±1.5x10-3) was significantly elevated compared to unexposed controls (5.7±1.0x10-3). Furthermore, 
the translocation frequency per cell was significantly higher in the subgroup that had been exposed to 
radiation as teenagers (22±4.3x10-3) compared to the subgroup exposed as adults (9.7±2.3x10-3). 
Increased skeletal incorporation of radiostrontium in teenagers, leading to higher radiation doses to the 
bone marrow, probably contributed to the observed increase in translocation frequency for this subgroup.  
In a more recent study of the Techa River populations, there was a dose relationship between the 
frequency of chromosomal aberrations (dicentric, ring) in T-lymphocytes (assessed in 1994–1996) and 
whole body 90Sr activity (detected by human radiation counter in 1993) for individuals residing in the 
Muslyumovo settlement (Ilyinskikh et al. 1999).  The frequency of chromosomal aberrations was 
3.8±0.8 for a non-exposed control group (whole-body 90Sr activity <100 nCi), and 8.9±0.7, 12.9±1.2, and 
18.7±1.9%, respectively, for exposed individuals with90Sr activity levels of 100–500, 500–1,000, and 
≥1,000 nCi.  In a few cancer patients who were injected with 3 mCi (111 MBq) of 89SrCl2 to treat severe 
pain from multiple bone metastases, the number of micronuclei present in the lymphocytes tripled in the 
week after exposure, but declined in succeeding weeks (Watanabe et al. 1998).  The authors found that 
the percentage of micronuclei, indicative of chromosomal damage, was equivalent to the damage 
observed in a separate in vitro experiment in which cells received a dose of 53 rad (0.53 Gy) by 
X-irradiation. 
In a long-term feeding study, chromosomal breaks were noted in leukocytes of miniature pigs that had 
developed leukemia as a result of exposures of 25 µCi 90Sr/day (925 kBq/day) or more for >1 year 
(Clarke et al. 1972; Howard 1970).  Unexpected (“unscheduled”) DNA synthesis was detected in the skin 
of female ICR mice several hours after external exposure to 10,000–30,000 rad (100–300 Gy) from a 
90Sr-90Y disk applicator (surface dose rate 228 rad/min) (Ootsuyama and Tanooka 1986).  Tritiated 
thymidine incorporation related to DNA repair was elevated to a greater degree in epithelial cells of the 
irradiated epidermis than in the dermis.  This difference appeared to be intrinsic to the cell type, since 
thymidine incorporation in hair follicle epithelium situated at the same depth as fibroblastic dermal cells, 
occurred at a faster rate.  The authors suggested that the somewhat slower rate of DNA repair in the 
dermis could contribute to the higher risk of cancer in the dermis, compared to the epidermis, following 
exposure to ionizing radiation. 
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A single intraperitoneal injection of 90Sr–90Y into Chinese hamsters (200–5,000 µCi/kg) resulted in an 
increasing number of chromosomal breaks/cell over time (between 2 and 224 days), as the cumulative 
radiation dose to the skeleton increased (Brooks and McClellan 1969).  The number of chromosomal 
breaks and chromatid/isochromatid deletions per bone marrow cell increased as a function of dose rate, or 
as the activity of radionuclide injected per body weight.  The relative number of chromatid exchanges and 
rings and dicentrics decreased with time after exposure, whereas the number of chromosomal exchanges 
increased. Abnormal chromosomal numbers were detected in the thymus, lymph nodes, and bone 
marrow of female ICR/JCL mice as late as 90 days after interperitoneal injection with 1 mCi/kg of 90Sr 
(Ito et al. 1976). 
In Vitro Exposure 
Stable Strontium.  In mutagenicity assays using the Rec- (recombination-repair-deficient) strain of 
Bacillus subtilis, strontium chloride had a negative effect in vitro (Kanematsu et al. 1980).  Furthermore, 
in a survey of the effect of metal salts, strontium was found to have no adverse effect on the fidelity of 
DNA synthesis in vitro, which was thought to be consistent with its reported lack of mutagenicity and 
carcinogenicity (Loeb et al. 1977). 
The only stable strontium compound known to be genotoxic is strontium chromate.  Strontium chromate 
induced sister chromatid exchanges in Chinese hamster ovary cells in vitro (Venier et al. 1985).  In the 
Ames test using the Salmonella typhimurium strain TA100, strontium chromate induced mutations in the 
presence, but not in the absence of S9 microsomes.  The genotoxicity of strontium chromate is related to 
the ability of the hexavalent chromium ion to enter cells and become metabolized, forming a reactive 
DNA-adduct. Strontium only contributes to the solubility of the salt (Elias et al. 1989, 1991). 
Radioactive Strontium.  Radioactive strontium has been shown to be genotoxic to human cells in vitro. 
In lymphocytes from freshly-drawn human blood, doses of 0.2–5.0 Gy (0.002–0.05 rad) increased the 
frequency of chromosomal aberrations (de Oliveira et al. 2001).  Acentric aberrations (acentrics and 
double minutes) increased at ≥0.2 Gy (0.002 rad), dicentric aberrations increased at ≥0.5 Gy (0.005 rad), 
and there was a slight indication that the frequency of centric rings increased at ≥3.0 Gy (0.03).  In the 
same study, results of an electrophoretic assay (comet assay) on single exposed lymphocytes revealed that 
DNA damage (evaluated by visual inspection and tail moment) occurred at doses as low as 0.2 Gy 
(0.002 rad). The varying frequencies for the different types of chromosomal aberrations were associated 
with the number of DNA breaks required for their formation and whether one or more chromosomes were 
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involved: acentrics requiring a single break and dicentrics requiring at least two breaks on different 
chromosomes.  Dose-related increases in micronucleus formation, predominantly derived from acentric 
chromosomes, were reported in human lymphocytes irradiated at doses between 0.3 and 3.0 Gy 
(0.003 and 0.030 rad) (Hall and Wells 1988; Mill et al. 1996). 
3.5 TOXICOKINETICS 
3.5.1 Absorption 
3.5.1.1 Inhalation Exposure 
Evidence for absorption of inhaled strontium in humans is provided by several cases of accidental 
exposure of workers to airborne radiostrontium (Navarro and López 1998; Petkau and Pleskach 1972; 
Rundo and Williams 1961).  Although these cases do not provide a complete quantitative description of 
the absorption of inhaled strontium in humans, they demonstrate clearly that inhaled aerosols of strontium 
compounds (e.g., SrCl2, SrTiO3) can be absorbed, as indicated by the detection of radiostrontium in urine 
and feces. 
In one case, a worker accidentally inspired an unknown quantity of 90SrCl2 (physical form unknown) and 
over the subsequent 800 days, 90Sr was excreted in the urine with half-times of 3.3 (52%), 17 (7%), and 
347 days (18%) (Petkau and Pleskach 1972).  The urinary:fecal excretion ratio was 3:1.  In a second case, 
a worker was exposed to 90SrCO3 (physical form unknown) with deposition within the nasal tract as well 
as the hands, face, and hair. The actual inhaled dose could not be determined; however, based on the 
excretion kinetics of 90Sr over the subsequent 300 days, the reconstructed internal dose was estimated to 
have been approximately 300–400 nCi (11.1–14.8 kBq) (Rundo and Williams 1961).  Excretion in urine 
occurred with half-times of 2.2 (>90%), 15, and 175 days, and the urinary:fecal excretion ratio over the 
first 24 days was 0.71.  In a third case, two workers accidentally inhaled 90SrTiO3 (physical form 
unknown), and 90Sr was detected in urine over a period of 225 days (Navarro and López 1998). 
Studies conducted in animals have shown that the rate of absorption depends on the chemical form of the 
inhaled strontium aerosol.  Compounds of greater solubility are, in general, more rapidly cleared from the 
lung.  For example, strontium is rapidly cleared from the lung after inhalation of SrCl2. In dogs that 
received a 2–22-minute nose-only exposure to an aerosol of 85SrCl2 (activity median aerodynamic 
diameter [AMAD] 1.4–2.7 µm, geometric standard deviation [GSD] 2.0), <1% of the initial lung burden 
remained in the lung 12 hours after the exposure; 37% of the body burden was distributed to the skeleton 
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within 12 hours after the exposure, and 84% was in the skeleton 4 days after the exposure (Fission 
Product Inhalation Project 1967a).  In contrast to the relatively rapid absorption of inhaled SrCl2, after 
exposures to strontium in particles of fused clay, absorption is much slower.  In dogs that received a nose-
only exposure to 90Sr in fused montmorillonite clay particles (AMAD 2.2 µm, GSD 1.7), the average half­
time of elimination of strontium from the lung was 490 days (Snipes et al. 1974a, 1974b).  Thus, 
strontium compounds of lower solubility are more slowly absorbed from the lung.  Support for this also 
comes from studies in which the rates of absorption of various compounds of strontium were compared in 
rats. Rats were exposed to aerosols of 85Sr carbonate, phosphate, fluoride, oxide, or titanate (particle sizes 
and doses not specified) (Willard and Snyder 1966).  Greater than 99% of the initial lung burden of 85Sr 
was cleared from the lung 5 days after inhalation of the carbonate, phosphate, fluoride, or oxide, whereas 
60% of the 85Sr remained in the lung after inhalation of the more insoluble strontium titanate. 
In rats exposed to airborne fly ash (sieved to have a particle diameter of distribution of 90% less than 
20 µm) for 6 hours, strontium was eliminated from the lung with a half-time of 23 days (observations 
were made for 30 days) (Srivastava et al. 1984b).  One day after the exposure, the tissue:plasma strontium 
concentration ratios were 0.3–0.5 in the liver, kidney, small intestine, and heart.  The report of this study 
does not indicate whether whole-body or nose-only exposures were utilized in the study; therefore, it is 
not possible to know for certain how much of the absorption may have resulted from ingestion of fly ash 
deposited on the animals.  Furthermore, given the relatively large particle size of the fly ash, it is likely 
that deposition in the respiratory tract was largely in the tracheobronchial and nasopharyngeal region, 
from which the strontium may have been cleared mechanically to the esophagus and swallowed.  
Nevertheless, studies in which 89Sr-enriched fly ash was instilled into the trachea of rats indicate that 
strontium in this form was partly absorbed and appeared in plasma and other tissues within days of the 
exposure (Srivastava et al. 1984a). 
Although intratracheal instillation does not precisely replicate inhalation exposure, these studies provide 
additional evidence that strontium compounds of greater solubility are absorbed more rapidly from the 
lung.  Strontium was cleared relatively rapidly from the lungs of rats that received an intratracheal dose of 
SrCl2 (half-times <1 day) and was eliminated from the body in the urine (4–6% of the initial body burden) 
and in the feces (10–18%) (Naményi et al. 1986).  By contrast, in rats that received an intratracheal dose 
of 360–760 µg Sr as SrTiO3, strontium was eliminated from the lung with half-times of 0.4 days (85%) 
and 130 days (15%); the long retention phase reflects the slow absorption of the insoluble SrTiO3 
deposited in the lung, whereas the rapid phase reflects the mechanical clearance from the 
tracheobronchial region (Anderson et al. 1999b). 
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Strontium has been shown to be absorbed from the nasopharyngeal region of the respiratory tract.  In 
hamsters administered 85SrCl2 (in saline solution) directly into the nasal tract, 67% of the 85Sr was 
absorbed in 4 hours and 63% was estimated to have been absorbed directly from the nasopharynx region 
of the respiratory tract (Cuddihy and Ozog 1973). 
3.5.1.2 Oral Exposure 
The fractional absorption of ingested strontium has been estimated in healthy human subjects or hospital 
patients who received an oral dose of strontium chloride (SrCl2) or ingested strontium in the diet 
(Table 3-7). Absorption was quantified in these studies from measurements of plasma strontium 
concentration-time profiles for ingested and intravenously injected strontium (bioavailability), or from 
measurements of the difference between the amount ingested and excreted in feces (balance).  
Collectively, the results of these studies indicate that approximately 20% (range, 11–28%) of ingested 
strontium is absorbed from the gastrointestinal tract.  Balance measurements can be expected to yield 
underestimates of absorption as a result of excretion of absorbed strontium in the feces (see 
Section 3.5.4); nevertheless, the two methods have yielded similar estimates of absorption. 
Vezzoli et al. (1998) compared the area under the plasma strontium concentration-time curves in adult 
males and females and found no significant difference (males, 10.6±0.6 mmol/L-minute; females, 
9.3±0.6 mmol/L-minute).  The subjects included groups of healthy age-matched men and women 
(15 males, 12 females) and groups of normocalcuric patients (29 males, 18 females) who had calcium-
oxalate urinary tract stones. Although the fraction absorbed could not be estimated in this study because 
the area under the curve for an intravenous dose was not measured, the results suggest that there were no 
substantive differences in absorption between males and females.  This conclusion may not be valid for 
physiologic states in which there is an increased demand for calcium such as pregnancy and lactation.  
Calcium absorption is higher in these states, and studies in animals suggest that strontium absorption may 
also be higher (Kostial et al. 1969b).  In general, strontium absorption appears to be a good indicator of 
calcium absorption in adult humans as both elements appear to share common mechanisms of absorption 
(Bianchi et al. 1999; Blumsohn et al. 1994; Milsom et al. 1987; Reid et al. 1986; Sips et al. 1994) (see 
Section 3.6.1). 
Studies conducted in infants and children indicate that approximately 15–30% of dietary strontium is 
absorbed, similar to estimates in adults (Alexander et al. 1974; Harrison et al. 1965; Kahn et al. 1969a; 
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Table 3-7. Summary of Estimates of Absorption of Ingested Strontium in Humans 
Dose and Absorption 
mediaa Subjects (N)b (% of dose)c Comment Reference 
Tracer 
44 mg, SrCl2 
44 mg, SrCl2 























Tracer in milk Adults (5) 













Healthy adults.  Absorption estimate based 
on whole body retention (R):  Roral/Riv. 
Healthy, fasted subjects adults.  Absorption 
estimate based on plasma AUCoral/AUCiv.d 
Healthy fasted subjects.  Absorption estimate 
based on plasma AUCoral/AUCi. 
Healthy subjects.  Dose administered with 
meal. Absorption estimate based on plasma 
AUCoral/AUCiv. 
Patients with osteoporosis or chronic renal 
failure. Dose administered with meal.  
Absorption estimate based on plasma 
AUCoral/AUCiv. 
Patients with osteoporosis.  Dose 
administered with meal.  Absorption estimate 
based on plasma AUCoral/AUCiv. 
Healthy fasted subjects.  Absorption estimate 
based on fraction of dose in plasma at 
3 hours. 
Healthy subjects without a pre-dosing fast.  
Absorption estimate based on whole body 
counting. 
Fasted patients with growth hormone 
deficiency, osteoporosis, hypothyroidism or 
hypercalcuric urinary tract stones.  Absorption 
estimate based on fraction of dose in plasma 
at 4 hours. 
Healthy fasted subjects.  Absorption 
estimated from cumulative urinary excretion. 
Healthy subjects.  Dose administered in milk, 
daily for 21–32 days.  Absorption estimated 
from whole body retention kinetics. 
Two health subjects, two patients with 
osteoporosis.  Absorption estimated from 
intake minus 20-day fecal excretion, 
corrected for fecal excretion after an 
intravenous dose. 
Likhtarev et al. 
1975 
Sips et al. 1995 
Sips et al. 1996 
Sips et al. 1996 




Bianchi et al. 
1999 
LeRoy et al. 
1966 
Sips et al. 1994 
Leeuwenkamp 
et al. 1990 
Rundo and 
Lilligraven 1966 
Uchiyama et al. 
1973 
0.8 mg/day Adults (11M) 18 (-17–42) Patients with various disorders, including Warren and 
diet osteoporosis.  Absorption estimate based on Spencer 1976 
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Table 3-7. Summary of Estimates of Absorption of Ingested Strontium in Humans 
Dose and Absorption 
mediaa Subjects (N)b (% of dose)c Comment Reference 
Tracer Adults (11M) 
1,500 mg/day Adults 
(5F, 1M) 
Diet Adults (9) 
5–100 mg, Children (5) 
SrCl2 4–14 years 
100 µg Infants 6–8 
breast milk days (12) 
600 µg Infants 












6-day balance; dietary intake minus fecal 
excretione. 
Patients with various disorders, including 
osteoporosis.  Absorption estimate based on 
estimated from 6-day balance; dietary intake 
minus fecal excretione. 
Patients with various illnesses.  Absorption 
estimated from dietary intake minus fecal 
excretion minus fecal excretion after and I.V. 
dose (endogenous fecal excretion). 
Patients with various illnesses.  Absorption 
estimate based on estimated from 6-day 
balance; dietary intake minus fecal 
excretion.e 
Patients with various illnesses.  Dose 
administered for 24–28 days.  Absorption 
estimated from dose minus 14-day fecal 
excretion. 
Healthy breast-feeding subjects.  Absorption 
estimate based on estimated from 3-day 
balance intake minus fecal excretion.e 
Healthy subjects.  Absorption estimate based 
on estimated from seven sequential 28-day 




Spencer et al. 
1960 
Spencer et al. 
1972a 
Sutton et al. 
1971b 
Harrison et al. 
1965 
Kahn et al. 
1969a 
aDoses are in mass of strontium. 

bNumber of males (M) or females (F) is presented if reported.
 
cValues are reported means ± standard deviation; values in parentheses are reported ranges. 

dAUC refers to the area under the plasma strontium concentration-time curve. 

eCalculated from reported individual subject data.
 
STRONTIUM 123 
3. HEALTH EFFECTS 
Sutton et al. 1971a).  Although age-related changes in strontium absorption cannot be discerned from the 
studies in humans, age-related changes in absorption of strontium have been observed in rats, suggesting 
the possibility of increased absorption of strontium during the neonatal period in humans.  Adult male rats 
that received a single oral dose of 1.4 mg Sr as SrCl2 absorbed 19% (±5 standard deviation [SD]) of the 
dose (Sips et al. 1997); this value is similar to that reported for humans (Sips et al. 1995, 1996).   
However, when absorption was estimated at various ages, absorption was found to decrease from 85% of 
the dose at 15 days of age to 8% of the dose at ages older than 89 days (Forbes and Reina 1972).  The 
differences between the adult estimates in these two studies may reflect the different methodologies; in 
the Sips et al. (1997) study, absorption was estimated from the area under the plasma strontium 
concentration-time curve for orally and intravenously administered strontium, whereas in the Forbes and 
Reina (1972) study, the absorption estimate was based on the measurements of 8-hour body burdens of 
strontium minus strontium in the gastrointestinal tract. 
The fractional absorption of strontium appears to increase in rats during lactation.  Rats that received a 
tracer dose of 85Sr as SrCl2 in drinking water between 14 and 16 days after the start of lactation absorbed 
twice as much strontium as control rats that were not lactating and received the same oral dose of 
strontium; 11% of the dose was absorbed in lactating rats compared to 5% in controls (Kostial et al. 
1969b).  Absorption was estimated in this study as the fraction of the dose in the skeleton, urine, and pups 
3 days after the start of exposure. 
The exact site of absorption of strontium in the gastrointestinal tract is not known; however, studies in 
hamsters suggest the possibility of absorption in both the stomach and small intestine.  In hamsters that 
received a gavage tracer dose of 85SrCl2, 37% was absorbed, whereas 20% was absorbed when the dose 
was administered to hamsters that had their pyloric sphincter ligated (Cuddihy and Ozog 1973).  Studies 
in preparations of in vitro and in situ isolated intestine of the rat provide direct evidence for strontium 
absorption in the small intestine (see Section 3.6.1). 
3.5.1.3 Dermal Exposure  
There is little evidence for systemic toxicity following dermal exposure to strontium compounds, which 
would suggest that they are not readily absorbed across the skin of humans.  Ilyin et al. (1975) estimated 
absorption rates for solutions of strontium chloride across intact or abraded skin of human subjects.  
Three groups of three male volunteers received topical applications of 85Sr as strontium chloride in 
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aqueous solution (pH 7.0) without a carrier.  In the first group, intact forearm skin (average area 8 cm2) 
was exposed for 6 hours.  In the second and third groups, the skin of the forearm was abraded with a 
metal grater just before the solution was applied; exposures were 6.1 cm2 for 30 minutes and 6.9 cm2 for 
6 hours, respectively.  For comparison, a fourth group received an intravenous injection of 85SrCl2. After 
exposure and decontamination of the skin, radioactivity measurements were taken over 40 days of the 85Sr 
present in the whole body, the patella, the right unexposed forearm, and, during the first 20 days, in daily 
urine samples.  Absorption of strontium was estimated from whole body or partial body 85Sr burdens, or 
urinary excretion of 85Sr in comparison to the same end points after an intravenous dose of 85SrCl2. The 
absorption of radiostrontium through intact skin over 6 hours was estimated to be 0.26% (range, 0.14– 
0.37%) of the applied dose, indicating that undamaged skin is a relatively effective barrier to penetration 
by strontium.  Strontium absorption was greater through scratched and abraded skin.  An average of 38% 
(range, 25.5–45.8%) of the applied dose was absorbed after 30 minutes and an average of 57.4% (range of 
coefficients, 55.7–65.3%) was absorbed after 6 hours.  No other studies were located regarding dermal 
absorption of strontium compounds in humans. 
An in vitro study evaluated penetration of 90Sr through abdominal skin removed from 5- or 9-day-old 
Wistar rats and arranged in vertical penetration cells (Bauerová et al. 2001).  The radionuclide in a 
chloride carrier solution (0.01–1.0% strontium chloride w/v) was applied to the epidermal surface; 
radioactivity of the permeated 90Sr in the receptor chamber solution was measured by liquid scintillation 
spectrometry.  Penetration was inversely related to concentration of the carrier solution.  Penetration of 
the radiostrontium through the hairless skin of 5-day-old rats over 24 hours was 4 times lower than 
through the hairy skin of 9-day-old rats:  at a carrier concentration of 0.1%, penetration was 0.5% for 
hairless skin of 5-day old rats compared to 2% for 9-day old rats.  The authors attributed this difference to 
the barrier provided by the intact stratum corneum in 5-day skin, indicating that hair follicles in skin of 
9-day-old rats increase the permeability of skin to strontium.  In experiments in which epidermal layers 
were stripped (by the 20x repeated application of adhesive tape) or entirely removed from skin of 5-day­
old rats, penetration was approximately 25% over 24 hours. 
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3.5.2 Distribution 
3.5.2.1 Inhalation Exposure 
Information on the distribution of inhaled strontium in humans is not available; however, it is reasonable 
to assume that the distribution of strontium absorbed into the systemic circulation after deposition in the 
respiratory tract would be similar to that absorbed after ingestion (see Section 3.5.2.2).  
Studies in animals have shown that strontium that is absorbed after an initial deposition in the respiratory 
tract ultimately distributes primarily to the skeleton.  In dogs that received a 2–22-minute nose-only 
exposure to aerosols of 85SrCl2 (AMAD 1.4–2.7 µm, GSD 2.0), 37% of the body burden was distributed 
to the skeleton within 12 hours after the exposure and 84% was in the skeleton 4 days after the exposure 
(Fission Product Inhalation Project 1967a).  Four to 6 days after a 30-minute inhalation exposure of rats 
to aerosols of 85Sr carbonate, phosphate, fluoride, or oxide (particle sizes and doses not specified), >99% 
of the body burden of 85Sr was in the skeleton (Willard and Snyder 1966).  Two days after rats received a 
10-minute head-only exposure to tracer levels of 85Sr or a mixture of 85Sr and 90Sr aerosols (AMAD 
1.8–2.8), at which time radioactive strontium could no longer be detected in the lung, the concentration in 
bone was 100–2,000 times that in soft tissues (Fission Product Inhalation Project 1967b).  The rank order 
of soft tissue concentrations (highest to lowest) was muscle > skin > liver > kidney.  In rats exposed to 
airborne fly ash (sieved to have a particle diameter of distribution of 90% less than 20 µm) for 6 hours, 
strontium was detected in various tissues; 1 day after the exposure, the tissue:plasma strontium 
concentration ratios were 0.3–0.5 in the liver, kidney, small intestine, and heart (Srivastava et al. 1984b). 
Information on the distribution of strontium absorbed after deposition in the respiratory tract can be 
derived from studies in which strontium compounds were instilled directly into the trachea.  Although 
intratracheal instillation does not precisely replicate inhalation exposure, the distribution of the absorbed 
strontium is likely to be similar to that which would be absorbed after inhalation.  In rats that received an 
intratracheal dose of 89Sr-enriched fly ash (sieved to have a particle diameter of distribution of 90% less 
than 20 µm), radioactivity was eliminated from the lung and appeared in plasma and other tissues within 
days of the exposure; tissue:plasma concentration ratios were >1 (1.5–2) in the liver, kidney, stomach, 
and small intestine, and <1 (0.7–0.9) in the spleen, heart, and brain (Srivastava et al. 1984a). The 
relatively high concentrations of strontium in the gastrointestinal tract may reflect the mechanical 
clearance of strontium from the airways to the esophagus. 
STRONTIUM 126 
3. HEALTH EFFECTS 
Although placental transfer of strontium has been demonstrated in humans and animals exposed to 
strontium by other routes of exposure (see Section 3.5.2.2), only one study has examined placental 
transfer after a dose to the respiratory tract.  Pregnant rats received an intratracheal dose of 89Sr-enriched 
fly ash (sieved to have a particle diameter of distribution of 90% less than 20 µm) on days 14–18 of 
gestation. The concentrations of strontium in whole fetus, liver, lung, heart, and kidney were not 
significantly different from controls that received an instillation of saline (Srivastava et al. 1990). 
3.5.2.2 Oral Exposure 
The distribution of absorbed strontium in the human body is similar to that of calcium, with 
approximately 99% of the total body burden in the skeleton (ICRP 1993).  The skeletal burden of stable 
strontium has been estimated from analyses of bone samples from human autopsies (Herring and Keefer 
1971a; O’Connor et al. 1980; Papworth and Vennart 1984; Tanaka et al. 1981).  Skeletal burden was 
estimated in Japanese adult males to be approximately 440 mg compared to 850 g of calcium (Tanaka et 
al. 1981). 
Papworth and Vennart (1984) analyzed published data on 90Sr and calcium concentrations in human bone 
tissues and diets of people in the United Kingdom during the period from 1955 to 1970 and concluded 
that approximately 4.75% of the dietary intake of 90Sr was taken up by the adult skeleton.  Approximately 
7.5% of the cortical bone 90Sr burden was eliminated from bone each year (equivalent to elimination half­
times of approximately 9.2 years).  The rate of elimination from trabecular bone was approximately 
4 times this value.  The same analysis yielded estimates of skeletal uptakes of strontium that varied with 
age, being highest, approximately 10%, in infants and during adolescence, ages in which bone growth 
rates are high relative to other ages. 
Strontium distributes relatively uniformly within the bone volume where it exchanges with calcium in 
hydroxyapatite (see Section 3.6.1), although small differences in the calcium and strontium distributions 
within bone have been reported. The Sr:Ca concentration ratio in bone increases with age from 
approximately 0.3 mg strontium/g Ca at birth to a value of 0.5 in adults (Papworth and Vannart 1984; 
Tanaka et al. 1981).  The Sr:Ca ratio in bone also has been shown to vary with the bone type; ratios in 
cortical bone were approximately 10–20% higher than in trabecular bone (Tanaka et al. 1981). 
Information on the distribution of strontium in soft tissue is extremely limited.  In rats that were exposed 
to 3.4 mg strontium/L (as SrCl2) in drinking water for 3 months, the serum concentration of strontium was 
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8.7 mg/L and tissue:serum strontium concentration ratios (based on the latter mean serum concentration) 
were as follows: liver, 0.7; heart, 1.2; muscle, 1.1; adrenal, 1.3; brain, 1.2; and bone, 1,300 (Skoryna 
1981b). Strontium:calcium ratios in these tissues were approximately 0.05–0.1.  Tissue:plasma strontium 
concentration ratios in rats 1–5 hours after they received an intraperitoneal injection of strontium revealed 
ratios <1 in the fat, spleen, liver, ovary, testis, skeletal muscle, and heart; and values of 1.2–1.7 in the 
lung, small intestine, salivary gland, kidney, and skin (Brues et al. 1969).  Tissue:plasma concentration 
ratios of seminal vesicles in mice increased to values exceeding 2 several days after an intraperitoneal 
dose of strontium (Brues et al. 1967). 
Information on the subcellular location of strontium in soft tissues is also extremely limited.  In rats that 
were exposed to 1.9 mg strontium/L (as SrCl2) in drinking water for 3 months, the strontium 
concentrations (per mg protein) in the mitochondrial, lysosomal, and microsomal fractions of liver were 
approximately 5 times that of cytosol (Skoryna 1981b).  A major fraction of the strontium in tissues, 
possibly as much as 50–80% appears to be bound to protein (Kshirsagar 1977). 
The partitioning of strontium in blood has not been extensively explored.  The concentrations of 
strontium in the erythrocyte and plasma fractions of human blood obtained from blood banks were 
7.2 µg/L in the erythrocyte fraction and 44 µg/L in the plasma fraction, suggesting that most of the 
strontium in blood resides in the plasma (Olehy et al. 1966).  The strontium concentration in serum from 
100 human subjects (health status not reported) was 53 µg/L, similar to the value reported for blood bank 
serum (Skoryna 1981b).  Strontium binds to proteins in human serum; however, the specific proteins to 
which strontium binds have not been characterized.  Alda and Escanero (1985) found that 45% of the 
strontium incubated with human serum at a concentration of 10 mg/L was ultrafilterable.  Harrison et al. 
(1955) reported a value of 60% for the ultrafilterable fraction of plasma at a plasma concentration of 
3.5 mg/L in two subjects who received an intravenous dose of 20 or 100 mg strontium chlorides.  Note 
that this concentration is 300–1,000 times that reported for serum concentrations in subjects that were not 
receiving strontium supplements (Olehy et al. 1966; Skoryna 1981b); at lower concentrations, a larger 
fraction of the serum strontium may be bound, as binding appears to be saturable (Alda and Escanero 
1985; Berg et al. 1973).  Values of 40–60% bound to protein have been reported for guinea pig and rabbit 
plasma or serum, respectively (Lloyd 1968; Twardock et al. 1971). 
Strontium in the maternal skeleton can be transferred to the fetus during pregnancy.  Studies of residents 
of the Techa River who were exposed to strontium as result of releases from a plutonium production plant 
provide evidence for fetal transfer of strontium (Tolstykh et al. 1998, 2001).  The fetal:maternal transfer 
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coefficient—the ratio of 90Sr concentrations in the fetal and maternal skeletons (expressed in becquerels 
per gram of calcium)—was determined for six subjects who were exposed prior to pregnancy and their 
seven stillborn infants (Tolstykh et al. 1998).  The transfer coefficients varied from 0.012 to 0.24, with the 
higher values associated with maternal exposures that occurred during adulthood and lower values 
associated with maternal exposures during childhood or adolescence.  The difference was not related to 
the maternal strontium burden at pregnancy and may reflect a lower availability of strontium deposited in 
cortical bone during periods of active bone growth. 
Studies in animals provide additional evidence for transfer of strontium through the placenta to the fetus.  
The fetus begins to accumulate strontium as the fetal skeleton develops.  In mice, ossification of the fetal 
skeleton begins on approximately the 14th day of gestation, at which point, the fetal strontium burden 
begins to increase (Olsen and Jonsen 1979).  In pregnant mice that received an injection of strontium at 
different stages of pregnancy, fetal strontium burden was 4.5% of the maternal dose administered on the 
18th day of pregnancy compared to 0.7% of the maternal dose administered on the 14th day of pregnancy 
(Rönnbäck 1986).  Thus, fetal transfer was highest when the maternal dose occurred at the time of 
greatest skeletal growth.  A similar observation has been made in rats; uptake of strontium by the fetus is 
highest (1–2% of an injected maternal dose) if the maternal dose is given on or after the 16th day of 
gestation when ossification of the fetal skeleton begins (Hartsook and Hershberger 1973; Wykoff 1971).  
The distribution of strontium in the fetus at the end of gestation is similar to that of the mother with most 
of the strontium burden in the skeleton.  In mice, the skeletal (long bones):soft tissue concentration ratio 
was approximately 40 in both the fetuses and dams (Jacobsen et al. 1978). 
Strontium enters mammary milk in humans and can be transferred to newborns during breast feeding 
(Harrison et al. 1965).  The concentration of strontium in breast milk of 12 healthy women was estimated 
to be 74 µg/L (range, 39–93) and the Sr:Ca concentration ratio was 0.24 µg strontium/mg Ca (Harrison et 
al. 1965).  In a study of the transport of trace elements, the concentration of strontium in colostrum 
samples collected from 29 healthy women during the first 3 days after delivery was found to be 
comparable to that in serum from venous blood samples taken 20 minutes before delivery (Rossipal et al. 
2000). In contrast, the concentration of calcium in colostrum was significantly increased over the level in 
maternal serum, which was indicative of active transport.  The authors concluded that the transfer of 
strontium was based primarily on a concentration gradient mode of action.  Numerous studies in animals 
provide additional evidence for transfer of strontium from breast milk to newborns during lactation 
(Hopkins 1967; Jacobsen et al. 1978; Kostial et al. 1969b; Rönnbäck et al. 1968).  In lactating rats that 
received an oral exposure to tracer concentrations 85Sr in drinking water during the 14th through 16th days 
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of lactation, approximately 5% of the ingested dose was recovered in the nursing pups 24 hours after the 
end of the 2-day exposure (Kostial et al. 1969b).  In a study in which lactating mice received an 
intraperitoneal injection of radioactive strontium, strontium levels of the nursing pups was approximately 
20% of that of the dams (Rönnbäck et al. 1968).  These results are consistent with the oral exposure study 
(Kostial et al. 1969b), if one assumes that approximately 25% of the oral dose was absorbed by the dam. 
The tissue distribution of strontium in lactating mice and their offspring was found to be similar after an 
intraperitoneal dose to the dams during lactation; concentrations in bone were approximately 1,000 times 
higher than liver and kidney (Jacobsen et al. 1978).  The strontium concentration in calvaria of the 
lactating pups, after 5 days of lactation, was approximately 3 times that of the dams, whereas the 
concentration in long bones of pups and dams were similar (Jacobsen et al. 1978).  The difference in the 
bone concentrations in the dams and pups may reflect the relatively higher rate of bone formation in the 
pups and associated incorporation of strontium into the new bone. 
3.5.2.3 Dermal Exposure 
In volunteers who were exposed to dermally applied 85SrCl2 in the left forearm, 85Sr was detected by 
external counting of the patella and right forearm 3 and 6 hours after the exposure was initiated, 
suggesting that the absorbed strontium had been taken up by bone (Ilyin et al. 1975).  Although no other 
studies were located regarding the distribution of dermally absorbed strontium, it is likely that the 
distribution would be similar to that absorbed from the oral route, with the most of the body burden in the 
skeleton (see Section 3.5.2.2). 
3.5.3 Metabolism 
The metabolism of strontium consists of binding interactions with proteins and, based on its similarity to 
calcium, probably complex formation with various inorganic anions such as carbonate and phosphate, and 
carboxylic acids such as citrate and lactate (Alda and Escanero 1985; Inoue et al. 1988; Kshirsagar 1977; 
Lloyd 1968; Twardock et al. 1971).  These types of interactions would be expected for all routes of 
exposure. These types of interactions would be expected for all routes of exposure including the 
following: 
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3.5.3.1 Inhalation Exposure 
3.5.3.2 Oral Exposure 
3.5.3.3 Dermal Exposure 
3.5.4 Elimination and Excretion 
3.5.4.1 Inhalation Exposure 
Whole body elimination times have been measured in dogs and rats that received inhalation exposures to 
SrCl2. In dogs that were exposed to aerosols of 85SrCl2 (AMAD 1.4–2.7 µm, GSD 2.0), elimination half­
times were 0.6 (59%), 9 (12%), and 300 days (29%) (Fission Product Inhalation Project 1967a).  The 
rapid early phase of elimination reflects the mechanical clearance of strontium deposited in the 
tracheobronchial region of the respiratory tract and transfer to the gastrointestinal tract and feces, whereas 
the slower elimination component reflects the elimination from the skeleton.  A similar pattern of 
elimination has been observed in rats.  In rats that were exposed to tracer levels of 85Sr or a mixture of  
85Sr and 90Sr aerosols (AMAD 1.8–2.8), the long-term whole-body elimination half-time, measured 5– 
230 days after exposure, was 330 days (Fission Product Inhalation Project 1967b). 
Strontium that is absorbed after an initial deposition in the respiratory tract is excreted in feces and urine.  
Evidence for this comes from accidental exposures to radioactive strontium.  In one case, a worker 
accidentally inspired an unknown quantity of 90SrCl2 (physical form unknown) and, over the subsequent 
800 days, the urinary:fecal excretion ratio was 3:1 (Petkau and Pleskach 1972).  The urinary:fecal 
excretion ratio of 3 is consistent with observations of long-term urinary:fecal excretion ratios observed in 
people who ingested radioactive strontium or short-term ratios in people who received an intravenous 
dose of radioactive strontium (see Section 3.5.4.2).  In a second case, a worker was exposed to 90SrCO3 
with deposition within the nasal tract as well as the hands, face, and hair and the urinary:fecal excretion 
ratio over the first 24 days was 0.71 (Rundo and Williams 1961).  The lower ratio in this case probably 
reflects the fecal contribution of strontium that was mechanically cleared from the respiratory tract over 
the shorter observation period (24 days compared to 800 days).  Similar observations have been made in 
animals.  In dogs that received a 2–22-minute nose-only exposure to aerosols of 85SrCl2 (AMAD 
1.4–2.7 µm, GSD 2.0), an initially large fecal component of excretion was followed by urinary:fecal 
excretion ratios of 1.0–1.4 (Fission Product Inhalation Project 1967a).  An increase over time in the 
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urinary:fecal excretion ratios from values <1 to 2–4 has also been observed after intratracheal instillation 
of SrCl2 in rats (Fission Product Inhalation Project 1967b; Namenyi et al. 1986). 
3.5.4.2 Oral Exposure 
The long-term (decades) elimination of strontium has been studied in people who were exposed to 
strontium in the Techa River area of Russia after fission products from a plutonium production process 
were released in the area.  Whole-body elimination half-times were estimated in a study population of 
361 males and 356 females to be 28 years in males and 16 years in females (Tolstykh et al. 1997).  Most 
of the difference in the elimination rate estimated for males and females resulted from a pronounced 
increase in the elimination rate in females after age 50 years.  The increase most likely reflects the 
increase in bone resorption that tends to occur in females after menopause.  Müller et al. (1966) estimated 
a similar value, 25 years, for the long-term elimination half-time of strontium in 56 radium dial painters.  
In two dial painters, long-term elimination half-times were estimated to be 9 years (Wenger and Soucas 
1975).  Estimates of the long-term elimination half-times of strontium reflect primarily the storage and 
release of strontium in bone.  Over shorter time periods after exposure, faster elimination rates are 
observed that reflect soft-tissue elimination as well as elimination from a more rapidly exchangeable pool 
of strontium in bone.  When whole-body elimination of a tracer dose of 85Sr was measured for periods of 
42–108 days in nine subjects, the mean elimination half-time was 91 days (±32, SD) (Likhtarev et al. 
1975).  In three healthy subjects that received a single oral dose of SrCl2, the estimated average whole-
body elimination half-times, estimated over 13 days, were 2 (30%) and 59 days (70%) (Uchiyama et al. 
1973).  Similar short-term rates of elimination have been observed within days to a few weeks after an 
intravenous injection of SrCl2 (MacDonald et al. 1965; Newton et al. 1990). 
Strontium that has been absorbed from the gastrointestinal tract is excreted primarily in urine and feces.  
In two dial painters, rates of urinary and fecal excretion of radium approximately 10 years after the 
exposure were approximately 0.03 and 0.01% of the body burden per 24 hours, respectively (Wenger and 
Soucas 1975).  The urine:fecal excretion ratio of 3 that was observed in the radium dial workers is 
consistent with ratios of 2–6 observed several days to weeks after subjects received an intravenous 
injection of SrCl2 (Bishop et al. 1960; Blake et al. 1989a, 1989b; Likhtarev et al. 1975; Newton et al. 
1990; Samachson 1966; Snyder et al. 1964; Uchiyama et al. 1973).  Thus, urine appears to be the major 
route of excretion of absorbed strontium.  The observation of fecal excretion of radioactive strontium 
weeks to decades after an oral exposure or over shorter time periods after an intravenous exposure 
suggests the existence of a mechanism for transfer of absorbed strontium into gastrointestinal tract, either 
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from the bile or directly from the plasma.  Evidence for direct secretion of strontium from the plasma into 
the intestine is provided by studies in animals (see Section 3.5.1).  The available information does not 
address the extent to which biliary excretion may also contribute to fecal excretion of strontium. 
As discussed in Section 3.5.2.2, absorbed strontium is eliminated in breast milk during lactation.  The 
concentration of strontium in breast milk of 12 healthy women was estimated to be 74 µg/L (range, 39– 
93) and the Sr:Ca concentration ratio was 0.24 µg strontium/mg Ca (Harrison et al. 1965). 
Strontium has been detected in human saliva and seminal fluid.  In healthy subjects who received a single 
intravenous injection of SrCl2, the saliva:plasma concentration ratio was 0.9 and the semen:plasma ratio 
was 0.6 (Harrison et al. 1967a). 
3.5.4.3 Dermal Exposure  
In volunteers who were exposed to dermally applied 85SrCl2 in the left forearm, 85Sr was excreted in urine 
(fecal excretion was not measured in this study) (Ilyin et al. 1975).  Although no other studies were 
located regarding the excretion of dermally absorbed strontium, it is likely that the excretion would be 
similar to that absorbed from the oral route, with urinary excretion being approximately 2–3 times greater 
than fecal excretion (see Section 3.5.4.2). 
3.5.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points. 
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
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tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
Similar models have been developed for radionuclides.  These PBPK models provide a scientifically 
sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental 
levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where 
doses were higher or were administered in different species.  Figure 3-4 shows a conceptualized 
representation of a PBPK model.  Figures 3-5 through 3-8 show models for radionuclides in general or 
specifically for strontium. 
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Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by 
inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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Figure 3-4. Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a  

Hypothetical Chemical Substance 
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Human Respiratory Tract Model for Radiological Protection (ICRP 1994a).     
Deposition. The ICRP (1994a) has developed a deposition model for behavior of aerosols and vapors in 
the respiratory tract. It was developed to estimate the fractions of radioactivity in breathing air that are 
deposited in each anatomical region of the respiratory tract.  ICRP (1994a) provides inhalation dose 
coefficients that can be used to estimate the committed equivalent and effective doses to organs and 
tissues throughout the body based on a unit intake of radioactive material.  The model applies to three 
levels of particle solubility and a wide range of particle sizes (approximately 0.0005–100 µm in 
diameter), and parameter values, which can be adjusted for various segments of the population (e.g., sex, 
age, level of physical exertion).  This model also allows one to evaluate the bounds of uncertainty in 
deposition estimates.  Uncertainties arise from natural biological variability among individuals and the 
need to interpret some experimental evidence that remains inconclusive.  It is applicable to particulate 
aerosols containing strontium, but was developed for a wide variety of radionuclides and their chemical 
forms. 
The ICRP deposition model estimates the amount of inhaled material that initially enters each 
compartment (see Figure 3-5).  The model was developed with the following 5 compartments:  (1) the 
anterior nasal passages (ET1); (2) all other extrathoracic airways (ET2) (posterior nasal passages, the naso- 
and oropharynx, and the larynx); (3) the bronchi (BB); (4) the bronchioles (bb); and (5) the alveolar 
interstitium (AI).  Particles deposited in each of the regions may be removed from each region and 
redistributed either upward into the respiratory tree or to the lymphatic system and blood by different 
particle removal mechanisms. 
For extrathoracic deposition of particles, the model uses experimental data, where deposition is related to 
particle size and airflow parameters, and scales deposition for women and children from adult male data.  
Similarly, to the extrathoracic region, experimental data served as the basis for lung (bronchi, bronchioles, 
and alveoli) aerosol transport and deposition.  A theoretical model of gas transport and particle deposition 
was used to interpret data and to predict deposition for compartments and subpopulations other than adult 
males. Table 3-8 provides reference respiratory values for the general Caucasian population under 
several levels of activity. 
Deposition of inhaled gases and vapors is modeled as a partitioning process which depends on the 
physiological parameters noted above as well as the solubility and reactivity of compound in the  













































*Compartment numbers shown in lower right corners are used to define clearance pathways. The 
clearance rates, half-lives, and fractions by compartment, as well as the compartment abbreviations are 
presented in Table 3-9. 
Source: ICRP 1994a 
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Figure 3-5. Compartment Model to Represent Particle Deposition and 

Time-Dependent Particle Transport in the Respiratory Tract* 
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Table 3-8. Reference Respiratory Values for a General Caucasian Population  
at Different Levels of Activity 
Activity: Resting (sleeping) Sitting awake Light exercise Heavy exercise 
Maximal workload: 8% 12% 32% 64% 
Breathing VT B fR VT B fR VT B fR VT B fR 
parameters: (L) (m3h-1) (min-1)  (L) (m3h-1) (min-1)  (L) (m3h-1) (min-1) (L) (m3h-1) (min-1) 
Age  Sex  
3 months 0.04 0.09 38 N/A N/A N/A 0.07 0.19 48 N/A N/A N/A 
1 year 0.07 0.15 34 0.1 0.22 36 0.13 0.35 46 N/A N/A N/A 
5 years 0.17 0.24 23 0.21 0.32 25 0.24 0.57 39 N/A N/A N/A 
10 years Male: 0.841 2.22 44 
Both: 0.667 1.84 46 
Female: 0.3 0.31 17 0.33 0.38 19 0.58 1.12 32 
15 years Male: 0.500 0.42 14 0.533 0.48 15 1.0 1.38 23 1.352 2.92 36 
Female: 0.417 0.35 14 0.417 0.40 16 0.903 1.30 24 1.127 2.57 38 
Adult Male: 0.625 0.45 12 0.750 0.54 12 1.25 1.5 20 1.923 3.0 26 
Female: 0.444 0.32 12 0.464 0.39 14 0.992 1.25 21 1.364 2.7 33 
aSee Annex B (ICRP 1994a) for data from which these reference values were derived. 

B = ventilation rate; fR = respiration frequency; h = hour; min = minute; N/A = not applicable; VT = tidal volume 
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respiratory tract (Figure 3-6).  The ICRP (1994a) model defines three categories of solubility and 
reactivity: SR-0, SR-1, and SR-2: 
•	 Type SR-0 compounds include insoluble and nonreactive gases (e.g., inert gases such as H2, He). 
These compounds do not significantly interact with the respiratory tract tissues and essentially 
all of the compound that is inhaled is exhaled.  Radiation doses from inhalation of SR-0 
compounds are assumed to result from the irradiation of the respiratory tract from the air spaces. 
•	 Type SR-1 compounds include soluble or reactive gases and vapors that are expected to be taken 
up by the respiratory tract tissues and may deposit in any or all of the regions of the respiratory 
tract, depending on the dynamics of the airways and properties of the surface mucous and airway 
tissues, as well as the solubility and reactivity of the compound. 
•	 Type SR-2 compounds include soluble and reactive gases and vapors that are completely retained 
in the extrathoracic regions of the respiratory tract.  SR-2 compounds include sulfur dioxide 
(SO2) and hydrogen fluoride (HF). 
Mechanical Clearance from the Respiratory Tract.  This portion of the model identifies the principal 
clearance pathways within the respiratory tract.  The model was developed to predict the retention of 
various radioactive materials.  Figure 3-7 presents the compartmental model and is linked to the 
deposition model (Figure 3-5) and to reference values presented in Table 3-9.  Table 3-9 provides 
clearance rates and deposition fractions for each compartment for insoluble particles.  The table provides 
rates of insoluble particle transport for each of the compartments, expressed as a fraction per day and also 
half-time.  ICRP (1994a) also developed modifying factors for some of the parameters, such as age, 
smoking, and disease status.  Parameters of the clearance model are based on human evidence for the 
most part, although particle retention in airway walls is based on experimental data from animal 
experiments. 
The clearance of particles from the respiratory tract is a dynamic process.  The rate of clearance generally 
changes with time from each region and by each route.  Following deposition of large numbers of 
particles (acute exposure), transport rates change as particles are cleared from the various regions.  
Physical and chemical properties of deposited material determine the rate of dissolution and as particles 
dissolve, absorption rates tend to change over time.  By creating a model with compartments of different 
clearance rates within each region (e.g., BB1, BB2, BBseq), the ICRP model overcomes problems 
associated with time-dependent functions.  Each compartment clears to other compartments by constant 
rates for each pathway. 
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Source: ICRP 1994a 
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Table 3-9. Reference Values of Parameters for the Compartment Model  

to Represent Time-dependent Particle Transport from the  





Clearance rates for insoluble particles   
Pathway From To Rate (d-1) Half-timea 
m1,4 AI1 bb1 0.02 35 days 
m2,4 AI2 bb1 0.001 700 days 
m3,4 AI3 bb1 0.0001 7,000 days 
m3,10 AI3 LNTH 0.00002 No data 
m4,7 bb1 BB1 2 8 hours 
m5,7 bb2 BB1 0.03 23 days 
m6,10 bbseq LNTH 0.01 70 days 
m7,11 BB1 ET2 10 100 minutes 
m8,11 BB2 ET2 0.03 23 days 
m9,10 BBseq LNTH 0.01 70 days 
m11,15 ET2 GI tract 100 10 minutes 
m12,13 ETseq LNET 0.001 700 days 
m14,16 ET1 Environment 1 17 hours 
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Table 3-9. Reference Values of Parameters for the Compartment Model  

to Represent Time-dependent Particle Transport from the  





Partition of deposit in each region between compartmentsb 
Fraction of deposit in region 
Region or deposition site Compartment assigned to compartmentc 
ET2 ET2 0.9995 
ETseq 0.0005 
BB BB1 0.993-fs 
BB2 fs 
BBseq 0.007 
bb bb1 0.993-fs 
bb2 fs 
bbseq 0.007 
AI AI1 0.3 
AI2 0.6 
AI3 0.1 
aThe half-times are approximate since the reference values are specified for the particle transport rates and are 

rounded in units of d-1. A half-time is not given for the transport rate from Al3 to LNTH, since this rate was chosen 

to direct the required amount of material to the lymph nodes.  The clearance half-time of compartment Al3 is 

determined by the sum of the clearance rates from it. 

bSee paragraph 181, Chapter 5  (ICRP 1994a) for default values used for relating fs to dae. 

cIt is assumed that the slow-cleared fraction fs is size-dependent.  For modeling purposes fs is taken to be: 

fs = 0 5. for d ae  ≤ . ρ χ µ  2 5  / m and 
0 63  d / − . )  . (  ρ χ 2 5  aefs = 0 5. e  for  d  ae > . ρ χ µ  2 5  / m 
AI = alveolar-interstitial region; BB = bronchial region; bb = bronchiolar region; BBseq = compartment representing 
prolonged retention in airway walls of small fraction of particles deposited in the bronchial region; bbseq = 
compartment representing prolonged retention in airway walls of small fraction of particles deposited in the 
bronchiolar region; d = day(s); ET = extrathoracic region; ETseq = compartment representing prolonged retention in 
airway tissue of small fraction of particles deposited in the nasal passages; GI = gastrointestinal; 
LNET = lymphatics and lymph nodes that drain the extrathoracic region; LNTH = lymphatics and lymph nodes that 
drain the thoracic region 
Source: ICRP 1994a 
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Particle transport from all regions is toward both the lymph nodes and the pharynx, and a majority of 
deposited particles end up being swallowed.  In the front part of the nasal passages (ET1), nose blowing, 
sneezing, and wiping remove most of the deposited particles.  Particles remain here for about a day.  For 
particles with AMADs a few micrometers or greater, the ET1 compartment is probably the largest 
deposition site.  A majority of particles deposited at the back of the nasal passages and in the larynx (ET2) 
are removed quickly by the fluids that cover the airways.  In this region, particle clearance is completed 
within 15 minutes.  
Ciliary action removes deposited particles from both the bronchi and bronchioles.  Though it is generally 
thought that mucocilliary action rapidly transports most particles deposited here toward the pharynx, a 
fraction of these particles are cleared more slowly.  Evidence for this is found in human studies.  For 
humans, retention of particles deposited in the lungs (BB and bb) is apparently biphasic.  The “slow” 
action of the cilia may remove as many as half of the bronchi- and bronchiole-deposited particles.  In 
human bronchi and bronchiole regions, mucus moves more slowly the closer it is to the alveoli.  For the 
faster compartment, it has been estimated that it takes about 2 days for particles to travel from the 
bronchioles to the bronchi and 10 days from the bronchi to the pharynx.  The second (slower) 
compartment is assumed to have approximately equal fractions deposited between BB2 and bb2, and both 
with clearance half-times estimated at 20 days.  Particle size is a primary determinant of the fraction 
deposited in this slow thoracic compartment.  A small fraction of particles deposited in the BB and bb 
regions is retained in the airway wall for even longer periods (BBseq and bbseq). 
If particles reach and become deposited in the alveoli, they tend to stay imbedded in the fluid on the 
alveolar surface or move into the lymph nodes.  The one mechanism by which particles are physically 
resuspended and removed from the AI region is coughing.  For modeling purposes, the AI region is 
divided into three subcompartments to represent different clearance rates, all of which are slow. 
Particle clearance from the alveolar-interstitial region has been measured in human subjects.  The ICRP 
model uses two half-times to represent clearance: about 30% of the particles have a 30-day half-time, and 
the remaining 70% are given a half-time of several hundred days.  Over time, AI particle transport falls, 
and some compounds have been found in lungs 10–50 years after exposure. 
Absorption into Blood.  The ICRP model assumes that absorption into blood occurs at equivalent rates in 
all parts of the respiratory tract, except in the anterior nasal passages (ET1), where no absorption occurs. 
Absorption is essentially a 2-stage process, as shown in Figure 3-7. First, there is a dissociation 
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(dissolution) of particles; then, the dissolved molecules or ions diffuse across capillary walls and are taken 
up by the blood.  Immediately following dissolution, rapid absorption is observed.  For some elements, 
rapid absorption does not occur because of binding to respiratory-tract components.  In the absence of 
specific data for specific compounds, the model uses the following default absorption rate values for those 
specific compounds that are classified as Types F (fast), M (medium), S (slow), and V (instantaneous): 
C For Type F, there is rapid 100% absorption within 10 minutes of the material deposited in the 
BB, bb, and AI regions, and 50% of material deposited in ET2. Thus, for nose breathing, there 
is rapid absorption of approximately 25% of the deposit in ET and 50% for mouth breathing. 
C		 For Type M, about 70% of the deposit in AI reaches the blood eventually.  There is rapid 
absorption of about 10% of the deposit in BB and bb, and 5% of material deposited in ET2. 
Thus, there is rapid absorption of approximately 2.5% of the deposit in ET for nose breathing, 
and 5% for mouth breathing. 
C		 For Type S, 0.1% is absorbed within 10 minutes and 99.9% is absorbed within 7,000 days, so 
there is little absorption from ET, BB, or bb, and about 10% of the deposit in AI reaches the 
blood eventually. 
C		 For Type V, complete absorption (100%) is considered to occur instantaneously. 
ICRP (1995) considers the experimental data on strontium carbonate, and chloride, and sulfate to support 
classification of these compounds as Type F.  Data on strontium particulates released from irradiated fuel 
support their classification as either Type F or M.  Data on strontium in fused aluminosilicate particles 
support a classification as Type S.  ICRP (1995) recommends assigning all strontium aerosols to Type M 
in the absence of specific information supporting an alternative classification. 
ICRP (1993) Strontium Biokinetics Model 
Description of the model. ICRP (1993) developed a compartmental model of the kinetics of 
alkaline earth elements, including strontium, in humans that is applicable to infants, children, adolescents, 
and adults. The model is based on a nearly identical model developed by Leggett (1992).  The fraction of 
ingested strontium that is absorbed (uptake to blood) is assumed to vary with age and have values of 
0.6 in infants up to 12 months of age, 0.4 from 12 months of age through 15 years, and 0.3 from age 
15 years through adulthood.  Absorbed strontium that enters the blood plasma is assumed to distribute to 
the skeleton, liver, and other tissues (Figure 3-8).  Excretion pathways included in the model are plasma 
to urine, plasma to feces, and liver to feces.  Transfer rate coefficients between compartments are age-
specific and, depending on the specific coefficient, values can change at ages 3 months, 1 year, 5 years, 
10 years, 15 years, and adult (>15 years).  The model assumes that 99% of the strontium that enters the 
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body and is not excreted is ultimately transferred to the skeleton and 1% is in soft tissues.  Skeletal 
deposition is assumed to distribute initially to the bone surface of either cortical or trabecular bone, from 
which it can exchange relatively rapidly with calcium in plasma or more slowly with calcium in the bone 
volume.  Two pools are assumed to exist within the bone volume, an exchangeable pool that 
communicates with surface bone, and a nonexchangeable pool from which strontium can be returned to 
plasma as a result of bone resorption.  Approximately 55% of the transfer from plasma to bone in adults is 
to the trabecular bone surface and 45% to the cortical bone surface. 
Validation of the model. The extent to which the ICRP model has been validated is not described in 
ICRP (1993). 
Risk assessment. The model has been used to establish radiation dose equivalents (Sv/Bq) of 
ingested 89Sr and 90Sr for ages 3 months to 70 years (ICRP 1993).  The model has also been applied by the 
ICRP to calculate limits on inhalation for 89Sr and 90Sr (ICRP 1995) and limits on inhalation or ingestion 
for 80Sr, 81Sr, 82Sr, 83Sr, 85Sr, 85mSr, 87mSr, 91Sr, and 92Sr (ICRP 1994b).  It was used in the U.S. Federal 
Guidance Report No. 13 (EPA 2000e) to calculate inhalation risk coefficients and ingestion risk 
coefficients (separately for food and water) for the following radionuclides: 80Sr, 81Sr, 82Sr, 83Sr, 85Sr, 
85mSr, 87mSr, 89Sr, 90Sr, 91Sr, and 92Sr. 
Target tissues. The model is designed to calculate 89Sr and 90Sr intake limits, based on radiation dose 
to all major organs, including the bone surfaces, bone marrow, and liver, to which the highest doses 
would be expected. 
Species extrapolation. The model is designed for applications to human dosimetry and cannot be 
applied to other species without modification. 
Interroute extrapolation. The model is intended for application to strontium reaching blood by 
absorption from lungs, gastrointestinal tract, or wound, or by injection. 
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3.6 MECHANISMS OF ACTION  
3.6.1 Pharmacokinetic Mechanisms 
Absorption.    Airborne particulate aerosols of strontium can be deposited in the respiratory tract when 
the aerosols are inhaled. Amounts and patterns of deposition of particulates in the respiratory tract are 
affected by the size of the inhaled particles, age-related factors that determine breathing patterns (e.g., 
nose breathing vs mouth breathing), airway geometry, and airstream velocity within the respiratory tract 
(Gehr 1994; James et al. 1994; Roy et al. 1994).  In general, large particles (>2.5 µm) deposit in the 
nasopharyngeal tract where high airstream velocities and airway geometry facilitate inertial impaction 
(Chan and Lippman 1980; James et al. 1994).  In the tracheobronchial and alveolar regions, where 
airstream velocities are lower, processes such as sedimentation and interception become important for 
deposition of smaller particles (<2.4 µm).  Breathing patterns, airflow velocity, and airway geometry 
change with age, giving rise to age-related differences in particle deposition (James 1978; James et al. 
1994; Phalen et al. 1985). Deposition in the various regions of the respiratory tract in children may be 
higher or lower than in adults depending on particle size; for submicron particles, fractional deposition in 
2-year-old children has been estimated to be 1.5 times greater than in adults (Xu and Yu 1986).  
Absorption of insoluble strontium is influenced by particle size and solubility as well as the pattern of 
regional deposition within the respiratory tract.  Larger particles (>2.5 µm) that are deposited in the 
ciliated airways (nasopharyngeal and tracheobronchial regions) can be transferred by mucociliary 
transport into the esophagus and swallowed.  Particles deposited in the alveolar region can be absorbed 
after extracellular dissolution or ingestion by phagocytic cells.  Strontium-bearing pulmonary alveolar 
macrophages (PAMs) can migrate either to the airways where mucocilliary transport to the esophagus can 
occur or to tracheobronchial lymph nodes.  The relative contributions of these two pathways to strontium 
absorption have not been quantified. 
The exact site of absorption of strontium in the gastrointestinal tract is not known; however, studies in 
hamsters suggest the possibility of absorption in both the stomach and small intestine.  In hamsters that 
received a gavage tracer dose of 85SrCl2, 37% was absorbed, whereas 20% was absorbed when the dose 
was administered to hamsters that had their pyloric sphincter ligated (Cuddihy and Ozog 1973).  In 
isolated, everted segments of small intestine of the rat, transfer from the mucosal (lumen) to the serosal 
(blood) side of the duodenum, jejunum, and ileum was observed.  The serosal:mucosal strontium 
concentrations were approximately 0.2–0.4, whereas the ratio for calcium in preparations of duodenum 
was 1.98 (Stantic and Gruden 1974).  Ratios >1 would be indicative of an active transport process; 
therefore, this study did not detect an active component of strontium transfer across the small intestine.  
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Measurements of the rate of uptake of strontium into slices of rat small intestine when incubated with 
increasing concentrations of strontium suggested the existence of a saturable uptake mechanism in the 
intestinal epithelium (Papworth and Patrick 1970).  The fractional absorption of a gavage dose of 
strontium appears to be a relatively constant ratio to that of calcium.  In rats, the strontium:calcium 
absorption ratio was 0.75 over a fairly wide range of absorbed fractions of calcium (Marcus and 
Wasserman 1965).  This suggests that strontium and calcium may be absorbed by similar mechanisms.  
Strontium has been shown to be a substrate for a Ca2+-ATPase on the basolateral membrane of the renal 
proximal tubule in the rat, which is thought to play an important role in the tubule reabsorption of calcium 
(Sugihira et al. 1992). 
Active vitamin D (calcitriol or 1,25(OH)2D3) has an indirect, delayed effect on the gastrointestinal 
absorption of strontium or calcium by inducing the synthesis of calcium-binding proteins in both humans 
and animals (Bianchi et al. 1999).  A calcitriol-inducible Ca2+-ATPase has been shown to be important in 
the absorption of calcium in the rat intestine, and may provide a common mechanism for absorption of 
calcium and strontium (Bronner et al. 1986).  Other possible common mechanisms may involve binding 
of calcium and strontium to an intracellular calcium-binding protein, calbindin-D, which is a 
1,25(OH)2D3-inducible calcium binding protein that is thought to play an important role in calcium 
absorption (Gross and Kumar 1990).  In a group of 18 66-year-old women who received calcitriol at a 
daily dose of 0.5 µg of calcitriol for two years, the intestinal absorption of strontium was 13.7% compared 
to 10.4% for the untreated controls (Sairanen et al. 2000); the basal absorption percentages before 
treatment were 8.7 and 9.2%, respectively.  Age-related decreases in the gastrointestinal absorption of 
strontium in men (ages 20–79) were found to be positively correlated with serum levels of insulin-like 
growth factor I (IGF-I) (Fatayerji et al. 2000).  These authors proposed that IGF-I increases strontium 
absorption by maintaining the structural integrity of the intestine and the sensitivity of the intestine to 
1,25(OH)2D and increasing the synthesis of calcium-binding protein in that tissue.  IGF-I also acts by 
stimulating the synthesis of 1,25(OH)2D in the kidney (Audi et al. 1999; Fatayerji et al. 2000). 
Distribution.    The close similarity in the distribution of strontium and calcium derives from the ability 
of strontium to interact with ligands that normally bind calcium (Skoryna 1981b).  These include 
hydroxyapatite, the main component of mineralized bone (Harrison et al. 1959; Schoenberg 1963) and a 
variety of calcium binding and transport proteins that are important in the physiological disposition of 
calcium in cells, including Ca2+-ATPases (Berman and King 1990; Mermier and Hasselbach 1976; 
Pfleger and Wolf 1975; Sugihira et al. 1992; Yu and Inesi 1995), Na+-Ca+-antiport (McCormack and 
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Osbaldeston 1990; Niggli 1989; Richard et al. 1989), and Ca2+ channels (Fukushi et al. 1995a, 1995b; 
Gregoire et al. 1993). 
Metabolism. As noted in Section 3.5.3, the metabolism of strontium consists of binding interactions 
with proteins and probably complex formation with various inorganic anions such as carbonate and 
phosphate, and carboxylic acids such as citrate and lactate. 
Excretion. The renal clearance of strontium has been measured in human subjects who received an 
intravenous injection of a dose of SrCl2 and is approximately 4–10 L/day and 2–3 times greater than renal 
calcium clearance (Blake et al. 1986, 1989a, 1989b; Harrison et al. 1955, 1966a; Newton et al. 1990; 
Samachson 1966).  Based on these estimates, the renal clearance of strontium is substantially less than the 
product of the glomerular filtration rate in humans (approximately 180–200 L/day) and the estimated rate 
of filtration of strontium, assuming that approximately 50% of the strontium in plasma is ultrafilterable 
(Harrison et al. 1955).  Thus, strontium appears to undergo net tubular reabsorption in the human kidney.  
The mechanism by which strontium is reabsorbed in the renal tubule has not been determined, although it 
is likely that it may share common transport mechanisms with calcium, possibly including the Na+­
Ca2+-antiport, Ca2+-ATPase and membrane Ca2+ channels, all of which are thought to play a role in the 
reabsorption of calcium (Friedman and Gesek 1995).  Direct evidence for this comes from in vitro studies 
of basolateral membranes isolated form the rat renal cortex (primarily proximal tubule).  In this 
preparation, strontium has been shown to be a substrate for a Ca2+-ATPase, which transports calcium 
from the proximal tubular cells into the plasma (Sugihira et al. 1992). 
The observation of fecal excretion of radioactive strontium for weeks to decades after an oral exposure or 
over shorter time periods after an intravenous exposure suggests the existence of a mechanism for transfer 
of absorbed strontium into gastrointestinal tract, either from the bile or directly from the plasma.  
Evidence for direct secretion of strontium from the plasma into the intestine is provided by studies 
conducted with the in situ lumen-perfused rat intestine.  When the lumen of either the small or large 
intestine was perfused (below the entrance of the bile duct) in situ, and radioactive strontium was injected 
intravenously, radioactive strontium was detected in the lumen, indicating that strontium was secreted 
from blood into the intestine (Palmer and Thompson 1961).  The amount of strontium secreted into the 
small intestine was approximately 4–8 times that in the large intestine; however, the strontium:calcium 
secretion ratio was approximately 1 in the small intestine and 1.3 in the large intestine.  The mechanism 
by which strontium is secreted into the intestine has not been determined.  Transfer of strontium from the 
serosal (blood) side of the intestinal epithelium to the mucosal (lumen) side of the epithelium has been 
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demonstrated in in vitro preparations of isolated rat colon mucosa.  Serosal-to-mucosal transfer was 
observed to be completely dependent on the transepithelial electrochemical potential for strontium, 
completely insensitive to calcium concentration of the serosal bathing medium, and unaffected by prior 
treatment of the rats with 1,2,-dihydroxyvitamin D3, which stimulated calcium transport in the same 
preparation (Karbach and Rummel 1987).  Based on these observations, transfer of strontium into the 
lumen of the colon in this preparation appeared to be explainable as a passive process. 
3.6.2 Mechanisms of Toxicity 
The fact that strontium is chemically similar to calcium allows it to exchange for calcium in bone and 
other cellular compartments that are enriched in calcium.  Many enzymes that are calcium-dependent will 
function when strontium is substituted, but changes in kinetic parameters may occur.  As discussed in 
Section 3.6.1, strontium can interact with secondary cell messenger systems and transporter systems that 
normally use calcium.  Furthermore, as described in Section 3.2.4 (Neurological Effects), synaptic 
transmission may be variably affected by strontium. Consequently, at high concentrations, differences in 
the chemical characteristics between strontium and calcium may be the basis for neurotoxic and 
neuromuscular perturbations associated with strontium intoxication. 
Effect of Metabolism on Toxicity.  Variations in the rate of absorption of soluble strontium compounds 
will affect the severity of their effects following oral exposure.  One report identified polymorphisms in 
three alleles for the vitamin D receptor that imparted a 40% difference in efficiency in intestinal strontium 
absorption in humans (Gennari et al. 1997).  The significance of this finding is unresolved, since other 
studies have found no link between vitamin D receptor genotypes and enteral absorption rates for calcium 
or strontium (Vezzoli et al. 2002; Wolf et al. 2000).  Furthermore, no association was found between 
vitamin D receptor polymorphisms and bone mineral density when other parameters are taken into 
consideration (Poggi et al. 1999).  However, daily administration of 0.5 µg of activated vitamin D to 
66-year-old women over 2 years increased both the rate of strontium absorption and the bone mineral 
density at the femoral neck and the lumbar spine (Sairanen et al. 2000).  The rate of strontium 
incorporation into bone may be influenced by other factors thought to affect bone mineralization, such as 
parathyroid hormone receptor, estrogen receptor 1, and others (Audi et al. 1999; Duncan et al. 1999).  
However, the effects of these factors on strontium utilization have not been established definitively.  
Genetic variants of the parathyroid hormone receptor 1 result in either increased or decreased bone 
mineralization (Duncan et al. 1999).  There is a potential physiological link between the estrogen receptor 
and vitamin D in osteoblasts, although the relationship to bone mineralization has not been established 
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(Audi et al. 1999); vitamin D regulates the expression of P450 aromatase, an enzyme expressed in 
osteoblasts that modulates the availability of estrogen to its receptor.  The cytokine interleukin-6 is 
associated with osteoclast differentiation, and therefore, could potentially be involved with the removal of 
strontium from bone (Audi et al. 1999; Duncan et al. 1999).  Persons with chronic kidney failure may be 
more susceptible to effects of excess strontium because of a reduced ability to excrete strontium 
(Apostolidis et al. 1998; see Section 3.12); in this study, plasma levels of strontium were 60% higher in 
afflicted patients compared to controls. A study in rats demonstrated that protein deficiency, especially in 
combination with ethanol consumption, may increase strontium incorporation into bone while reducing 
fecal and urinary excretion of strontium (Gonzales-Reimers et al. 1999; see Section 3.12).   
Differences in bone physiology suggest that adult rats may have a higher susceptibility to stable or 
radioactive strontium effects than adult humans.  Unlike most mammals (including humans), the 
epiphyseal growth plate of the long bones of rats never entirely transforms into bone after sexual 
maturity, so that bone growth continues throughout life (although reduced after the age of 12 months) 
(Leininger and Riley 1990).  Thus, incorporation of strontium into the skeleton is likely to be relatively 
higher in adult rats compared to other mammals. 
Stable Strontium.  The toxicity of excess stable strontium is related to its interference in biological 
processes that normally involve calcium, most notably, skeletal development.   
Calcium Absorption. In animals, excess strontium indirectly suppresses the activation of vitamin D3 in 
the kidney, which severely reduces the expression of calbindin D mRNA and the translation of 
calbindin D protein in the duodenum (Armbrecht et al. 1979, 1998; Omdahl and DeLuca 1972).  As a 
result, duodenal absorption of calcium is reduced.  The reported inverse correlation between the amount 
of strontium that is absorbed and the levels of parathyroid hormone (Vezzoli et al. 1998) suggest that 
changes in parathyroid hormone levels mediate this effect.  While there are no data on strontium-binding 
to the calcium receptor of the parathyroid gland, it is likely that strontium binds in place of calcium, 
mimicking calcium and thereby suppressing parathyroid hormone levels.  A reduction in parathyroid 
hormone levels will decrease the level of 1-hydroxylase available to activate vitamin D3. 
Bone Toxicity. In addition to its effect on calcium absorption, excess absorbed strontium adversely 
affects bone development in several ways, leading to the development of rickets in young laboratory 
animals and possibly in children under special circumstances (Özgür et al. 1996).  Strontium binds 
directly to hydroxyapatite crystals, which may interfere with the normal crystalline structure of bone 
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(Storey 1961).  In addition, excess strontium may prevent the normal maturation of chondrocytes in the 
epiphyseal plates of long bones (Matsumoto 1976).  Excess strontium apparently interferes with the 
mineralization of complexed acidic phospholipids that is thought to help initiate the formation of 
hydroxyapatite crystals in developing bone (Neufeld and Boskey 1994).  As a result, affected bone 
contains an excess of complexed acidic phospholipid and a significantly lower ash weight.  Insufficient 
mineralization reduces the strength of bones, so that the inability to resist compression from increasing 
body weight results in bone distortion (bowing). 
Anaphylactic Response After Inhalation Exposure. There was one case of anaphylaxis reported in a 
paramedic who inhaled strontium-containing smoke in an enclosed space (Federman and Sachter 1997; 
see Section 3.2.1.2). Although other irritants in the smoke may have contributed to the incident, there is 
supporting evidence that large concentrations of stable strontium can stimulate the release of histamine 
from mast cells (Alm and Bloom 1981a, 1981b; Atkinson et al. 1979; Foreman 1977; Foreman and 
Mongar 1972a, 1972b; Foreman et al. 1977).  Stable strontium stimulates degranulation in several cell 
types (see Section 3.2.5 Hematological Effects) and it has been suggested that it acts by mimicking the 
receptor-linked rise in calcium that is the usual trigger for such events (Best et al. 1981).  It is conceivable 
that the conditions of the paramedic’s exposure were such to result in locally high concentrations of 
strontium in the respiratory tract, thereby eliciting histamine release and contraction of smooth muscle. 
Radioactive Strontium. The adverse health effects of radioactive strontium are related to its sequestration 
in bone, the high energy of its beta emissions, and, in the case of 90Sr, its long half-life and the radiation 
from the decay product, 90Y, produced in the body after intake of 90Sr. An extensive discussion of 
ionizing radiation and its health effects is found in the Appendix D of this document and in the 
Toxicological Profile for Ionizing Radiation (Agency for Toxic Substances and Disease Registry 1999).  
There is some evidence that body size or skeletal density may affect the outcome of exposures to 
radioactive strontium.  It was suggested that two cows that survived large oral doses of 90Sr owed their 
survival to their breed characteristics (Cragle et al. 1969).  The massive skeletons of Holsteins have wide 
bone marrow cavities so that tissue in the center of the bone marrow is not within range of the 1 cm beta 
emissions from radiostrontium (and radioyttrium) bound to bone.  Conversely, mice and rats are more 
vulnerable than large animals to radioactive strontium because all bone marrow tissues are within striking 
range. This renders rats and mice less useful than larger mammals as models for human exposure to 
radioactive strontium.  In addition, adult rats are less satisfactory models than adults of other species 
because of the persistence of the epiphyseal cartilaginous plate, which will result in the incorporation of 
larger amounts of radioactive strontium into bone.   
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Bone Toxicity. Beta emissions from radiostrontium bound to bone resulted in various bone lesions 
(trabecular osteoporosis, sclerosis, osteolytic lesions), particularly in animals that were exposed 
chronically (Book et al. 1982; Clarke et al. 1972; Momeni et al. 1976).  In young rats and rabbits exposed 
orally to 90Sr, necrotic effects on the vasculature of developing bone secondarily disrupted the process of 
osteogenesis (Casarett et al. 1962; Downie et al. 1959).  Disruption in the metaphyseal microvasculature 
disorganized the transformation of cartilage into bone, so that chondrocytes inappropriately resumed 
active proliferation. 
Pancytopenia. The severe reduction in hematopoetic tissue results from irradiation of the bone marrow 
by radiostrontium incorporated into bone.  At high exposure levels, thrombocytopenia may lead to platelet 
loss severe enough to cause hemorrhaging and the resulting anemia will be exacerbated by destruction of 
erythropoietic tissue.  Impaired immune function results from the genetic damage to lymphocytes.   
Carcinogenicity. Radioactive strontium is a genotoxic carcinogen.  Following exposure in vivo, 
cytogenetic analysis has revealed aneuploidy, chromosomal breaks, gaps, rings, and exchanges  (see 
Table 3-5), which are manifestations of unrepairable changes in DNA.  It is generally understood that 
radiation-induced damage to genes that regulate cell growth is a major factor in the development of 
cancer in affected cells, and the observation of chromosomal breaks in leukemic cells of miniature swine 
following chronic oral exposure to 90SrCl2 is consistent with this idea (Clarke et al. 1972; Howard 1970).  
However, the specific genes involved in radiostrontium-induced malignancies have not been identified.  
Because of strontium’s chemical properties, which determine its distribution in the body, exposure to 
sufficient radiostrontium results in an increased risk of malignancy for particular tissues.  In dogs, acute 
inhalation of insoluble 90Sr particles that lodged in the lungs resulted in chronic radiation exposure to the 
lungs, leading to pulmonary hemangiomas and carcinomas of pulmonary epithelia (Snipes et al. 1979).  
Other tissues were subsequently affected as the radioactive particles were cleared from the lungs.  
Following acute inhalation of soluble 90SrCl2 aerosols, some dogs developed carcinomas of nasal airway 
tissues, probably resulting from irradiation of these tissues from the 90Sr bound to the underlying bone 
(Gillett et al. 1987b). Following oral or inhalation exposures, absorbed 90Sr was distributed to bone, from 
which it irradiated the surrounding tissues and induced various kinds of osteosarcomas, as well as 
malignancies of hematopoietic tissues in bone marrow (see Section 3.3.2.7). 
Induction of Delayed Fibrosis Following External Exposure.  A single high-dose external exposure to 
beta radiation can elicit acute epidermal reactions, late connective tissue damage, and carcinogenesis in 
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murine skin, as was demonstrated in experiments that used 90Sr as a convenient beta source (Randall and 
Coggle 1996; see Section 3.3.3.7).  A biochemical change that is associated with both acute and late 
effects is the enhanced expression of mRNA and protein for transforming growth factor beta 1 
(TGF-beta l, Randall and Coggle 1995, 1996).  Following an acute exposure to beta radiation from a 90Sr 
source that is sufficient to generate moist desquamation, CBA/ca mouse skin exhibited two separate peaks 
of TGF-beta l expression (Randall and Coggle 1996).  The first, occurring within the first few weeks after 
exposure, coincided with a period of epithelial hyperplasia that occurred during and after the phase of re-
epithelialization.  TGF-beta l expression declined to a low at 3 months postexposure, but then rose to 
another peak at about 9 months.  Expression was especially high in the fibrotic dermis, which was also the 
site of skin tumors that appeared at about 9 months.  TGF-beta l expression in tumors was elevated by 
1.8 to 87 times the level in unirradiated control skin from the same animal.  The implication of this study 
is that sustained high expression of transforming growth factor-betal may drive the progressive fibrosis 
and, possibly, contribute to malignancy following radiation damage.  Another study from this laboratory 
indicates that there may be genetic differences in the control of TGF-beta l expression, and therefore, 
susceptibility to long-term effects of radiation damage (Randall and Coggle 1995).  
3.6.3 Animal-to-Human Extrapolations 
The toxic effects of stable and radioactive strontium have been similar in all species studied.  However, as 
mentioned in Section 3.6.2, adult rats are not an optimal model for bone effects in adult humans because 
of the lack of a Haversian (bone remodeling) system in the rat and because of the persistence of the 
epiphyseal cartilaginous plate into adulthood (Leininger and Riley 1990).  Because the epiphyseal 
cartilage persists, the long bones of rats continue to lengthen during adulthood, and therefore, the rates of 
incorporation of strontium will be proportionally higher.  This will make adult rats more susceptible to 
adverse effects of both stable and radioactive strontium.  This caveat does not apply to young rats, which 
are comparable to the young of other species.  In general, rodents are not optimal models for 
radiostrontium effects because their small size ensures that most of their tissues will be within the 
effective range of beta emissions from radiostrontium bound to bone.  Larger laboratory animals, such as 
dogs or non-human primates, avoid the problems of both radiation scatter to adjacent tissues and closure 
of the epiphysis as they become adults. 
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3.7 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the 
Environmental Protection Agency (EPA) to develop a screening program for “...certain substances 
[which] may have an effect produced by a naturally occurring estrogen, or other such endocrine 
effect[s]...”.  To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and 
Testing Advisory Committee (EDSTAC), which in 1998 completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors.  In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992).  These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997c).  Stated 
differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis.  As 
a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and 
neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, 
and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
No studies were located regarding endocrine disruptive effects in humans resulting from inhalation, oral, 
or dermal exposure to stable or radioactive strontium.  Stable strontium, as an analog to calcium, is 
unlikely to cause endocrine disruption at normal levels of exposure.  Endocrine glands, such as the 
pituitary, that are in close association with bone could potentially be damaged by irradiation from 
radioactive strontium incorporated into bone.  For example, increases in tumors of the pituitary and 
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ovaries were observed in rats following gestational exposure to injected 90Sr (Rönnbäck and Nilssen 
1982; Schmahl and Kollmer 1981; Schmahl et al. 1979; Section 3.4.5.7).  However, endocrine function 
was not tested in these studies. Ingested radioactive strontium had no effect on reproductive function in 
animals, suggesting that it did not affect reproductive hormones to an obvious degree (Clarke et al. 1972; 
Finkel et al. 1960).  However, no study has specifically investigated the endocrine system. 
3.8 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
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and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
The ubiquitous nature of stable strontium in soils and water supplies, and the chemical similarity of 
strontium to calcium, ensure that strontium will unavoidably be incorporated into the human body to 
some degree.  Because of the requirement for high calcium intake during the period of bone development, 
the absorption and retention of strontium is higher in children than in adults; an ICRP (1993) model 
postulates that the fractional gastrointestinal absorption of strontium by infants (up to 12 months) is 
double that of adults (see Sections 3.5.1.2 and 3.5.5).  Consequently, children are more at risk than adults 
from exposures to excess stable strontium or radioactive strontium. 
Stable Strontium.  A Turkish epidemiological study indicated that children with probable deficient 
vitamin D status (from insufficient exposure to sunlight) and diets low in calcium and animal protein were 
more likely to develop rickets as a result of exposure to excess dietary strontium (Özgür et al. 1996).  The 
rachitic signs of craniotabes, rachitic rosary, bulging at the wrist, genu valgus, genu varus, and delayed 
closure of the fontanelles represented biomarkers of effect in children exposed to excess strontium.  This 
study is consistent with numerous animal studies that demonstrated abnormal skeletal development (i.e., 
rickets) in young animals exposed to sufficiently high levels of dietary strontium (Kshirsagar 1976; 
Matsumoto 1976; Morohashi et al. 1994; Reinholt et al. 1985; Storey 1961, 1962; Svensson et al. 1985, 
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1987).  Young rats may be sensitive to levels of ingested strontium that have no effect on adults (Storey 
1961). 
Children or young animals are likely to be more sensitive than adults to excess strontium, in part, because 
the rates of intestinal strontium absorption may be higher, although this has not been consistently 
demonstrated in humans (see Section 3.5.1.2 and Table 3-7).  The ICRP (1993) biokinetic model for 
strontium assumes that the fraction of ingested strontium that is absorbed decreases from 0.6 in infancy to 
0.3 in adulthood (see Section 3.5.5); some models assume the absorbed dose may be 8 times higher in 
infants compared to adults (NCRP 1991).  These estimates are consistent with rat studies in which rates of 
strontium absorption were much higher (4–8 times) in weanlings compared to adults (Forbes and Reina 
1972; Harrison et al. 1966b).  This age-dependent difference in absorption may be partly explained by the 
duodenal level of vitamin-D-dependent calbindin D protein (a calcium-binding protein involved in 
absorption), which is much lower in old rats than in young rats (Armbrecht et al. 1979).  Armbrecht et al. 
(1998) have demonstrated that the translation of calbindin D-9k mRNA into protein declines in the rat 
duodenum with age and this would be expected to reduce the rates of intestinal absorption of calcium and 
strontium in older animals.   
Children are particularly vulnerable to excess strontium because the immature skeleton has a high rate of 
bone remodeling, and strontium adversely affects bone development in several ways, as demonstrated in 
animal studies.  In chickens and rats, excess strontium suppresses the activation of vitamin D3 in the 
kidney, which severely reduces the expression of calbindin D mRNA and the translation of calbindin D 
protein in the duodenum (Armbrecht et al. 1979, 1998; Omdahl and DeLuca 1972).  As a result, duodenal 
absorption of calcium is reduced.  Strontium also binds directly to hydroxyapatite crystals, which may 
interfere with the normal crystalline structure of bone in rats (Storey 1961).  In addition, excess strontium 
may prevent the normal maturation of chondrocytes in the epiphyseal plates of long bones of rats 
(Matsumoto 1976).  Excess strontium apparently interferes with the mineralization of complexed acidic 
phospholipids that is thought to help initiate the formation of hydroxyapatite crystals in developing bone 
(Neufeld and Boskey 1994).  As a result, affected bone contains an excess of complexed acidic 
phospholipid and a significantly lower ash weight.  This finding is consistent with the reduced rate of 
matrix vesicle degradation observed by Reinholt et al. (1984) in rachitic cartilage in strontium-treated 
rats. 
The placenta does not accumulate strontium nor does it prevent transfer of strontium to the fetus 
following maternal exposure (see Section 3.5.2.2). However, no studies were located that addressed 
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developmental effects following maternal exposure to stable strontium in humans or animals.  Stable 
strontium is also transferred to nursing infants through breast milk of exposed mothers at a ratio of 
approximately 0.24 µg strontium/mg Ca (Harrison et al. 1965).  These levels are unlikely to be 
sufficiently high to perturb bone development in the fetus.  Strontium stored in maternal bone because of 
prior exposure can be mobilized during pregnancy or lactation, resulting in fetal or infant exposure 
(Tolstykh et al. 1998). 
Alginates, carbohydrates rich in guluronic acid, have been found to reduce peak exposure to strontium 
(see Section 3.12.1).  Sutton et al. (1971a) showed that gastrointestinal absorption of stable 84Sr was 
reduced 4-fold in children who were simultaneously given 10% sodium alginate-97% guluronic acid.  
Exposure to sunlight to enhance vitamin D status and diets with adequate calcium, phosphorus and 
protein may be considered to some degree protective against the effects of stable strontium (see 
Section 3.12). 
Radioactive Strontium. During the period of above-ground nuclear weapons testing, the possible effects 
in children resulting from exposure to 90Sr in radioactive fallout was a matter of concern.  However, no 
studies have been able to identify unequivocally any increase in infant mortality, childhood cancers, or 
genetic damage in humans that could be attributed to oral or inhalation exposure to 90Sr in fallout (NCRP 
1991; Shaw and Smith 1970).  In the Techa River populations that received higher oral doses of radiation, 
including radiostrontium, individuals who were exposed as teenagers exhibited a significantly higher 
frequency of stable chromosomal translocations compared to individuals who were exposed as adults 
(Bauchinger et al. 1998). Adverse pregnancy outcomes (mortality from developmental anomalies, 
chromosomal anomalies, labor complications, and other unspecified perinatal conditions) were elevated 
in the progeny of exposed individuals from the Techa River cohort, 60% of whom were exposed to 
radiation as teenagers (Kossenko et al. 1994).  However, Kossenko et al. (1994) calculated that relatively 
high radiation doses (20–480 rem or 0.2–4.8 Sv) to the parental gonad would be required to double the 
incidences of stillbirths, miscarriages, early neonatal mortality, or lethal developmental effects.  (Note 
that the gonadal radiation doses may have primarily been caused by exposure to external gamma radiation 
[Akleyev et al. 1995]).  No increase in cancer incidence was observed among the progeny of the exposed 
Techa River population (Kossenko 1996).  Dermal effects (slight dermal atrophy, telangectiasis, and 
pigmentation changes) were reported as delayed reactions to superficial 90Sr treatments for facial 
hemangiomas in adults and children (Bekerus 1970).  However, this study did not compare the relative 
sensitivity of children and adults. 
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It would not be expected that the immediate consequences of radioactive strontium exposure would differ 
in children and adults at the cellular level; that is, the initial damage to proteins and nucleic acids caused 
by ionizing radiation would be the same.  Thus, children and adults might be expected to have similar 
effects following exposure to solid radiostrontium sources apposed to the skin or to insoluble particles of 
radiostrontium lodged in the lungs.  However, as discussed in Appendix Section D.4.1, ionizing radiation 
is more damaging to actively mitotic cells than to differentiated postmitotic cells, largely because genetic 
lesions become permanent when cell division occurs before repair can occur.  Since children have 
proportionally more mitotic cells than adults, the biological effect of radiation exposure in children would 
be expected to be proportionally more severe.  Other developmental aspects contribute to the higher 
potential vulnerability of children to radiation effects. One is the higher rate of gastrointestinal absorption 
in children, as discussed for Stable Strontium, above.  In addition, animal studies indicate that the young 
are more vulnerable than adults to inhalation or oral exposures to radioactive strontium in soluble form, 
because of higher rates of retention in the developing skeleton (see Stable Strontium section above).  
Thus, a given absorbed dose of soluble radiostrontium will have a longer biological half-life in young 
animals compared to adults, leading to higher cumulative radiation doses to bone and surrounding soft 
tissues and more severe adverse effects (see Section 3.3).  Examples of this age-related difference in 
severity are discussed under Section 3.2.2.2 Musculoskeletal Effects (especially Storey 1961, the basis for 
the intermediate oral MRL) and Section 3.3.2.2 Hematological Effects (Cragle et al. 1969), and 
Section 3.3.2.6 Reproductive Effects (Clarke et al. 1970).  Young animals exhibit the same types of 
effects as adults (e.g., malignancies), in addition to other effects specific to their developmental stage.  
For example, radioactive strontium disturbed osteogenesis of long bones in young rats by damaging the 
epiphyseal cartilaginous discs, and the vasculature that supports resorption (Casarett et al. 1962).  In 
weanling rats, irradiation of the marrow prevented its invasion of metaphyseal cartilage, thereby causing 
cartilage to resume active proliferation, rather than undergo transformation into bone.  Because of 
disruption of these processes, cartilage and fibrous marrow were sometimes incorporated into cortical 
bone, resulting in weakness or fracture. For all species studied, a long-term effect of 90Sr incorporation in 
young animals or in utero was a higher incidence of bone-associated cancers compared to animals 
exposed as adults (Clarke et al. 1972; Finkel et al. 1960; White et al. 1993).  Size differences may 
contribute to the possible higher vulnerability of children to bone marrow effects from retained 
radiostrontium.  Since bone marrow cavities in children have smaller diameters, a larger proportion of the 
hemopoietic bone marrow is within the approximate centimeter range of beta radiation emitted from 
radiostrontium bound to the endochondral surface. 
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There are two theoretical ways in which the fetus might be exposed to radiation from the decay of 
radioactive strontium: from transfer of strontium across the placenta or from proximity to radiation 
emitted from the maternal body.  Placental transfer of radioactive strontium to the fetus has been 
demonstrated in humans (Sikov et al. 1991, Stather et al. 1992) and animals (rodent: Onyskowova and 
Josifko 1985, Taylor and Bligh 1992; pig: Palmer et al. 1969).  Studies of residents of the Techa River 
who were exposed to strontium as a result of an accident at a plutonium production plant provide 
evidence that fetal exposures can result from previous maternal exposures.  The fetal:maternal strontium 
concentration ratio in four subjects who were exposed prior to pregnancy varied from 0.012 to 0.24, with 
the higher values associated with maternal exposures that occurred during adulthood and lower values 
associated with maternal exposures during childhood or adolescence (Tolstykh et al. 1998).  A dosimetry 
study in minipigs determined that exposure of the fetal thymus (ages 55–110 days of gestation) to 
radiostrontium (90Sr–90Y) is related to the amount that is incorporated by the fetus after placental transfer; 
no appreciable radiation reached the thymus from radiostrontium in the maternal uterine wall (Palmer et 
al. 1969).  Palmer et al. (1969) indicated that results might vary for other organs, for younger fetuses 
(which may be relatively closer to the maternal uterine wall or pelvic bone), or for single fetuses 
compared to multiple fetuses (as in the pig).  As discussed in Section 4.2, strontium isotopes and their 
transformation product isotopes differ with respect to their emission energies; this factor is another 
variable that will determine whether the fetus is subject to radiation from the maternal body. 
Animal studies demonstrate that the developmental consequences of injecting pregnant females with 
radioactive strontium are qualitatively different depending on the gestational day of administration 
(Finkel and Biskis 1969; Finkel et al. 1972; Hopkins et al. 1967). This is partly related to temporal 
differences in the onset of osteogenic activity and calcification in different parts of the skeleton.  For 
example, the increase in calcification of the basioccipital and sphenoid bones of the skull occurring by 
gestational day 18 of the rat probably contributed to the development of pituitary gland tumors after an 
injection of 90Sr was administered that day (Schmahl and Kollmer 1981; Schmahl et al. 1979).  A single 
injection administered to pregnant mice late in gestation transiently affected fertility of male offspring by 
suppressing spermatocyte maturation, but severely depressed oocyte maturation of the female offspring 
(De Rooij and Rönnbäck 1989; Nilsson and Henricson 1969; Rönnbäck 1979, 1980, 1981a, 1981b). 
Radioactive strontium, like stable strontium, can be transferred to infants through breast milk of exposed 
mothers (Harrison et al. 1965).  Rönnbäck (1981a) demonstrated that the numbers of oocytes (all stages) 
in the ovary was reduced in neonatal mice that were exposed to radioactive strontium in the milk of 
surrogate females that had been given high doses by injection. 
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Various methods for reducing the body burden and toxic effect of radioactive strontium have been 
investigated (see Section 3.12).  Only the administration of alginates high in guluronic acid, described in 
the previous section, has been validated in children (Sutton et al. 1971a).  A single oral dose of aluminum 
phosphate antacid gel taken soon after exposure is a recommended treatment for reducing absorption of 
ingested strontium (Ellenhorn et al. 1997; Haddad et al. 1998).  This would be a suitable treatment for 
children as long as the dosage recommendations were followed, since excess ingestion of aluminum 
phosphate can cause rickets (Chines and Pacifici 1990; Pivnick et al. 1995).  A diet high in calcium would 
tend to reduce the incorporation of radioactive strontium into bone (Steinbach 1968). 
3.9 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to strontium are discussed in Section 3.9.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
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tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by strontium are discussed in Section 3.9.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.11 “Populations That Are Unusually Susceptible”. 
3.9.1 Biomarkers Used to Identify or Quantify Exposure to Strontium  
The biomarkers to quantify exposure to stable or radioactive strontium are similar in children and adults. 
Stable strontium is ubiquitous in the diet and can be measured in urine, blood and feces by a number of 
methods outlined in Section 7.1.  After exposure, approximately 99% of the absorbed strontium that is 
retained is found in bone and connective tissues (Schroeder et al. 1972).  Normal background levels of 
strontium were measured by emission spectrography in cadaver tissue from 168 American subjects 
(Tipton 1981; Tipton and Cook 1963).  Average strontium levels in human tissues expressed as ppm ash 
were as follows: rib bone 110 ppm, vertebra 100 ppm, aorta 33 ppm, ileum 25 ppm, duodenum 11 ppm, 
lung 8.2 ppm, kidney 5.2, heart 2.6 ppm, and liver 1.6 ppm.  In a small group of adult males, the mean 
strontium concentration in plasma was 29 µg/L (Sutton et al. 1971b).   
Soluble radioactive strontium can be detected in urine, blood, or feces by liquid scintillation counting.  
Whole body counters (or chest counters for inhalation exposures) can measure internal radioactive 
strontium deposited in bone following high level exposures (see Section 7.1.1). Children tend to 
incorporate strontium more homogenously throughout bone than is the case for adults. 
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3.9.2 Biomarkers Used to Characterize Effects Caused by Strontium  
Deformities of bone in response to excess strontium can be detected by radiography. Exposure to excess 
stable strontium may cause specific abnormalities in bone calcification that can lead to obvious bone 
deformities, particularly in the young.  Such ‘rachitic’ signs in children include craniotabes, rachitic 
rosary, conspicuous bulging at the wrist, genu valgus, genu varus, and delayed closure of the fontanelles 
(Özgür et al. 1996). However, excess exposure to other metals, such as aluminum (Bhattacharyya et al. 
1995; Carmichael et al. 1984; Chines and Pacifici 1990; Pivnick et al. 1995; Woodson 1998) or 
deficiencies in calcium, vitamin D, and/or phosphate can generate the same effects.  Thus, this is not a 
specific biomarker for strontium, but can be confirmatory.  Although bone biopsies can measure 
strontium chemically, these tests are not warranted because of the relatively high risk/benefit ratio. 
Exposure to radioactive strontium may result in lowered blood cell counts, which can be detected using 
standard clinical laboratory methods. However, exposure to other sources of ionizing radiation has 
similar effects.  Sufficiently high exposures to radioactive strontium can result in genetic damage to 
tissues adjacent to bone. Recently, Sutherland et al. (2000a, 2000b) developed a molecular biological 
strategy to identify clustered lesions in DNA resulting from in vitro cellular exposure to gamma radiation. 
It is possible that this technique might be adapted to evaluate genetic damage in blood cells following 
exposure to radioactive strontium, although, again, it would not be specific for radiostrontium, but rather 
for ionizing radiation.  It is uncertain whether the technique would be applicable for the chronic exposures 
characteristic of absorbed radiostrontium compared to the acute high-dose exposures for which it was 
designed. 
3.10 INTERACTIONS WITH OTHER CHEMICALS  
Several agents reduce the absorption or retention of strontium, reducing its toxic effects (see 
Section 3.12). 
Calcium. Strontium has chemical properties similar to calcium, but is less efficient than calcium in most 
biological processes.  Calcium and strontium appear to compete for the same transporter elements in the 
intestine (Bianchi et al. 1999; Blumsohn et al. 1994; Milsom et al. 1987; Reid et al. 1986; Sips et al. 
1994), but calcium is preferentially absorbed.  Co-administration strontium and calcium reduces the 
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uptake of strontium and also reduces skeletal retention of strontium (Palmer et al. 1958; Roushdy et al. 
1980, 1981; Steinbach 1968).  
Anions. Oral administration of phosphate, as aluminum phosphate antacid gel, reduces the 
gastrointestinal absorption of strontium by increasing its excretion in feces (Carr and Nolan 1968; Keslev 
et al. 1972; Spencer et al. 1969a, 1969b).  Oral administration of sulfates at the same time as strontium 
reduces its retention in the skeleton (Volf 1964).  These agents are discussed in Section 3.12.1. 
3.11 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to strontium than will most persons 
exposed to the same level of strontium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of strontium, or compromised function of organs 
affected by strontium.  Populations who are at greater risk due to their unusually high exposure to 
strontium are discussed in Section 6.7, Populations With Potentially High Exposures. 
In general, children, who are in the stage of active bone synthesis and growth, are more vulnerable to 
adverse effects of strontium.  A more detailed discussion of children’s susceptibility can be found in 
Section 3.8. The following discussion is limited to other individual variations or health conditions that 
may modify the usual effects of strontium. 
Protein Deficiency and Ethanol Consumption. Protein-deficient diets may increase the adverse effects 
of exposure to excess stable strontium or to radioactive strontium, by reducing clearance and increasing 
incorporation into bone. A metabolic experiment in adult male Wistar rats showed that consumption of a 
protein-deficient diet increased the intestinal absorption of dietary strontium and its incorporation into 
bone, while reducing fecal and urinary excretion of strontium (Gonzales-Reimers et al. 1999).  When rats 
were given ethanol in addition to the protein-deficient diet, incorporation of strontium into bone was 
significantly enhanced, although ethanol given with a protein-normal diet tended to reduce strontium 
incorporation through its diuretic effects.  
Renal Disorders.  Patients with chronic kidney failure may be more susceptible to excess strontium than 
the general population, because of a reduced ability to excrete strontium and retain calcium (Apostolidis 
et al. 1998). In such patients, plasma levels of strontium were found to be 60% higher compared to 
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controls. In a variety of studies, uremic patients on dialysis were found to have significantly higher levels 
of strontium in serum, muscle, and brain tissue compared to normal undialized controls (Alfrey et al. 
1975; Couttenye et al. 1999; D’Haese and De Broe 1996; D’Haese et al. 1999, 2000; Krachler et al. 2000; 
Schrooten et al. 1999).  Although the high level of strontium in serum in uremic patients was correlated 
with the high level of strontium in the local tap water, it is also possible that uremic patients may have 
reduced rates of strontium excretion. 
Paget’s Disease (osteitis deformans).  Patients with Paget’s disease (osteitis deformans) had a higher than 
normal retention rate following administration of 85Sr (Tothill et al. 1983).  Part-body retention 
measurements demonstrated that diseased bone had relatively higher uptakes of strontium compared to 
undiseased bone. Pagetic bone contains a higher proportion of small mineral crystals with greater surface 
area, which accounts for its increased ability to accumulate strontium.  Reflecting the high degree of 
osteoclast activity in Paget’s disease, diseased bone had an increased turnover of 85Sr, compared to 
undiseased bone in the same patient.  Since bone metabolism is locally accelerated in persons with this 
disease, they are likely to develop higher body burdens of radioactive strontium than healthy adults. 
Rheumatoid Arthritis or Seronegative Spondarthritis.  Patients with active rheumatoid arthritis or 
seronegative spondarthritis were found to have significantly higher levels of strontium and calcium in 
their granulocytes (Hällgren et al. 1984).  The strontium overload was thought to be linked to the degree 
of inflammation and was positively related to serum levels of the acute-phase protein haptoglobin; 
corticosteroid therapy differentially reduced the strontium content of granulocytes compared to calcium.  
It is not known whether granulocytes in persons with active disease would take up relatively more 
radiostrontium from plasma, and therefore incur more damage, than would be the case for otherwise 
healthy individuals under an identical exposure scenario. 
Diabetes.  Persons with diabetes may be more vulnerable to adverse effects from dermally-applied 
radioactive strontium.  Thinning of the sclera developed in a diabetic patient who had been treated for 
pterygium with a single dose (1,700–1,800 rad; 17–18 Gy) of 90Sr (Wesberry and Wesberry 1993; see 
Section 3.3.3.2).  This reaction was not observed in 170 other eyes treated at that dose level; however, the 
authors did not state whether other diabetics were in the group that was unaffected.  Conversely, in rats 
made diabetic by injection of streptozotocin, the absorption of strontium in the duodenum was 
significantly reduced, which would appear to be protective (Miller and Schedl 1976). 
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Genetic Polymorphisms. Polymorphisms in genes that may affect rates of strontium (calcium) absorption 
and bone mineralization are currently under investigation.  In a study of postmenopausal women with 
osteoporosis, polymorphisms of vitamin D receptor genes apparently caused a 40% variation in the rate of 
strontium absorption (Gennari et al. 1997); however, another study found no association between vitamin 
D receptor polymorphisms and bone mineral density in osteoporotic women (Poggi et al. 1999).  
Similarly, 3’-end region polymorphisms of the vitamin D receptor were found to have no effect on enteral 
strontium absorption or bone mineral density in patients with calcium kidney stone disease (Vezzoli et al. 
2002).  Insulin-like growth factor (IGF-I) is correlated with age-related changes in strontium absorption in 
men (Fatayerji et al. 2000), but polymorphisms have not been evaluated.  Other candidate genes that may 
affect bone mineralization include the parathyroid hormone receptor 1, the estradiol receptor, collagen 
type I alpha 1, transforming growth factor-beta 1, interleukin-6, calcitonin receptor, alpha2-HS­
glycoprotein, osteocalcin, calcium-sensing receptor, interleukin-1 receptor antagonist, beta-3-adrenergic 
receptor, apolipoprotein E, glucocorticoid receptor, and epidermal growth factor (Audi et al. 1999; 
Duncan et al. 1999). The relative contribution of these factors on bone mineralization has yet to be 
clarified and whether any polymorphisms increase susceptibility to adverse effects of strontium remains 
to be determined. 
3.12 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to strontium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to strontium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. The following texts provide specific information about treatment following exposures 
to strontium: 
Ellenhorn MJ, Schonwald S, Ordog G, et al., eds.  1997.  Medical toxicology:  Diagnosis and treatment of 
human poisoning. 2nd ed. Baltimore, MD: Williams & Wilkins, 1682–1723. 
Haddad LM, Shannon MW, Winchester JF, eds.  1998.  Clinical management of poisoning and drug 
overdose. 3rd ed. Philadelphia, PA: W.B. Saunders, 413–425. 
Viccellio P, ed. 1998.  Emergency toxicology.  2nd ed.  Philadelphia, PA: Lippincott-Raven, 991–996. 
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3.12.1 Reducing Peak Absorption Following Exposure  
Human exposure to strontium and its compounds occurs primarily by inhalation and ingestion, since 
absorption is poor following dermal contact.  Current suggestions for reducing absorption of 
radiostrontium include ingestion of antacids containing aluminum phosphate (Ellenhorn et al. 1997; 
Haddad et al. 1998).  Treatment is most effective when it is initiated within 2 hours of exposure.   
The threat of nuclear fallout from atomic weapons testing was the impetus for a large number of studies 
that investigated methods to prevent absorption of radiostrontium, while not adversely affecting the 
absorption of calcium.  Reasonably effective strategies have included alginates, aluminum phosphate, and 
sulfates. Less effective or less practical strategies have included cold, diet, dietary fiber, flavones, and 
stable strontium. 
Alginates.  Alginates are carbohydrates derived from seaweed that have been found to reduce the 
absorption of strontium in humans and animals, without significantly affecting the absorption of calcium.  
When 10% sodium alginate-97% guluronic acid was given orally along with the stable marker 84SrCl2 to 
children (ages 2.5–10 years), plasma 84Sr was reduced by 75% and urinary excretion of the tracer was 
reduced 72% (Sutton et al. 1971a).  The authors concluded that absorption was reduced 4-fold.  In adults, 
sodium alginate extracts administered as a liquid or in bread, reduced strontium absorption by 50% in 
humans and 3-fold in rats (Gong et al. 1991).  Alginates with a high guluronic acid/mannuronic acid ratio 
were found to be more effective in humans and rats (Carr and Nolan 1968; Gong et al. 1991). Sodium 
alginate administered orally to rats effectively reduced the whole body retention of 85strontium that had 
been administered intratracheally (Naményi et al. 1986).  Calcium alginate added to the diet of female 
goats reduced the transfer of 85strontium to milk, which was attributed to a reduction in strontium 
absorption (Beresford et al. 1999).  In rats given 89Sr and 45Ca by gavage, alginate treatment, particularly 
in combination with stable calcium, differentially increased the fecal excretion of 89Sr and reduced the 
skeletal retention of 89Sr (Light et al. 1970a). 
Aluminum Phosphate Antacid Gel.  Aluminum phosphate antacid gels, administered just prior to or 
shortly after oral strontium exposure, have been shown to reduce absorption of strontium by increasing its 
excretion in feces in humans (Spencer et al. 1969a, 1969b), rats (Carr and Nolan 1968), and mice (Keslev 
et al. 1972). A practical advantage of this treatment is that the gels are readily available as over-the­
counter pharmaceuticals.  In elderly men who had been maintained on a low calcium diet for several 
weeks, oral administration of an antacid gel just prior to oral 85Sr/45Ca exposure reduced plasma 
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radiostrontium levels by 88%, but reduced radiocalcium levels by only 38% (Spencer et al. 1969a).  In the 
same study group, antacid treatment reduced strontium absorption by 57% when given 0.5 hours after 
exposure, but by only 43%, 1 hour after exposure (Spencer et al. 1969b).  In similar studies on rats fed 
antacid for several days prior to exposure, the absorption of strontium was reduced by 83%, whereas there 
was no effect on the absorption of calcium (Carr and Nolan 1968).  In mice, an aluminum phosphate gel 
reduced the absorption of strontium by about 13-fold and of calcium by about 3-fold (Keslev et al. 1972). 
Sulfates.  In rats orally exposed to radiostrontium and monitored on day 2, oral administration of barium 
sulfate in combination with sodium sulfate or magnesium sulfate reduced radiostrontium retention in the 
femur by nearly 80% (Volf 1964).  Treatment was effective if given within 10 minutes of exposure, but 
not if delayed more than 80 minutes.  Strontium sulfate was less effective, reducing radiostrontium 
retention by only 30%.  Volf (1964) did not determine whether the effectiveness of the barium sulfate 
combination therapy was a result of increased diuresis or decreased bioavailability by means of 
adsorption to radiostrontium in the intestine. 
The following treatments have been shown to be less effective or less practical. 
Diet or Dietary Fiber.  A pulverized solid diet administered to rat sucklings over 8 hours resulted in 10– 
20% less whole body retention of 85Sr (reduced absorption) than cow milk (Kostial et al. 1981b, 1984). 
Supplementing cow milk with trace elements did not improve its effectiveness, ruling out the possibility 
that trace elements in the food competitively inhibited intracellular transport of ingested strontium. 
Rather, the authors suggested that the solid diet contained ligands for strontium that reduced the amount 
of strontium available for transport.  Another study demonstrated that the inclusion of cellulose fiber into 
the diet of suckling rats decreased the retention of simultaneously administered 85Sr/45Ca by 20% 
(Momčilovič and Gruden 1981).  However, cellulose fiber was less satisfactory than alginates, both in 
effectiveness and in the lack of discrimination between strontium and calcium. 
Flavones.  In rats given doses of flavone (Ipriflavone, 7-isopropyl-isoflavone, or Morin, 
2',2,4',5,7-pentahydroxy-flavone) for 3 weeks prior to acute oral exposure to radiostrontium, the whole 
body retention of radiostrontium was reduced by 50 and 30%, respectively, after 1 month (Gachályi et al. 
1988).  Similar experiments on pregnant rats demonstrated that both flavones reduced fetal uptake of 
radiostrontium administered to dams on gestational days 17/18 and 19/20.  No studies were located that 
demonstrated the usefulness of flavones for emergency situations, rather than as pretreatments. 
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Stable Strontium.  In weanling rats previously given varying amounts of strontium lactate in the diet, 4 or 
6% strontium lowered the retention of injected radiostrontium to a greater extent than the retention of 
injected radiocalcium (Teree et al. 1965).  The disadvantage of this treatment is the adverse effect on bone 
development caused by excess stable strontium. 
3.12.2 Reducing Body Burden  
Absorption of strontium can vary with the chemical form of the compound and its solubility. Those 
strontium compounds that are readily absorbed following inhalation or oral exposure are rapidly 
distributed throughout the body (see Section 3.5).  Because of its similarity to calcium, strontium entering 
the circulation preferentially accumulates in bone. Methods for reducing the body burden of 
radiostrontium that have been tested in animals include calcium, chelators (with variable results), 
hemodialysis, and magnesium sulfate.  Exposure to cold temperatures, use of the few pharmacological 
agents that have been tested, and use of stable strontium are less satisfactory treatments. 
Calcium.  In human patients with osteoporosis who were injected with tracer doses of 85SrCl2, 
intravenous infusions of calcium gluconate significantly increased urinary excretion of strontium, but had 
no effect on fecal excretion (Spencer et al. 1967d). This effect was attributed to the decreased renal 
tubular reabsorption of calcium under these conditions.  Calcium gluconate was more effective than 
magnesium chloride tested in the same study.  A 10-day series of injections with a combination of 
calcium and calciferol reduced the retention of 90Sr in rabbits by 70%, if the treatments started as soon as 
24 hours after exposure (George et al. 1979).  If treatments were delayed 96 hours, the removal of 
strontium was reduced by 50%.  Slightly less effective treatments included calcium alone, sodium citrate, 
or a combination of calcium and magnesium, which reduced strontium retention by 40, 30, and 20%, 
respectively.  A 3-week diet high in calcium and low in phosphorus, initiated 24 hours after injection of 
90Sr into rats, significantly reduced the incorporation of the isotope into bone (Steinbach 1968).  In rats, 
pretreatment with diets rich or adequate in calcium tend to result in lower accumulations of 
radiostrontium in bone following exposure than diets poor in calcium (Palmer et al. 1958; Roushdy et al. 
1980, 1981).  However, administration of a high-calcium diet to rats following a month-long parenteral 
exposure to radiostrontium, only slightly reduced the strontium content of the femur after 65 days (Ray et 
al. 1956). 
Chelators. Chelators are not effective once strontium has become incorporated into hydroxyapatite.  A 
variety of chelators have been tested in rodents, with variable results.  In general, chelators did not 
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successfully increase the excretion of radiostrontium, if administered 6 or 24 hours after exposure (e.g., 
Llobet et al. 1991a, 1991b, 1992a).  In tests on rats, the cryptator hexaoxa-diamine macrobicycle was 
effective when given simultaneously with radiostrontium (Müller 1970).  The aza crown ether 2NaCa 
Kryptofix 22 was effective in tests on mice and rats when administered intravenously or intratracheally 
within 1 hour of exposure to radiostrontium (Varga et al. 1994).  Other aza crown ethers and other 
chelators have been tested on mice following parenteral exposure to strontium, but their effectiveness has 
been so variable and no consistent conclusions can be drawn (Colomina et al. 1991; Llobet et al. 1992b; 
Ortega et al. 1989).  For example, Na2Ca EGTA (Na2Ca ethylenglycol-bis-(β-amino-ethyl-ether)-N,N’­
tetraacetic acid) increased fecal excretion of subcutaneously administered strontium (nitrate), but 
decreased urinary excretion to the same degree, and thus, there was no net change (Colomina et al. 1991). 
Chelators that were not at all effective in rodent studies include monosodium glutamate, Tiron 
(4,5-dihydroxy-1,3-benzene-disulfonic acid), DMSA (2,3-dimercaptosuccinic acid), succinic acid, malic 
acid, CaNa2CTDA (cyclohexanediaminetetraacetic acid), and THPC, a cyclic derivative of EDTA 
(Kostial et al. 1979; Llobet et al. 1992b; Ortega et al. 1989). 
The chelating agent, zirconium citrate, administered intraperitoneally in several injections soon after 
parenteral exposure to 90Sr, significantly reduced the number of mice with bone tumors, reduced the 
multiplicity of tumors, and delayed the onset of tumors (Zander-Principati and Kuzma 1964).  
Measurements of external brehmsstrahlung emissions 10–12 months later demonstrated that mice treated 
with zirconium citrate had a reduced body burden of radiostrontium, which is the likely cause of the 
reduced tumor rate.  One source of uncertainty regarding this study, despite the claims of low toxicity for 
zirconium citrate, is the unexplained reduction in lifespan in all the groups treated with the chelator. 
Cold. In mice exposed to low temperature (9 EC), the rate of urinary excretion of a radiostrontium tracer 
was increased (Wedin 1972; Wedin et al. 1972).  This was attributed to a specific effect of cold on the 
rate of diuresis. However, since the rate of calcium excretion was not measured in this study, but is also 
known to be increased by cold, the usefulness of this finding is not clear.  Urinary excretion rates of 
radioactive strontium in mice intraperitoneally injected with 85Sr were increased about 10% by transfer to 
4 EC (Nilsson and Rönnbäck 1988). 
Hemodialysis. Hemodialysis is only effective if administered soon after exposure to strontium.  In 
100-day-old calves injected with 85Sr, a 12-hour hemodialysis session administered 4, 14, or 24 hours 
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later resulted in removal of only 14, 4, and 2.5% of the administered dose, respectively (Downey et al. 
1964). 
Magnesium. In human patients with osteoporosis who were injected with tracer doses of 85SrCl2, 
intravenous infusions of magnesium chloride significantly increased urinary excretion of strontium, but 
had no effect on fecal excretion (Spencer et al. 1967a).  Magnesium chloride was not as effective as 
calcium gluconate tested in the same study.  Magnesium sulfate injected 10 minutes after 85SrCl2 
significantly reduced the body burden of strontium in rats, irrespective of the dietary calcium or 
vitamin D status (Roushdy et al. 1980, 1981). 
Pharmacological Agents.  Tests of the effectiveness of hormones or drugs in reducing the body burden of 
strontium have been disappointing.  In rats, progesterone had no significant effect on radiostrontium 
retention, whereas estrogen actually increased the amount of 90Sr in the femur (Steinbach 1968).  In 
rabbits, the steroid prednislone, thyroxine, and the diuretic furosemide removed only about 30, 15, and 
10%, respectively, of the administered dose of 90Sr (George et al. 1979). 
Phosphorus-reduced Diet.  A diet low in phosphorus (0.017%, Ca/P ratio of 21.5) was most effective in 
mobilizing radiostrontium from the rat skeleton (Ray et al. 1956). Nearly 85% of the strontium 
incorporated into the femur was removed by the 50th day; only 0.24% of the injected dose remained in the 
femur.  However, this diet caused serious adverse effects: minimal increase in body weight, delayed 
growth and narrowing of epiphyseal discs in the tibia, reduced ash weight of the femur, and poor health 
necessitating termination of the experiment.  Consumption for 64 days of a diet ‘subminimal’ in 
phosphorus (0.21%, Ca/P ratio of 2.19) removed nearly 64% of the radiostrontium incorporated into the 
femur.  Rats exhibited normal body weight gain and ash weight of the femur, but there were 
histopathological changes in the epiphyseal discs and trabeculae of the tibia.  Although the low and 
‘subminimal’ phosphorus diets were relatively effective in reducing the body burden of radiostrontium, 
the potential for adverse health effects from inadequate phosphorus intake reduces the value of this 
strategy. 
Strontium-free Diet.  In young rats maintained on a diet high in strontium for 28 days, returning to a 
normal diet low in strontium noticeably reversed the adverse effect on bone mineralization (Johnson et al. 
1968).  The reduced percentage of ash in bone began to show improvement after 2 weeks and was nearly 
normal after 5 weeks.  In addition, the abnormal deposition of osteoid in vertebrae was repaired. 
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3.12.3 Interfering with the Mechanism of Action for Toxic Effects  
Hyperbaric oxygen therapy was successfully used to treat a case of scleral necrosis resulting from 90Sr 
therapy following pterygiectomy (Green and Brannen 1995).  Repeated hyperoxygenation enhanced 
neovascularization and regrowth of the scleral tissue that had become avascular and abnormally thin as a 
result of exposure to beta radiation. 
In tests on irradiated skin of guinea pigs, anti-inflammatory compounds reduced the permeability of the 
dermal vasculature to plasma proteins by up to 30% (Song et al. 1968).  However, since drug treatment 
was administered both before and after irradiation, this study is not definitive proof of the efficacy of 
these compounds. 
3.13 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of strontium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of strontium. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.13.1 Existing Information on Health Effects of Strontium 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals are 
summarized in Figure 3-9 for stable strontium and in Figure 3-10 for radioactive strontium.  The purpose 
of these figures is to illustrate the existing information concerning the health effects of strontium.  Each 
dot in the figure indicates that one or more studies provide information associated with that particular  
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effect. The dot does not necessarily imply anything about the quality of the study or studies, nor should 
missing information in this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s 
Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency 
for Toxic Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. 
3.13.2 Identification of Data Needs 
In the following discussion, the toxicity (carcinogenicity) of inhaled strontium chromate is omitted, since 
its adverse effects are attributed to hexavalent chromium (see Section 3.2.1.7).  Unless otherwise stated, 
the proposed investigations refer to studies of health effects in animals. 
Acute-Duration Exposure.     
Stable Strontium.  Information from injection and kinetic studies in humans and oral, inhalation, and 
injection studies in animals indicates that bone is the primary target tissue of absorbed stable strontium.  
The acute database is inadequate for deriving MRLs.  A data need for an acute inhalation study is 
discussed under Data Needs for Immunotoxicity.  Animal studies have shown that stable strontium is not 
toxic at low doses (Kroes et al. 1977).  On the other hand, high oral doses of stable strontium can severely 
depress the serum levels of 1,25-dihydroxyvitamin D in rats within a week, which has an adverse effect 
on calcium absorption (Armbrecht et al. 1979, 1998).  Of the two available acute oral toxicity studies, one 
employed ineffective doses, and the other used a single high dose (Kroes et al. 1977; Kshirsagar 1976).  
Thus, there is a need for an acute-duration oral study that would enable an analysis of dose-response 
relationships with regard to strontium ingestion and skeletal effects.  Consideration should be given to 
comparing the relative effects of different forms of strontium (e.g., strontium chloride, strontium 
carbonate, strontium phosphate), and different modes of delivery (in food, in water), since these factors 
probably affect the bioavailability of ingested strontium.  In addition, such a study could provide a basis 
for investigating possible biomarkers of effect (by monitoring changes in the serum levels of vitamin D, 
1,25-dihydroxyvitamin D, calcium, phosphorus, phosphatases, and other biomarkers) that could be used 
to characterize the early systemic response to strontium. 
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Radioactive Strontium. Acute-duration inhalation or oral administration of radioactive strontium caused 
adverse effects. No dermal studies were conducted.  Rather, external studies used solid strontium 
apposed to the skin, which did not provide an opportunity for dermal absorption (Hoshino and Tanooka 
1975; Randall and Coggle 1995; Song et al. 1968).  In dogs, inhalation of relatively insoluble particles of 
radiostrontium resulted in prominent damage to pulmonary tissues (Benjamin et al. 1975, 1976c; Snipes 
et al. 1979). Inhalation or ingestion of soluble radiostrontium resulted in radiostrontium incorporation 
into bone and subsequent chronic radiation exposure of the surrounding tissues (inhalation: Gillett et al. 
1987a, 1987b; oral: Casarett et al. 1962; Cragle et al. 1969).  No inhalation or oral MRLs could be 
derived because the effects of exposure, even at the lowest levels, were serious.  There is a need for an 
inhalation study using soluble strontium aerosols that would test a lower range of exposure levels than 
had previously been employed, primarily to assess the effects on the lymphocyte population; existing 
studies found chronic depression of lymphocyte numbers even at the lowest concentrations.  Existing 
acute-duration oral studies are inadequate because either the study size was small and/or a single dose was 
used. There is a need for an acute oral multi-dose study, in particular, one comparing effects in young 
and adult animals, primarily for the purpose of relating genotoxicity to dosage.  Dermal studies using 
strontium applied to the skin should be conducted to evaluate systemic effects that might occur following 
the kind of exposure that might occur in the vicinity of a hazardous waste site.   
Intermediate-Duration Exposure.     
Stable Strontium.  An intermediate oral MRL was derived on the basis of a study that showed young rats 
were more susceptible to adverse skeletal effects (rickets) than adults (Storey 1961).  A considerable 
number of studies support this finding (see Section 3.2.2.2 Musculoskeletal Effects).  No intermediate 
inhalation study was located.  The necessity for an intermediate inhalation study should be evaluated once 
the data from the proposed acute inhalation study are assessed.  No intermediate dermal study was 
located, but given the low cytotoxicity of stable strontium, such a study does not seem necessary. 
Radioactive Strontium. No intermediate-duration inhalation, oral, or dermal studies were located.  There 
is a need for intermediate-duration inhalation and oral studies, using low levels of exposure, to help define 
the risk associated with longer-term exposures, such as may occur from radiostrontium releases at nuclear 
fuel reprocessing facilities or nuclear power plants into air, into drinking water, or settling onto croplands.  
The primary focus of these studies should be hematological and immunological effects.  Some 
information is available in intermediate external studies, but in these, radiostrontium was not applied to 
the skin in a form that could be absorbed.  Dermal studies need to be conducted to assess the systemic 
risks that children might incur by playing in the open after radiostrontium has settled on the ground.   
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Chronic-Duration Exposure and Cancer.     
Stable Strontium.  There were no adequate chronic-duration studies of stable strontium effects in humans 
or animals.  In a review paper, Skoryna (1981a) briefly mentioned that oral administration of low doses of 
strontium had no adverse effect in rats over a 3-year period or over several generations, but provided no 
experimental details.  A chronic-duration oral study would be useful for evaluating the long-term health 
effects of strontium ingestion.  Some consideration should be given to comparing the effects of 
compounds having different chemical properties (e.g., strontium chloride, strontium carbonate, and 
strontium phosphate). 
Although there are no chronic studies of stable strontium exposure, the rest of the database provides no 
evidence to suspect that stable strontium might be carcinogenic.  It does not appear that a long-term 
carcinogenesis study would prove useful. 
Radioactive Strontium. There is no chronic inhalation study for radioactive strontium.  Such a study 
should be considered after an intermediate inhalation study is conducted, as a means of evaluating long-
term exposure to low levels of radioactivity on the immune system.  The Techa River cohort represents 
the major source of information regarding the health effects of chronic exposure to radiostrontium: 
suppression of hematopoiesis and immune function (Akleyev et al. 1995).  Chronic oral administration of 
radioactive strontium has been shown to suppress hematopoiesis and lymphocyte function in animals 
(Dungworth et al. 1969; Howard 1970).  Since these effects were observed at the lowest exposure levels, 
chronic oral studies using even lower exposure levels are needed to evaluate potential adverse effects on 
the immune system.  A single clinical study reported late-developing changes in the skin following 
chronic application of solid strontium (external exposure) to treat hemangioma (Bekerus 1970).  It is not 
clear that the database needs a chronic dermal study of radiostrontium applied to the skin in a form that 
might be absorbed, since significant dermal absorption of strontium only occurs through abraded skin (see 
Section 3.5.1.3).   
An increase in the incidence of leukemia has been reported in the Techa River cohort, which received 
doses of 10 rem (0.1 Sv) or more from radioactive strontium (Kossenko 1996; Kossenko et al. 2000).  
Chronic oral administration of radioactive strontium was shown to increase the incidence of bone-
associated cancer in animals (Book et al. 1982; Clarke et al. 1972; Finkel et al. 1960; White et al. 1993; 
Zapol’skaya et al. 1974). No chronic inhalation or dermal studies were located.  Since the dynamics of 
strontium uptake into bone are known, estimations of the risk of cancer in humans following inhalation 
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exposure can be derived using dose-response data from the Techa River cohort and the beagle inhalation 
studies. There is no realistic scenario for chronic dermal exposure at damaging levels. 
Genotoxicity.     
Stable Strontium.  In vitro studies listed in Table 3-6 demonstrate a lack of adverse effects from treatment 
with stable strontium.  A single gavage study in mice is the only evidence for genotoxicity of stable 
strontium (at doses of 140–1,400 mg/kg), but it seems likely that the bolus delivery may have influenced 
the outcome (Ghosh et al. 1990).  None of the intermediate-duration studies (no chronic study is 
available) presented any evidence of effects that could be attributed to genotoxicity.  Additional 
genotoxicity studies on stable strontium appear to be unnecessary. 
Radioactive Strontium. The genotoxicity of radioactive strontium is well-documented.  In the Techa 
River cohort, an elevated frequency of stable chromosomal translocations was observed (Bauchinger et al. 
1998).  Other evidence includes in vitro cytogenetic studies (see Table 3–6), and, by implication, the 
increased cancer rates that were observed in most investigations (see Data Needs for Cancer).  However, 
the mechanism of radiostrontium genotoxicity (i.e., the specific DNA alterations that occur following 
exposure) has yet to be characterized.  Recently, Sutherland et al. (2000a, 2000b) developed molecular 
biological assays for characterizing clustered DNA lesions caused by exposure to gamma radiation.  If 
such a technique were to be developed for radiostrontium-exposed cells, it might provide a means of 
recording molecular damage.   
Reproductive Toxicity. 
Stable Strontium.  There is no evidence regarding the effect of stable strontium on reproduction, but 
levels of exposure possible by inhalation or dermal routes are not likely to be harmful.  Stable strontium 
was found to have beneficial effects when it was used in solutions designed for testing the functional 
capacity of human spermatozoa in vitro (Mortimer 1986; Mortimer et al. 1986).  The possible 
consequences of excess strontium ingestion on reproduction need to be explored.  Such experiments 
should compare the relative toxicity of stable strontium compounds that have different properties and may 
have different rates of absorption (e.g., strontium chloride, strontium carbonate and strontium phosphate). 
Radioactive Strontium. In the Techa River cohort, average radiation doses to the gonads of up to 74 rem 
(0.74 Sv) had no effect on birth rate, fertility, or the incidence of spontaneous abortions (Kossenko et al. 
1994).  However, the contribution of radiostrontium to the gonadal radiation dose is likely to have been 
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negligible compared to that of external gamma radiation.  Multigenerational oral studies in animals 
demonstrated a dose-dependent effect of radioactive strontium on reproduction.  In pigs, only the highest 
doses affected fetal survival, and in those treated as adults, there was no effect on litter size, percentage of 
stillborn, or birth weight (Clarke et al. 1970, 1972; McClellan et al. 1963).  Injection studies have reported 
a higher incidence of adverse reproductive effects, perhaps because of the higher dose levels.  Injection of 
male mice prior to mating increase the rate of fetal death, and there is some evidence that radioactive 
strontium selectively accumulates in the testis (Reddi 1971).  Injection of pregnant female mice reduced 
the reproductive capacity of female offspring, reducing the numbers of oocytes of all stages in the ovary 
(Rönnbäck 1981a, 1981b).  Thus, the fetal reproductive system appears to be vulnerable to radioactive 
strontium.  Further studies to evaluate the dose-response of gonadal effects, including cytogenetic aspects, 
would appear to be warranted. 
Developmental Toxicity.     
Stable Strontium.  The main developmental effect of stable strontium is impaired bone development 
(rickets) following oral exposure at high doses (Johnson et al. 1968; Kshirsagar 1976; Marie and Hott 
1986; Neufeld and Boskey 1994; Ögzur et al. 1996; Reinholt et al. 1984; Storey et al. 1961, 1962).  
Inhalation and dermal exposures are unlikely to be high enough to have an adverse effect.  The oral 
developmental toxicity studies have concentrated on the initiation of rickets in young children or young 
animals during the postnatal or juvenile periods, but none have addressed the effect of maternal exposures 
on the fetus during gestation or on the neonate during lactation.  The relative effectiveness of strontium 
compounds that have different properties (e.g., strontium chloride, strontium carbonate, and strontium 
phosphate) needs to be evaluated with regard to maternal absorption, placental transfer, fetal toxicity, and 
postnatal toxicity during lactation.  In addition, behavioral testing should be conducted on the young 
animals to determine whether there are any neurological consequences of fetal exposure to excess stable 
strontium. 
Radioactive Strontium. In the Techa River cohort, individuals who were exposed to high levels of 
radiostrontium as teenagers had a higher frequency of stable transformations than those who were adults 
at the time (Bauchinger et al. 1998); the differences were attributed to increased skeletal incorporation of 
radiostrontium in the young.  The progeny of the exposed cohort showed an elevated incidence of adverse 
pregnancy outcomes (mortality from developmental anomalies, chromosomal anomalies, labor 
complications, and other unspecified perinatal conditions), but no increase in the incidence of cancer 
(Kossenko et al. 1994).  Multigenerational oral studies in animals showed no teratogenic effect of 
radioactive strontium administered from the time of conception, but showed reduced survival of the F1 
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generation because of an increased incidence of bone-associated cancer (Clarke et al. 1970; Finkel et al. 
1960; McClellan et al. 1963).  Injection of high doses of radioactive strontium during gestation had 
teratogenic effects on the fetus, primarily skeletal abnormalities (Hopkins et al. 1967; Finkel and Biskis 
1969). Injections had qualitatively different effects depending on the day of gestation, because of 
regional differences in rates of bone mineralization during gestation.  More information is needed 
regarding the effect of the timing of maternal exposure relative to developmental stages.  In addition, 
developmental studies that evaluate neurological effects in the offspring are needed. 
Immunotoxicity.     
Stable Strontium.  There is no evidence that oral or dermal exposures to stable strontium affect the 
immune system.  However, one case report described an anaphylactic reaction to inhalation of smoke that 
contained ~30% strontium among other irritants (Federman and Sachter 1997). Strontium’s possible 
involvement is supported by reports that excess strontium elicits degranulation of mast cells in vitro, 
causing histamine release (Alm and Bloom 1981a, 1981b; Atkinson et al. 1979; Foreman 1977; Foreman 
and Mongar 1972a, 1972b; Foreman et al. 1977).  For this reason, a short-term inhalation study would 
help to determine whether strontium by itself can elicit anaphylaxis and, if so, identify the effective 
concentration levels. 
Radioactive Strontium. There is evidence that immunosuppression, resulting from irradiation of bone 
marrow, may occur in humans and animals following absorption of radioactive strontium. 
Immunological effects were noted in the Techa River cohort, which received relatively high radiation 
doses to bone marrow following ingestion of food and water contaminated with radiostrontium (Akleyev 
et al. 1995). In animal studies, the lowest applied inhalation or oral doses were reported to result in 
lymphopenia lasting as long as 2 years (Benjamin et al. 1976c; Howard 1970; Jones et al. 1976).  There 
appears to be a need for studies that examine the effect of a lower range of exposures on immune 
function.  Another reason for such studies comes from the reports demonstrating that NK cells may be 
preferentially eliminated following injection of 89Sr or 90Sr (Emmanuel et al. 1981; Gidlund et al. 1990; 
Haller and Wigzell 1977; Wiltrout et al. 1989), with the result that the organism’s ability to defend 
against lymphoid tumors is impaired (Haller and Wigzell 1977; Luevano et al. 1981).  The implication is 
that reduced cellular defenses may compound the effect of genotoxicity, increasing the risk of cancer.  
However, it is not known whether NK cells are equally vulnerable at lower exposure levels. 
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Neurotoxicity.     
Stable Strontium.  The only evidence for neurotoxicity of stable strontium is a report of hindlimb 
paralysis following intermediate-duration ingestion of excess strontium (Johnson et al. 1968).  Given the 
absence of any other evidence for neurotoxicity, it is possible that, in this case, the paralysis may have 
resulted from compression of the hypertrophic epiphyseal cartilage, which was insufficiently mineralized 
to support the weight of the body.  Additional neurotoxicity studies in adult animals for stable strontium 
do not appear to be necessary. 
Radioactive Strontium. Neurological effects were reported in the Techa River population that was 
exposed to radiostrontium from water and food contaminated from releases at a plutonium processing 
plant between 1949 and 1956 (Akleyev et al. 1995).  However, external gamma radiation, also released at 
this time, undoubtedly contributed to these effects.  A single instance of epilepsy in a dog exposed by 
inhalation to a high concentration represents the only evidence for neurotoxicity of radioactive strontium 
in animals (Gillett et al. 1987b).  The authors concluded that epilepsy was not related to treatment.  
However, no studies have specifically measured behavioral or neurological deficits in exposed animals.  
The database needs studies that measure neurological effects in offspring following exposure in utero 
and/or during lactation. 
Epidemiological and Human Dosimetry Studies.     
Stable Strontium.  Strontium is ubiquitous in the environment, so everyone is exposed to it to some 
degree. Children who exhibit pica behavior or persons living in areas with high levels of strontium in the 
drinking water may have higher exposures than the general population.  A Turkish epidemiological study 
demonstrated a higher incidence of rickets among children living in rural communities whose diet was 
based on grain crops grown in local soil containing high levels of strontium (Özgür et al. 1996).  This 
study did not attempt to measure strontium levels in the affected children.  In addition, this study may not 
be directly applicable to conditions in the United States, given the different diet and the availability of 
foods from a wider geographic range.  One epidemiological study found that relatively high levels of 
strontium in the drinking water had no adverse effect on cardiovascular health, and, in fact appeared to 
have a beneficial effect on the rate of mortality from hypertension with heart disease (Dawson et al. 
1978).  Information regarding the higher levels in drinking water could be used to design animal 
experiments for evaluating chronic exposure effects, which are currently lacking in the database.  In one 
case-control study that tried to account for the higher incidence of liver cancer in 1984 on Chongming 
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Island in China, no association was found with the levels of stable strontium detected in hair (Wang et al. 
1990). 
Radioactive Strontium. Dosimetry data are available for approximately 16,000 members of the Techa 
River population that was exposed to radiostrontium because of releases from a plutonium processing 
plant between 1949 and 1956 (Kossenko et al. 1997).  Since exposure levels in this population were 30– 
100 times higher than the maximum exposure from global fallout, this cohort represents the largest group 
of subjects available for examining health effects of chronic radiation exposure.  Subpopulations living in 
certain regions within the Techa River area received different levels of exposure, so that dose 
relationships are being established for health effects.  In addition, investigators have been able to examine 
the effect of developmental age at the time of exposure on health outcomes.  Although individuals were 
exposed to multiple sources of radiation during the first years (including 137Cs bound in soft tissues), in 
recent decades, their radiation exposure was primarily from 90Sr incorporated into bone.  The health 
effects have been similar to those observed for animals exposed chronically to radiostrontium, and have 
included suppression of hematopoeisis and leukemia (Akleyev et al. 1995; Kossenko 1996; Kossenko et 
al. 1997, 2000).  
A Danish epidemiological study found no association between the incidence of thyroid cancer in 
Denmark between 1943 and 1988 and the levels of skeletal incorporation of 90Sr from fallout (Sala and 
Olsen 1993).  However, the reason for this study is uncertain since strontium is not taken up preferentially 
in the thyroid, unlike iodine, which is incorporated into thyroid hormones (T3 and T4).  A Scottish 
epidemiological study found no evidence for increased risks of total cancers, leukemia and non­
Hodgkin’s lymphoma, or acute myeloid leukemia for cohorts of children born during the period of highest 
fallout (radiostrontium) exposure (Hole et al. 1993). The few cases of bone tumors showed a 
nonsignificant increase for children born during the ‘high risk’ period.  The reduction in fallout from 
above-ground nuclear weapons testing has reduced the exposure of the general population to radioactive 
strontium.  Currently, populations working at or living in the vicinity of nuclear power plants or 
reprocessing facilities might have higher than background exposures.  Workers at the facilities may have 
less exposure because protective equipment and safety procedures are in use.  Environmental levels of 
radiostrontium that are measured near these facilities could be used to guide exposure levels in the 
toxicity experiments proposed above.  
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Biomarkers of Exposure and Effect.     
Exposure. 
Stable Strontium.  Levels of stable strontium can be measured in blood or urine to determine exposures 
of any duration.  Within a few days, most of the retained strontium is found in bone, but because of bone 
remodeling, strontium will be released over time and be detectable in blood and urine.  Inductively 
coupled plasma mass spectroscopy (ICP-MS) was able to detect strontium in amniotic fluid and maternal 
plasma at levels of 0.03 and 0.06 ppb, respectively, in untreated humans (Silberstein et al. 2001).  The 
sensitivity of this method is adequate to detect unusual accumulations of strontium.  No additional 
biomarkers of exposure to stable strontium appear to be needed. 
Radioactive Strontium. Exposures to radioactive strontium can be determined readily by measuring 
levels of radioactivity in blood or urine by liquid scintillation counting techniques.  In addition, whole 
body counters can determine the level of radiostrontium retained in the skeleton.  There appears to be no 
need for additional biomarkers of exposure to radioactive strontium. 
Effect. 
Stable Strontium.  The typical signs of rickets (craniotabes, rachitic rosary, bulging at the wrist, genu 
valgus, genu varus, and delayed closure of the fontanelles) represent biomarkers of exposure to excess 
stable strontium in children (Özgür et al. 1996).  Excess strontium ingestion has been shown to depress 
serum levels of 1,25-dihydroxyvitamin D in rats (Armbrecht et al. 1998).  Since vitamin D insufficiency 
by itself can also cause rickets, measurement of both vitamin D levels and strontium levels in serum 
would be required to determine the role of strontium in a particular case.  As mentioned above (Data 
Needs for Acute-Duration Studies), the proposed toxicity studies could be used to develop biomarkers for 
early effects following exposure to excess strontium.  An array of biomarkers could possibly be 
developed to monitor the course of pathology before the signs of rickets fully appear. 
Radioactive Strontium. A reduction in blood cell counts is a biomarker of effect for radioactive 
strontium.  However, many other conditions can have the same result.  Cytogenetic analysis of blood cells 
can reveal whether exposure to radioactive strontium has been sufficient to cause genotoxicity (see 
Table 3-5). A new method for evaluating DNA damage in cells exposed to gamma radiation has been 
developed using molecular biological techniques (Sutherland et al. 2000a, 2000b).  It may be possible to 
STRONTIUM 185 
3. HEALTH EFFECTS 
develop such an assay for evaluating exposure to radioactive strontium, which would also specifically 
identify the kind of DNA lesions produced.  
Absorption, Distribution, Metabolism, and Excretion.  More information is needed comparing 
the relative rates of absorption for different chemical forms of strontium that may vary in solubility. 
Solubility differences would affect the duration of residence of particles in the lung, which might have 
significant effects in the case of radiostrontium exposure.  A comparison of gastrointestinal absorption 
rates for different chemical forms and for different vehicles of administration (food or water) has not been 
conducted. Results of such studies would help predict outcomes following different kinds of exposure.  
Nothing is known regarding dermal absorption of strontium taken up in soil, which is a type of exposure 
that children would be likely to encounter.  However, studies of dermal absorption from soil would be of 
low priority given that significant dermal absorption of soluble strontium only occurred through abraded 
skin (See Section 3.5.1.3) and the amounts available from dry soil would be biologically insignificant 
under any realistic exposure scenario.  Absorbed strontium is understood to distribute primarily to the 
bone and to be retained longer in the young than in adults.  The combination of the ICRP PBPK model for 
strontium and animal-based studies on Observed Ratios of strontium and calcium (Comar and Wasserman 
1964) is sufficient to estimate strontium turnover during pregnancy and lactation and in the elderly. 
Comparative Toxicokinetics.  The target organ for stable and radioactive strontium is the same in 
humans and animals, namely, bone.  Young rats can serve as a model for children’s exposures, but adult 
rats are less suitable, since the epiphyseal plate remains cartilaginous into adulthood (Leininger and Riley 
1990). For this reason, adult rats could be expected to incorporate proportionally higher levels of 
strontium than adult humans.  Furthermore, remodeling of bone in rats is not analogous to that in humans.  
The rat would probably not be a good model for evaluating placental transfer of strontium to the fetus 
because of differences in placental tissue organization. 
Methods for Reducing Toxic Effects. Both stable and radioactive strontium are readily absorbed by 
the intestine, apparently through calcium transporter elements (Bianchi et al. 1999; Blumsohn et al. 1994; 
Milsom et al. 1987; Reid et al. 1986; Sips et al. 1994).  Numerous methods have been tested for 
alleviating the effects of exposure to strontium (see Section 3.12).  Oral administration of alginates with a 
high guluronic acid content or a single dose of aluminum phosphate antacid gel are currently 
recommended for reducing peak absorption of strontium shortly after exposure.  The toxicities of excess 
stable and radioactive strontium are related to their rapid sequestration into bone. Most strategies for 
treatment involve high calcium in combination with other agents to enhance the replacement of strontium 
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in bone by calcium.  There does not appear to be a need for new studies at this time.  However, as 
mentioned in Section 3.6.2, polymorphisms in genetic factors that may affect rates of strontium 
absorption and bone mineralization are currently under investigation and potentially could regulate the 
effectiveness of treatment.  If relevant polymorphisms are identified, then the existing methods for 
reducing toxic effects should be tested using stable strontium tracers to determine whether genetic factors 
affect the outcome of treatment.   
Children’s Susceptibility.     
Stable Strontium.  The effect of excess stable strontium ingestion on bone development is well 
documented: strontium-induced rickets has been reported in children and young animals.  The particular 
vulnerability of children, because of the immaturity of the skeleton, is well understood.  The intestinal 
rate of strontium absorption and the retention of strontium in the developing bone is known to be higher 
in infants and children than in adults.  It is known that the fetus can be exposed to strontium following 
previous maternal exposure, but adequate information regarding changes in the rates of strontium 
mobilization from the maternal skeleton or changes in rates of intestinal absorption of strontium during 
the course of pregnancy is lacking.  There is a need for studies to develop this information to fill in gaps 
in existing PBPK models for strontium; this effort would have the additional benefit of being applicable 
to other bone-seeking radioisotopes.  Another issue to be considered is the relative bioavailability of 
strontium in the different chemical compounds (e.g., strontium chloride, strontium carbonate, strontium 
phosphate). Since children may be exposed to strontium by pica behavior, there is a need for animal 
studies that would investigate variations in absorption (bioavailability) when strontium is ingested in the 
form of soil. 
Biomarkers of exposure and effect are established for children.  Since the primary biomarker of effect, 
rickets, is a late-stage phenomenon, it would be useful to precisely establish a constellation of biomarkers 
that would identify a precursor condition.  Such markers might include relative serum levels of vitamin D, 
calcium, phosphorus, and alkaline phosphatases, as well as strontium itself.  The alginate method for 
reducing peak absorption of strontium has been validated in children (Sutton et al. 1971a). 
Radioactive Strontium. Numerous oral exposures have demonstrated the enhanced risk of reproductive 
effects and cancer in animals exposed to radiostrontium in utero or during lactation.  At the higher levels 
used in injection studies, teratogenic effects were observed on bone development.  The possibility of 
neurological deficits from gestational exposure to radioactive strontium, resulting from radiostrontium 
incorporation into the cranium and subsequent irradiation of adjacent brain tissue, should be explored. 
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The toxicokinetic and bioavailability issues mentioned in the previous section on stable strontium apply 
to radioactive strontium.  Low-level exposure studies should be conducted to evaluate possible 
impairment of immune function, which results from irradiation of bone marrow by radiostrontium 
incorporated into bone and which has been observed in animal studies at higher levels. 
Radioactive strontium is its own biomarker of exposure in children and adults.  The primary biomarkers 
of effect, also applicable to children and adults, are a reduction in lymphocyte and other blood cell counts, 
which closely match the intensity of exposure.  The alginate method for reducing peak absorption, 
described above, has been validated for children (Sutton et al. 1971a).  It is not clear whether another 
recommended treatment, a single dose of aluminum phosphate antacid gel, would be safe for children, 
since it can have toxic effects in children at high doses.  Either method would only be effective if 
administered very soon after exposure (within an hour). 
Data needs relating to both prenatal and childhood exposures and developmental effects expressed either 
prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above. 
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 
Exposures of Children. 
3.13.3 Ongoing Studies 
Stable Strontium.  Two currently funded research programs that specifically mention stable strontium are 
probably using it as a surrogate for calcium in physiological experiments.  In a study sponsored by the 
National Institute of Mental Health, Dr. J.A. Dzubay (1997) of the Oregon Health Sciences University is 
conducting in vitro experiments on the activity of NMDA (N-methyl D-aspartate) channels in the 
hippocampus; these are membrane channels controlled by NMDA receptors that regulate the influx of 
calcium into neurons.  In work funded by the National Institute of Neurological Disorders and Stroke, Dr. 
David Lovinger (1999) of Vanderbilt University Medical Center is studying glutamatergic and 
dopaminergic synaptic transmission in the neostriatum.  In a third study, sponsored by the National 
Institute of General Medical Sciences, Dr. J. Bell (1998) of Fayetteville State University in North 
Carolina is examining the effect of metal salts on the fidelity of DNA synthesis.  It appears that this 
research may provide additional genotoxicity information regarding stable strontium. 
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Radioactive Strontium. The single largest population available for studying the long-term health effects 
of radiostrontium is the Techa River cohort that was exposed from contaminated drinking water and food 
following releases from a plutonium processing plant between 1949 and 1956 (Akleyev et al. 1995; 
Bauchinger et al. 1998; Kossenko 1996; Kossenko et al. 1994, 1997, 2000; Shagina et al. 2000; Tolstykh 
et al. 1998). In addition to the studies reviewed in this toxicological profile, further analysis of this 
population is expected to continue under the auspices of the Urals Research Center for Radiation 
Medicine. 
Additional information regarding the toxicity of radioactive strontium is likely to emerge from studies 
related to the therapeutic use of strontium isotopes.  In programs funded by the National Heart Lung and 
Blood Institute, Dr. Sou-Tung Chiu-Tsao (1999) of the Beth-Israel Medical Center, New York, and Dr. 
Ravinder Nath (1999) of Yale University Medical Center, are investigating 90Sr along with other isotopes 
for intravascular brachytherapy delivered at the time of angioplasty.  Dr. Carl J. Pepine (1998) of the 
Department of Veterans Affairs Medical Center, Gainesville, Florida, is conducting a clinical trial to 
evaluate a commercial product for intravascular brachytherapy.  Dr. Timothy Kuzel (1999) of the 
Department of Veterans Affairs Medical Center, Chicago, Illinois, is conducting a Phase I/II trial of 89Sr 
in conjunction with mitoxantrone and hydrocortisone in the treatment of bone metastases in patients with 
hormone-refractory prostate cancer.  In work funded by the National Center of Research Resources, Dr. 
Franco Muggia (1999) of the New York University Medical Center is conducting an open label Phase II 
study to evaluate the effect and toxicity of Doxil, a liposomal encapsulated doxirubicin, and 89Sr in 
combination for treating hormone-refractory metastatic prostate cancer.  In a study sponsored by the 
National Institute on Deafness and Other Communication Disorders, Dr. Gina M. Nelson (1999) of the 
University of Alabama at Birmingham is conducting laboratory tests in rodents in order to develop a 
radiation treatment for cancer of the mouth that will be less likely to destroy the sense of taste than 
current procedures. Radiostrontium will be held in a device to expose the tongue to beta radiation. 
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4.1 CHEMICAL IDENTITY  
Strontium is an alkaline earth element in Group IIA of the periodic table.  Because of its high reactivity, 
elemental (or metallic) strontium is not found in nature; it exists only as molecular compounds with other 
elements. The chemical information for elemental strontium and some of its compounds is listed in 
Table 4-1. Radioactive isotopes of strontium (e.g., 89Sr and 90Sr, see Section 4.2) are the primary cause of 
concern with regard to human health (see Chapter 3).  
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES  
The physical properties of strontium metal and selected strontium compounds are listed in Table 4-2.  The 
percent occurrence of strontium isotopes and the radiologic properties of strontium isotopes are listed in 
Table 4-3. 
Strontium can exist in two oxidation states: 0 and +2.  Under normal environmental conditions, only the 
+2 oxidation state is stable enough to be of practical importance since it readily reacts with both water 
and oxygen (Cotton and Wilkenson 1980; Hibbins 1997).  There are 26 isotopes of strontium, 4 of which 
occur naturally. The four stable isotopes, 84Sr, 86Sr, 87Sr, and 88Sr, are sometimes referred to as stable 
strontium.  The most important radioactive isotopes, 89Sr and 90Sr, are formed during nuclear reactor 
operations and during nuclear explosions by the nuclear fission of 235U, 238U, or 239Pu. For example, 235U 
is split into smaller atomic mass fragments such as 90Sr by a nuclear chain reaction initiated by high 
energy neutrons of approximately 1 million electron volts (or 1 MeV).  These smaller atomic mass 
fragments are referred to as fission by-products.  This process is illustrated below: 
235U + 1n 6 90Sr + 89Sr + other fission by-products 
90Sr is the more dangerous of the two isotopes due to its long half-life (29 years).  90Sr decays by emission 
of a beta-particle with a maximum energy of 0.546 MeV and the creation of an 90Y isotope, or progeny 
product.  Unlike other radioactive isotopes that decay by beta-emission, 90Sr does not directly release high 
energy photons or gamma-ray radiation (γ). However, the progeny product of 90Sr, 90Y, is both a beta-
particle (2.28 MeV maximum energy) emitter and to a minor degree for 0.02% of all disintegrations, a 
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Table 4-1. Chemical Identity of Strontium and Strontium Compounds 
Strontium Strontium Strontium Strontium 
Property Strontium (0) acetate carbonate chloride chromate 
Chemical formula Sr C4H6O4Sr CO3Sr Cl2Sr CrH2O4Sr 






 Sr+2 O Cr O-Sr 




Synonyms None Strontium Carbonic acid, Strontium Chromic acid, 
diacetate strontium salt dichloride strontium salt 
(1:1); 
strontianite 
Trade names No data No data No data No data No data 
Identification numbers 
 CAS registry 7440-24-6 543-94-2 1633-05-2 10476-85-4 7789-06-2 
 NIOSH RTECS WK7849000 AJ4725000 No data WK8400000 GB3240000 
 EPA hazardous No data No data No data No data D007 
 waste 
OHM/TADS No data No data No data No data No data 
 DOT/UN/NA/IMO UN 1383/IMO No data No data No data 9149/NA 9149 
 shipping 4.2 
HSDB 2545 No data 5845 No data 2545 
NCI No data 75799 112224 No data No data 
STCC No data No data No data No data 49 633 77 
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Table 4-1. Chemical Identity of Strontium and Strontium Compounds 
Strontium Strontium Strontium Strontium Strontium 
Property fluoride hydroxide nitrate phosphate oxide 
Chemical formula F2Sr H2O2Sr N2O6Sr O8P2Sr3 OSr 




O-O O -O O
Sr+2 Sr+2 Sr+2
 





Synonyms Strontium Strontium Nitrate de No data Strontia, 









Trade names No data No data No data No data No data 
Identification 
numbers
 CAS registry 7783-48-4 18480-07-4 10042-76-9 7446-28-8 1314-11-0
NIOSH WK8925000 WK9100000 WK9800000 No data No data
RTECS 
 EPA hazardous No data No data No data No data No data
 waste 
 OHM/TADS No data No data No data No data No data
 DOT/UN/NA/IMO No data No data UN 1507 No data No data
 shipping Oxidizer 
IMO 5.1 
HSDB
 No data No data No data No data No data
NCI
 No data No data No data No data No data
STCC
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Table 4-1. Chemical Identity of Strontium and Strontium Compounds 
Strontium Strontium Strontium Strontium 
Property peroxide sulfate sulfide titanate 
Chemical formula O2Sr O4SSr SSr O3SrTi 
Chemical structure SrO2 SrSO4 SrS SrTiO3 
O O 
Sr+2 O S O- Ti 
Sr S -O O--O O-
O- Sr+2 
Sr+2 
Synonyms Strontium Celestine, Strontium No data 
dioxide celestite monosulfide 
Trade names No data No data No data No data 
Identification numbers
 CAS registry
 1314-18-7 7759-02-6 1314-96-1 12060-59-2
 NIOSH RTECS
 WL0100000 No data WL0400000 No data
 EPA hazardous
 No data No data P107/D003 No data
 waste 
 OHM/TADS No data No data No data No data
 DOT/UN/NA/IMO UN 1509 No data No data No data
 shipping Oxidizer 
IMO 5.1 
HSDB
 788 No data 12 No data
NCI
 No data No data No data No data
STCC
 49 187 55 No data No data No data 
CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances; STCC = Standard Transportation Commercial Code 
Source: ChemFinder 2002; HSDB 2002; Lide 2000 
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Table 4-2. Physical and Chemical Properties of Strontium and  
Strontium Compoundsa 









Molecular weight, 87.62 205.71 147.63 158.53 203.62 
g/mole 













Boiling point 1,382 °C Not applicable Decomposes at 1,250 °C No data 
Density, g/cm3 2.64 2.099 
1,100 °C 
3.5 3.05 3.90 
Odor No data No data Odorless No data No data 
Odor threshold:
 Water No data No data No data No data No data
 Air No data No data No data No data No data 
Solubility:
 Water Decomposes 369 g/L (cold) 0.11 g/L at 538 g/L 30 g/L at 
18 °C at 20 °C 100 °C
 Organic Alcohol Alcohol, No data Alcohol, Acetic acid 
 solvents(s) slightly acetone 
Partition 
coefficients:
 Log Kow No data No data No data No data No data
 Log Koc No data No data No data No data No data 
Vapor pressure 5 mmHg No data No data No data No data 
at 847 °C 
Henry’s Law No data No data No data No data No data 
constant 
Autoignition No data No data No data No data No data 
temperature 
Flashpoint No data No data No data No data No data 
Flammability limits No data No data No data No data No data 
Explosive limits No data No data No data No data No data 
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Strontium Strontium Strontium Strontium 
Property peroxide sulfate sulfide titanate 
Molecular weight, 119.63 183.68 119.70 183.52 
g/mole 
Color White Colorless Gray White 
Physical state Solid Solid Solid Solid 
Melting point Decomposes at 1,605 °C >2,000 °C No data 
215 °C 
Boiling point No applicable No data No data No data 
Density, g/cm3 4.56 3.96 3.70 4.810 
Odor Odorless No data Hydrogen No data 
sulfide in moist 
air 
Odor threshold:
 Water Not applicable No data No data No data
 Air Not applicable No data No data No data 
Solubility:
 Water Decomposes 0.14g/L at Decomposes Insoluble
30 °C 
 Organic Alcohol Slightly in No data No data 
 solvents(s) alcohol 
Partition 
coefficients:
 Log Kow No data No data No data No data
 Log Koc No data No data No data No data 
Vapor pressure No data No data No data No data 
Henry’s Law No data No data No data No data 
constant 
Autoignition No data No data No data No data 
temperature 
Flashpoint No data No data No data No data 
Flammability limits No data No data No data No data 
Explosive limits No data No data No data No data 
aSource: HSDB 2002, unless otherwise stated 
bMerck 1989 
cLide 1995 
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Table 4-3. Percent Natural Occurrence and Radioactive Properties  
of Isotopes of Strontium 
Natural 
CAS registry abundance Beta energies, 
Isotope number (by weight %) MeV Half-life Activity, Ci/gram 
84Sr 15758-49-3 0.56 No data Stable No data 
85Sr 13967-73-2 No data 1.065a 65 days 35,400 
86Sr 13982-14-4 9.86 No data Stable No data 
87Sr 13982-64-4 7.00 No data Stable No data 
88Sr 14119-10-9 82.58 No data Stable No data 
89Sr 14158-27-1 No data 1.495 51 days 27,800 
90Sr 10098-97-2 No data 0.546 29 years 143 
91Sr 14331-91-0 No data 2.707 10 hours 3.4x106 
92Sr 14928-29-1 No data 1.911 3 hours 1.1x107 
aDecay mechanism by electron capture with gamma emission 
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beta-particle and gamma-ray (2.19 keV) emitter.  The decay product of 90Y is 90Zr, a stable isotope.  The 
reaction is: 
90Sr (t½=29 yrs) 6 90Y (t½=64 hrs) + β-(0.546MeV) 6	 90Zr (stable) + β-(2.28 MeV)  (99.98 %)
 
90Zr (stable) + β-(0.523 MeV) + γ(1.75 MeV) 

89Sr, like 90Sr, is a fission product of 235U, 238U, or 239Pu.  It decays to 89Y by emission of a beta-particle of 
1.495 MeV 89Y. 89Sr has half-life of 51 days (Lide 1995).  
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5.1 PRODUCTION 
Strontium is a naturally occurring element that makes up approximately 0.02–0.03% of the earth’s crust.  
In nature, strontium is present in igneous rocks in amounts averaging 375 ppm.  The principal strontium 
minerals of commercial interest are celestite (SrSO4) and strontianite (SrCO3). Strontium is also a minor 
component of other mineral deposits and may occur in or near sedimentary rocks associated with beds or 
lenses of gypsum, anhydrite, and rock salt; in veins associated with limestone and dolomite; or dispersed 
in shales, marls, and sandstones.  In the United States, there are deposits of celestite in Texas, 
Washington, Arizona, Ohio, and California.  The U.S. Geological Survey (USGS) estimated U.S. 
resources of celestite and strontianite at 2,500,000 tons, containing 1,130,000 tons of strontium (Adams 
1975). However, domestic deposits of these minerals are not economically exploitable, and strontium has 
not been mined in the United States since 1959. 
Celestite is converted to SrCO3, the common commercial form of strontium.  The black ash method 
(alternatively known as the calcining method) and the soda method (also known as direct conversion) are 
the two most common recovery techniques for strontium.  The black ash method produces chemical grade 
strontium carbonates, which are 98% strontium carbonate and 2% byproducts and impurities.  The soda 
ash method produces technical grade strontium carbonates, containing at least 97% strontium carbonate.  
The black ash method is the preferred means of strontium carbonate production because it yields a higher-
grade product (USGS 1998). 
During World War II, the U.S. government began stockpiling celestite for defense applications.  In 1963, 
Congress determined that the stockpile was unnecessary, and by 1973, all of the stockpiled high-grade 
celestite was sold.  The remaining low-grade celestite material, approximately 12,000 metric tons, has 
been listed by the Defense National Stockpile Center of the Defense Logistics Agency as valueless.  In 
1998, Congress authorized the remaining stockpile for disposal.  The only U.S. strontium carbonate 
producer using celestite is the Chemical Products Corporation of Cartersville, Georgia.  A number of U.S. 
companies manufacture strontium compounds from strontium carbonate.  Mallinkrodt Inc. of St. Louis, 
Missouri, produces strontium chloride, and Rockwood Pigments Corporation of Beltsville, Maryland, 
produces strontium chromate.  Production of other strontium compounds is on a limited scale (USGS 
1998, 1999). 
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Radioactive strontium, or 89Sr and 90Sr, does not occur in nature.  It is the direct result of anthropogenic 
activity.  As discussed in Chapter 4, 89Sr and 90Sr are produced by nuclear fission. Nearly all of the 90Sr 
generated in the United States is present in spent nuclear reactor fuel rods.  These fuel rods are currently 
located at the commercial reactor facilities or at Department of Energy (DOE) facilities across the United 
States. After 1 year of decay of nuclear fuel rods, 90Sr represents 3.7% by mass of the total fission 
product inventory.  A limited amount of 89Sr and 90Sr is produced for industrial, scientific, and medicinal 
applications through the process of fission product recovery.  During the period of 1974–1984, 90Sr was 
recovered and converted into solid forms.  Typically, 90Sr is combined with fluorine to produce strontium 
fluoride (90SrF2) or with chlorine (Cl2) to produce strontium chloride (90SrCl2). These solids were placed 
in double walled capsules to be used for commercial and medical applications.  90Sr is available from 
Pacific Northwest National Laboratory located at the DOE facility in Hanford, Washington. The Hanford 
inventory of 90Sr embodies one of the largest sources of this nuclide in the world (DOE 1996b, 1996c).  
5.2 IMPORT/EXPORT 
In 2001, 100% of celestite used in the United States was imported from Mexico.  Of the 38,500 metric 
tons of strontium minerals and compounds imported in 2001, approximately 94% were imported from 
Mexico, 6% from Germany, and 2% from other countries.  From the period of 1954–1974, demand for 
strontium imports (both mineral and compound) has steadily increased from approximately 3,200 to 
16,000 metric tons.  From 1994 to 2001, the importation of strontium minerals and compounds for 
consumption has remained relatively steady at approximately 31,000–38,500 metric tons.  The apparent 
consumption of all strontium imports in the United States is 97%.  The total export volume of strontium 
compounds during 1993–2001 was more than 20 times lower than the quantities of strontium minerals 
and compounds imported during the same period.  Exports of strontium compounds has varied from 
1,120 metric tons in 1994 to 1,040 metric tons in 2001 (USGS 1998, 1999, 2002).  
5.3 USE 
In 2001, more than 85% of all strontium consumed in the United States was used in the manufacture of 
ceramics and glass products, primarily in television faceplate glass and secondarily in ceramic ferrite 
magnets (strontium ferrite) and other ceramic and glass applications.  All color televisions and other 
devices containing cathode-ray tubes (CRT) sold in the United States are required by law to contain 
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strontium in the faceplate glass of the picture tube to block x-ray emissions.  Major manufacturers of 
television picture tube glass incorporate about 8% by weight of strontium oxide (SrO) into the glass 
faceplate material.  Strontium is added to the glass melt in the form of strontium carbonate. Upon heating 
and solidification, it is transformed to SrO.  Other uses for strontium compounds include pyrotechnics 
(strontium nitrate), paint pigments (strontium chromate), fluorescent lights (strontium phosphate), getters 
in zinc production (strontium carbonate), alloy (strontium metal), and medicines (strontium chloride, 
strontium peroxide).  Strontium metal has limited commercial use.  One minor use of strontium is as an 
alloy material for the production of aluminum castings.  Most commercial uses of strontium compounds 
and products use strontium carbonate as the feed material (Hibbins 1997; USGS 1999, 2002). 
The radioactive isotope 89Sr (also known by the pharmaceutical brand name Metastron™) is used as a 
cancer therapeutic to alleviate bone pain. 85Sr has been used in medical applications, such as radiologic 
imagining of bones, in minor commercial applications, such in radioisotope thermoelectric generators 
(RTG), as a beta-particle standard source, and in instruments that measure thickness and density of 
materials (Murray 1994).  90Sr has been used in RTGs at remote locations (e.g., lighthouses) throughout 
the former Soviet Union (Alimov 2003).  Many of these 90Sr RTGs in the former Soviet Union are 
completely unguarded against potential thieves or intruders, lacking such minimal security measures as 
fences or even signs warning of radioactive dangers.  The biggest danger coming from these unprotected 
RTGs is their availability to terrorists who can use the radioactive materials (e.g., 90Sr) contained in them 
to make so-called “dirty bombs”, which are bombs that are triggered by standard explosives, but disperse 
radioactivity. 
5.4 DISPOSAL 
Most nonradioactive strontium minerals, strontium compounds, and strontium-containing materials do not 
require special disposal and handling requirements.  However, some chemical forms may be classified as 
hazardous materials if the compound is chemically reactive, flammable, or toxic.  Care should be taken to 
read and understand all of the hazards, precautions, and safety procedures for each specific chemical 
form.  In addition, all federal, state, and local laws and regulations should be investigated and 
subsequently followed with regard to disposal and handling of the specific chemical form of the strontium 
compound or material. 
Radioactive strontium does require special disposal and handling requirements and is regulated by the 
Nuclear Regulatory Commission (USNRC).  Radioactive waste-containing radioactive strontium can be 
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grouped into three categories: low-level waste (LLW); high-level waste (HLW) and spent nuclear fuel; 
and mixed waste.  As defined by the Nuclear Waste Policy Act, high-level radioactive waste is “the 
highly radioactive material resulting from the reprocessing of spent nuclear fuel, including liquid waste 
produced directly in reprocessing and any solid material derived from such liquid waste that contains 
fission products in sufficient concentration.”  However, most classifications of HLW also include spent 
nuclear fuel. Most HLW was generated from the production of plutonium.  A small fraction is related to 
the recovery of enriched uranium from naval reactor fuel.  This waste typically contains highly 
radioactive, short-lived high activity fission by-products as well as other long-lived isotopes, hazardous 
chemicals, and toxic heavy metals.  90Sr contamination is only a small fraction of the activity of HLW.  
Liquid HLW is typically stored in large underground tanks of either stainless steel or carbon steel, 
depending on whether they are acid or alkaline solutions.  There are about 100 million gallons of high-
level liquid waste stored in underground tanks in Washington, South Carolina, Idaho, and New York.  
These tanks contain a variety of radioactive liquids, solids, and sludges.  Some of the liquid wastes have 
been solidified into glass, ceramic slag, salt cakes, and sludges (DOE 1996a; Murray 1994). 
Spent nuclear fuels, such as fuel elements and irradiated targets used in nuclear reactors, are currently 
disposed of at the commercial nuclear power plants and DOE facilities where they were produced.  Spent 
fuel is highly radioactive due to the large concentration of fission products and must be stored in special 
water-cooled pools that shield and cool the material.  Most of the 90Sr remains trapped in the spent fuel 
rod matrix and is never released.  Roughly all DOE spent fuel, about 3,000 metric tons, is stored at four 
sites: Hanford, Savannah River, Idaho National Engineering Laboratory, and West Valley, New York.  
Commercial reactors have generated more than 30,000 metric tons of spent fuel. The spent fuel from 
these facilities is stored at the more than 100 commercial nuclear reactor sites around the United States.  
The establishment of an HLW and spent fuel repository for both DOE and commercial waste is currently 
under evaluation at Yucca Flats, Nevada. It is not projected to be in operation until after the year 2010 
(DOE 1996b; Eisenbud 1987; Murray 1994). 
Mixed waste contains both radioactive and chemically hazardous materials such as toxic, corrosive, 
flammable, or explosive materials. The radioactive component may be either HLW or LLW. All liquid 
HLW is mixed waste, usually in the presence of organic solvents or heavy metals in addition to 
radioactive components.  Disposal of mixed wastes is regulated by EPA under the Resource Conservation 
and Recovery Act (RCRA) and by the USNRC under the Atomic Energy Act.  EPA and USNRC have 
developed special procedures on how to handle and dispose of this special category.  DOE operates an 
incinerator in Oak Ridge, Tennessee that burns mixed hazardous radioactive wastes (DOE 1996a).  
STRONTIUM 203 
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
Low-level waste is all radioactive waste that cannot be classified as HLW, spent fuel, or mixed waste.  
Low-level does not necessarily mean low radioactivity or low environmental hazards.  However, the bulk 
of LLW has relatively little radioactivity and practically no transuranic elements.  Thus, LLW usually 
does not require shielding from radioactivity or heat removal equipment.  Most LLW is acceptable for 
near-surface land disposal.  LLW types that may be contaminated with 90Sr include both wet and dry 
wastes. Examples of the physical form of LLW are spent ion exchange resins, filter sludges, filter 
cartridges, evaporator bottoms, compactable trash, non-compactable trash, irradiated components, ashes 
produced from the incineration of combustible material, contaminated detergents or solvents, organic 
liquids, and discarded contaminated equipment or tools.  Of the LLW generated today, approximately 
64% of the volume and 70% of the radioactivity are generated as a result of nuclear power plant activities 
or supporting fuel cycle operations.  Other sources of LLW are industrial, academic, government, and 
medical. Radiostrontium contamination accounts for only a small fraction of the activity of LLW.  LLW 
is typically packaged in drums or boxes and buried in shallow pits or trenches.  Approximately 3 million 
cubic meters of LLW generated in the United States have been disposed of this way.  LLW from DOE 
sources is currently disposed of at several DOE facilities across the United States.  Only two sites accept 
non-DOE LLW, Barnwell, South Carolina and Richland, Washington.  Over half of the LLW in the 
eastern United States is disposed of at the Barnwell site.  As required by the Federal LLRW (Low Level 
Radioactive Waste) Policy Act in 1980 and in the 1985 amendments, states or interstate compacts are 
required to build facilities to contain LLW generated from sources within their boundaries.  However, 
other than Barnwell, South Carolina and Richland, Washington sites, no other facility in the United States 
is currently accepting LLW from non-DOE sources.  Currently, many generators store LLW on-site until 
additional facilities can be constructed in the future (DOE 1996a; Eisenbud 1987; Murray 1994).  
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6.1 OVERVIEW 
Strontium and 90Sr have been identified in at least 102 and 12, respectively, of the 1,636 hazardous waste 
sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2003).  
However, the number of sites evaluated for strontium and strontium-90 are not known.  The frequency of 
these sites can be seen in Figures 6-1 and 6-2, respectively.  Of these sites, all are located within the 
United States and none are located in the Commonwealth of Puerto Rico. 
Strontium is widely distributed in the earth’s crust and oceans.  Strontium is released into the atmosphere 
primarily as a result of natural sources, such as entrainment of dust particles and resuspension of soil.  
Radioactive strontium is released into the environment as a direct result of anthropogenic activities.  
Stable strontium can neither be created nor destroyed.  However, strontium compounds may transform 
into other chemical compounds.  Radioactive strontium is formed by nuclear reactions.  Radioactive 
decay is the only mechanism for decreasing the concentration of radiostrontium.  The half-life of 90Sr is 
29 years.  Eventually, all of the radioactive strontium will be converted to stable zirconium (see 
Section 4.2). 
Strontium present in the atmosphere is in the form of wet or dry aerosols.  The principal chemical species 
in the air is strontium oxide (SrO).  Strontium oxide will react rapidly in the presence of moisture to form 
Sr+2 and SrOH+ ions. Strontium is dispersed by atmospheric cycling and is subsequently deposited by wet 
deposition on the earth’s surface.  In surface water and groundwater, strontium exists primarily as a 
hydrated ion.  Strontium can form ionic complexes with other inorganic or organic substances. Strontium 
is relatively mobile in water.  However, the formation of insoluble complexes or sorption of strontium to 
soils can reduce its mobility in water.  Strontium sorbs to soils by ion exchange, and tends to be more 
mobile in soils with a high concentration of exchangeable ions or in soils with low cation exchange 
capacities. Strontium is taken up and retained by aquatic and terrestrial plants and is concentrated in the 
boney tissues of animals that eat contaminated vegetation.  The average concentration of strontium in 
urban air is 20 ng/m3 (Dzubay and Stevens 1975).  The concentration of 90Sr in the atmosphere has 
steadily decreased since its maximum concentration in 1963.  The mean concentration of strontium in 
U.S. surface water is <1 mg/L.  Dissolved strontium has been detected in groundwater and surface water 
used for drinking water supplies with average concentrations of 0.81 and 1.1 mg/L, respectively (EPA 
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2002b).  The median concentration of 90Sr in drinking water for 1995 was 0.1 pCi/L (3.7 mBq/L).  Human 
exposure to strontium and radiostrontium can result from consumption of food, drinking water, or 
incidental ingestion of soil or dust contaminated with strontium.  Food and drinking water are the largest 
sources of exposure to strontium and radiostrontium.  Grain, leafy vegetables, and dairy products 
contribute the greatest percentage of dietary strontium and radiostrontium to humans. 
6.2 RELEASES TO THE ENVIRONMENT 
The TRI data should be used with caution because only certain types of facilities are required to report.  
This is not an exhaustive list. 
6.2.1 Air 
Strontium naturally occurs in the earth’s crust and is released into the atmosphere as a result of natural 
processes such as entrainment of dust particles, resuspension of soil by wind, and sea spray.  Entrainment 
of soil and dust particles with significant concentrations of strontium would be most significant in areas 
with higher soil strontium concentrations.  Coastal regions have higher concentrations of strontium due to 
sea spray (Capo et al. 1998).  Human activities, including milling and processing of strontium 
compounds, burning of coal, land application of phosphate fertilizers, and using pyrotechnic devices, 
release strontium into the atmosphere (Lee and von Lehmden 1973; Ondov et al. 1989; Perry 1999; Que 
Hee et al. 1982; Raven and Loeppert 1997).  The effect of these activities is illustrated by the deposition 
rates of strontium measured in peat cores of northern Indiana.  Deposition has increased by a factor of 
7 from 8.1 mg strontium/m2/year in presettlement times (1339–1656) to 57.0 mg strontium/m2/year 
between 1970 and 1973 (Cole et al. 1990). 
Strontium discharged into the atmosphere from the operation of coal fired power plants depends on the 
strontium concentration in coal, the amount of coal burned, and the efficiency of fly ash recovery.  
Approximately 90% of coal mass is consumed during the combustion process, leaving 10% as a residual 
nonvolatile material (fly ash) containing 100–4,000 ppm (or mg/kg) of strontium (Furr et al. 1977).  
Atmospheric concentrations of strontium emitted from coal fired power plants have been found to range 
from 17 to 2,718 µg/m3 in the western United States and are approximately 9,786 µg/m3 in the eastern 
United States (Ondov et al. 1989; Que Hee et al. 1982).  Phosphate fertilizers are known to contain 
between 20 and 4,000 µg strontium/g solid by weight (Lee and von Lehmden 1973; Raven and Loeppert 
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1997). Strontium can be released into the atmosphere in windblown soil to which phosphate fertilizers 
have been applied. Pyrotechnic displays release low levels of strontium on the order of 9 ng/m3 in the 
immediate environment of the display (Perry 1999). 
Strontium has been identified in air at 9 sites collected from the 102 NPL hazardous waste sites where it 
was detected in some environmental media (HazDat 2003). 
Radioactive strontium (e.g., 90Sr) was released into the atmosphere from aboveground testing of nuclear 
weapons during the period of 1945–1980.  Nuclear weapon testing injects radioactive material into the 
stratosphere, which results in wide dispersal of radionuclides.  However, atmospheric deposition of 90Sr 
has steadily decreased from a high in 1963 of approximately 1.10x108 GBq (3.0 MCi) to <3,000 Ci in 
1990, which suggests that global concentrations of 90Sr in the atmosphere have declined (DOE 1996c).  
Other sources of regional contamination from radiostrontium include large-scale nuclear power plant 
accidents such as the Chernobyl disaster in the Ukraine (April 1986), which resulted in releases of about 
2.2 MCi (8.1x107 GBq) of 89Sr and 0.22 MCi (8.1x106 GBq) of 90Sr into the atmosphere (Eisenbud 1987).  
However, although some 90Sr reached the upper atmosphere and was subsequently transported around the 
world, most of the radiostrontium was deposited as regional fallout in eastern Europe (Eisenbud 1987).  
Routine releases of radiostrontium in 1993 from the operation of nuclear power plants around the United 
States are summarized in Table 6-1 (USNRC 1993a).  In 1993, releases of radiostrontium (i.e., 89Sr, 90Sr, 
and 91Sr) for boiling water reactors (BWR) and pressurized water reactors (PWR) (the two common 
designs of nuclear reactors in the United States) were 72.1 and 3.3 mCi (2.67 and 0.12 GBq), 
respectively. The total annual releases of radiostrontium from nuclear power plants in the United States 
(75.4 mCi or 2.79 GBq) are insignificant compared to releases of 90Sr from the testing of nuclear 
weapons. In the former Soviet Union between the years 1949 and 1956, large-scale environmental 
contamination occurred in the region surrounding the Mayak plutonium production complex in the Ural 
region of Russia (Eisenbud and Gesell 1997).  Releases of radioactive liquid wastes into the Techa River, 
both planned and accidental, of about 1017 Bq (2.7 MCi) resulted. 90Sr contributed about 12% (or 
0.23 MCi) to the total activity released (Tokareva et al. 2000).  Other minor releases of 90Sr have involved 
accidents with rockets or satellites that have disintegrated in the atmosphere.  The Soviet satellite 
Cosmos 954 powered by a plutonium fueled nuclear reactor released 3.1x103 GBq (83 Ci) of 90Sr to the 
regional atmosphere in northern Canada in 1978 (Eisenbud 1987).  The Department of Energy (DOE) and 
its predecessor agencies have been involved in operations that have released radiostrontium into the 
atmosphere.  Over the 43-year operating period at the DOE Savannah River Site in South Carolina, about 
1.1x102 GBq (3 Ci) of 90Sr were released into the atmosphere, primarily from the chemical separation and  
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Table 6-1. Radiostrontium Releases from Nuclear Power Plants for 1993 
Annual total site environmental releases for 1993 
Water Air 
Installation Locationa 89Sr, 90Sr, 91Sr, 92Sr, mCi 89Sr, mCi 90Sr, 91Sr, 
mCi mCi mCi mCi mCi 
Boiling Water Reactors
 Browns Ferryb Decatur, AL 41.1 2.05 No data 0.40 0.19 No data No data
 Brunswickb Wilmington, No data No data No data 0.0062 0.099 0.0027 No data 
NC 
Clinton Clinton, IL No data No data No data No data 0.06 No data No data
 Cooper Omaha, NE 4.69 15.8 No data 0.082 No data No data No data
 Dresdenb Joliet, IL 0.056 0.085 No data No data 0.67 0.004 No data 
Duane Arnold Cedar Rapids, No data No data No data No data 0.018 0.0009 No data 
IA 
Edwin I. Hatch Baxley, GA 6.29 0.43 5.20 0.65 12.0 0.24 No data
 Fermi Laguna 0.19 No data No data No data 0.14 0.0003 4.0 
Beach, MI 
Grand Gulf Vicksburg, MS 0.32 0.29 No data No data 0.003 0.002 No data
 Hope Creek Wilmington, No data No data No data No data No data No data No data
DE 
 Humbolt Bayb Eureka, CA No data 36.5 No data No data No data 0.002 No data
 James A. Syracuse, NY 0.44 No data No data No data 0.045 7.3x10-7 No data
Fitzpatrick 
 LaCrosseb LaCross, WI No data 0.28 No data No data No data 0.0003 No data 
LaSalle Ottawa, IL No data No data No data No data No data No data No data
 Limerick Phildelphia, 20.0 0.44 No data No data 16.4 0.31 No data
PA 
Millstone New London, 3.30 0.15 No data 0.55 0.22 0.0006 No data 
CT 
Monticello St.Cloud, MN No data No data No data No data 0.59 0.003 No data 
Nine Mile Point Oswego, NY <0.0001 No data No data No data 5.90 0.004 No data 
Oyster Creek Toms River, No data No data No data No data 1.17 0.014 No data 
NJ 
Peach Bottom Lancaster. PA 0.19 0.056 No data No data 4.9 0.021 3.76
 Perry Painesville, 0.22 0.008 No data No data 1.8 0.009 4.87
OH 
Pilgram Boston, MA 1.63 0.086 No data No data 5.8 0.024 No data 
Quad-Cites Moline, IL 0.050 0.018 No data 0.12 0.61 0.0014 No data 
River Bend Baton Rouge, 5.3 0.31 No data No data 0.30 0.0095 No data
LA 
 Shoreham Brookhaven, 0.025 No data No data No data No data No data No data 
NY 
Susquehanna Berwick, PA 0.0088 No data No data 0.0011 0.0003 No data No data
 Vermont Yankee Brattleboro, No data No data No data No data 2.83 0.054 No data 
VT 
WNP-2 Richland, WA 0.55 0.057 No data No data 3.5 0.012 1.61 
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Table 6-1. Radiostrontium Releases from Nuclear Power Plants for 1993 
Annual total site environmental releases for 1993 
Water Air 
Installation Locationa 89Sr, 90Sr, 91Sr, 92Sr, mCi 89Sr, mCi 90Sr, 91Sr, 
mCi mCi mCi mCi mCi 
Total 84.4 56.6 5.20 1.81 57.2 0.72 14.2 
Pressurized Water Reactors 
 Arkansas One Russellville, 2.81 1.17 No data 0.59 0.000955 No data No data
AR 
 Beaver Valley Shippingport, No data No data No data 0.08 No data No data No data 
PA 
Big Rock Point Charlevoix, MI 0.02 0.17 No data No data 0.21 0.006 2.73 
Braidwood Joliet, IL 3.68 158.4 No data 0.017 No data No data No data
 Byron Byron, IL 152.4 0.56 No data No data No data No data No data 
Callaway Fulton, MO 17.6 1.12 No data No data 0.004 No data No data
 Calvert Cliffs Washington, 0.83 0.37 No data No data No data No data No data 
DC 
Catawaba Rock Hill, SC No data No data No data 0.41 No data No data No data 
Comache Peak Glen Rose, TX No data No data No data 0.029 No data No data No data 
Crystal River Tampa, FL 3.03 10.2 No data 3.57 0.001 0.001 No data 
Davis-Besse Toledo, OH No data No data No data No data No data No data No data 
Diablo Canyon San Luis 0.16 0.057 No data 0.003 No data No data No data 
Obispo, CA 
Donald C. Cook St. Joseph, MI No data 0.029 No data No data 0.080 0.0005 No data
 Fort Calhoun Omaha, NE 0.61 0.77 No data No data No data 0.0007 No data 
H.B. Robinson Hartsville, SC No data No data No data No data No data No data No data
 Haddam Neck Middletown, 0.076 1.52 No data No data 0.0002 0.0002 No data
CT 
 Harrisb Raleigh, NC No data No data No data No data No data No data No data
 Indian Pointb Peekskill, NY 0.077 0.007 No data No data No data No data No data
 Joseph M. Dothan, AL No data 0.028 No data 0.10 No data No data No data 
Farley 
Kewaunee Green Bay, WI 0.92 0.051 No data No data No data No data No data 
Maine Yankee Wicassett, ME 0.15 No data No data No data No data No data No data 
McGuire Charlotte, NC 0.20 No data No data No data No data No data No data
 North Annac NW No data No data No data No data No data No data No data 
Richmond, VA 
Oconee Greenville, SC No data No data No data No data No data No data No data
 Palisades South Haven, 0.003 0.012 No data No data 0.011 0.0042 No data 
MI 
Palo Verde Phoenix, AZ No data No data No data No data 0.19 0.0009 No data
 Point Beach Manitowoc, WI 0.012 0.11 0.0052 No data No data 0.0001 No data
 Prairie Island Minneapolis, No data No data No data 0.029 0.0006 0.0003 No data 
MN 
R.E. Ginna Rochester, NY 0.30 0.090 No data No data No data No data No data 
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Table 6-1. Radiostrontium Releases from Nuclear Power Plants for 1993 
Annual total site environmental releases for 1993 
Water Air 
Installation Locationa 89Sr, 90Sr, 91Sr, 92Sr, mCi 89Sr, mCi 90Sr, 91Sr, 
mCi mCi mCi mCi mCi 
 Rancho Secob Sacramento, No data 0.0013 No data No data No data No data No data
CA 
 San Onofreb San Clemente, 4.26 0.36 No data 0.48 No data No data No data
CA 
 Seabrook Portsmouth, No data No data No data No data No data No data No data
NH 
Sequoyah Daisy, TN 0.35 0.29 0.023 0.54 No data No data No data 
South Texas Bay City, TX No data No data No data No data No data No data No data 
St. Lucie Ft. Pierce, FL 1.21 1.83 No data No data No data 0.0012 No data 
Summer Columbia, SC 0.0007 0.021 No data No data No data No data No data
 Surry Newport No data No data No data No data No data No data No data
News, VA 
 Three Mile Harrisburg, PA 0.034 0.83 No data No data No data 0.0003 No data
Islandb 
 Trojanb Portland, OR 0.24 0.029 No data No data No data No data No data
 Turkey Pointb Florida City, 12.7 3.55 No data No data No data No data No data
FL 
Vogtle Augusta, GA 1.64 0.19 No data No data 0.0025 0.0003 No data
 Waterford New Orleans, No data No data No data 0.23 No data No data No data 
LA 
Wolf Creek Burlington, KS No data 0.092 0.0087 No data No data No data No data
 Yankee Roweb Greenfield, MA No data No data No data No data No data No data No data 
Zion Waukegan, IL No data No data No data 5.93 No data No data No data 
Total 207.1 182.8 0.04 11.5 0.50 0.02 2.73 
aPost office state abbreviations used 
bFacilities that are permanently or indefinitely shut down 
cAir 85Sr 8.17x106 
Source: NRC 1993b 
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reprocessing of nuclear fuel (Carlton et al. 1998, 1999).  Between 1944 and 1972, about 64 Ci 
(2.4x103 GBq) of 90Sr and 700 Ci (2.6x104 GBq) of 89Sr was released into the atmosphere at the DOE 
Hanford site in Washington state from the routine operation of chemical plants used to separate plutonium 
from spent reactor fuel (CDC 1994).  
90Sr has been identified in air at 3 sites collected from the 12 NPL hazardous waste sites where it was 
detected in some environmental media (HazDat 2003).  
6.2.2 Water 
Releases of strontium to surface water and groundwater results from the natural weathering of rocks and 
soils and from the discharge of waste water directly into streams and aquifers.  Intentional and 
unintentional releases of radioactive strontium directly into streams have occurred at DOE sites across the 
country.  Over the period of 1954–1989, about 104 Ci (3.8x103 GBq) of 90Sr and 216 Ci (8.0x103 GBq) of 
89Sr were released to streams in the vicinity of the Savannah River Site (Carlton et al. 1998; Cummins et 
al. 1991).  During the period from 1952 to 1991, >129 Ci of 90Sr in waste water was discharged into pits, 
wells, and infiltration ponds at the Idaho Chemical Processing Plant in Idaho, some of which may have 
found its way into surface or groundwater (Bartholomay et al. 1995).  Minor releases of radioactive 
strontium to water occur annually from nuclear power plants.  Table 6-1 summarizes the releases of 
radioactive strontium from nuclear power plants into surface waters in 1993 (USNRC 1993a).  Releases 
of radiostrontium (i.e., 89Sr, 90Sr, 91Sr, and 92Sr) into surface waters in 1993 from BWR and PWR were 
146.2 mCi (5.41 GBq) and 401.4 mCi (14.9 GBq), respectively.  
Strontium has been identified in surface water and groundwater at 25 and 55 sites, respectively, collected 
from the 102 NPL hazardous waste sites where it was detected in some environmental media.  90Sr has 
been identified in surface water and groundwater at 3 and 7 sites, respectively, collected from the 12 NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 2003).  
6.2.3 Soil 
Strontium is ubiquitous in the environment and is present in nearly all rocks and soils.  It is released to 
land in solid waste and from the use of phosphate fertilizers.  90Sr is found in nearly all soils in the United 
States. 90Sr that is deposited at a specific site varies widely, depending primarily on rainfall.  Intentional 
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and unintentional releases of radioactive strontium have occurred at DOE sites across the country.  
Between 1954 and 1989 at the Savannah River Site, 105 Ci (3.9x103 GBq) of 89Sr and 299 Ci 
(1.1x104 GBq) of 90Sr were released into onsite seepage basins (DOE 1991).  About 100 million gallons 
of liquid HLW are stored in underground tanks in Hanford, Washington, Savannah River, South Carolina, 
Idaho National Engineering Laboratory, Idaho, and West Valley, New York; these tanks contain a variety 
of radioactive liquids, solids, and sludges with unknown characteristics.  Sixty-seven tanks at the Hanford 
site have suspected leaks of HLW into the surrounding soil.  The largest three confirmed leaks at the 
Hanford site have released 115,000, 70,000, and 55,000 gallons of HLW, respectively, which may contain 
90Sr as well as other radionuclides (DOE 1996a). 
Strontium has been identified in soil and sediment at 32 and 16 sites, respectively, collected from the 
102 NPL hazardous waste sites where it was detected in some environmental media.  90Sr has been 
identified in soil and sediment at 3 and 1 sites, respectively, collected from the 12 NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2003). 
6.3 ENVIRONMENTAL FATE 
6.3.1 Transport and Partitioning 
Strontium, present in crustal materials, is released by the weathering force of wind and water.  Strontium 
leaves the oceans, the largest reservoir of dissolved strontium, by deposition in marine carbonate 
sediment.  Some strontium is transported from oceans to the atmosphere in sea spray, returning to the 
terrestrial environment in the form of precipitation (Capo et al. 1998). 
Strontium released into the atmosphere from natural and anthropogenetic activities is transported and 
redeposited on the earth by dry or wet deposition.  Dry deposition results from gravitational settling, 
impact, and sorption on surfaces (NCRP 1984).  Experimental data on dry deposition of strontium, 
present in the ambient atmosphere, is limited.  Rain, sleet, snow, or other forms of moisture can wash 
airborne particles containing strontium from the atmosphere by the process of wet deposition.  Wet 
deposition depends on conditions such as particle solubility, air concentration, rain drop size distribution, 
and rain fall rate (NCRP 1984).  Hirose et al. (1993) examined the mechanism of aerial deposition of 90Sr 
derived from the Chernobyl accident, and found that 96% of atmospheric 90Sr returned to earth as wet 
deposition. 
STRONTIUM 215 
6. POTENTIAL FOR HUMAN EXPOSURE 
Like calcium, strontium has moderate mobility in soils and sediments, and sorbs moderately to metal 
oxides and clays (Hayes and Traina 1998).  The Sr2+ ion is strongly hydrated and is firmly coordinated 
with six or more water molecules in aqueous solution.  When Sr2+ ions sorb on negatively charged 
mineral surface sites, the hydration sphere is retained (O’Day et al. 2000).  Strontium sorbs as hydrated 
ions on the surface of clay minerals (kaolinite), weathered minerals (amorphous silica), and iron oxides 
(Sahai et al. 2000). Sorbed carbonate on iron oxides enhances the sorption of Sr2+ and permits the 
nucleation of Sr2+ as strontium carbonate (Sahai et al. 2000).  On calcite (calcium carbonate), Sr2+ 
sorption occurs by electrostatic attraction as hydrated ions.  However, at higher concentrations, 
precipitation of strontianite (strontium carbonate) occurs, and strontium is likely to be less mobile 
(Parkman et al. 1998).   
A wide variation of Kd values have been published in the literature for Sr2+ sorption (NCRP 1984) that 
reflect differences in soil and sediment conditions as well as the analytical techniques used (Bunde et al. 
1997).  The in situ Kd values of stable strontium and 90Sr determined in soil cores taken from the fallout 
area of the 1945 blast in Nagasaki, Japan were 496 and 300 L/kg, respectively (Mahara 1993). Migration 
rates for 90Sr in soils from this area were estimated to be 4.2 mm/year when the percolation rate of soil 
water was 2,500 mm/year.  Most 90Sr remained close to the soil surface in these soils.  In 1996, at most 
sites in the contaminated zone near Chernobyl, the main content of 90Sr (more than 95% of activity) was 
located in the upper 30-cm layer.  Only at a few sites (<1% of all sites) had a significant part of the 90Sr 
(>20%) migrate deeper than 30 cm (Kashparov et al. 2001).  A high migration ability of 90Sr is observed 
only in low-humus sands.  In soils from Belarus near the Chernobyl accident site, Kd values were 43, 59, 
and 150 L/kg for soddy-podzolic, soddy-loamy sandy, and peaty-gley soils, respectively (Sokolik et al. 
2001).  Organic matter in soils has a substantial effect on the transport of strontium through soils into 
groundwater.  Kd values decreased down the soil profile in Podzol forest soil with an organic rich top soil 
and lower clay layers, from 140 to 44 L/kg (Bunzl and Schimmack 1989).  Sr2+ chemically complexes 
with organic matter by partially neutralizing exchangeable sites on organic matter resulting in the 
precipitation of organic matter-Sr2+ complexes (Helal et al. 1998a).  High concentrations of ion 
exchangeable Ca2+ in soil enhances the complexation of Sr2+ with organic matter and increases the 
removal of Sr2+ from solution, which results in reduced Sr2+ mobility (Helal et al. 1998a).  However, 
nitrate fertilizers inhibit the formation of Sr2+-organic matter complexes and increase Sr2+ mobility (Helal 
et al. 1998b). Kd values of 15–40 L/kg were measured for 90Sr2+ in aquifer sediments near Liquid Waste 
Disposal Facilities at the Hanford site in Washington, where rapid ion exchange dominates (DOE 1996d).  
Kd was measured for 90Sr2+ in aquifer sediments beneath waste water ponds that contained high salt 
concentrations at the Idaho National Environmental and Engineering Laboratory (INEEL) (Bunde et al. 
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1998); and values ranged from 56 to 62 L/kg at initial concentrations of sodium and potassium of 300 and 
150 mg/L, respectively.  For initial aqueous concentrations of sodium between 1,000 and 5,000 mg/L, Kd 
values were 4.7 and 19 L/kg, respectively.  At the Chalk River Nuclear Laboratory in Ontario, Canada, a 
90Sr waste plume in groundwater initially advanced rapidly as 90Sr was out competed by high 
concentrations of Ca2+ and Mg2+ for sorption sites in sediments, and as concentrations of Ca2+ and Mg2+ 
declined, the migration of the 90Sr plume slowed (Toran 1994).  High salt concentrations (marine, brines, 
or high salinity water) can increase the mobility of 90Sr2+ by decreasing strontium sorption to sediments 
(Bunde et al. 1997, 1998) and increase the transport of strontium with the environmental cycling of water.   
Strontium is not necessary for growth or reproduction for most plants, but is typically absorbed to satisfy 
the plant’s metabolic requirements for calcium (NCRP 1984).  Soil to plant concentration ratios for 
strontium (the ratio of the concentration of strontium in wet vegetation to the concentration of strontium 
in dry soil) are 0.017–1.0 (NCRP 1984), and indicate that strontium can be easily absorbed into plants 
from soil.  The uptake of strontium by plants is greatest in sandy soils having low clay and organic matter 
content (Baes et al. 1986).  The concentration of nutritive mineral elements in soil such as calcium lower 
the intake of strontium to the aboveground phytomass.  The average reduction of the soil-to-plant 
concentration ratios for 90Sr caused by amendment with Ca or K is around 50–60% (Lembrechts 1993). 
Strontium may be deposited on plant surfaces from the atmosphere, remain on the plant, be washed off, or 
be absorbed directly into the plant through leaves.  Contamination by direct deposition on foliage surfaces 
is predominantly a short-term mechanism with a weathering half-life of approximately 14 days (Lassey 
1979).  Carini et al. (1999) examined the mechanism of translocation in three species of fruit-bearing 
plants exposed to aerial deposition of 85Sr and found that translocation of 85Sr is localized to the area of 
contamination on the plant.  However, uptake of strontium through the leaves is minor compared to root 
uptake. Once absorbed in the plant, strontium translocates to other parts of the plant, such as the leaves or 
fruit. Translocation of strontium in plants is affected by the particular species and stage of organism 
growth, and the most metabolically active parts (growing) will accumulate higher concentrations of 
strontium (Kodaira et al. 1973).  
Strontium, taken up by plants and translocated to the aboveground plant compartments, has been observed 
for deep-rooted plants such as chasima (Chrysothamnus nauseosus), mulberry vegetation (Morus alba), 
quaking aspen (Populus tremuloides), and red maple (Acer rubrum) growing on top of low level waste 
burial sites or contaminated soils (Cooper and Rahman 1994; DOE 1995; Fresquez et al. 1996a).  The top 
growth of the plant material releases strontium to the soil surface through leaf fall.  Downward migration 
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of 90Sr is slowed by recycling of the contaminated litter by vegetation (Cooper and Rahman 1994). 
Subsurface 90Sr can be transported from soil to top soil by burrowing animals, and is spread to the 
surrounding environment via animal tissues and fecal deposits.  At the Subsurface Disposal Area at the 
INEL, deer mice had the highest contamination of all animals from ingestion of 90Sr-contaminated low 
level nuclear waste. In addition, the biotic intrusion of soils covering the waste site brings water 
infiltration into buried LLW (Arthur and Janke 1986). 
The uptake or bioaccumulation of strontium by plants and organisms is the mechanism by which 
strontium in air, water, and soil enters into the food chain of humans.  Bioconcentration factors (BCFs) 
have been measured by several investigators in both aquatic and terrestrial organisms for 90Sr (NCRP 
1984).  BCF values for 90Sr in aquatic, terrestrial, and wetland ecosystems at the Savannah River Site 
were reported by Friday (1996) and are summarized in Table 6-2.  The study illustrates that the organisms 
with the highest uptake are aquatic organisms such as fish (large-mouthed bass), macroinvertebrates 
(insects), macrophytes (white-water lilies and bladderwort), and zooplankton.  Because of the similarity 
of strontium to calcium, boney fish had a very high BCF, with a value >50,000 measured in the boney 
tissue (Friday 1996).  In the muscle tissue of boney fish, BCF values for 90Sr ranged from high (benthic 
invertebrate and fish feeders; 610) to very high (piscivores; 3,400).  Because strontium and calcium are 
chemically similar, the concentration of calcium in water can influence the bioaccumulation of strontium 
in biota.  Organisms such as fish bioaccumulate strontium with an inverse correlation to levels of calcium 
in water. However, this correlation is not universal and does not apply to other organisms such as algae 
and plants (NCRP 1984). 
6.3.2 Transformation and Degradation 
Because strontium is an element, its atoms do not degrade by environmental processes such as hydrolysis 
or biodegradation. However, radioactive strontium will be subject to radioactive decay and 
transformation to other elements.  Eventually, all of the radioactive strontium will be transformed into 
stable zirconium by the process of radioactive decay (see Section 4.2): 
90Sr (t½ = 29 years) – 90Y (t½ = 64 hours) + β- – 90Zr (stable) + β-
Both radioactive and nonradioactive strontium compounds are subject to both biotic and abiotic 
transformation mechanisms. 
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Table 6-2. Selected Bioconcentration Factors for 90Sr in Aquatic, Wetland, and 

Terrestrial Ecosystems at the Savannah River Site  

Bioconcentration factors for 90Sr 
Organism Minimum Maximum Mean 
Algae 600 
Clam, shell 1,300 
Fish muscle 
Insect and bottom invertebrate feeders 
 Piscivores 





Insect and bottom invertebrate feeders 
 Piscivores 
Benthic invertebrate and fish feeders 





Macroinvertebrates, larvae 520 54,000 27,300 
Macrohytes (rooted vascular) 2,100 8,500 5,500 







Pine tree, leaves 0.88 1.69 1.29 
Soybeans 2.51 







Source: Friday 1996 
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6.3.2.1 Air 
The presence of strontium and radioactive strontium compounds in the atmosphere results from both 
natural and anthropogenetic activities (see Section 6.2.1).  Strontium is emitted into the atmosphere as 
strontium oxide (SrO) during thermal processes.  SrO is unstable and reacts with moisture or carbon 
dioxide in the air to form strontium hydroxide (Sr[OH]2) or strontium carbonate (SrCO3), respectively. 
Sr[OH]2 in contact with water in clouds or during washout by rain will ionize to form Sr2+ and SrOH+ ions. 
There is no evidence in the literature for interaction of SrO with other compounds in the atmosphere.  
6.3.2.2 Water 
Strontium exists almost exclusively in the environment as a +2 cation, and will form different species, 
some of which are more soluble than others.  Because the different species have different solubilities, they 
will have different mobilities in the environment and different exposure potentials.  Strontium exists as a 
hydrated cation, an ionic solution complex, or an ionic salt.  In the environment, typical solution species 
for strontium are Sr2+ and SrOH+, and some strontium compounds (SrCO3 and SrSO4) are practically 
insoluble in neutral water (Cotton and Wilkenson 1980; see Table 4-2).   
6.3.2.3 Sediment and Soil 
The principal abiotic processes that transform strontium in soils and sediments are mediated by sorption 
and desorption reactions between the soil solution and matrix (precipitation, complexation, and ion 
exchange), and controlled by pH, ionic strength, solution speciation, mineral composition, organic matter, 
biological organisms, and temperature (see Section 6.3.1).  For many soil systems, in the short term, 
strontium sorption is dominated by simple ion exchange, and strontium ions are readily exchangeable.  At 
longer timescales, however, strontium ions may relocated into sterically hindered sites that are not readily 
exchangeable (Bunker et al. 2000).  
In the vicinity of the Chernobyl accident site, 90Sr has leached from “hot” fuel particles (which have 
dissolved) and now may interact with natural soil components (Sokolik et al. 2001).  In situations where 
soil is incorporated into a nuclear fireball (e.g., Semipalatinsk Nuclear Test Site, Kazakhstan), the 
resulting fused silicates that form are usually comparatively insoluble.  Typically, 90Sr in these particles 
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are tightly bound with the majority of 90Sr undergoing radioactive decay before being released by 
weathering (Gastberger et al. 2000).  
6.3.2.4 Other Media  
No data were located in the literature on the transport or degradation of stable or radioactive strontium in 
other media. 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Strontium is widely distributed throughout the earth and has continuously cycled between the atmosphere, 
biosphere, hydrosphere, and lithosphere for many millions of years.  Table 6-3 illustrates the average or 
range of concentrations of strontium in earth materials (Capo et al. 1998).  Anthropogenic activities have 
increased local concentrations of strontium as a consequence of the development of an industrialized 
human society.  Before the 1940s, radioactive strontium was not present in the environment at any 
measurable levels. 
In the United States, commercial nuclear power plant operators are required to monitor and report any 
detectable quantities of radioactive materials released to the environment (USNRC 1996).  Table 6-1 
summarizes releases of radiostrontium isotopes with half-lives >8 hours to the atmosphere and water for 
1993 from PWR and BWR nuclear power plants.  Nearly all of the radioactive material reported as 
released in effluents are from planned releases from normal plant operation or anticipated operational 
occurrences. The latter includes unplanned releases of radioactive materials from miscellaneous actions 
such as equipment failure, operator error, or procedure error, and are not of such consequence as to be 
considered an accident (USNRC 1993a). 
6.4.1 Air 
According to two surveys, the strontium content in urban air ranges from 4 to 100 ng/m3 and averages 
20 ng/m3 (Dzubay and Stevens 1975).  The arithmetic mean concentration of strontium in urban air was 
measured as 29.1 ng/m3 in the Los Angeles basin during 1985 (Witz et al. 1986).  Urban air in Illinois 
between 1985 and 1988 averaged 0.9–4.8 ng/m3 (Sweet et al. 1993).  Areas where higher strontium 
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Table 6-3. Average or Ranges of Concentration of Strontium in Earth Materials 
Material Concentration of strontium 
Geologic (ppm) 
 Average crust 























 Roots (spruce) 













Source: Capo et al. 1998 
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concentrations are prevalent are near coal burning plants where strontium can be released with stack 
emissions (as discussed in Section 6.2.1).  
Before the 1940s, radiostrontium was not present in the air at any significant concentrations.  
Concentrations of 90Sr in the atmosphere peaked at about 10 MCi (0.37 GBq) in 1963 coincident with the 
period of extensive atmospheric nuclear weapons testing.  Since the signing of the Nuclear Test Ban 
Treaty of 1963, the concentration of 90Sr has steadily dropped through the latter 35 years by deposition 
and radioactive decay (DOE 1996c; Eisenbud 1987).  Recent levels of 90Sr in air were not located. 
6.4.2 Water 
Surveys of strontium in surface waters and municipal water supplies across the United States show that 
strontium is present in nearly all fresh waters in amounts <1 mg/L (USGS 1963).  The National Drinking 
Water Contaminant Occurrence Database (NDOD), which contains data from public water supplies 
(PWS), where testing is performed at many points in the system, including the intake and at various 
points in the treatment and distribution systems, as well as at the point where the drinking water can be 
labeled "finished", lists the number of detections and concentrations of strontium.  The average 
concentrations of strontium in PWS waters from the United States derived from surface water and 
groundwater were 1.10 (range, 0.2–3.68 mg/L) and 0.81 mg/L (range, 0.010–3.5 mg/L), respectively 
(EPA 2002b).  The average concentrations of strontium in streams of the United States are between 0.5 
and 1.5 mg/L.  Strontium concentrations >1 mg/L are found in streams of the southwest, where the total 
dissolved solids content is the highest of any area of the continental United States.  Streams of most of the 
Atlantic slope basins, southern United States, upper Great Lakes region, and Pacific northwest contain 
concentrations of strontium that are generally <0.5 mg/L strontium (USGS 1963).  Some exceptions are 
areas where there are celestite-rich limestone deposits, such as regions of northwestern Ohio and eastern 
Florida (USGS 1963). The average concentration of strontium in sea water is approximately 8 mg/L 
(Demayo 1986).  In groundwater, the average concentration of strontium is <0.5 mg/L.  High 
concentrations of strontium, >1 mg/L, have been in observed in the southwestern United States.  
Unusually high concentrations of strontium, >20 mg/L, have been observed for some wells in central 
Wisconsin (USGS 1963). The NDOD lists the number of detections and concentrations of strontium in 
groundwater and surface water at several locations around the United States from ambient water samples 
(EPA 2002b).  Dissolved strontium was detected in groundwater at 4,353 of 4,383 sites (99.3% of sites), 
with an average concentration of 1.6 mg/L (range, 0.0009–200 mg/L).  The average dissolved strontium 
concentration in lake/reservoirs and springs were 1.09 mg/L (97.6% of sites; range, 0.002–170 mg/L) and 
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0.64 mg/L (100% of sites; range, 0.028–3.2 mg/L), respectively.  In other surface waters, dissolved 
strontium was detected at 1,572 of 1,595 sites (98.6% of sites), with an average concentration of 362 µg/L 
(range, 0.0005–30 mg/L).  The concentration of dissolved strontium in publicly owned treatment works 
(POTW) influents was between 0.025 and 0.45 mg/L (EPA 1981).  The average concentrations of 
strontium in rain and snow were 0.7–383 and 0.01–0.76 µg/L, respectively (Capo et al. 1998).  
90Sr concentration in surface waters of the north Pacific Ocean has decreased steadily since the early 
1960s to present day levels of approximately 23–81 pCi/m3 (1–3 Bq 90Sr/m3) sea water. This value is 
estimated by dividing the concentration levels for 137Cs by the global fallout activity ratio measured for 
137Cs/90Sr of 1.5 (Hamilton et al. 1996).  The EPA ERAMS program monitors ambient concentrations of 
90Sr in drinking water at 78 sites.  ERAMS data serve to assess trends and anomalies in concentrations, 
and to compare with standards set forth in the EPA National Interim Primary Drinking Water 
Regulations. Table 6-4 summarizes drinking water composite samples for the period of January– 
December in 1995 taken at the 78 sites in major population centers or near selected nuclear facilities 
(EPA 2000a).  The median concentration of 90Sr in drinking water for this period was 0.1 pCi/L (4 mBq).  
Sites with above average levels of 90Sr, Detroit and Niagara Falls, recorded levels of 0.4 and 0.5 pCi/L 
(~15 mBq/L), respectively.  In a 1974 study, a concentration of 0.09 pCi/L 90Sr (3 mBq/L) in drinking 
water was measured in Los Angeles, California (Kraybill 1983).  In a survey that examined 169 wells 
used for public drinking water in California (Storm 1994), 16 wells measured recordable concentrations 
of 90Sr, with an average concentration of 105 pCi/L (4 Bq/L).  The NDOD lists the number of detections 
of 90Sr in ambient groundwater at several locations around the United States.  Dissolved 90Sr was detected 
in groundwater at 18 out of 104 sites (17%), with an average concentration of 1.46 nCi/L (53.9 Bq) (EPA 
2002b).  The concentrations of 90Sr in groundwater at the 91 waste sites located at 18 DOE facilities were 
between 0.05 and 231,000 pCi/L (2 mBq and 9 kBq) (DOE 1992).  River water taken from the Ebro River 
basin (Northeast Spain) during 1994 had a mean 90Sr level of  6.6 mBq (0.18 pCi) and ranged from 5.9 to 
7.6 mBq/L (0.16 to 0.21 pCi/L) (Pujol and Sanchez-Cabeza 2000). 90Sr in the Ebro River waters could be 
attributed solely to global fallout.  The DOE Environmental Measurements Laboratory program measures 
the 90Sr content of wet deposition in selected sites across the world to determine global trends in 90Sr 
deposition. The data for the year 1990 are presented in Table 6-5 for cities in the United States.  The 
average total annual wet deposition of 90Sr in the United States was 5 pCi/m2 (0.2 Bq/m2) during this 
period. The precipitation samples with the highest total 90Sr concentrations were obtained from New 
York City and Nome, Alaska with annual totals of 10 and 8 pCi/m2 (0.4 and 0.3 Bq/m2), respectively.  In 
all cases, the 90Sr concentrations in rain were low, which suggests that the atmospheric content of 90Sr in 
1990 was small and decreasing (DOE 1996c). 
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Table 6-4. 90Sr in Drinking Water (Composites) for January–December 1995 
90Sr 
Statea City Total solids (mg/L) pCi/L ±2F 
AK Fairbanks 162.0 0.0 0.2 
AL Dothan 160.0 0.1 0.1 
AL Montgomery 55.2 0.1 0.2 
AL Muscle Shoals 82.0 0.2 0.2 
AL Scottsboro 87.0 0.2 0.2 
AR Little Rock 28.8 0.0 0.2 
CA Berkeley 8.0 0.1 0.2 
CA Los Angeles 318.0 0.0 0.1 
CO Denver 140.0 0.0 0.2 
CO Platteville 138.0 0.0 0.2 
CT Hartford 36.6 0.3 0.2 
DE Dover 191.0 ND — 
FL Miami 150.0 0.2 0.2 
FL Tampa 252.0 0.3 0.2 
GA Baxley 165.0 0.0 0.2 
GA Savannah 147.0 ND — 
HI Honolulu 208.0 0.1 0.1 
IA Cedar Rapids 121.0 0.1 0.2 
ID Boise 95.5 ND — 
ID Idaho Falls 219.0 ND — 
IL Morris 474.0 ND — 
IL West Chicago 337.0 0.1 0.1 
KS Topeka 364.0 0.2 0.2 
LA New Orleans 226.0 0.2 0.2 
MA Lawrence 93.8 0.2 0.2 
MD Baltimore 89.8 0.1 0.2 
MD Conowingo 155.0 0.1 0.2 
ME Augusta 85.2 0.3 0.2 
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Table 6-4. 90Sr in Drinking Water (Composites) for January–December 1995 
90Sr 
Statea City Total solids (mg/L) pCi/L ±2F 
MI Detroit 79.8 0.4 0.2 
MI Grand Rapids 125.0 0.3 0.2 
MN Minneapolis 93.8 0.3 0.2 
MN Red Wing 238.0 0.0 0.2 
MO Jefferson City 283.0 0.0 0.2 
MS Jackson 86.8 0.2 0.2 
MS Port Gibson 313.0 0.0 0.1 
MT Helena 61.8 0.1 0.2 
NC Charlotte 46.8 0.1 0.2 
NC Wilmington 110.0 0.2 0.2 
ND Bismarck 329.0 0.0 0.2 
NE Lincoln 305.0 0.1 0.2 
NH Concord 81.2 0.1 0.2 
NJ Trenton 92.7 0.1 0.2 
NJ Waretown 52.0 0.0 0.2 
NM Santa Fe 279.0 ND — 
NV Las Vegas 248.0 0.1 0.2 
NY Albany 68.8 0.3 0.2 
NY New York City 44.5 0.0 0.2 
NY Niagara Falls 99.2 0.5 0.2 
NY Syracuse 94.8 0.3 0.2 
OH Cincinnati 198.0 0.2 0.2 
OH Columbus 362.0 0.0 0.3 
OH East Liverpool 215.0 0.3 0.2 
OH Painesville 126.0 0.2 0.3 
OH Toledo 148.0 0.3 0.3 
OK Oklahoma City 62.6 0.3 0.2 
OR Portland 19.2 0.1 0.2 
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Table 6-4. 90Sr in Drinking Water (Composites) for January–December 1995 
90Sr 
Statea City Total solids (mg/L) pCi/L ±2F 
PA Columbia 121.0 0.1 0.2 
PA Harrisburg 51.2 0.1 0.2 
PA Philadelphia 165.0 0.0 0.2 
PA Philadelphia- 207.0 0.1 0.2 
Queen 
PA Philadelphia-Baxter 101.0 0.2 0.2 
PA Pittsburgh 178.0 0.2 0.2 
PC Corozal 71.6 0.1 0.2 
RI Providence 52.8 0.3 0.2 
SC Barnwell 73.6 0.0 0.2 
SC Columbia 28.2 0.0 0.2 
SC Jenkinsville 165.0 ND — 
SC Seneca 35.2 0.1 0.2 
TN Chattanooga 82.2 0.2 0.2 
TN Knoxville 93.8 0.0 0.2 
TX Austin 180.0 0.0 0.2 
VA Doswell 193.0 0.0 0.2 
VA Lynchburg 45.2 0.1 0.2 
VA Virginia Beach 91.2 0.3 0.2 
WA Richland 77.2 0.1 0.2 
WA Seattle 29.8 0.0 0.2 
WI Genoa City 194.0 ND — 
WI Madison 234.0 ND — 
aPost office state abbreviations used 
ND = not detected;  
2F = counting error term reported at the 2F  (95%) confidence level 
Source: EPA 1995 
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0.0 8.5 0.0 6.5 — 15.9 — 29.7 0.0 60.5 
Argonne, 
Illinois 
0.1 18.6 0.1 33.4 0.1 26.9 0.0 29.5 0.2 108.4 
Birmingham, 
Alabama 



























0.0 3.4 0.0 5.6 0.1 25.9 0.1 12.1 0.2 47.1 
Houston, 
Texas 
0.0 31.4 0.0 26.0 0.0 22.0 0.0 21.8 0.0 101.2 
Lihue, Hawaii 0.0 36.7 0.0 14.5 0.0 12.2 0.1 36.6 0.1 100.0 
Mauna Loa, 
Hawaii 
0.0 54.5 0.0 0.3 0.1 7.5 0.0 44.9 0.1 107.2 
Miami, 
Florida 
0.0 9.4 0.0 54.8 0.0 48.0 0.1 19.1 0.2 131.1 
New York, 
New York 
— 28.7 0.1 42.5 0.1 46.0 0.1 37.5 0.4 154.7 
Nome, Alaska 0.1 5.4 0.0 10.8 0.2 27.0 0.1 13.2 0.3 56.3 
Vermillion, 
South Dakota 




0.1 16.7 0.1 5.3 0.1 0.1 0.0 4.1 0.2 26.2 
Wooster, 
Ohio 
0.0 16.5 0.1 28.0 0.0 43.5 0.0 36.9 0.1 124.8 
Average 0.03 22.0 0.03 22.5 0.06 25.3 0.04 26.2 0.2 96.0 
aIn Bq/m3 
bIn cm 
Source: DOE 1996d 
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6.4.3 Sediment and Soil 
Table 6-3 summarizes the average or range of concentrations of strontium in soils and bedrock minerals.  
The average concentrations of strontium in the earth’s crust and the exposed upper crust are 370 and 
337 mg/kg, respectively.  Soils, on average, have approximately 240 mg/kg Sr (Capo et al. 1998; EPA 
1995a). Some materials, such as soil amendments, are routinely applied to agricultural lands.  Typical 
concentrations of strontium in soil amendments are: POTW sewage sludges, 250±192 ppm (mg/kg dry 
weight); phosphate fertilizers, 610 mg/kg; limestone, 610 mg/kg; and manure, 80 mg/kg dry weight (EPA 
1995a; Mumma et al. 1984).  
The background level of 90Sr in soils of the United States from global fallout will depend upon the 
historical transport and deposition inventory at that particular location.  The mean regional background 
concentration of 90Sr in soils in proximity to the Los Alamos National Laboratory from 1974 to 1994 was 
320±250 pCi/kg dry weight soil (Fresquez et al. 1996b).  This value has decreased with time due to 
radioactive decay of 90Sr. The range of concentrations for 90Sr in soils and sediments at 91 waste sites 
located at the 18 DOE facilities around the United States was 0.02–540,000 pCi/kg (DOE 1992).  The 
total content of 90Sr on surface soil in the 30 km contaminated zone around Chernobyl accident site in the 
Ukraine (not including the reactor site and waste storage) was about 8.1x1014 Bq (2.2x107 Ci) in 1997, 
which corresponds to about 0.4–0.5% of the Chernobyl reactor inventory at the time of the accident 
(Kashparov et al. 2001). Ten years after the accident, about 95% of the 90Sr activity is associated with the 
upper 10–20 cm layer of soil for most of the soils in this area.  Mean 90Sr activity in soil at a Chernobyl­
contaminated field site in the Ukraine was 36 Bq dry weight (0.97 nCi dry weight) (Malek et al. 2002).  
Levels of 90Sr in soils from Belarus situated at a distance of ~40 km from the Chernobyl accident site 
ranged from 50 to 640 kBq/m2 (1.4–17 µCi/m2), while levels at a distance of 200–250 km ranged from 
10–80 kBq/m2 (270–2,200 nCi/m2) (Sokolik et al. 2001). 
The mean activity of 90Sr in lacustrine and marine sediments from Antarctica in 1989–1996 ranged from 
0.17 to 0.76 Bq/kg dry weight (4.59–20.5 pCi/kg dry weight) and from <0.10 to 0.21 Bq/kg dry weight 
(<2.7–5.78 pCi/kg dry weight), respectively (Jia et al. 1999).  The 90Sr activities in marine sediments 
ranged from 117 to 1,277 mBq/kg (3.16 and 34.5 pCi/kg) and from 304 to 1,799 mBq/kg  
(8.21–48.6 pCi/kg) at two sites off atomic power stations in South Korea (Yang et al. 2002). 90Sr2+ ions in 
sediments are characterized by reversible ion exchange processes that lead to low 90Sr activity in 
sediments (Jia et al. 1999). 
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6.4.4 Other Environmental Media 
The range of concentrations of strontium in fruits and vegetables is summarized in Table 6-6 (Barnes 
1997).  The highest concentrations are observed in leafy vegetables, such as cabbage (64.2 mg Sr/kg dry 
weight) (USGS 1980). 
The range of concentrations of 90Sr in food stuffs is summarized in Table 6-7.  The highest concentrations 
were observed in fresh vegetables (8.8 pCi/kg dry weight=0.33 Bq/kg dry weight) and dry beans 
(15.9 pCi/kg dry weight=0.59 Bq/kg dry weight) (Eisenbud 1987).  The U.S. Food and Drug 
Administration Radionuclides in Foods program monitors radionuclides (e.g., 90Sr) in the food supply as 
part of the Total Diet Study (TDS).  For the years 1994 and 1995, about 60 foods with historically high 
90Sr levels were analyzed (Capar and Cunningham 2000).  90Sr was detected in about 65% of these foods.  
The greatest concentration was in mixed nuts at 2 Bq/kg (50 pCi).  Approximately 200 reactor-survey 
food test portions, including raw vegetables, food crops (primarily fruits), fish, and milk, were collected 
in the vicinities of 33 nuclear reactors (Cunningham et al. 1994).  Ninety-four percent of the reactor-
survey food test portions had 90Sr activities between 0 and 0.74 Bq/kg (0 and 20 pCi), and 6% had activity 
concentration between 0.74 and 7.4 Bq/kg (20 and 200 pCi/kg).  The EPA ERAMS program monitors 
ambient concentrations of 90Sr in pasteurized milk at 42 sites in major population centers, and is used to 
assess trends and anomalies in concentrations.  Table 6-8 summaries pasteurized milk samples for the 
period of July 1997 (EPA 2002b).  The average concentration of 90Sr in pasteurized milk during this 
period for the 42 sites was 0.9 pCi/L (33 mBq/L).  Sites with above average levels of 90Sr in pasteurized 
milk were observed at (listed in order of decreasing activity of 90Sr): Minot, North Dakota; Grand Rapids, 
Michigan; Spokane, Washington; Cleveland, Ohio; Cincinnati, Ohio; Memphis, Tennessee; St. Paul, 
Minnesota; Chicago, Illinois; Detroit, Michigan; San Francisco, California; Baltimore, Maryland; and 
Wilmington, Delaware.  Dietary intake of 90Sr peaked in 1965 at 1.1 Bq/day (30 pCi/day), during a period 
of atmospheric testing of nuclear weapons, and has continued to decline to <0.05 Bq/day (<1.2 pCi/day) 
after 1987 (Cunningham et al. 1989).  Dietary intake of 90Sr in the United States from 1961 to 1991 is 
illustrated in Figure 6-3. 
Sato et al. (1977) determined the concentration of strontium in tobacco leaves as 141 µg/g.  The average 
concentration of strontium in the ash of 12 brands of cigarettes was measured as 373 µg/g (Iskander 
1986).  No significant difference was observed in the concentration of strontium in the cigarette filter 
before and after smoking (Sato et al. 1977).  The ranges of concentrations of strontium in waste materials 
are: municipal solid waste (MSW) 11–35 µg/g; incineration fly ash 110–220 µg/g (Lisk 1988); coal fly 
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Table 6-6. Concentration of Strontium in Fruit Juices and Produce 
Fruit juice and produce Average liquid concentration Average solid concentration 
(µg/L)a (ppm)b 
Apple 13.58 















 Concord 0.3661 













 Brazilian 0.0417 
California 0.5368 
 Florida 0.0933 
 Navel 0.5209 
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Table 6-6. Concentration of Strontium in Fruit Juices and Produce 







Tomato sauce	 0.8894 
aBarnes 1997 
bUSGS 1980; values are parts per million, dry weight 
Table 6-7. 90Sr in the Human Diets During 1982 
New York City San Francisco 
Diet category 
Intake 
kg/year g Ca/year 
Percent Percent Percent 
yearly pCi pCi yearly pCi pCi yearly 



















































































































































































1 pCi=37 mBq (conversion factor) 
Source: DOE 1984 
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Table 6-8. 90Sr in Pasteurized Milk in July 1997 
City 90Sr (pCi/L) 
Montgomery 0.98 
Los Angeles 0.66 
Sacramento 0.26 














Grand Rapids 1.78 
St. Paul 1.44 




























Table 6-8. 90Sr in Pasteurized Milk in July 1997 















aPost office state abbreviations used 
Source: EPA 2000b 
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Source: Cunningham et al. 1994 
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ash 30–7,600 µg/g; coal bottom ash 170–6,400 µg/g; flue-gas desulfurization by-products 70–3,000 µg/g; 
oil ash 50–920 µg/g; (Eary et al. 1990); and compost 260–420 µg/g (Evans and Tan 1998).  
Levels of 90Sr were measured in tissue samples of animals killed by motorists near the low-level 
radioactive disposal site at Los Alamos National Laboratory and from background locations. The mean 
concentration of 90Sr in tissues from deer and elk killed near the low-level radioactive disposal site were 
460 and 230 mBq/kg (12 and 7.0 pCi), respectively, while concentrations at background locations were 
130 and 6.3 mBq/kg (3.5 and 1.7 pCi), respectively (Ferenbaugh et al. 2002).  Between 1994 and 1996, 
levels of skeletal 90Sr in small mammals in the Exclusion Zone at Chernobyl, Ukraine averaged 297 Bq/g 
(8.0 nCi/g) (Chesser et al. 2000).  
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
The primary routes of human exposure to strontium are from inhalation of aerosols and ingestion of food 
and drinking water containing strontium.  The intake of strontium, therefore, depends upon the 
concentration of strontium in air, drinking water, and in the food items that comprise a person’s diet, 
which may be highly variable.  The average concentration of strontium in urban air is about 20 ng 
strontium/m3 (see Section 6.4.1).  Assuming that an adult breathes approximately 20 m3 of air per day, the 
inhalation exposure would be 400 ng strontium/day.  This value may be somewhat higher for persons 
living near sources of strontium emission.  Workers employed at industrial facilities that produce, 
process, and use strontium and strontium compounds will have higher exposures.  Similarly, strontium is 
taken into the body by ingestion of drinking water.  Using the concentration of strontium in U.S. drinking 
water to be 1 mg/L (see Section 6.4.2), and the consumption rate as 2 L/day, the strontium intake from 
drinking water would be 2 mg/day.  In a 1994 total diet study in the United Kingdom, the total dietary 
exposure to stable strontium was estimated at 1.3 mg/day (Ysart et al. 1999).  As part of an Australian 
Market Basket Survey in 1994, the estimated daily intakes of strontium for female adults ranged from 
0.89 to 1.2 mg/day (Gulson et al. 2001).  Combining air, water, and diet exposures estimates, the total 
daily exposure to strontium is ~3.3 mg/day.  
External exposure to 90Sr is not a concern because of minor emission of penetrating radiation from 90Sr. 
No estimate of the concentration of 90Sr in air is available (see Section 6.4.1).  However, it is assumed that 
ambient concentrations of 90Sr in the atmosphere are small relative to exposures from water and diet.  If 
the concentration of 90Sr in average U.S. drinking water is estimated as 0.1 pCi/L (4 mBq/L) or one 
radiochemical event per 5–10 minutes (see Section 6.4.2), and the consumption rate of drinking water by 
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a normal adult is assumed to be 2 L/day, then the exposure from drinking water would be 0.2 pCi 
(7 mBq) per day.  Since the inception of the TDS Radionuclides in Foods program in 1961, intake levels 
of 90Sr in food have steadily declined from a peak level in 1965 of 1.1 Bq/day (30 pCi/day), to below 
0.2 Bq/day (5 pCi/day) (Cunningham et al. 1989).  A DOE Environmental Measurements Laboratory 
study estimated the average dietary intake of 90Sr from 19 diet categories for individuals living in the 
urban areas of New York City and San Francisco.  Table 6-6 summarizes the data from this study (DOE 
1984).  For both locations, vegetables accounted for more than a third of the yearly dietary intake of 90Sr 
at 36%.  In the vegetable group, fresh vegetables were the largest contributors of 90Sr dietary intakes.  The 
next largest contributor of 90Sr was grains and dairy products.  Using a conservative estimate of total 
dietary exposure for 90Sr of 5 pCi/day (0.19 Bq/day) and drinking water exposure of 0.2 pCi/day 
(7 mBq/day), the total estimated daily exposure to strontium is approximately 5.2 pCi/day (0.19 Bq/day). 
Current population exposure levels to 90Sr will be lower than this value as a result of decreasing 
concentrations of 90Sr in the environment.  However, this value may be somewhat higher for persons 
living near sources of 90Sr, such as DOE facilities, and for workers employed at government facilities that 
produce, process, and use 90Sr and 90Sr waste compounds. 
Table 6-9 summarizes measurements of concentrations of strontium in human tissues and body fluids 
resulting from consumption of food and water and from natural background sources (Tsalev 1984); these 
are nonoccupationally exposed populations.  The highest concentrations of strontium are in the bones and 
teeth (Iyengar et al. 1978; Tsalev 1984).  
The distributions of 90Sr in the body are significantly different for males and females.  As expected, the 
highest concentrations of 90Sr are measured in the boney tissue.  Males and females averaged 10.4 and 
65 pCi/kg (0.38 and 2.4 Bq/kg) wet weight, respectively.  Males had a much higher concentration of 90Sr 
in the muscular tissue compared to females.  The heart and psoas muscles had respective concentrations 
of 90Sr for men averaging 13.9 and 18.7 pCi/kg (0.51 and 0.69 Bq) wet weight versus respective 
concentrations of 7.4 and 1.9 pCi/kg (0.27 Bq/kg and 70 mBq/kg) wet weight for females (Baratta and 
Ferri 1966). Approximately 1,000 human teeth, collected in southern Ukraine in 1990–1991, had 90Sr 
activities ranging from 1.0 to 16.3 mBq/g ash (0.027–0.44 pCi/q ash) (Kulev et al. 1994). 
Strontium can be released into the atmosphere as a result of glass manufacturing.  In one study, the 
median ambient air concentration of strontium that both art glass makers and formers were chronically 
exposed was 0.1 µg strontium/m3 (Apostoli et al. 1998).  A National Occupational Exposure Survey 
conducted by NIOSH during 1981–1983 estimated the number of workers potentially exposed to 
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Table 6-9. Strontium Concentrations in Human Body Fluids and Tissues 
Sample Unitsa Mean Range 
Blood µg/L 27 No data 
Bone µg/g 138 63–281 
Brain µg/g 0.08 No data 
Dental plaque µg/g 48 <0.5–1,880 
Erythrocytes µg/L 7.2 No data 
Feces µg/day 1.5 No data 
Hair µg/g 4.2 0.75–10.8 
Kidney µg/g 0.1 No data 
Liver µg/g 0.15 No data 
Lung µg/g 0.38 No data 
Milk µg/L 20 17–295 
Muscle µg/g 0.05 No data 
Nails (finger) µg/g(dry weight) No data 0.43–0.86 
Plasma or serum µg/L 40 10–70 
Saliva µg/L 11 8–63 
Sweat mg/7 hour 0.96 No data 
Tooth (dentin) µg/g 115 14–286 
Tooth (enamel) µg/g 128 14–286 
Urine µg/L No data <0.01–0.03 
aValues are per wet weight unless otherwise noted. 
Source: Tsalev 1984 
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strontium compounds in the workplace: strontium chloride (8,289), strontium fluoride (5,607), strontium 
hydroxide (385), and strontium nitrate (1,895) (NOES 1983).   
Workers engaged in nuclear fuel cycle operations, such as the handling of radioactive strontium wastes, 
decontamination and decommissioning workers, contaminated soils, and waters may be potentially 
exposed to radioactive strontium.  A case of accidental inhalation and dermal exposure to strontium 
titanate contaminated with 90Sr used for lightning rods was recorded, which resulted in an exposure of 
approximately 105 Bq (2.7 mCi) to the workers (Navarro and Lopez 1998). 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in 3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (USNRC 
1993a). 
As part of an Australian Market Basket Survey in 1994, the estimated daily intakes of strontium for 
6-month-old infants fed exclusively breast milk or infant formula were 47 and 254 µg/day, respectively 
(Gulson et al. 2001). The mean concentration of strontium in amniotic fluid and placenta ranged from 
0.03 to 0.05 mg/L and from 1.6 to 3.2 µg/L, respectively, for mothers from Portugal (Carvalho et al. 
2001). Harrison (1965) notes that strontium in human breast milk is transferred to newborns during 
breast feeding. 
Specific information on the exposure of children to radiostrontium is limited.  As for adults in the general 
population, small exposures to children occur from normal ingestion of food and drinking water and 
inhaling air. These exposures may be higher in areas near nuclear fuel processing sites and hazardous 
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waste sites containing radiostrontium.  Future accidental exposures could potentially occur from nuclear 
weapons detonation and consequent contamination of air, water, and food. 
Children typically ingest a higher percentage of diary products compared to adults.  Levels of 90Sr in body 
tissues tend to increase with age (Glowiak and Pacyna 1978).  In a study in the Soviet Union between 
1959 and 1971, children were reported to have elevated levels of 90Sr in bone tissue between the ages of 
1 and 4 years (Marei et al. 1976).  The elevated levels of 90Sr for children of this age were determined to 
be a direct result of diet, primarily from 90Sr contaminated cow’s milk.  In a 1978 study in Poland, 
females between 0 and 20 years of age had the highest level of 90Sr accumulation in the gonad tissues for 
all age levels (Glowiak and Pacyna 1978).  No explanation as to a cause for this accumulation was 
provided.  For 1979–1994 births, the average concentration of 90Sr in deciduous teeth from children of 
Western Suffolk County (New York), Eastern Suffolk County (New York), Dade County (Miami, 
Florida), and Ocean County (New Jersey) were 1.56, 1.02, 2.80, and 1.54 pCi/g calcium, respectively 
(Gould et al. 2000).  No additional information is available on whether children differ from adults in their 
weight-adjusted intake of strontium.  There is no information on 90Sr levels in amniotic fluid, meconium, 
cord blood, neonatal blood, or breast milk.  
At hazardous waste sites, radiostrontium that is found in excess of natural background levels is most 
likely to be in soil and presents a special hazard for young children.  Hand-to-mouth activity resulting in 
inadvertent soil consumption or intentional consumption of soil (pica behavior) will result in oral 
exposure to radiostrontium.  Young children often play close to the ground and frequently play in dirt, 
which increases their dermal exposure to radiostrontium in dust and soil.  The degree of hazard in each 
case depends on the form of strontium present at the waste site. 
Compared to adults, the potential for radiostrontium exposure is greater for children who consume foods 
(e.g., milk, grains) produced in areas with elevated concentrations of radiostrontium in the soil and for 
children with elevated concentrations of radiostrontium in their drinking water.  Children are more likely 
to be exposed to 90Sr in cow’s milk produced in contaminated areas.  Table 6-8 summaries pasteurized 
milk samples in the United States for July 1997 (EPA 2002b).  The average concentration of 90Sr in 
pasteurized milk during this period was 0.9 pCi/L (33 mBq/L).  
Other home exposures are unlikely since no household products or products used in crafts, hobbies, or 
cottage industries contain significant amounts of radiostrontium.  Radiostrontium exposure to children 
from parents’ work clothes, skin, hair, tools, or other objects from the workplace is possible if the parent 
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is exposed to radiostrontium at work.  However, no specific cases of home contamination with 
radiostrontium were located in the literature. 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
Cigarettes and tobacco leaves are known to contain strontium, and individuals who smoke may be 
exposed to higher levels of strontium.  Strontium has been found in the tobacco leaves and ash of 
cigarettes at average levels of 141 and 373 mg/kg, respectively (Iskander 1986).  
The potential for 90Sr exposure is greater for individuals who consume foods grown in areas with elevated 
concentrations of 90Sr in soil, and for individuals with elevated concentrations of 90Sr in drinking water.  
Industries where higher exposures to 90Sr are known to occur include nuclear weapons test sites, nuclear 
weapons production, and nuclear reactors facilities.  Populations with potentially high exposure include 
DOE employees involved in heavy construction, decontamination activities, chemical processing, and 
fabrication. 
Populations with a relatively short food chains (e.g., Arctic peoples) and a higher per capita consumption 
of country foods that have elevated levels of contamination from radionuclides, will have a higher 
exposure to 90Sr (Barrie et al. 1992).  Caribou or reindeer feeding on arctic vegetation are more likely to 
accumulate higher body burdens of 90Sr in edible tissues than other herbivorous animals with less 
restrictive diets (Witkamp 1966).  Concentrations of 90Sr in caribou meat per gram of calcium were high 
(150 pCi/g Ca) compared with those of Alaskan-grown cabbage (6 pCi/g Ca) and potatoes (8 pCi/g Ca), 
marine fish (5 pCi/g Ca), and whale meat (1 pCi/g Ca).  Arctic peoples, who depend on caribou and 
reindeer for sustenance, may have an elevated body burden of 90Sr compared to other people who 
consume a more varied diet (Witkamp 1966).  However, the 1966 peak levels reported in this study are 
expected to have fallen to minuscule levels since the Test Ban Treaty of 1962.  
6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of strontium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
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initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of strontium.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. Relevant data on the physical and chemical properties of 
strontium and strontium compounds are available in the literature and are sufficient to permit estimation 
of its environmental fate (ChemFinder 2002; Cotton and Wilkenson 1980; Hibbins 1997; HSDB 2002; 
Lide 1995, 2000; Merck 1989; Sigma-Aldrich 2000).  The physical and chemical properties of 
radiostrontium and radiostronium compounds are expected to be equivalent to those for stable strontium.  
Data on the radioactive properties of isotopes of strontium are available (Lide 1995).  
Production, Import/Export, Use, Release, and Disposal.    Data regarding the past and present 
production and import/export volumes for strontium are available (Adams 1975; USGS 1998, 1999, 
2002). The uses of strontium and strontium compounds are well known with more than 85% of all 
strontium consumed in the United States used in the manufacture of ceramics and glass products (Hibbins 
1997; USGS 1999, 2002).  Strontium is found in food products such as fruits and vegetables (Barnes 
1997; USGS 1980).  Since strontium is not covered under Superfund Amendments and Reauthorization 
Act (SARA), Title III, manufacturers and users are not required to report releases to the EPA’s Toxics 
Release Inventory (TRI).  Most nonradioactive strontium minerals, strontium compounds, and strontium-
containing materials do not require special disposal and handling requirements. 
Data regarding the past and present production and import/export volumes for radiostrontium are limited 
(DOE 1996b, 1996c). The uses of radiostrontium and radiostrontium compounds are restricted primarily 
to medicinal, analytical, and power generation applications (Alimov 2003; Murray 1994).  Radioactive 
strontium (e.g., 90Sr) was released into the atmosphere from aboveground testing of nuclear weapons 
during the period of 1945–1980.  Nuclear weapon testing injects radioactive material into the 
stratosphere, which results in wide dispersal of radionuclides.  However, atmospheric deposition of 90Sr 
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has steadily decreased from a high in 1963 of approximately 1.10x108 GBq (3.0 MCi) to <3,000 Ci in 
1990, which suggests that global concentrations of 90Sr in the atmosphere have declined (DOE 1996c).   
The disposal of radiostrontium and radiostrontium contaminated wastes is governed by the U.S. Nuclear 
Regulatory Commission (USNRC) regulations, and releases of radiostrontium and radiostrontium 
contaminated wastes are governed by USNRC and EPA regulations.   
Environmental Fate. Information about the partitioning and mobility of strontium and strontium 
compounds in the environment is available (Bunde et al. 1997; Bunzl and Schimmack 1989; Hayes and 
Traina 1998; Helal et al. 1998a, 1998b; O’Day et al. 2000; Parkman et al. 1998; Sahai et al. 2000).  
Strontium released into the atmosphere from natural and anthropogenetic activities is transported and 
redeposited on the earth by dry or wet deposition (NCRP 1984).  Because strontium is an element, its 
atoms do not degrade by environmental processes such as hydrolysis or biodegradation. 
Information about the partitioning and mobility of 90Sr in environment is available (Bunde et al. 1997, 
1998; DOE 1996d; Kashparov et al. 2001; Mahara 1993; Sokolik et al. 2001; Toran 1994).  
Radiostrontium released into the atmosphere from anthropogenetic activities is transported and 
redeposited on the earth by dry or wet deposition (NCRP 1984).  Radiostrontium does not degrade by 
environmental processes such as hydrolysis or biodegradation.  However, radioactive strontium will be 
subject to radioactive decay and transformation to other elements.  Eventually, all of the radioactive 
strontium will be transformed into stable zirconium by the process of radioactive decay.  Additional 
information on the environmental fate of 90Sr in different forms of mixed waste may be beneficial.  
Studies investigating mixed waste matrixes may be useful information for accessing the current and 
potential risk of the storage of liquid HLW in buried underground tanks.  Mixed waste forms that pose the 
highest potential risk include mixtures such as metals-radiostrontium, metals-radiostrontium-organic 
acids, metals-radiostrontium-complexing agents, and metals-radiostrontium-ketones (DOE 1992).  
Bioavailability from Environmental Media.    The absorption and distribution of strontium and 
radiostrontium as a result of inhalation, dermal, or oral exposures have been discussed in Sections 3.5.1 
and 3.5.2. Limited information on the bioavailability of strontium and radiostrontium from 
environmental media (e.g., plants and animals) is available.  Additional studies on the bioavailability of 
strontium and radiostrontium from environmental media would be useful.  
Food Chain Bioaccumulation. The uptake or bioaccumulation of strontium and radiostrontium by 
plants and organisms is the mechanism by which strontium and radiostrontium in air, water, and soil enter 
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into the food chain of humans.  Information on tissue levels of strontium and radiostrontium indicating 
storage in the organism as a result of exposure to contaminated media would be useful.  Information on 
whether strontium and radiostrontium are biomagnified (increased levels in predators resulting from the 
consumption of contaminated prey organisms) would also be helpful. 
Exposure Levels in Environmental Media. Strontium has been detected in air (Dzubay and 
Stevens 1975; Sweet et al. 1993; Witz et al. 1986), water (Capo et al. 1998; EPA 1981, 2002b; USGS 
1963), soil (Capo et al. 1998; EPA 1995a), plants (Sato et al. 1977), and foodstuff (Barnes 1997; USGS 
1980). Reliable monitoring data for the levels of strontium in contaminated media at hazardous waste 
sites are needed so that the information obtained on levels of strontium in the environment can be used in 
combination with the known body burden of strontium to assess the potential risk of adverse health 
effects in populations living in the vicinity of hazardous waste sites.  In a 1994 total diet study in the 
United Kingdom, the total dietary exposure to stable strontium was estimated at 1.3 mg/day (Ysart et al. 
1999).  As part of an Australian Market Basket Survey in 1994, the estimated daily intakes of strontium 
for female adults ranged from 0.89 to 1.2 mg/day (Gulson et al. 2001).  Combining air, water, and diet 
exposures estimates, the total daily exposure to strontium is ~3.3 mg/day. 
Radiostrontium has been detected in air (DOE 1996c; Eisenbud 1987), water (DOE 1992, 1996c; EPA 
2000a, 2002b; Hamilton et al. 1996; Kraybill 1983; Pujol and Sanchez-Cabeza 2000), soil (DOE 1992; 
Fresquez et al. 1996b; Kashparov et al. 2001; Malek et al. 2002; Sokolik et al. 2001), and foodstuffs 
(Capar and Cunningham 2000; Cunningham et al. 1989, 1994; Eisenbud 1987; EPA 2002b).  Information 
on levels of radiostrontium is needed.  Exposure levels of 90Sr in environmental media have decreased as 
a result of radioactive decay from a high in the 1960s.  However, updated information on the 
concentration levels in air, water, soil, and food (e.g., milk products) may be useful.  Specific monitoring 
of radiostrontium in airborne particulates may also be beneficial.  Reliable monitoring data for the levels 
of  radiostrontium in contaminated media at hazardous waste sites may be useful so that the information 
obtained on levels of radiostrontium in the environment can be used in combination with the known body 
burden of radiostrontium to assess the potential risk of adverse health effects in populations living in the 
vicinity of hazardous waste sites.  Using a conservative estimate of total dietary exposure for 90Sr of 
5 pCi/day (0.19 Bq/day) (Cunningham et al. 1989) and drinking water exposure of 0.2 pCi/day 
(7 mBq/day) (EPA 2000a), the total estimated daily exposure to strontium is approximately 5.2 pCi/day 
(0.19 Bq/day).  
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Exposure Levels in Humans. Strontium has been detected in human tissues, as illustrated in 
Table 6-9 (Tsalev 1984). The highest concentrations of strontium are in the bones and teeth (Iyengar et 
al. 1978; Tsalev 1984).  However, these data are not current (within 3 years).  Additional human tissue 
monitoring data for strontium is needed for populations surrounding hazardous waste sites.  This 
information is necessary for assessing the need to conduct health studies on these populations.  
90Sr has been detected in human tissues with the highest concentrations measured in boney tissues 
(Baratta and Ferri 1966; Kulev et al. 1994).  However, these data are not current (within 3 years).  
Exposure levels of humans to 90Sr have decreased as a result of radioactive decay from a high in the 
1960s.  Additional human tissue monitoring data for radiostrontium is needed for populations surrounding 
hazardous waste sites. This information is necessary for assessing the need to conduct health studies on 
these populations. 
Exposures of Children. Children are exposed to strontium in the same manner as adults, primarily 
by food and water intake.  No information was available on unique exposure pathways for children (e.g., 
pica children, dermal).  However, children typically ingest a higher percentage of diary products 
compared to adults.  Data exist on the levels of strontium in human breast milk (Gulson et al. 2001).  
Additional body burden studies on children are needed for strontium.  Additional studies are needed to 
determine whether children are different in their weight-adjusted intake of strontium.  Better and more 
recent information on exposure levels of strontium to children may be beneficial. 
Children are exposed to radiostrontium in the same manner as adults, primarily by food and water intake.  
No information was available on unique exposure pathways for children (e.g., pica children, dermal).  
However, children typically ingest a higher percentage of diary products compared to adults.  Exposure 
levels of children to 90Sr have decreased as a result of radioactive decay from a high in the 1960s.  Data 
exist on the levels of 90Sr in deciduous teeth (Gould et al. 2000).  Additional body burden studies on 
children are needed for radiostrontium.  Additional studies are needed to determine whether children are 
different in their weight-adjusted intake of radiostrontium.  Better and more recent information on 
exposure levels of radiostrontium to children may be beneficial. 
Child health data needs relating to susceptibility are discussed in Section 3.13.2 Identification of Data 
Needs: Children’s Susceptibility. 
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Exposure Registries. No exposure registries for strontium or radiostrontium were located.  These 
substances are not currently compounds for which a subregistry has been established in the National 
Exposure Registry. These substances will be considered in the future when chemical selection is made 
for subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance. 
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2002) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  These 
studies are summarized in Table 6-10.  
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Table 6-10. Ongoing Studies on the Environmental Effects of Strontiuma 
Investigator Affiliation Study 	 Sponsor 
Ron, Elaine NIH 	 Studies of populations exposed to occupational NIH 
sources of radiation 
Helt, JE ANL 	 Waste volume reduction using surface DOE-OEM 
characterization and decontamination by laser 
ablation 
Todd, Terry A INEEL 	 Laboratory radioactive waste solvent extraction DOE-OEM 
and ion exchange 
Smith, Robert W INEEL 	 Calcite precipitation and trace metal partitioning DOE-OEM 
in groundwater and the vadose zone:  
Remediation of 90Sr and other divalent metals 
and radionuclides in arid western environments 
Louie, Gary D PNNL 	 Chemical separations for nuclear waste disposal DOE-OEM 
Louie, Gary D PNNL 	 Chemical speciation of strontium, americium, and DOE-OEM 
curium in waste 
ANL = Argonne National Laboratory; DOE-OEM = Department of Energy-Office of Environmental Management; 
INEEL = Idaho National Engineering and Environmental Laboratory; NIH = National Institute of Health; PNNL = 
Pacific Northwest National Laboratory 
aSource: FEDRIP 2002 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring strontium, its metabolites, and other biomarkers of exposure and effect to 
strontium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
Its companion manual, the Draft Multi-Agency Radiological Laboratory Analytical Protocols (MARLAP) 
manual, robustly describes relevant analytical equipment and methods, and became available for public 
comment in July 2001 (MARLAP 2001). 
7.1 BIOLOGICAL MATERIALS 
Strontium can enter the human body through inhalation, ingestion, or penetration through the skin.  
Measurement of the quantities of radiostrontium in the body can be performed by two primary methods, 
in vivo measurements and in vitro measurements.  These types of measurements are called bioassays.  
In vivo techniques measure the quantities of internally deposited radiostrontium directly using a whole 
body counter, while in vitro techniques permit estimation of internally deposited strontium by analysis of 
body fluids, excreta, or (in rare instances) tissues obtained through biopsy or postmortem tissue 
sectioning. Some of these analytical methods are summarized in Table 7-1. 
7.1.1 Internal Strontium Measurements 
In vivo (or direct) measurements of radioactive strontium in the body are made with radiation detector 
systems and associated electronics called whole body counters that measure radiation as it leaves the body 
from internally deposited radioactive strontium.  This system measures the emission of gamma rays or 
x-rays from internally deposited radionuclides.  These counters are insensitive to beta particles emitted 
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Table 7-1. Analytical Methods for Determining Strontium in Biological Samples 
Sample Analytical Detection Percent 
matrix Sample preparation method limit recovery Reference 
Blood Acidification with nitric GFAAS 0.13 mg/L 94.5–102.5 Burguera et al. 
acid; dilution; addition of 1999 
La matrix modifier 
Blood Acid digestion; iron TRXF 0.04 µg/mL No data Prange et al. 1989 
extraction; clean-up by ion 
exchange; thin film 
deposition 
Blood Acid digestion; dilution ICP-AES 0.3 µg/L 113 NIOSH 1994; 
Piette et al. 1994 
Blood serum Dry ashing; neutron TNA 0.02 µg/mL 75–90 Teree and Cohn 
activation; chemical 1966 
separation 
Blood serum Acidification and dilution ICP-MS No data 99 Muñiz et al. 1999 
Bone Acidification with nitric GFAAS 0.13 mg/L 96.5–102.9 Burguera et al. 
acid; dilution; addition of 1999 
La matrix modifier. 
Bone Acid digestion ICP-MS 6 µg/g dry No data Outridge et al. 1996 
weight 
Bone ash Acid dissolution; clean-up β-GPC No data No data Mutschke and 
by coprecipitation and Pribilla 1967 
scavenging 
Hair Ashed PIXE 1 µg/g No data Clayton and 
Wooller 1985 
Tissues Acid digestion; dilution ICP-AES No data 113 NIOSH 1994 
Tissues Complexometric digestion GFAAS 2.2 ng/g 99±4.2 D’Haese et al. 1996 
in TMAH/EDTA matrix 
with heat 
Urine Acidification with nitric GFAAS 0.13 mg/L 98.8–101.5 Burguera et al. 
acid; dilution; addition of 1999 
La matrix modifier 
Urine Coprecipitation with LSC 7 dpm/L 95±5 Dietz et al. 1991 
calcium phosphate; (0.82 Bq/L 
sample wet ashed with or 
nitric acid; extraction and 22 pCi/L) 
separation on Crown 
ether loaded 
chromatographic column 
Urine Wet ashed; precipitation LSC 0.6 pCi 100 Kramer and Davies 
with oxalate; acid (22 mBq) 1982 
dissolution; chemical 
extraction 
β-GPC (total radioactive strontium) = beta gas proportional counter; Bq = Becquerel; dpm = disintegrations per 
minute; EDTA = ethylenediamine tetraacetic acid; GFAAS (total strontium) = graphite furnace atomic absorption 
spectroscopy; ICP-AES (total strontium) = inductively coupled plasma atomic emission spectroscopy; ICP-MS 
(isotopic strontium composition) = inductively coupled plasma-mass spectrometry; La = Lanthanum; LSC (isotopic 
quanitification of 89Sr and 90Sr) = liquid scintillation counting; pCi = pico curies (10-12 curies); PIXE (total 
strontium) = proton induced x-ray emission; TMAH = tetramethylammonium hydroxide; TNA (total 
strontium) = thermal neutron activation and radiometric measurement; TRXF (total strontium) = total-reflection x-ray 
fluorescence 
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from radiostrontium; thus, the utility for radiostrontium is limited to high exposure measurements. In 
vivo assays are the most direct method of quantifying internally deposited radioactive materials.  The 
determinations of 90Sr levels are achieved by measuring, with a phoswich detector, the bremsstrahlung of 
the 90Y beta rays (photons with energies ranging from 30 to 160 keV).  The most commonly used 
detectors for measurement of 90Y bremsstrahlung (i.e., electromagnetic radiation) by in vivo counting are 
sodium iodide or phoswich (NaI and CsI sandwich) (Tokareva et al. 2000).  For whole-body counting, a 
scanning-bed geometry in a special shielding room is typically used.  Although whole body counters may 
be used in many configurations, a chest counter is usually used for inhaled radioactive materials.  In vivo 
analysis is widely used throughout the nuclear industry, both commercial and government, for quantifying 
levels of insoluble radioactive materials in the body (Kozheurov 1994).  
In vivo counting systems are calibrated using tissue-equivalent phantoms.  These phantoms have shapes 
similar to the human torso and are made of polystyrene or other tissue equivalent material.  Standard 
radioactive strontium sources of known activity are inserted at locations where strontium would be 
expected to accumulate in a human body.  Relationships are determined between the radioactive 
strontium activity measured by the detection system and the known activity in the phantom (Kozheurov 
1994). 
7.1.2 In Vivo and In Vitro Radiostrontium Measurements 
In vitro radioactive strontium analyses are routinely performed in support of a personnel monitoring 
program or in cases where the size of an operation does not justify the cost of whole body counter 
facilities. These analyses are usually done on urine samples, but other types of body materials (e.g., feces 
or blood) may also be used.  Urinalysis is effective for analysis of transportable or soluble strontium. 
Strontium may also be measured in fecal material using the same methods identified above for urinalyses, 
except that this matrix requires extensive preparation. 
7.2 ENVIRONMENTAL SAMPLES 
Two types of methods are commonly used for measurement of strontium and radiostrontium in 
environmental samples.  The first is field surveys using portable survey instruments, and the second is 
analysis of samples procured in the field that are returned to the laboratory for quantification. 
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7.2.1 Field Measurements of Radiostrontium  
Radiostrontium measurements in the field are typically qualitative in nature in that the instruments simply 
respond to beta emissions, regardless of their origin. However, the levels can be measured quantitatively 
if key parameters are known, such as the relative abundances of all beta-emitting isotopes present, the 
thickness of the layer being assessed, and the detection efficiency of the instrument for the type of surface 
being assessed.  Measurements in the past have typically been made using portable, hand-held Geiger-
Mueller or beta scintillation detectors equipped with a count rate meter, which detect beta radiation while 
discriminating against other forms of ionizing radiation in the same area.  Survey instruments can provide 
a quick estimate or a measure of the level of activity that might be present.  However, more accurate 
measurements of radioactive strontium may require that samples be taken for laboratory analyses.  
7.2.2 Laboratory Analysis of Environmental Samples 
Analytical methods for measuring strontium in environmental samples are summarized in Table 7-2.  The 
available methods can be divided into two groups: chemical methods to determine the total mass of 
strontium in a sample and radiological methods to determine amounts of radioactive isotopes.  
Environmental media that have been tested for strontium include air filters, swipes, biota, water, soil, and 
others. A full range of laboratory analysis methods has been used to quantify the total strontium or its 
radioactive isotopes. 
The chemical methods for detecting total strontium include spectrophotometry, fluorometry, kinetic 
phosphorescence, atomic absorption spectroscopy (e.g., flame and graphite furnaces), energy dispersive 
x-ray analysis (i.e., EDAX), x-ray fluorescence spectrometry, and inductively coupled plasma 
spectroscopy-atomic emission and mass spectrometry applications (i.e., ICP-AES and ICP-MS). 
The quantity of radioactive strontium is typically determined by gas-flow proportional, liquid 
scintillation, and Cherenkov counting techniques (Scarpitta et al. 1999).  The standard EPA analytical 
procedure to determine radiostrontium in water is Method 905.0, and several methods are permutations of 
this procedure. A stable strontium carrier is added to the water sample so that 89Sr and 90Sr are 
precipitated as insoluble carbonates. The sample then undergoes a preliminary counting that represents 
the total strontium activity (89, 90Sr) plus a small fraction of 90Y that has grown in by radioactive decay. 
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Sample matrix Sample preparation Analytical method detection limit recovery References 
Air	 Particulate collection 
on cellulose filter; 
acid digestion 
Water	 Acid digestion 
Water	 Filtration; acid 
digestion; add matrix 
modifier 
Water	 Wet acid digestion 
Drinking, raw, 	 Wet acid digestion; 
and waste 	 addition of Sr carrier 
water	 and precipitation as 
SrCO3; extraction of 
Yttrium; precipitation 
of Yttrium oxalate. 
Water	 Complex EDTA; ion 
chromatography; 
precipitate Sr effluent 
fraction as SrCO3 
Water (high Sr 	 Ion chromatography; 
concentration)	 dilution 
Saline water	 Dilution 
Soils and 	 Digest organic 




Soils and 	 Fuse with NaOH­
sediments	 Na2CO3; dissolve in 
acid; ion exchange 
Vegetation and 	Dry ash; 
food	 complexation with 
EDTA; ion exchange 
chromatography; 
precipitate Sr effluent 
fraction as SrCO3 




FAAS (Method D4185) 
Spectrophotometric 
measurement (total 
strontium) (Method 911.03) 
FAAS (Method D3920; 
7780) 
ICP-AES (Method 200.15) 
β-GPC (Method 973.66; 
7500-Sr) 
β-GPC (Method 008) 
β-GPC 
FAAS (Method D3352) 
β-GPC 
β-GPC (Method 008-S) 
β-GPC (Method 008-V) 













No data	 ATSM 1999 
No data	 AOAC 1990 
No data	 ASTM 1999; 
OSW 1992 
No data	 EMMI 2000a 
93–99	 AOAC 1990; 
APHA 1992 
No data	 EMMI 2000b 
No data	 EMMI 2000c, 
2000d 
100–106 ASTM 1999 
No data	 EMMI 2000c, 
2000d 
No data	 EMMI 2000b 
No data 	 EMMI 2000b 
No data	 AOAC 1990 
89Sr and 90Sr measured separately by measuring 90Y in-growth 
ß-GPC (total radioactive strontium) = beta gas proportional counter; EDTA = ethylenediamine tetraacetic acid; FAAS 
(total strontium) = flame atomic absorption spectroscopy; ICP-AES (total strontium) = inductively coupled plasma 
atomic emission spectroscopy 
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The 90Y is allowed to reach equilibrium (e.g., approximately a 2-week period) and then is separated with 
stable yttrium-carrier as yttrium hydroxide (i.e., Y(OH)3 ). The Y(OH)3 precipitates are converted to the 
oxalate and the solid oxalate is beta counted in a low background gas-flow proportional counter.  The 90Sr 
concentration is determined from the 90Y activity and the 89Sr concentration by difference.  Variations of 
the above method involve different techniques of selectively separating strontium from environmental 
samples.  Using the various separation methods already described, Cherenkov counting, in conjunction 
with liquid scintillation, has also been use to detect 90Sr by measuring the concentration of its progeny, 
90Y, in solution (Scarpitta et al. 1999). 
Horwitz et al. (1991) developed an extraction chromatography technique in which strontium can be 
selectively separated from other interfering radionuclides such as alkaline and alkaline earth element ions.  
The technique uses an extraction column (e.g., Sr-resin) with a crown ether (4,4’(5’)-bis(tert­
butylcyclohexano)-18-crown-6) sorbed on an inert polymeric porous support. A sample with 90Sr 
digested in concentrated nitric acid is diluted and loaded on the Sr-resin column in ~3 M nitric acid.  
Interfering elements are removed from the column with ~1 M nitric acid and strontium ions are 
subsequently eluted with a dilute acid solution. 90Sr ions are then beta counted using a low background 
gas flow proportional counter or Cherenkov counting of 90Y as previously discussed (Grahek et al. 1999; 
Torres et al. 2000, 2002).  One disadvantage with this technique is some ions interfere with the strontium 
separation. For example, potassium diminishes the capacity of the Sr-resin column to retain strontium; 
lead also shows a very strong retention on the Sr-resin and irreversibly blocks Sr adsorption sites (Miró et 
al. 2002).  Recently, improvements have been made to the extraction process using a wetting film 
technique, which has been shown to reduce ionic interferences (Miró et al. 2002). 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of strontium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of strontium. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
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reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    Analytical methods with 
satisfactory sensitivity and precision are available to determine the levels of strontium in human tissues 
and body fluids.  Strontium and radiostrontium are found in essentially all food, water, and air, so 
everyone is exposed to some levels.  Recently, Sutherland et al. (2000a, 2000b) developed a molecular 
biological strategy to identify clustered lesions in DNA resulting from in vitro cellular exposure to 
gamma radiation. It is possible that this technique might be adapted to evaluate genetic damage in blood 
cells following exposure to radioactive strontium.  This method, however, will not be specific for 90Sr 
effects. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Analytical methods with the required sensitivity and accuracy are available for quantification 
of strontium, both total and isotopic, in environmental matrices (Table 7-2).  Knowledge of the levels of 
strontium in various environmental media, along with the appropriate modeling (see Chapters 3 and 5), 
can be used to evaluate potential human exposures through inhalation and ingestion pathways. 
7.3.2 Ongoing Studies 
No ongoing studies investigating new methods for detection and speciation of strontium or radiostrontium 
were identified in the Federal Research in Progress database (FEDRIP 2002). 
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The international, national, and state regulations and guidelines regarding stable strontium in air, water, 
and other media are summarized in Table 8-1.  The regulations and guidelines regarding radioactive 
strontium are summarized in Tables 8-2 and 8-3. 
Stable Strontium.  An MRL of 2.0 mg strontium/kg/day for intermediate-duration oral exposure to 
strontium was calculated by dividing a NOAEL of 140 mg strontium/kg/day for skeletal toxicity in young 
rats (Storey 1961) by an uncertainty factor of 30 and a modifying factor of 3 (see Appendix A). 
The EPA derived a chronic reference dose (RfD) of 0.6 mg/kg/day for strontium (IRIS 2002). The RfD is 
based on a NOAEL of 190 mg strontium/kg/day for skeletal toxicity in young rats (Storey 1961). 
The EPA has not classified stable strontium for human carcinogenicity (IRIS 2002).  A number of 
agencies have classified strontium chromate as a human carcinogen by the inhalation route, on the basis 
of occupational and animal studies.  The carcinogenicity of strontium chromate is attributed to the 
hexavalent chromium ion and not to strontium.  The American Conference of Governmental Industrial 
Hygienists (ACGIH) has given strontium chromate the classification A2, suspected human carcinogen, 
and has established an 8-hour time-weighted-average (TWA) of 0.0005 mg/m3 for occupational exposure 
(ACGIH 2002).  The International Agency for Research on Cancer (IARC) has assigned strontium 
chromate, along with other chromates, to Group 1, as a human carcinogen (IARC 1990, 2002a).  No other 
stable strontium compound is listed by IARC. 
Radioactive Strontium.  No MRLs were derived for inhalation or oral exposures to radioactive strontium. 
The EPA has not derived reference concentrations (RfCs) or RfDs for radioactive strontium (IRIS 2002), 
nor does the Integrated Risk Information System (IRIS) database provide cancer assessments for 
radioisotopes of strontium.  This function is the responsibility of the EPA Office of Radiation and Indoor 
Air (ORIA). All radionuclides, including radioisotopes of strontium, are classified as known human 
(Group A) carcinogens. This classification is based on results of epidemiological studies of Japanese 
atomic bomb survivors, underground uranium miners, radium dial painters, and patients subjected to a 
variety of radiation treatments, as well as results of laboratory animal research and mammalian tissue 
culture studies. ORIA has published cancer slope factors (mortality and morbidity cancer risk estimates) 
for all known radionuclides, by various exposure routes (inhalation, drinking water ingestion, food 
ingestion, soil ingestion, immersion in a cloud, and external exposure from contaminated soil) for five age 
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Table 8-1. Regulations and Guidelines Applicable to Stable Strontium 
Agency Description 	 Information Reference 
INTERNATIONAL 
Guidelines: 
 IARC Carcinogenicity classification IARC 1990, 





ACGIH TLV (8-hour TWA) ACGIH 2002
 Strontium chromate 10x5-4 mg/m3 
EPA HAP  HSDB 2001 
 Strontium chromate 

NIOSH REL No data 

OSHA PEL No data 

b. 	Water 
EPA Drinking water guideline 4 mg/L HSDB 2001 
 Health Advisories EPA 2000d 
 10-kg child 
1 Day 25 mg/L 
10 Day 25 mg/L 
Lifetime 4 mg/L 
DWEL 20 mg/L 
USNRC 	 Maximum ambient environmental level 10 mg/L HSDB 2001 
in potable water 
c. 	Food No data 
d. 	Other 
ACGIH Carcinogenicity classification  ACGIH 2002
 Strontium chromate A2b 
EPA 	 Carcinogenicity classification Group Dc EPA 2000d 
RfD 6x10-1 mg/kg/day IRIS 2001 
 Reportable quantity EPA 2001a 
 Strontium chromate 1,000 pounds 40CFR302.4 
Toxic pollutants and hazardous  EPA 2001b 
substances required to be identified 40CFR122, 
Appendix D 
STATE 
a. 	Air No data 
b. 	Water 
Florida Drinking water guideline 4.2 mg/L HSDB 2001 
Maine Drinking water guideline 2.4 mg/L HSDB 2001 
c. 	Food No data 
d. 	Other 
Arizona Soil remediation levels BNA 2001 
 Residential 4.6x104 mg/kg
 
 Non residential 1x106 mg/kg 
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Table 8-1. Regulations and Guidelines Applicable to Stable Strontium 
Agency Description Information Reference 
STATE (cont.) 
Florida Toxic substances in the workplace; Strontium chromate BNA 2001 
Florida substance list 
aGroup 1: carcinogenic to humans (refers to hexavalent chromium) 
bA2: suspected human carcinogen (refers to hexavalent chromium) 
cGroup D: not classifiable as to human carcinogenicity 
ACGIH = American Conference of Governmental Industrial Hygienists; BNA = Bureau of National Affairs; 
CFR = Code of Federal Regulations; DWEL = drinking water equivalent level; EPA = Environmental Protection 
Agency; HAP = hazardous air pollutant; HSDB = Hazardous Substances Data Bank; IARC = International Agency for 
Research on Cancer; IRIS = Integrated Risk Information System; NIOSH = National Institute for Occupational Safety 
and Health; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; 
REL = recommended exposure limit; RfD = reference dose; TLV = threshold limit values; TWA = time-weighted 
averages; USNRC = National Research Council 
STRONTIUM	 260 
8. REGULATIONS AND ADVISORIES 
Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 














Recommended dose limitsa; 
effective dose 
Annual equivalent dose 









 Effective dose 
Annual equivalent dose in 
Lens of the eye 
Skinc 
Hands and feet 
Concentration levels for 
environmental compliance for 
90Sr 
Methods for estimating 
radionuclide emissions 
Test method for measuring 
radionuclide emissions from 
stationary sources 
Safety and health regulations 
for construction for ionizing 
radiation 
Toxic and hazardous 
substances for ionizing 
radiation 









20 mSv per year, 
averaged over defined 





Group 1d IARC 2001b, 
2001c 









 EPA 2001d 
40CFR61, 
Appendix E 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 







d. 	Other: Occupational 
DOE 
Analytical methods for 
radioactivity of 90Sr 
Detection limits for man-made 
beta particle and photon 
emitters for 90Sr 
Maximum contaminant levels 
in community water systems; 
average annual concentrations 
assumed to produce a total 
body or organ dose of 
4 millirem/year
90Sr 
 Critical organ 
Monitoring frequency for 
radioactivity in community 
water systems; annual 
monitoring 








Sources of radiation used for 
inspection of food; sealed 
units producing radiation 
Individual monitoring 
Limits for members of the 
public entering a controlled 
area (total effective dose 
equivalent in a year) 
Limits for the embryo/fetus 
from conception to birth 
Occupational dose limits for 
general employees; total 
effective dose equivalent 
Radio chemical EPA 2001g 
40CFR141.25 
(a) 








Analysis of four EPA 2001h 














0.01 rem (0.001 Sv) DOE 2001b 
10CFR835.208 
0.5 rem (0.005 Sv) DOE 2001c 
10CFR835.206 
5 rems (0.05 Sv) DOE 2001d 
10CFR835.202 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
DOE Occupational dose limits for 
general employees; sum of the 
deep dose equivalent for 
external exposures and the 
committed dose equivalent to 
any organ or tissue other than 
the lens of the eye 
Occupational dose limits for 
general employees 
Lens of the eye dose 
equivalent 
Shallow dose equivalent to 
the skin or to any extremity 
Planned special exposures 
Occupational dose limits for 
minors (total effective dose 
equivalent in a year) 
Radiation standards; inhaled 










Carriage by public highway; 
requirements for Class 7 
(radioactive material); total 
transport index number 
General requirements for 
shipments and packages; 
Class 7 (radioactive) materials 
Scope and definitions 
General design requirements 
Table of activity limits-
excepted quantities and 
articles
General requirements for 
shipments and packages; 
Class 7 (radioactive) materials 




15 rems (0.15 Sv) 
50 rems (0.5 Sv) 












50 	DOT 2001c 
49CFR177.842 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
DOT Requirements for determining 
A1 and A2 values for radio­
nuclides and for the listing of 
radionuclides on shipping 
papers and labels 
Radiation level limitations; any 
normally occupied space 
except carriers operating 
under the provisions of a state 
or federally regulated radiation 
protection program and 
wearing radiation dosimetry 
devices 
Radiation level limitations; any 
point 2 meters (6.6 feet) from 
the outer lateral surfaces, 
excluding top and underside 
Radiation level limitations; 
external surface radiation level 
not to be exceeded under 
conditions normally incident to 
transportation packages 
exceeding the radiation limit 
Transport by exclusive use 
shipment 
 Conditional maximum 
radiation level 
Outer surface of vehicles 
including top and underside 
Superfund; reportable quantity 
for 90Sr 
e. 	Other: General Population 
EPA Annual possession quantities 
for environmental compliance 
of 90Sr 
 Gaseous form 
 Liquid/powder forms 






(200 mrem/hour) and 
the transport index (TI) 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description Information Reference 
NATIONAL (cont.) 
EPA Environmental standards for EPA 2001i 
management and storage of 40CFR191, 
spent nuclear fuel, high-level Subpart A 
and transuranic radioactive 
wastes; applicability and 
definitions 
 Whole body 25 mrem 
Thyroid 75 mrem 
 Other critical organs 25 mrem 
Environmental standards for  EPA 2001i 
disposal of spent nuclear fuel, 40CFR191, 
high-level and transuranic Subpart B 
radioactive wastes; 
applicability, definitions, 
containment and individual 
protection requirements 
Environmental standards for 1,000/1,000 MTHM EPA 2001i 
groundwater protection of 40CFR191, 
spent nuclear fuel, high-level Subpart C 
and transuranic radioactive 
wastes; applicability and 
definitions; release limits for 
containment requirements of 
90Sr 
Hazardous waste injection D004–D011 wastes EPA 2001j 
restrictions; waste specific 40CFR148.18 
prohibitions; newly listed and 
identified wastes 
Land disposal restrictions;  EPA 2001l 
effective dates of injected 40CFR268, 
prohibited hazardous wastes Appendix VIII 
Radioactive waste; release 1,000 Ci EPA 2001c 
limits for containment 
requirementsk for 90Sr 
40CFR191, 
Appendix A 
Reportable quantity of 90Sr 1x10-1 Ci EPA 2001e 
40CFR302.4, 
Appendix B 
Standards for the control of  EPA 2001k 
residual radioactive materials 40CFR192, 
from inactive uranium Subpart A 
processing sites; definitions; 
control of residual radioactive 
materials and their listed 
constituents 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
EPA 	 Standards for cleanup of land 
and buildings contaminated 
with residual radioactive 
materials from inactive 
uranium processing sites 
Guidance for implementation 
Standards for management of 
uranium byproduct materials 
pursuant to Section 84 of the 
Atomic Energy Act of 1954, as 
amended 
Standards for management of 
thorium byproduct materials 
pursuant to Section 84 of the 
Atomic Energy Act of 1954, as 
amended 
 Underground injection control 
regulations for Class V 
injection wells 




 Specific gravity 
Byproduct material listing 
(90Sr) 
 Column 1 
 Column 2 
Byproduct material listing 
Dose to an embryo/fetus 
(dose equivalent during the 
entire pregnancy) 
 Licensing ice detection 
devices (90Sr) 
Occupational dose limits for 
adults (total effective dose 
equivalent) in a year 
Sum of the deep-dose 
equivalent and the committed  
dose equivalent to any 
individual organ or tissue 
other than the lens of the eye 






 EPA 2001k 
40CFR192, 
Subpart D 
 EPA 2001k 
40CFR192, 
Subpart E 









1x10-2 Ci Schedule A 
1x19-4 Ci 
0.1 µCi 	 USNRC 2001a 
10CFR30.71, 
Schedule B 
0.5 rem (5 mSv) 	 USNRC 2001m 
10CFR20.1208 
≤50 µCi 	 USNRC 2001c 
10CFR31.10 
5 rems (0.05 Sv) 	 USNRC 2001n 
10CFR20.1201 
50 rems (0.5 Sv) 	 USNRC 2001n 
10CFR20.1201 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
USNRC Annual limits to the lens of the 
eye, to the skin, and to the 
extremities 
Lens dose equivalent 
Shallow-dose equivalent to 
the skin or to any extremity 
Occupational dose limits for 
minors 
Occupational values for oral 
ingestion (ALI) of 90Sr 
 Class Df 
 Medical use—90Sr as a use of 
unsealed byproduct material 
for uptake, dilution, and 
excretion studies 
 Medical use—90Sr as a sealed 
source in an applicator for 
treatment of superficial eye 
conditions 
Physical protection for spent 
nuclear fuel and high-level 
radioactive waste 
 Radioactive waste; 
classification of 90Sr 
 Column 1l
 Column 2 
 Column 3 
Standards for protection 
against radiation—dose limits 
for individual members of the 
public; total effective dose 
equivalent to individual 
Standards for protection 
against radiation; dose limits 
for individual members of the 
public; dose from external 
source 
 Quality assurance—90Sr 
Quantity of licensed material 




15 rems (0.15 Sv) 
50 rems (0.50 Sv) 
10% of the annual dose USNRC 2001o 
limits specified for adult 10CFR20.1207 




3x101 µCi (bone surf) Appendix B 
4x101 
 USNRC 2001k 
10CFR35.100
 USNRC 2001j 
10CFR35.4000 







0.1 rem/year 	 USNRC 2001q 
10CFR20.1301 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
USNRC Quantity of radioactive 
material requiring need for an 
emergency plan for 
responding to a release (90Sr) 
 Release fraction 
Quantity 
Standards for protection 
against radiation; quantity of 





ACGIH TLV-TWA (90Sr) 
 Effective dose 
Any single year 
Averaged over 5 years 
Annual equivalent dose to 
Lens of the eye 
 Skin 
Hands and feet 
Embryo-fetus exposures once 
the pregnancy is known 
Monthly equivalent dose 
Dose to the surface of 
women’s abdomen (lower 
trunk) 
Intake of radionuclide 
NIOSH REL (TWA) 
b. 	Water 
EPA MCLG for beta particles 
MCL for beta particles 
Health advisory for beta 




FDA Derived intervention leveln 


























2 mSv for the remainder 
of the pregnancy 
1/20 ALI 
No data 
No final MCLG, but zero 
proposed in 1991 
4 mrem 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
NATIONAL (cont.) 
d. 	Other 
EPA Effective dose equivalent 
Adult 
Lens of the eye 
All other organs 
Juvenile workers (<18 years 
old) 
 Pregnant workers 
Carcinogenicity slope factorsq 
Ingestion—lifetime excess 

















Carcinogenicity slope factorsq 
Ingestion—lifetime excess 















Carcinogenicity slope factorsq 
Ingestion—lifetime excess 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description Information Reference 
NATIONAL (cont.) 
EPA Carcinogenicity slope factorsr 
Inhalation—lifetime excess 
EPA 2002 









Carcinogenicity slope factorss 
External exposure—risk/year 










NCRP Occupational exposurest 
Effective dose limits 
NCRP 1993 
Annual 50 mSv 
Cumulative 10 mSv x age 
 Occupational exposurest 
Equivalent dose annual limits 
for tissues and organs 
Lens of eye 




Public exposures (annual) 
Effective dose limit, 1 mSv 
NCRP 1993 
continuous or frequent 
exposures 
Public exposures (annual) 




Public exposures (annual) 
Equivalent dose limits for 
tissues and organst 
Lens of eye 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 





Concentrations in air above 
natural background (90Sr) 
 Occupational 
Non occupational  
Concentrations in air above 
natural background 
S 1x10-9 µCi/mL 
I 5x10-9 µCi/mL 
S 3x10-11 µCi/mL 
I 2x10-10 µCi/mL 
S 3x10-11 µCi/mL 
I 2x10-10 µCi/mL 
BNA 2001 
BNA 2001 
New Jersey Maximum permissible average 
concentrations of radioactive 
materials in air (85mSr) 
 Occupational
 Non occupational 
S 4x10-5 µCi/mL 
I 3x10-5 µCi/mL 
S 1x10-6 µCi/mL 





Drinking water guidelines 





Arkansas  Concentrations in water above 
natural background (90Sr) 
 Occupational
 Non occupational 
S 1x10-5 µCi/mL 
I 1x10-3 µCi/mL 
S 3x10-7 µCi/mL 
I 4x10-5 µCi/mL 
BNA 2001 
California Drinking water guidelines 







Colorado Standards applicable to 
surface waters 
8 pCi/L BNA 2001 
 Groundwater quality 
standards 
8 pCi/L BNA 2001 
Connecticut Drinking water guidelines 8 pCi/L HSDB 2001 
Florida Drinking water guidelines 




FL DEP 2000 
Idaho Primary constituent standards 
for groundwater (90Sr) 
8 pCi/L ID Department of 
Health & Welfare 
1999 
Illinois Drinking water guidelines 
Water quality standard (90Sr) 
8 pCi/L 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description 	 Information Reference 
STATE (cont.) 
New Jersey Maximum permissible average 
concentrations of radioactive 
materials in water (85mSr) 
 Occupational
 Non occupational 
Indiana 	 Maximum contaminant levels 
in community water systems; 
average annual concentra­
tions assumed to produce a 
total body or organ dose of 
4 millirem/year
90Sr 
 Critical organ 
Maine Drinking water guidelines 
Michigan 	 Maximum contaminant levels 
in community water systems; 
average annual 
concentrations assumed to 
produce a total body or organ 
dose of 4 millirem/year
90Sr 
 Critical organ 
New Hampshire Drinking water guidelines 
Wisconsin Drinking water guidelines 
c. 	Food 
d. 	Other 




 Specific gravity 
Standard for protection 
against radiation 




Delaware Average annual concentration 
assumed to produce a total 
body or organ dose of 
4 rem/year (90Sr) 
Critical organ (bone marrow) 
Nevada Quantities of radioactive 
material for signs, labels, and 
signals 
BNA 2001 
S 0.2 µCi/mL 
I 0.2 µCi/mL 
S 0.007 µCi/mL 









8 pCi/L HSDB 2001 












0.1 µCi 	 BNA 2001 
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Table 8-2. Regulations and Guidelines Applicable to Radioactive Strontium 
Agency Description Information Reference 
aThe limits apply to the sum of the relevant doses from external exposure in the specified period and the 50-year 
committed dose (to age 70 years for children) from intakes in the same period.
bWith the further provision that the effective dose should not exceed 50 mSv in any single year.  Additional 
restrictions apply to the occupational exposure of pregnant women.
cThe limitation on the effective dose provides sufficient protection for the skin against stochastic effects.  An additional 
limit is needed for localized exposures in order to prevent deterministic effects.
dGroup 1: human carcinogen 
eIn special circumstances, a higher value of effective dose could be allowed in a single year, provided that the 
average over 5 years does not exceed 1 mSv per year.
fClass D: all soluble compounds except SrTiO 
gClass Y: all insoluble compounds and SrTiO 
hClass D: refers to materials with retention times in the pulmonary region of <10 days 
iClass W: refers to materials with retention times in the pulmonary region of 10–100 days 
jClass Y: refers to materials with retention times in the pulmonary region of >100 days
kRelease limit per 1,000 metric tons of heavy metal (MTHM) or other unit of waste 
lColumn 1: The sum of the fractions rule for mixtures of radionuclides.  For determining classification for waste that 
contains a mixture of radionuclides, it is necessary to determine the sum of fractions by dividing each nuclide’s 
concentration by the appropriate limit and adding the resulting values.  The appropriate limits must all be taken from 
the same column of the same table.  The sum of the fractions for the column must be less than 1.0 if the waste class 
is to be determined by the column.  Example: A waste contains 90Sr in a concentration of 50 Ci/m3 and 137Cs of 22 
Ci/m3. Since the concentrations both exceed the values in Column 1, Table 2, they must be compared to Column 2 
values. For 90Sr fraction 50/150=0.33;  for 137Cs fraction, 22/44=0.5;  the sum of the fractions=0.83. Since the sum is 
less than 1.0, the waste is Class B. 
mGroup A: human carcinogen 
nDerived intervention levels (DIL) are concentrations of radioactivity in food whose consumption would deliver a 
committed effective dose equivalent equal to the most limiting of the protection action guides (PAGs) developed by 
FDA (1998). 
oThe FDA-recommended Derived Intervention Level (DIL) for radionuclides of 89Sr, is defined as the DIL for the most 
sensitive age group (3 months) that was calculated from the most limiting Protective Action Goal (PAG; 50 mSv 
committed dose equivalent to the bone). 
pThe FDA-recommended Derived Intervention Level (DIL) for radionuclides of 90Sr, is defined as the DIL for the most 
sensitive age group (15 years) that was calculated from the most limiting Protective Action Goal (PAG; 50 mSv 
committed dose equivalent to the bone). 
qRadioactive slope factors calculated by EPA’s Office of Radiation and Indoor Air (ORIA).  Slope factors are central 
estimates in a linear model of the age-averaged, lifetime attributable radiation cancer incidence (fatal and nonfatal 
cancer) risk per unit of activity ingested, expressed as risk per picocurie (pCi). 
rInhalation slope factors are central estimates in a linear model of the age-average, lifetime attributable radiation 
cancer incidence (fatal and nonfatal cancer) risk per unit of activity inhaled, expressed as risk per picocurie (pCi). 
sExternal slope factors are central estimates of the lifetime attributable radiation cancer incidence risk for each year of 
exposure to external radiation from photon-emitting radionuclides distributed uniformly in a thick layer of soil, 
expressed as risk/year per pCu per gram of soil. 
tSum of external and internal exposures but excluding doses from natural sources. 
ACGIH = American Conference of Governmental Industrial Hygienists; ADEC = Alaska Department of Environmental 
Conservation; ALI = annual limits on intake; BNA = Bureau of National Affairs; CFR = Code of Federal Regulations; 
DAC = derived air concentration; DEP = Department of Environmental Protection; DOE = Department of Energy; 
DOT = Department of Transportation; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; HSDB = Hazardous Substances Data Bank; I = insoluble; IARC = International Agency for Research 
on Cancer; ICRP = International Commission on Radiological Protection; MCL = maximum contaminant level; 
MCLG = maximum contaminant level goal; MDEQ = Michigan Department of Environmental Quality; 
mSv = millisievert; MTHM = metric tons of heavy metal; NCRP = National Council on Radiation Protection; 
NIOSH = National Institute for Occupational Safety and Health; USNRC = Nuclear Regulatory Commission; 
OSHA = Occupational Safety and Health Administration; PAG = protective action guide; REL = recommended 
exposure limit; S = soluble; TWA = time-weighted average 
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Table 8-3. Effective Dose Coefficientsa (e(50)) and Annual Limits on Intakeb (ALI) 
for Occupational Exposures to Radioactive Strontium Isotopes 
Radio­
nuclide Inhalation, 1µm AMADc Inhalation, 5µm AMAD Ingestion 
Absorp- einh (50) ALI ALI einh (50) ALI ALI eing (50) ALI ALI 
Half-life tion type f1d (Bq) (mCi) (Bq) (mCi) (Bq) (mCi) 
80Sr 
1.67 hr 	 fast 0.3 7.6x10-11 2.6x108 7.11 1.3x10-10 1.5x108 4.158 3.4x10-10 5.9x107 1.590
 slow 0.01 1.4x10-10 1.4x108 3.86 2.1x10-10 9.5x107 2.574 3.5x10-10 5.7x107 1.544 
81Sr 
0.425 hr fast 0.3 2.2x10-11 9.1x108 24.57 3.9x10-11 5.1x108 13.860 7.7x10-11 2.6x108 7.020 
 slow 0.01 3.8x10-11 5.3x108 14.22 6.1x10-11 3.3x108 8.861 7.8x10-11 2.6x108 6.93 
82Sr 
25.0 d 	 fast 0.3 2.2x10-9 9.1x106 0.245 3.3x10-9 6.1x106 0.164 6.1x10-9 3.3x106 0.089
 slow 0.01 1.0x10-8 2.0x106 0.054 7.7x10-9 2.6x106 0.070 6.0x10-9 3.3x106 0.090 
83Sr 
1.35 d 	 fast 0.3 1.7x10-10 1.2x108 3.179 3.0x10-10 6.7x107 1.801 4.9x10-10 4.1x107 1.103
 slow 0.01 3.4x10-10 5.9x107 1.589 4.9x10-10 4.1x107 1.103 5.8x10-10 3.5x107 0.932 
85Sr 
64.8 d 	 fast 0.3 3.9x10-10 5.1x107 1.386 5.6x10-10 3.6x107 0.965 5.6x10-10 3.6x107 0.965
 slow 0.01 7.7x10-10 2.6x107 0.702 6.4x10-10 3.1x107 0.845 3.3x10-10 6.1x107 1.638 
85mSr 
1.16 hr 	 fast 0.3 3.1x10-12 6.5x109 174.00 5.6x10-12 3.6x109 96.53 6.1x10-12 3.3x109 88.61 
 slow 0.01 4.5x10-12 4.4x109 120.00 7.4x10-12 2.7x109 73.05 6.1x10-12 3.3x109 88.61 
87mSr 
2.8 hr 	 fast 0.3 1.2x10-11 1.7x109 45.05 2.2x10-11 9.1x108 24.57 3.0x10-11 6.7x108 18.02 
 slow 0.01 2.2x10-11 9.1x108 24.57 3.5x10-11 5.7x108 15.44 3.3x10-11 6.1x108 16.38 
89Sr 
50.5 d 	 fast 0.3 1.0x10-9 2.0x107 0.540 1.4x10-9 1.4x107 0.386 2.6x10-9 7.7x106 0.208
 slow 0.01 7.5x10-9 2.7x106 0.072 5.6x10-9 3.6x106 0.097 2.3x10-9 8.7x106 0.235 
90Sr 
29.1 yr 	 fast 0.3 2.4x10-8 8.3x105 0.023 3.0x10-8 6.7x105 0.018 2.8x10-8 7.1x105 0.019
 slow 0.01 1.5x10-7 1.3x105 0.004 7.7x10-8 2.6x105 0.007 2.7x10-9 7.4x106 0.200 
91Sr 
9.5 hr 	 fast 0.3 1.7x10-10 1.2x108 3.180 2.9x10-10 6.9x107 1.864 6.5x10-10 3.1x107 0.832
 slow 0.01 4.1x10-10 4.9x107 1.318 5.7x10-10 3.5x107 0.948 7.6x10-10 2.6x107 0.711 
92Sr 
2.7 hr 	 fast 0.3 1.1x10-10 1.8x108 4.914 1.8x10-10 1.1x108 3.003 4.3x10-10 4.7x107 1.257
 slow 0.01 2.3x10-10 8.7x107 2.350 3.4x10-10 5.9x107 1.590 4.9x10-10 4.1x107 1.103 
aICRP (1994)
bFor internal exposures, ICRP (1994) recommends an effective dose limit of 100 mSv over 5 years (averaging 20 mSv 
per year).  The Annual Limits on Intake (ALI in Bequerels) were calculated by dividing the annual effective dose limit 
(0.02 Sv) by the dose coefficient (e(50)) in Sieverts/Bequerel.  

cICRP (1994) calculated inhalation dose coefficients for particles with AMAD of 1 or 5 µm. 

dFractional absorption factor used by ICRP (1994: Annexes E and F) to calculate effective dose coefficients.  A value 

of 0.3 was used for unspecified strontium compounds and 0.01 was used for strontium titanate. 

ALI = Annual Limits on Intake; AMAD = Activity Median Average Diameters; Bq = Bequerels; Ci = Curies; d = day; 
hr = hour; yr = year 
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groups and 14 radiogenic cancer cites (EPA 2000e). These factors are used to calculate the lifetime 
excess total cancer risk per unit intake or exposure to radiation (under the different exposure scenarios).  
Slope factors for radioactive strontium isotopes are listed in Table 8-2.  IARC has determined that all 
internally deposited beta emitters, including radioactive strontium, are carcinogenic to humans and has 
assigned them to Group 1 (IARC 2001, 2002b).  
Because of the potential for ionizing radiation to cause deterministic (acute radiation syndrome) and 
nondeterministic (cancer) health effects in exposed individuals, safe dose guidelines and regulations have 
been established for radionuclides in air and water by a number of international and national agencies 
(Tables 8-2 and 8-3). Regulations and guidelines that protect against deterministic effects are based on 
identified acute thresholds doses for those effects, with a reduction to protect sensitive populations and 
provide safety margins to account for uncertainties.  Those that protect against nondeterministic effects 
use the observed frequencies with which those effects occur at high doses, account for uncertainties that 
may exist, and assume a linear dose-effect relationship to calculate the doses at which the effects would 
be presumed to occur at some acceptable frequency, such as the range of 10-4–10-6, which EPA often 
considers. This proportionality assumes a linear no threshold (LNT) dose effect curve.  During the last 
decade, there have been reductions in LNT-based public radiation dose limits and site cleanup levels that 
have increased the scope and cost of medical, occupational, and environmental radiation protection 
efforts. Some recent studies found a reduction in health effects when the dose was delivered at lower 
dose rates, indicating a potential application to future protection guidelines and regulations. 
The International Commission on Radiological Protection (ICRP) provides guidance on the fundamental 
principles regarding the biological effects of exposure to ionizing radiation and recommends exposure 
limits based on these analyses.  In the United States, the National Council on Radiation Protection and 
Measurements (NCRP) was chartered in 1964 by the U.S. Congress to:  (1) disseminate information of 
public interest and recommend radiation levels to protect the public, (2) support cooperation among 
organizations concerned with radiation protection, (3) develop basic concepts about radiation protection, 
and (4) cooperate with the ICRP and the International Commission on Radiation Units and 
Measurements.  Even though the NCRP is a nongovernmental organization, it provides recommendations 
that guide the establishment of federal radiation policies, agency requirements, and statutory laws.  
Through the governmental agencies that rely on NCRP recommendations, the work of this organization 
has a significant impact on the many activities in the United States involving the use of radiation and 
radioactive materials. 
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The EPA sets radiation safety policy and basic safety standards.  The execution of this policy is assigned 
to the various regulatory agencies, including the EPA itself, for application to the specific activities that 
they regulate. The U.S. Nuclear Regulatory Commission (USNRC), an independent government agency, 
regulates commercial nuclear power reactors; research/test/training reactors; fuel cycle facilities; and the 
transport, storage, and disposal of nuclear materials and waste (USNRC 1997).  The EPA is responsible 
for protecting the public and the environment and for cleanup of radioactively contaminated sites (EPA 
1997a). 
The Food and Drug Administration (FDA) develops standards for radioactive material concentrations in 
food (FDA 1998) and in medical devices used in radiation therapy (FDA 1997). The FDA recently 
updated its guidance document that presents recommended action levels for accidental radioactive 
contamination of foods, both domestic and imported (FDA 1998).  These derived intervention levels 
(DILs) are estimated levels in food that could lead to individuals receiving a radiation equivalent dose 
equal to the FDA protection action guide (PAG) that is set as the more limiting of either 0.5 rem (5 mSv) 
for committed effective dose or 5 rem (50 mSv) committed dose equivalent to any individual tissue or 
organ. Derived intervention levels, which are based on food intake rates, are calculated for different age 
groups and the DIL for the most vulnerable group is then adopted to provide a conservative margin of 
safety for the entire population.  For 90Sr, with a half-life of 29 years, the DIL is based on the dose to the 
bone surface in 15-year-old individuals, who have the highest rate of bone growth.  For 89Sr, with a half-
life of 50.5 days, 3-month-old infants represent the most sensitive group because of the higher doses to 
the lower intestine from milk consumption.  Table 8-2 presents the DILs adopted for the two strontium 
isotopes. 
Transport of radioactive materials is regulated by the Department of Transportation (DOT) in conjunction 
with the USNRC. Coordinating government emergency response to accidents involving radioactive 
materials is the responsibility of the Federal Emergency Management Administration (FEMA). 
National regulations governing the occupational exposure to ionizing radiation include USNRC 
regulations (10 CFR 20), the Occupational Safety and Health Administration (OSHA) standards for 
ionizing radiation (29 CFR 1910.1096), and the Department of Energy (DOE) standards for occupational 
radiation protection (10 CFR 835).  National regulations concerning general population exposure to 
radiation have been developed as proposed by the EPA and as finalized by the USNRC based on the dose 
limit recommendations of the ICRP (ICRP 1996) and the NCRP (NCRP 1993).  The EPA and USNRC 
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also use the BEIR reports of the National Academy of Sciences and the UNSCEAR reports on biological 
effects to help develop the U.S. standards in line with the NCRP and the ICRP consensus standards. 
Currently, there are 29 "NRC Agreement States."  An agreement state is any state that has entered into an 
agreement with the USNRC under Section 274 of the Atomic Energy Act of 1954, as amended.  The 
USNRC relinquishes to these states the majority of its regulatory authority over source, by-product, and 
special nuclear material in quantities not sufficient to form a critical mass.  However, the regulation of 
nuclear reactors is under USNRC jurisdiction.  In the remaining states, USNRC still handles all of the 
inspection, enforcement, and licensing responsibilities. 
The basic philosophy of radiation safety is to minimize unnecessary radiation exposure.  The specific 
objectives of radiation safety guidance as stated by NCRP are (1) to prevent the occurrence of severe 
radiation-induced deterministic (nonstochastic) disease, and (2) to limit the risk of the nondeterministic 
(stochastic) effects (fatal cancer and genetic effects) to a reasonable level compared with nonradiation 
risks and in relation to societal needs, benefits gained, and economic factors.  In addition to regulations 
that set upper limits on radiation dose, the concept of ALARA (As Low As Reasonably Achievable) was 
introduced to ensure that workplace endeavors resulting in exposures to radiation provide sufficient 
benefits that offset any potential detriment they cause (ACGIH 2002).  The goal is not to eliminate all 
radiation exposure, which would not be possible, but instead to strive for an appropriate balance between 
protection of public health and reasonable costs (economic, social, etc.) while maintaining desirable dose 
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Some terms in this glossary are generic and may not be used in this profile. 
Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in 
contact with the skin. For oral or inhalation routes, this is normally the product of the intake quantity and 
the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a 
single intake or mg/kg/day for multiple intakes.  For dermal exposure, this is the amount of material 
applied to the skin, and is normally divided by the body mass and expressed as mg/kg.   
Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by 
ionizing radiation.  Units: rad (rad), gray (Gy). 
Absorbed Fraction—A term used in internal dosimetry.  It is that fraction of the photon energy (emitted 
within a specified volume of material) which is absorbed by the volume.  The absorbed fraction depends 
on the source distribution, the photon energy, and the size, shape and composition of the volume. 
Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after 
contact, or the process by which radiation imparts some or all of its energy to any material through which 
it passes. 
Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma-
radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or 
per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.  The total 
absorption coefficient is the sum of individual energy absorption processes (see Compton Effect, 
Photoelectric Effect, and Pair Production). 
Absorption Coefficient, Linear—A factor expressing the fraction of a beam of x- or gamma radiation 
absorbed in a unit thickness of material.  In the expression I=Ioe-µx, Io is the initial intensity, I the intensity 
of the beam after passage through a thickness of the material x, and µ is the linear absorption coefficient. 
Absorption Coefficient, Mass—The linear absorption coefficient per cm divided by the density of the 
absorber in grams per cubic centimeter.  It is frequently expressed as µ/ρ, where µ is the linear absorption 
coefficient and ρ the absorber density. 
Absorption Ratio, Differential—Ratio of concentration of a nuclide in a given organ or tissue to the 
concentration that would be obtained if the same administered quantity of this nuclide were uniformly 
distributed throughout the body. 
Activation—The process of making a material radioactive by bombardment with neutrons or protons. 
Activity—The number of radioactive nuclear transformations occurring in a material per unit time (see 
Curie, Becquerel). The term for activity per unit mass is specific activity. 
Activity Median Aerodynamic Diameter (AMAD)—The diameter of a unit-density sphere with the 
same terminal settling velocity in air as that of the aerosol particle whose activity is the median for the 
entire size distribution of the aerosol. 




Acute Exposure, Radiation—The absorption of a relatively large amount of radiation (or intake of a 
radioactive material) over a short period of time. 
Acute Radiation Syndrome—The symptoms which taken together characterize a person suffering from 
the effects of intense radiation.  The effects occur within hours or days. 
Ad libitum—Available in excess and freely accessible.  
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit surface area or 
per unit weight of organic carbon of a specific particle size in the soil or sediment to the concentration of 
the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—See Distribution Coefficient 
Alpha Particle—A positively charged particle ejected spontaneously from the nuclei of some radioactive 
elements.  It is identical to a helium nucleus, i.e., 2 neutrons and two protons, with a mass number of 4 
and an electrostatic charge of +2. 
Alpha Track—The track of ionized atoms (pattern of ionization) left in a medium by an alpha particle 
that has traveled through the medium. 
Annihilation (Positron-Electron)—An interaction between a positive and a negative electron in which 
they both disappear; their rest mass, being converted into electromagnetic radiation (called annihilation 
radiation) with two 0.51 MeV gamma photons emitted at an angle of 180E to each other. 
Annual Limit on Intake (ALI)—The derived limit for the amount of radioactive material taken into the 
body of an adult worker by inhalation or ingestion in a year.  It is the smaller value of intake of a given 
radionuclide in a year by the reference man that would result in a committed effective dose equivalent of 
5 rem or a committed dose equivalent of 50 rem to any organ or tissue. 
Atom—The smallest particle of an element that cannot be divided or broken up by chemical means.  It 
consists of a central core called the nucleus, which contains protons and neutrons and an outer shell of 
electrons. 
Atomic Mass (u)—The mass of a neutral atom of a nuclide, usually expressed in terms of "atomic mass 
units." The "atomic mass unit" is one-twelfth the mass of one neutral atom of carbon-12; equivalent to 
1.6604x10-24 g. 
Atomic Mass Number—See Mass Number. 
Atomic Number—The number of protons in the nucleus of an atom.  The "effective atomic number" is 
calculated from the composition and atomic numbers of a compound or mixture.  An element of this 
atomic number would interact with photons in the same way as the compound or mixture.  (Symbol: Z). 
Atomic Weight—The weighted mean of the masses of the neutral isotopes of an element expressed in 
atomic mass units. 
Attenuation—A process by which a beam from a source of radiation is reduced in intensity by 
absorption and scattering when passing through some material. 
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Attenuation Coefficient—The fractional reduction in the intensity of a beam of radiation as it passes 
through an absorbing medium.  It may be expressed as reduction per unit distance, per unit mass 
thickness, or per atom, and is called the linear, mass, or atomic attenuation coefficient, respectively. 
Auger Effect—The emission of an electron from the extranuclear portion of an excited atom when the 
atom undergoes a transition to a less excited state. 
Background Radiation—The amount of radiation to which a member of the general population is 
exposed from natural sources, such as terrestrial radiation from naturally occurring radionuclides in the 
soil, cosmic radiation originating from outer space, and naturally occurring radionuclides deposited in the 
human body. 
Becquerel (Bq)—International System of Units unit of activity and equals that quantity of radioactive 
material in which one transformation (disintegration) occurs per second (see Units). 
 Terabecquerel (TBq)—One trillion becquerel. 

 Gigabecquerel (GBq)—One billion becquerel. 

 Megabecquerel (MBq)—One million becquerel. 

 Kilobecquerel (kBq))—One thousand becquerel.

 Millibecquerel (mBq)—One-thousandth of a becquerel. 

 Microbecquerel (µBq)—One-millionth of a becquerel. 

Beta Particle—An electron that is emitted from the nucleus of an atom during one type of radioactive 
transformation.  A beta particle has a mass and charge equal in magnitude to that of the electron.  The 
charge may be either +1 or -1.  Beta particles with +1 charges are called positrons (symbolized β+), and 
beta particles with -1 charges are called negatrons (symbolized β-). 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biologic Effectiveness of Radiation—See Relative Biological Effectiveness. 
Biological Half-time—The time required for a biological system, such as that of a human, to eliminate by 
natural process half of the amount of a substance (such as a chemical substance, either stable or 
radioactive) that has entered it. 
Biomagnification—The progressive increase in the concentration of a bioaccumulated chemical in 
organisms as that chemical is passed from the bottom to the top of the food web. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Body Burden, Chemical—The total amount of a chemical found in an animal or human body. 
Body Burden, Radioactivity—The amount of radioactive material found in an animal or human body. 
Bone Seeker—Any compound or ion which migrates in the body and preferentially deposits into bone. 
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Branching—The occurrence of two or more modes by which a radionuclide can undergo radioactive 
decay.  For example, 214Bi can undergo alpha or beta minus decay, 64Cu can undergo beta minus, beta 
plus, or electron capture decay.  An individual atom of a nuclide exhibiting branching disintegrates by one 
mode only. The fraction disintegrating by a particular mode is the "branching fraction" for that mode.  
The "branching ratio" is the ratio of two specified branching fractions (also called multiple 
disintegration). 
Bremsstrahlung—X rays that are produced when a charged particle accelerates (speeds up, slows down, 
or changes direction) in the strong field of a nucleus. 
Buildup Factor—The ratio of the radiation intensity, including both primary and scattered radiation, to 
the intensity of the primary (unscattered) radiation. 
Cancer Effect Level (CEL)—The lowest dose of chemical or radiation in a study, or group of studies, 
that produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control. 
Capture, Electron—A mode of radioactive decay involving the capture of an orbital electron by its 
nucleus. Capture from a particular electron shell, e.g., K or L shells, is designated as "K-electron capture" 
or "L-electron capture." 
Capture, K-Electron—Electron capture from the K shell by the nucleus of the atom.  Also loosely used 
to designate any orbital electron capture process. 
Carcinogen—A chemical or radiation that is capable of inducing cancer. 
Carcinoma—Malignant neoplasm composed of epithelial cells, regardless of their derivation. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research but are not actual research studies. 
Cataract—A clouding of the crystalline lens of the eye which obstructs the passage of light. 
Ceiling Value—A concentration of a substance that should not be exceeded, even temporarily. 
Charged Particle—A nuclear particle, atom, or molecule carrying a positive or negative charge. 
Chronic Exposure—A long-term, continuous exposure to a chemical or radioactive material.  For 
example, exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 




Collective Dose—The sum of the individual doses received in a given period of time by a specified 
population from exposure to a specified source of radiation.  Collective dose is expressed in units such as 
man-rem and person-sievert. 
Compton Effect—An attenuation process observed for x- or gamma radiation in which an incident 
photon interacts with an orbital electron of an atom to produce a recoil electron and a scattered photon 
whose energy is less than the incident photon. 
Containment—The confinement of a chemical or radioactive substance in such a way that it is prevented 
from being dispersed from its container or into the environment, or is released only at a specified rate. 
Contamination—Deposition of a stable or radioactive substance in any place where it is not desired. 
Cosmic Rays—High-energy particulate and electromagnetic radiations that originate outside the earth's 
atmosphere and interact with the atmosphere to produce a shower of secondary cosmic rays. 
Count (Radiation Measurements)—The external indication of a radiation-measuring device designed to 
enumerate ionizing events.  It refers to a single detected event.  The term “count rate” refers to the total 
number registered in a given period of time.  The term is sometimes erroneously used to designate a 
disintegration, ionizing event, or voltage pulse. 
Counter, Gas-flow Proportional (GPC)—An instrument for detecting beta particle radiation.  Beta 
particles are detected by ionization of the counter gas which results in an electrical impulse at an anode 
wire. 
Counter, Geiger-Mueller (GM counter)—Highly sensitive, gas-filled radiation-measuring device that 
detects (counts) individual photons or particulate radiation. 
Counter, Scintillation—The combination of a crystal or phosphor, photomultiplier tube, and associated 
circuits for counting light emissions produced in the phosphors by ionizing radiation.  Scintillation 
counters generally are more sensitive than GM counters for gamma radiation. 
Counting, Cerenkov—Relatively energetic β-particles pass through a transparent medium of high 
refractive index and a highly-directional, bluish-white light ("Cerenkov" light) is emitted.  This light is 
detected using liquid scintillation counting equipment.  
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Curie (Ci)—A unit of radioactivity.  One curie equals that quantity of radioactive material in which there 
are 3.7x1010 nuclear transformations per second. The activity of 1 gram of radium is approximately 1 Ci. 
Attocurie (aCi)—One-thousandth of a femtocurie (3.7x10-8 disintegrations per second). 
 Femtocurie (fCi)—One-billionth of a microcurie (3.7x10-5 disintegrations per second).
 Megacurie (MCi)—One million curies (3.7x1016 disintegrations per second). 
 Microcurie (µCi)—One-millionth of a curie (3.7x104 disintegrations per second). 
 Millicurie (mCi)—One-thousandth of a curie (3.7x107 disintegrations per second). 
 Nanocurie (nCi)—One-billionth of a curie (3.7x101 disintegrations per second). 
 Picocurie (pCi)—One-millionth of a microcurie (3.7x10-2 disintegrations per second). 
Daughter Products—See Progeny and Decay Product 
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Decay Chain or Decay Series—A sequence of radioactive decays (transformations) beginning with one 
nucleus. The initial nucleus, the parent, decays into a daughter or progeny nucleus that differs from the 
first by whatever particles were emitted during the decay.  If further decays take place, the subsequent 
nuclei are also usually called daughters or progeny.  Sometimes, to distinguish the sequence, the daughter 
of the first daughter is called the granddaughter, etc. 
Decay Constant (λ)—The fraction of the number of atoms of a radioactive nuclide which decay in unit 
time (see Disintegration Constant). 
Decay Product, Daughter Product, Progeny—A new nuclide formed as a result of radioactive decay.  
A nuclide resulting from the radioactive transformation of a radionuclide, formed either directly or as the 
result of successive transformations in a radioactive series.  A decay product (daughter product or 
progeny) may be either radioactive or stable. 
Decay, Radioactive—Transformation of the nucleus of an unstable nuclide by spontaneous emission of 
radiation, such as charged particles and/or photons (see Disintegration). 
Delta Ray—An electron removed from an atom of a medium that is irradiated, or through which 
radiation passes, during the process of ionization (also called secondary electron).  Delta rays cause a 
track of ionizations along their path. 
Derived Air Concentration (DAC)—The concentration of radioactive material in air that, if breathed by 
the reference man for a working year of 2000 hours under conditions of light work (at a rate of 1.2 liters 
of air per hour), would result in an intake of one ALI (see Annual Limit on Intake). 
Deterministic Effect—A health effect, the severity of which varies with the dose and for which a 
threshold is believed to exist (also called a non-stochastic effect). 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical or radiation prior to conception (either parent), during prenatal development, 
or postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any 
point in the life span of the organism. 
Disintegration Constant—Synonymous with decay constant.  The fraction of the number of atoms of a 
radioactive material that decays per unit time (see Decay Constant.) 
Disintegration, Nuclear—A spontaneous nuclear transformation (radioactivity) characterized by the 
emission of energy and mass from the nucleus.  When large numbers of nuclei are involved, the process is 
characterized by a definite half-life (see Transformation, Nuclear). 
Distribution Coefficient (Kd)—Describes the distribution of a chemical between the solid and aqueous 
phase at thermodynamic equilibrium, is given as follows: 
[C]sKd = [C]w , Units = (L solution)/(kg solid),  
where [C]s is the concentration of the chemical associated with the solid phase in units of (mg)/(kg solid), 
and [C]w is the concentration of the chemical in the aqueous phase in units of (mg)/(L solution).  As the 




Dose—A general term denoting the quantity of a substance, radiation, or energy absorbed.  For special 
purposes it must be appropriately qualified.  If unqualified, it refers to radiation absorbed dose. 
Absorbed Dose—The energy imparted to matter by ionizing radiation per unit mass of irradiated 
material at the place of interest.  The unit of absorbed dose is the rad.  One rad equals 100 ergs 
per gram.  In SI units, the absorbed dose is the gray which is 1 J/kg (see Rad). 
Cumulative Dose (Radiation)—The total dose resulting from repeated or continuous exposures 
to radiation. 
Dose Assessment—An estimate of the radiation dose to an individual or a population group usually by 
means of predictive modeling techniques, sometimes supplemented by the results of measurement. 
Dose Equivalent (DE)—A quantity used in radiation safety practice to account for the relative biological 
effectiveness of the several types of radiation.  It expresses all radiations on a common scale for 
calculating the effective absorbed dose.  The NRC defines it as the product of the absorbed dose, the 
quality factor, and all other modifying factors at the location of interest.  ICRP has changed its definition 
to be the product of the absorbed dose and the radiation weighting factor.  (The unit of dose equivalent is 
the rem.  In SI units, the dose equivalent is the sievert, which equals 100 rem.) 
Dose, Fractionation—A method of administering therapeutic radiation in which relatively small doses 
are given daily or at longer intervals. 
Dose, Protraction—A method of administering therapeutic radiation by delivering it continuously over a 
relatively long period at a low dose rate. 
Dose, Radiation—The amount of energy imparted to matter by ionizing radiation per unit mass of the 
matter, usually expressed as the unit rad, or in SI units, the gray.  100 rad'1 gray (Gy) (see Absorbed 
Dose). 
Committed Dose Equivalent (HT,50)—The dose equivalent to organs or tissues of reference (T) 
that will be received from an intake of radioactive material by an individual during the 50 years 
following the intake. 
Committed Effective Dose Equivalent (HE,50)—The sum of the products of the weighting 
factors applicable to each of the body organs or tissues that are irradiated and the committed dose 
equivalent to those organs or tissues. 
Effective Dose —A dose value that attempts to normalize the detriment to the body (for cancer 
mortality and morbidity, hereditary effects, and years of life lost) from a non-uniform exposure to 
that of a uniform whole body exposure.  Effective dose is calculated as the sum of products of the 
equivalent dose and the tissue weighting factor (wT) for each tissue exposed.  (E = ∑DT,R wR wT)). 
Effective Dose Equivalent (HE)—This dose type is limited to internal exposures and is the sum 
of the products of the dose equivalent to the organ or tissue (HT) and the weighting factors (wT) 
applicable to each of the body organs or tissues that are irradiated.  (HE = ∑wT HT). 
STRONTIUM 374 
10. GLOSSARY 
Equivalent Dose—A dose quantity that places the biological effect of all radiation types on a 
common scale for calculating tissue damage.  Alpha particles, for example, are considered to 
cause 20 times more damage than gamma rays.  Equivalent dose is calculated as the sum of 
products of the average absorbed dose (in gray) in an organ or tissue (DT,R) from each type of 
radiation and the radiation weighting factor (wR) for that radiation (∑DT,R wR). 
External Dose—That portion of the dose equivalent received from radiation sources outside the 
body. 
Internal Dose—That portion of the dose equivalent received from radioactive material taken into 
the body. 
Limit—A permissible upper bound on the radiation dose. 
Maximum Permissible Dose (MPD)—The greatest dose equivalent that a person or specified 
part thereof shall be allowed to receive in a given period of time. 
Median Lethal Dose (MLD)—Dose of radiation required to kill, within a specified period 
(usually 30 days), 50% of the individuals in a large group of animals or organisms.  Also called 
the LD50, or LD50/30 if for 30 days. 
Threshold Dose—The minimum absorbed dose that will produce a detectable degree of any 
given effect. 
Tissue Dose—Absorbed dose received by tissue in the region of interest, expressed in rad (see 
Dose, Gray, and Rad). 
Dose Rate—The amount of radiation dose delivered per unit time.  Generically, the rate at which 
radiation dose is delivered to any material or tissue. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Dosimetry—Quantification of radiation doses to cells, tissues, organs, individuals or populations 
resulting from radiation exposures. 
Early Effects (of radiation exposure)—Effects that appear within 60 days of an acute exposure. 
Electron—A stable elementary particle having an electric charge equal to ±1.60210x10-19 C (Coulombs) 
and a rest mass equal to 9.1091x10-31 kg. A positron is a positively charged "electron" (see Positron). 
Electron Volt—A unit of energy equivalent to the energy gained by an electron in passing through a 
potential difference of one volt.  Larger multiple units of the electron volt are frequently used:  keV for 
thousand or kilo electron volts; MeV for million or mega electron volts (eV).  1 eV=1.6x10-12 erg. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 




Energy—Capacity for doing work.  Gravitationally, "potential energy" is the energy inherent in a mass 
because of its spatial relation to other masses.  Chemically or radiologically, “potential energy” is the 
energy released when a chemical reaction or radiological transformation goes to completion.  "Kinetic 
energy" is the energy possessed by a mass because of its motion (SI unit: joules): 
Binding Energy (Electron)—The amount of energy that must be expended to remove an 
electron from an atom. 
Binding Energy (Nuclear)—The energy represented by the difference in mass between the sum 
of the component parts and the actual mass of the nucleus.  It represents the amount of energy 
that must be expended to break a nucleus into its component neutrons and protons. 
Excitation Energy—The energy required to change a system from its ground state to an excited 
state. Each different excited state has a different excitation energy. 
Ionizing Energy—The energy required to knock an electron out of an atom.  The average energy 
lost by electrons or beta particles in producing an ion pair in air or in soft tissue is about 34 eV. 
Radiant Energy—The energy of electromagnetic radiation, such as radio waves, visible light, x 
and gamma rays. 
Enrichment, Isotopic—An isotopic separation process by which the relative abundances of the isotopes 
of a given element are altered, thus producing a form of the element that has been enriched in one or more 
isotopes and depleted in others.  In uranium enrichment, the percentage of uranium-235 in natural 
uranium can be increased from 0.7% to >90% in a gaseous diffusion process based on the different 
thermal velocities of the constituents of natural uranium (234U, 235U, 238U) in the molecular form UF6. 
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based 
on health effects information. A health advisory is not a legally enforceable federal standard, but serves 
as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Equilibrium, Radioactive—In a radioactive series, the state which prevails when the ratios between the 
activities of two or more successive members of the series remains constant. 
Secular Equilibrium—If a parent element has a very much longer half-life than the daughters 
(so there is not appreciable change in its amount in the time interval required for later products to 
attain equilibrium) then, after equilibrium is reached, equal numbers of atoms of all members of 
the series disintegrate in unit time.  This condition is never exactly attained, but is essentially 
established in such a case as 226Ra and its transformation series to stable 206Pb. The half-life of 
226Ra is about 1,600 years; of 222Rn, approximately 3.82 days, and of each of the subsequent 
members, a few minutes.  After about a month, essentially the equilibrium amount of radon is 
present; then (and for a long time) all members of the series disintegrate the same number of 
atoms per unit time.  At this time, the activity of the daughter is equal to the activity of the parent. 
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Transient Equilibrium—If the half-life of the parent is short enough so the quantity present 
decreases appreciably during the period under consideration, but is still longer than that of 
successive members of the series, a stage of equilibrium will be reached after which all members 
of the series decrease in activity exponentially with the period of the parent.  At this time, the 
ratio of the parent activity to the daughter activity is constant. 
Equilibrium, Electron—The condition in a radiation field where the energy of the electrons entering a 
volume equals the energy of the electrons leaving that volume. 
Excitation—The addition of energy to a system, thereby transferring it from its ground state to an excited 
state. Excitation of a nucleus, an atom, or a molecule can result from absorption of photons or from 
inelastic collisions with other particles.  The excited state of an atom is an unstable or metastable state and 
will return to ground state by radiation of the excess energy. 
Exposure (Chemical)—Contact of an organism with a chemical or physical agent.  Exposure is 
quantified as the amount of the agent available at the exchange boundaries of the organism (e.g., skin, 
lungs, gut) and available for absorption. 
Exposure (Radiation)—Subjection to ionizing radiation or to a radioactive material.  For example, 
exposure in air is a measure of the ionization produced in air by x or gamma radiation; the sum of the 
electric charges on all ions of one sign produced in air when all electrons liberated by photons in a 
volume of air are completely stopped in air (dQ), divided by the mass of the air in the volume (dm). The 
unit of exposure in air is the roentgen, or coulomb per kilogram (SI units). One roentgen is equal to 
2.58x10-4 coulomb per kilogram (C/kg). 
Fission, Nuclear—A nuclear transformation characterized by the splitting of a nucleus into at least two 
other nuclei with emission of several neutrons, accompanied by the release of a relatively large amount of 
energy. 
Gamma Ray, Penetrating—Short wavelength electromagnetic radiation of nuclear origin. 
Genetic Effect of Radiation—Inheritable change, chiefly mutations, produced by the absorption of 
ionizing radiation by germ cells.  Genetic effects have not been observed in any human population 
exposed at any dose level. 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Gray (Gy)—SI unit of absorbed dose, 1 J/kg.  One gray equals 100 rad (see Units). 
Half-life, Effective—See Half-Time, Effective. 
Half-life, Radioactive—Time required for a radioactive substance to lose 50% of its activity by decay.  
Each radio-nuclide has a unique physical half-life.  Known also as physical half-time and symbolized as 
Tr or Trad. 
Half-time, Biological—Time required for an organ, tissue, or the whole body to eliminate one-half of any 
absorbed substance by regular processes of elimination.  This is the same for both stable and radioactive 
isotopes of a particular element, and is sometimes referred to as half-time, symbolized as tbiol or Tb. 
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Half-time, Effective—Time required for a radioactive element in an organ, tissue, or the whole body to 
be diminished 50% as a result of the combined action of radioactive decay and biological elimination, 
symbolized as Te or Teff. 
Biological half-time × Radioactive half-lifeEffective half-time = Biological half-time + Radioactive half-life 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.  Literally, “in 
glass.” 
In Vivo—Occurring within the living organism.  Literally, “in life.” 
Intensity—Amount of energy per unit time passing through a unit area perpendicular to the line of 
propagation at the point in question. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Internal Conversion—Process in which a gamma ray knocks an electron out of the same atom from 
which the gamma ray was emitted.  The ratio of the number of internal conversion electrons to the 
number of gamma quanta emitted in the de-excitation of the nucleus is called the "conversion ratio." 
Ion—Atomic particle, atom or chemical radical bearing a net electrical charge, either negative or positive. 
Ion Pair—Two particles of opposite charge, usually referring to the electron and positive atomic or 
molecular residue resulting after the interaction of ionizing radiation with the orbital electrons of atoms. 
Ionization—The process by which a neutral atom or molecule acquires a positive or negative charge. 
Primary Ionization—(1) In collision theory:  the ionization produced by the primary particles as 
contrasted to the "total ionization" which includes the "secondary ionization" produced by delta 
rays.  (2) In counter tubes:  the total ionization produced by incident radiation without gas 
amplification. 
Specific Ionization—Number of ion pairs per unit length of path of ionizing radiation in a 
medium; e.g., per centimeter of air or per micrometer of tissue. 
Total Ionization—The total electric charge of one sign on the ions produced by radiation in the 
process of losing its kinetic energy. For a given gas, the total ionization is closely proportional to 
the initial ionization and is nearly independent of the nature of the ionizing radiation.  It is 
frequently used as a measure of absorption of radiation energy. 
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Ionization Density—Number of ion pairs per unit volume. 
Ionization Path (Track)—The trail of ion pairs produced by an ionizing particle in its passage through 
matter. 
Ionizing Radiation—Any radiation capable of knocking electrons out of atoms and producing ions.  
Examples: alpha, beta, gamma and x rays, and neutrons. 
Isobars—Nuclides having the same mass number but different atomic numbers. 
Isomers—Nuclides having the same number of neutrons and protons but capable of existing, for a 
measurable time, in different quantum states with different energies and radioactive properties.  
Commonly the isomer of higher energy decays to one with lower energy by the process of isomeric 
transition. 
Isotopes—Nuclides having the same number of protons in their nuclei, and hence the same atomic 
number, but differing in the number of neutrons, and therefore in the mass number.  Identical chemical 
properties exist in isotopes of a particular element.  The term should not be used as a synonym for nuclide 
because isotopes refer specifically to different nuclei of the same element. 
 Stable Isotope—A nonradioactive isotope of an element. 
Joule—The S.I. unit for work and energy.  It is equal to the work done by raising a mass of one newton 
through a distance of one meter (J = Nm), which corresponds to about 0.7 ft-pound. 
Kerma (k)—A measure of the kinetic energy transferred from gamma rays or neutrons to a unit mass of 
absorbing medium in the initial collision between the radiation and the absorber atoms.  The SI unit is 
J/kg. The special name of this unit is the rad (traditional system of units) or Gray (SI). 
Labeled Compound—A compound containing one or more radioactive atoms intentionally added to its 
structure. By observations of radioactivity or isotopic composition, this compound or its fragments may 
be followed through physical, chemical, or biological processes. 
Late Effects (of radiation exposure)—Effects which appear 60 days or more following an acute 
exposure. 
LD50/30—The dose of a chemical or radiation expected to cause 50% mortality in those exposed within 
30 days. For radiation, this is about 350 rad (3.5 gray) received by humans over a short period of time. 
Lethal Concentration(Lo) (LCLo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population 
within a specified time, usually 30 days. 
Lethal Dose(Lo) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals within a specified time, usually 30 days. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
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Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Linear Energy Transfer (LET)—A measure of the energy that a charged particle transfers to a material 
per unit path length.  
Average LET—The energy of a charged particle divided by the length of the path over which it 
deposits all its energy in a material.  This is averaged over a number of particles. 
High-LET—Energy transfer characteristic of heavy charged particles such as protons and alpha 
particles where the distance between ionizing events is small on the scale of a cellular nucleus. 
Low-LET—Energy transfer characteristic of light charged particles such as electrons produced 
by x and gamma rays where the distance between ionizing events is large on the scale of a 
cellular nucleus. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or group 
of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Lung Clearance Class (fast, F; medium, M; slow, S)—A classification scheme for inhaled material 
according to its rate of clearance from the pulmonary region of the lungs to the blood and the 
gastrointestinal tract. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Mass Numbers (A)—The number of nucleons (protons and neutrons) in the nucleus of an atom. 
Minimal Risk Level—An estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mutagen—A substance that causes changes (mutations) in the genetic material in a cell.  Mutations can 
lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 




Neutrino (ν)—A neutral particle of infinitesimally small rest mass emitted during beta plus or beta minus 
decay.  This particle accounts for conservation of energy in beta plus and beta minus decays.  It plays no 
role in damage from radiation. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a substance at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Nuclear Reactor—A power plant that heats the medium (typically water) by using the energy released 
from the nuclear fission of uranium or plutonium isotopes instead of burning coal, oil, or natural gas.  All 
of these sources of energy simply heat water and use the steam which is produced to turn turbines that 
make electricity or propel a ship. 
Nucleon—Common name for a constituent particle of the nucleus.  Applied to a proton or neutron. 
Nuclide—A species of atom characterized by the constitution of its nucleus.  The nuclear constitution is 
specified by the number of protons (Z), number of neutrons (N), and energy content; or, alternatively, by 
the atomic number (Z), mass number A(N+Z), and atomic mass.  To be regarded as a distinct nuclide, the 
atom must be capable of existing for a measurable time.  Thus, nuclear isomers are separate nuclides, 
whereas promptly decaying excited nuclear states and unstable intermediates in nuclear reactions are not 
so considered. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Pair Production—An absorption process for x- and gamma radiation in which the incident photon is 
absorbed in the vicinity of the nucleus of the absorbing atom, with subsequent production of an electron 
and positron pair (see annihilation).  This reaction can only occur for incident photon energies exceeding 
1.02 MeV. 
Parent—Any radionuclide nuclide which, upon disintegration, yields a new nuclide (termed the progeny 
or daughter), either directly or as a later member of a radioactive series. 
Permissible Exposure Limit (PEL)—A maximum allowable atmospheric level of a substance in 
workplace air averaged over an 8-hour shift. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
STRONTIUM 381 
10. GLOSSARY 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism and excretion of chemicals by the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—A model comprising a series of 
compartments representing organs or tissue groups with realistic weights and blood flows.  These models 
require a variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, 
alveolar ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical 
information such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Photoelectric Effect—An attenuation process observed for x and gamma radiation in which an incident 
photon interacts with a tightly bound inner orbital electron of an atom delivering all of its energy to knock 
the electron out of the atom.  The incident photon disappears in the process. 
Photon—A quantum of electromagnetic energy (E) whose value is the product of its frequency (ν) in 
hertz and Planck's constant (h).  The equation is:  E = hν. 
Population dose—See Collective dose. 
Positron—A positively charged electron. 
Potential, Ionization—The energy expressed as electron volts (eV) necessary to separate one electron 
from an atom, resulting in the formation of an ion pair. 
Power, Stopping—A measure of the ability of a material to absorb energy from an ionizing particle 
passing through it; the greater the stopping power, the greater the energy absorbing ability (see Linear 
Energy Transfer). 
Progeny—The decay product or daughter products resulting after a radioactive decay or a series of 
radioactive decays.  The progeny can also be radioactive, and the chain continues until a stable nuclide is 
formed. 
Proton—Elementary nuclear particle with a positive electric charge equal numerically to the charge of 
the electron and a rest mass of 1.007 mass units. 
Quality—A term describing the distribution of the energy deposited by a particle along its track; 




Quality Factor (Q)—The linear-energy-transfer-dependent factor by which absorbed doses are 
multiplied to obtain (for radiation protection purposes) a quantity that expresses - on a common scale for 
all ionizing radiation - the approximate biological effectiveness of the absorbed dose. 
Type of radiation Quality Factor 
X, gamma, or beta 1 
Alpha particles 20 
Neutrons of unknown energy 10 
High energy protons 10 
Rad—The traditional unit of absorbed dose equal to 100 ergs per gram, or 0.01 joule per kilogram (0.01 
Gy)  in any medium (see Absorbed Dose). 
Radiation—The emission and propagation of energy through space or through a material medium in the 
form of waves (e.g., the emission and propagation of electromagnetic waves, or of sound and elastic 
waves). The term radiation or radiant energy, when unqualified, usually refers to electromagnetic 
radiation. Such radiation commonly is classified according to frequency, as microwaves, infrared, visible 
(light), ultraviolet, and x and gamma rays (see Photon.) and, by extension, corpuscular emission, such as 
alpha and beta radiation, neutrons, or rays of mixed or unknown type, as cosmic radiation. 
Radiation, Annihilation—Photons produced when an electron and a positron unite and cease to 
exist. The annihilation of a positron-electron pair results in the production of two photons, each 
of 0.51 MeV energy. 
Radiation, Background—See Background Radiation. 
Radiation, Characteristic (Discrete)—Radiation originating from an excited atom after removal 
of an electron from an atom.  The wavelength of the emitted radiation is specific, depending only 
on the element and particular energy levels involved. 
Radiation, External—Radiation from a source outside the body. 
Radiation, Internal—Radiation from a source within the body (as a result of deposition of 
radionuclides in body tissues). 
Radiation, Ionizing—Any electromagnetic or particulate radiation capable of producing ions, 
directly or indirectly, in its passage through matter (see Radiation). 
Radiation, Monoenergetic—Radiation of a given type in which all particles or photons originate 
with and have the same energy. 
Radiation, Scattered—Radiation which during its passage through a substance, has been 
deviated in direction. It may also have been modified by a decrease in energy. 
Radiation, Secondary—A particle or ray that is produced when the primary radiation interacts 
with a material, and which has sufficient energy to produce its own ionization, such as 
bremsstrahlung or electrons knocked from atomic orbitals with enough energy to then produce 
ionization (see Delta Rays). 
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Radiation Weighting Factor (also called Quality Factor)—In radiation protection, a factor (1 for x-
rays, gamma rays, beta particles; 20 for alpha particles) weighting the absorbed dose of radiation of a 
specific type and energy for its effect on tissue. 
Radioactive Material—Material containing radioactive atoms. 
Radioactivity—Spontaneous nuclear transformations that result in the formation of new elements.  These 
transformations are accomplished by emission of alpha or beta particles from the nucleus or by the 
capture of an orbital electron. Each of these reactions may or may not be accompanied by a gamma 
photon. 
Radioactivity, Artificial—Man-made radioactivity produced by particle bombardment or 
nuclear fission, as opposed to naturally occurring radioactivity. 
Radioactivity, Induced—Radioactivity produced in a substance after bombardment with 
neutrons or other particles.  The resulting activity is "natural radioactivity" if formed by nuclear 
reactions occurring in nature and "artificial radioactivity" if the reactions are caused by man. 
Radioactivity, Natural—The property of radioactivity exhibited by more than 50 naturally 
occurring radionuclides. 
Radioisotope—An unstable or radioactive isotope of an element that decays or disintegrates 
spontaneously, emitting radiation.   
Radionuclide—Any radioactive isotope of any element.  Approximately 5,000 natural and artificial 
radioisotopes have been identified. 
Radiosensitivity—Relative susceptibility of cells, tissues, organs, organisms, or any living substance to 
the injurious action of radiation.  Radiosensitivity and its antonym, radioresistance, are used 
comparatively, rather than absolutely. 
Reference Dose (RfD)—An estimate of the daily exposure of the human population to a potential hazard 
that is likely to be without risk of deleterious effects during a lifetime.  The RfD is operationally derived 
from the NOAEL (from animal and human studies) by a consistent application of uncertainty factors that 
reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on 
a professional judgment of the entire database on the chemical.  The RfDs are not applicable to non-
threshold effects such as cancer. 
Relative Biological Effectiveness (RBE)—The RBE is a factor used to compare the biological 
effectiveness of absorbed radiation doses (i.e., rad) due to different types of ionizing radiation.  More 
specifically, it is the experimentally determined ratio of an absorbed dose of a radiation in question to the 
absorbed dose of a reference radiation (typically 60Co gamma rays or 200 kVp x rays) required to produce 
an identical biological effect in a particular experimental organism or tissue (see Quality Factor). 
Rem—The traditional unit of dose equivalent that is used in the regulatory, administrative, and 
engineering design aspects of radiation safety practice.  The dose equivalent in rem is numerically equal 
to the absorbed dose in rad multiplied by the quality factor (1 rem is equal to 0.01 sievert). 
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Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act.  Quantities 
are measured over a 24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Roentgen (R)—A unit of exposure (in air) to ionizing radiation.  It is the amount of x or gamma rays 
required to produce ions carrying 1 electrostatic unit of electrical charge in 1 cubic centimeter of dry air 
under standard conditions.  Named after William Roentgen, a German scientist who discovered x rays in 
1895. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the 
atoms are located; in particular, the absorption of radiation within a sample being assayed. 
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed 
for up to 15 minutes continually.  No more than four excursions are allowed per day, and there must be at 
least 60 minutes between exposure periods.  The daily TLV-TWA may not be exceeded. 
SI Units—The International System of Units as defined by the General Conference of Weights and 
Measures in 1960. These units are generally based on the meter/kilogram/second units, with special 
quantities for radiation including the becquerel, gray, and sievert. 
Sickness, Acute Radiation (Syndrome)—The complex symptoms and signs characterizing the condition 
resulting from excessive exposure of the whole body (or large part) to ionizing radiation.  The earliest of 
these symptoms are nausea, fatigue, vomiting, and diarrhea, and may be followed by loss of hair 
(epilation), hemorrhage, inflammation of the mouth and throat, and general loss of energy.  In severe 
cases, where the radiation dose is relatively high (over several hundred rad or several gray), death may 
occur within two to four weeks.  Those who survive six weeks after exposure of a single high dose of 
radiation may generally be expected to recover. 
Sievert (Sv)—The SI unit of any of the quantities expressed as dose equivalent. The dose equivalent in 
sieverts is equal to the absorbed dose, in gray, multiplied by the quality factor (1 sievert equals 100 rem).  
The sievert is also the SI unit for effective dose equivalent, which is the sum of the products of the dose 
equivalent to each organ or tissue and its corresponding tissue weighting factor. 
Specific-Activity—Radioactivity per unit mass of a radionuclide, expressed, for example, as Ci/gram or 
Bq/kilogram. 
Specific Energy—The actual energy per unit mass deposited per unit volume in a small target, such as 
the cell or cell nucleus, as the result of one or more energy-depositing events.  This is a stochastic 
quantity as opposed to the average value over a large number of instance (i.e., the absorbed dose). 
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Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Stochastic Effect—A health effect that occurs randomly and for which the probability of the effect 
occurring, rather than its severity, is assumed to be a linear function of dose without a threshold (also 
called a nondeterministic effect). 
Stopping Power—The average rate of energy loss of a charged particle per unit thickness of a material or 
per unit mass of material traversed. 
Surface-seeking Radionuclide—A bone-seeking internal emitter that deposits and remains on the bone 
surface for a long period of time, although it may eventually diffuse into the bone mineral.  This contrasts 
with a volume seeker, which deposits more uniformly throughout the bone volume. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Target Theory (Hit Theory)—A theory explaining some biological effects of radiation on the basis that 
ionization, occurring in a discrete volume (the target) within the cell, directly causes a lesion which 
subsequently results in a physiological response to the damage at that location.  One, two, or more "hits" 
(ionizing events within the target) may be necessary to elicit the response. 
Teratogen—A chemical that causes birth defects. 
Threshold Limit Value (TLV)—The maximum concentration of a substance to which most workers can 
be exposed without adverse effect.  TLV is a term used exclusively by the ACGIH.  Other terms used to 
express similar concepts are the MAC (Maximum Allowable Concentration) and PEL (Permissible 
Exposure Limits). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
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Tissue Weighting Factor (Wt)—Organ- or tissue-specific factor by which the equivalent dose is 
multiplied to give the portion of the effective dose for that organ or tissue.  Recommended values of 
tissue weighting factors are: 
Tissue/Organ Tissue Weighting Factor 
Gonads 0.70 










Bone surface 0.01 
Remainder (adrenals, brain, upper large 0.05 
intestine, small intestine, pancreas, spleen, 
thymus, and uterus) 
Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, which 
is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The absorption, distribution and elimination of toxic compounds in the living organism. 
Toxicosis—A diseased condition resulting from poisoning. 
Transformation, Nuclear—The process of radioactive decay by which a nuclide is transformed into a 
different nuclide by absorbing or emitting particulate or electromagnetic radiation. 
Transition, Isomeric—The process by which a nuclide decays to an isomeric nuclide (i.e., one of the 
same mass number and atomic number) of lower quantum energy.  Isomeric transitions (often abbreviated 
I.T.) proceed by gamma ray and internal conversion electron emission. 
Tritium—The hydrogen isotope with one proton and two neutrons in the nucleus (Symbol: 3H).  It is 
radioactive and has a physical half-life of 12.3 years. 
Unattached Fraction—That fraction of the radon daughters, usually 218Po and 214Po, which has not yet 
attached to a dust particle or to water vapor. As a free atom, it has a high probability of being exhaled and 
not retained within the lung.  It is the attached fraction which is primarily retained. 
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data.  UFs 
are intended to account for (1) the variation in sensitivity among the members of the human population, 
(2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating 
from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using 
LOAEL data rather than NOAEL data.  Usually each of these factors is set equal to 10. 
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Units, Prefixes—Many units of measure are expressed as submultiples or multiples of the primary unit 
(e.g., 10-3 curie is 1 mCi and 103 becquerel is 1 kBq). 
Factor Prefix Symbol Factor Prefix Symbol 
10-18 atto A 103 kilo k 
10-15 femto F 106 mega M 
10-12 pico p 109 giga G 
10-9 nano N 1012 tera T 
10-6 micro Μ 1015 peta P 
10-3 milli M 1018 exa E 
10-2 centi C 
Units, Radiological— 
Units Equivalents 
Becquerel* (Bq) 1 disintegration per second = 2.7x10-11 Ci 
Curie (Ci) 3.7x1010 disintegrations per second = 3.7x1010 Bq 
Gray* (Gy) 1 J/kg = 100 rad 
Rad (rad) 100 erg/g = 0.01 Gy 
Rem (rem) 0.01 sievert 
Sievert* (Sv) 100 rem 
*International Units, designated (SI) 
Working Level (WL)—Any combination of short-lived radon daughters in 1 liter of air that will result in 
the ultimate emission of 1.3x105 MeV of potential alpha energy. 
Working Level Month (WLM)—A unit of exposure to radon daughters corresponding to the product of 
the radon daughter concentration in Working Level (WL) and the exposure time in nominal months 
(1 nominal month = 170 hours).  Inhalation of air with a concentration of 1 WL of radon daughters for 
170 working hours results in an exposure of 1 WLM. 
X rays—Penetrating electromagnetic radiations whose wave lengths are very much shorter than those of 
visible light. They are usually produced by bombarding a metallic target with fast electrons in a high 
vacuum.  X rays (called characteristic x rays) are also produced when an orbital electron falls from a high 
energy level to a low energy level. 
Zero-Threshold Linear Hypothesis (or No-Threshold Linear Hypothesis)—The assumption that a 
dose-response curve derived from data in the high dose and high dose-rate ranges may be extrapolated 
through the low dose and low dose range to zero, implying that, theoretically, any amount of radiation 
will cause some damage. 
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 




MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical name(s): Strontium 
CAS number(s): 7440-24-6 
Date:   March 2004 
Profile status: Third draft, post-public 
Route: [ ] Inhalation [X] Oral 
Duration: [ ] Acute [X] Intermediate [ ] Chronic 
Key to figure: 16 
Species: Rat 
MRL: 2.0 [X] mg/kg/day [ ] ppm  [ ] mg/m3 
Reference: Storey E.  1961. Strontium ‘rickets’:  Bone calcium and strontium changes.  Austral Ann 
Med 10:213-222. 
Experimental design: Groups of five young (40–60 g) and three adult (200–250 g) female rats were fed a 
diet containing 1.6% calcium, 0.9% phosphorus, and 0, 0.19, 0.38, 0.75, 1.0 (young only), 1.5, or 3% 
strontium as strontium carbonate for 20 days.  Initial and final body weights were recorded.  Terminal 
levels of calcium and strontium were measured in serum and in five selected ashed bones for each dose 
level. Both tibia from each animal were processed histologically, and the proximal epiphyseal cartilages 
were measured. 
Effects noted in study and corresponding doses: The strontium intakes were calculated to be 0, 140, 550, 
1,080, 1,460, 2,220, or 4,975 mg strontium/kg/day in young rats, and 0, 170, 350, 690, 1,370, or 2,750 mg 
strontium/kg/day in adult rats.  The serum calcium levels were not significantly changed in either young 
or adult animals, but at the high doses, the serum calcium/strontium ratio was about 1 in young rats and 
1.4 in adults.  In young rats, increased strontium ingestion resulted in abnormal thickening of the 
epiphyseal cartilage plate, approximately doubled at the highest dose.  No histological effect was noted at 
the lowest dose (140 mg strontium/kg/day), but alterations in the appearance of the cartilage plate 
(irregular, thicker, with areas of uncalcified bone matrix in the distal ends of the metaphyseal trabeculae 
and proximal end of the diaphysis) were observed at 550 mg strontium/kg/day.  Irregularities in the 
organization of the cells of hypertrophic zone, in the pattern of calcification, and in the deposition of 
osteoid were more conspicuous with increasing dose.  In tibias, the dry weight, ash weight, ash 
percentage, and calcium in ash were significantly reduced with increased strontium intake.  Adult rats 
were less affected by strontium ingestion than young animals.  In adult rats, the no-effect level was 
690 mg strontium/kg/day.  In adults, changes in tibia histology (thicker epiphyseal cartilage, increased 
width of metaphyseal osteoid seams) were noted at or above 1,370 mg strontium/kg/day.  At 2,750 mg 
strontium/kg/day, osteoid tissue was deposited near vascular canals and the areas of bone resorption were 
reduced. In adult rat tibias, the dry weight, ash weight, ash percentage, and calcium in ash were only 
significantly affected at the highest dose.  This study demonstrates the difference in sensitivity to 
strontium between young and old animals.  The LOAEL for the young rats (550 mg/strontium/kg/day) is 
a NOAEL for the adults (<690 mg strontium/kg/day). 
Dose and end point used for MRL derivation: 

This study identifies a NOAEL of 140 mg/kg/day for skeletal toxicity in young rats. 

[X] NOAEL [] LOAEL: 
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Uncertainty factors used in MRL derivation: 
[ ] 1 [ ] 3  []  10 (for use of a LOAEL) 

[ ] 1 [] 3  [X]   10 (for extrapolation from animals to humans) 

[ ] 1 [X ] 3  [] 10 (for human variability)
 
Modifying factor used in MRL derivation: 3 

MRL = NOAEL / (UF)(MF) = 140 mg/kg/day / (30)(3) = 2 mg/kg/day
 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?
 
Food intake was based upon an allometric equation using the average body weight in kg (EPA 1988):   

F = 0.056 x bw0.6611 . 

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: NA 
Was a conversion used from intermittent to continuous exposure?  If so, explain: NA 
Other additional studies or pertinent information that lend support to this MRL: If an MRL were to be 
derived from the adult rat NOAEL of 690 mg/kg/day, then an uncertainty factor of 100 would be applied 
(10 for interspecies extrapolation and 10 for human variability), giving a value of 
690/100=6.9 mg/kg/day.  Because the young rats represent a sensitive population, just as juveniles would 
be the most sensitive human group, the selection of the NOAEL implicitly factors in human variability to 
some degree.  Therefore, a smaller uncertainty factor is chosen for intraspecies extrapolation (3 for human 
variability).  However, since the study duration was only 20 days, there is uncertainty whether the 
NOAEL would be valid for intermediate exposures extending up to 1 year.  In addition, the focus of the 
study was skeletal effects, and no other organ system was examined.  To adjust for these potential sources 
of uncertainty, a modifying factor of 3 is applied to the NOAEL.  The MRL is derived using the young rat 
NOAEL of 140 mg/kg/day and a total uncertainty factor of 30 (10 for interspecies extrapolation and 3 for 
human variability), and a modifying factor of 3 (for short study duration and limited end point 
evaluation), giving a value of 140/(30x )=1.6 mg/kg/day; rounding off to whole numbers, the intermediate 
oral MRL is 2.0 mg/kg/day. 
Abnormal bone mineralization (rickets) resulting from ingestion of excess strontium has been observed in 
many rodent studies.  Several studies identified a similar NOAEL (110–168 mg strontium/kg/day) in 
weanling rats (Grynpas et al. 1996; Kroes et al. 1977; Morohashi et al. 1994).  Similar LOAELs  
(500–565 mg strontium/kg/day) for abnormal bone mineralization in weanling rats have been reported 
(Johnson et al. 1968; Morohashi et al. 1994; Neufeld and Boskey 1994).  Slight skeletal effects were 
noted in mice at 350 mg/kg/day (Marie and Hott 1986).  The relevance of the rodent studies to humans is 
suggested by a Turkish epidemiological study indicating that excess oral exposure to strontium may
contribute to the development of rickets in children (Ögzür et al. 1996).   
The skeletal effects of excess strontium are known to be related to its chemical similarity to calcium.  
Excess strontium adversely affects bone development in several ways.  In chickens and rats, excess 
strontium suppresses the activation of vitamin D3 in the kidney, which severely reduces the expression of 
calbindin D mRNA and the translation of calbindin D protein in the duodenum (Armbrecht et al. 1979, 
1998; Omdahl and DeLuca 1972).  As a result, duodenal absorption of calcium is reduced.  Strontium 
also binds directly to hydroxyapatite crystals, which may interfere with the normal crystalline structure of 
bone in rats (Storey 1961).  In addition, excess strontium may prevent the normal maturation of 
chondrocytes in the epiphyseal plates of long bones of rats (Matsumoto 1976).  Excess strontium 
apparently interferes with the mineralization of complexed acidic phospholipids that is thought to help 
STRONTIUM A-5 
APPENDIX A 
initiate the formation of hydroxyapatite crystals in developing bone (Neufeld and Boskey 1994).  As a 
result, affected bone contains an excess of complexed acidic phospholipid and a significantly lower ash 
weight, reducing its strength. 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.10, "Interactions with Other Substances,” and Section 3.11, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 




See Sample LSE Table 3-1 (page B-6) 
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exists, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) 	NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 




(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 

exists. The same health effects appear in the LSE table. 

(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38r is one of three studies for which CELs were derived.  The diamond 




(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 




Nitschke et al. 1981 






(CEL, lung tumors, 
nasal tumors) 















































TABLE 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation 









a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
























































APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
Some terms are generic and may not be used in this profile. 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALI annual limit on intake 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DAC derived air concentration 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
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DOE Department of Energy 
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
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MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
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OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
USNRC United States Nuclear Regulatory Commission 
























white blood cell 
World Health Organization 
greater than 
greater than or equal to 
equal to 
less than 








cancer slope factor 
negative 
positive 
weakly positive result 
weakly negative result 
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Understanding the basic concepts in radiation physics, chemistry, and biology is important to the 
evaluation and interpretation of radiation-induced adverse health effects and to the derivation of radiation 
protection principles. This appendix presents a brief overview of the areas of radiation physics, 
chemistry, and biology and is based to a large extent on the reviews of Mettler and Moseley (1985), 
Hobbs and McClellan (1986), Eichholz (1982), Hendee (1973), Cember (1996), and Early et al. (1979). 
D.1 RADIONUCLIDES AND RADIOACTIVITY 
The substances we call elements are composed of atoms.  Atoms in turn are made up of neutrons, protons 
and electrons: neutrons and protons in the nucleus and electrons in a cloud of orbits around the nucleus.  
Nuclide is the general term referring to any nucleus along with its orbital electrons.  The nuclide is 
characterized by the composition of its nucleus and hence by the number of protons and neutrons in the 
nucleus. All atoms of an element have the same number of protons (this is given by the atomic number) 
but may have different numbers of neutrons (this is reflected by the atomic mass numbers or atomic 
weight of the element).  Atoms with different atomic mass but the same atomic numbers are referred to as 
isotopes of an element. 
The numerical combination of protons and neutrons in most nuclides is such that the nucleus is quantum 
mechanically stable and the atom is said to be stable, i.e., not radioactive; however, if there are too few or 
too many neutrons, the nucleus is unstable and the atom is said to be radioactive.  Unstable nuclides 
undergo radioactive transformation, a process in which a neutron or proton converts into the other and a 
beta particle is emitted, or else an alpha particle is emitted.  Each type of decay is typically accompanied 
by the emission of gamma rays.  These unstable atoms are called radionuclides; their emissions are called 
ionizing radiation; and the whole property is called radioactivity.  Transformation or decay results in the 
formation of new nuclides some of which may themselves be radionuclides, while others are stable 
nuclides. This series of transformations is called the decay chain of the radionuclide.  The first 
radionuclide in the chain is called the parent; the subsequent products of the transformation are called 
progeny, daughters, or decay products. 
In general there are two classifications of radioactivity and radionuclides:  natural and artificial (man­
made). Naturally-occurring radioactive materials (NORMs) exist in nature and no additional energy is 
necessary to place them in an unstable state.  Natural radioactivity is the property of some naturally 
occurring, usually heavy elements, that are heavier than lead.  Radionuclides, such as radium and 
uranium, primarily emit alpha particles.  Some lighter elements such as carbon-14 and tritium (hydrogen­
3) primarily emit beta particles as they transform to a more stable atom.  Natural radioactive atoms 
heavier than lead cannot attain a stable nucleus heavier than lead.  Everyone is exposed to background 
radiation from naturally-occurring radionuclides throughout life.  This background radiation is the major 
source of radiation exposure to man and arises from several sources.  The natural background exposures 
are frequently used as a standard of comparison for exposures to various artificial sources of ionizing 
radiation. 
Artificial radioactive atoms are produced either as a by-product of fission of uranium or plutonium atoms 
in a nuclear reactor or by bombarding stable atoms with particles, such as neutrons or protons, directed at 
the stable atoms with high velocity.  These artificially produced radioactive elements usually decay by 
emission of particles, such as positive or negative beta particles and one or more high energy photons 
(gamma rays).  Unstable (radioactive) atoms of any element can be produced. 
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Both naturally occurring and artificial radioisotopes find application in medicine, industrial products, and 
consumer products. Some specific radioisotopes, called fall-out, are still found in the environment as a 
result of nuclear weapons use or testing. 
D.2 RADIOACTIVE DECAY 
D.2.1 Principles of Radioactive Decay 
The stability of an atom is the result of the balance of the forces of the various components of the nucleus.  
An atom that is unstable (radionuclide) will release energy (decay) in various ways and transform to 
stable atoms or to other radioactive species called daughters, often with the release of ionizing radiation.  
If there are either too many or too few neutrons for a given number of protons, the resulting nucleus may 
undergo transformation.  For some elements, a chain of daughter decay products may be produced until 
stable atoms are formed.  Radionuclides can be characterized by the type and energy of the radiation 
emitted, the rate of decay, and the mode of decay.  The mode of decay indicates how a parent compound 
undergoes transformation. Radiations considered here are primarily of nuclear origin, i.e., they arise from 
nuclear excitation, usually caused by the capture of charged or uncharged nucleons by a nucleus, or by the 
radioactive decay or transformation of an unstable nuclide.  The type of radiation may be categorized as 
charged or uncharged particles, protons, and fission products) or electromagnetic radiation (gamma rays 
and x rays).  Table D-1 summarizes the basic characteristics of the more common types of radiation 
encountered. 
D.2.2 Half-Life and Activity 
For any given radionuclide, the rate of decay is a first-order process that is constant, regardless of the 
radioactive atoms present and is characteristic for each radionuclide.  The process of decay is a series of 
random events; temperature, pressure, or chemical combinations do not effect the rate of decay.  While it 
may not be possible to predict exactly which atom is going to undergo transformation at any given time, it 
is possible to predict, on average, the fraction of the radioactive atoms that will transform during any 
interval of time. 
The activity is a measure of the quantity of radioactive material.  For these radioactive materials it is 
customary to describe the activity as the number of disintegrations (transformations) per unit time.  The 
unit of activity is the curie (Ci), which was originally related to the activity of one gram of radium, but is 
now defined as that quantity of radioactive material in which there are: 
1 curie (Ci) = 3.7x1010 disintegrations (transformations)/second (dps) or 2.22x1012 disintegrations 
(transformations)/minute (dpm). 
The SI unit of activity is the becquerel (Bq); 1 Bq = that quantity of radioactive material in which there is 
1 transformation/second. Since activity is proportional to the number of atoms of the radioactive 
material, the quantity of any radioactive material is usually expressed in curies, regardless of its purity or 
concentration. The transformation of radioactive nuclei is a random process, and the number of 
transformations is directly proportional to the number of radioactive atoms present.  For any pure 
radioactive substance, the rate of decay is usually described by its radiological half-life, TR, i.e., the time 
it takes for a specified source material to decay to half its initial activity.  The specific activity is the 
activity of a radionuclide per mass of that radionuclide.  If properly qualified, it can refer to activity per 
unit mass of related materials, such as the element itself or a chemical compound labeled with the 




The activity of a radionuclide at time t may be calculated by: 
-0.693t/Trad A = Aoe
where A is the activity in dps or curies or becquerels, Ao is the activity at time zero, t is the time at which 
measured, and Trad is the radiological half-life of the radionuclide (Trad and t must be in the same units of 
time). The time when the activity of a sample of radioactivity becomes one-half its original value is the 
radioactive half-life and is expressed in any suitable unit of time. 
Table D-1. Characteristics of Nuclear Radiations 
Typical Path lengthb 
Radiation Rest massa Charge energy range Air Solid Comments 
Alpha (α) 4.00 amu +2 4–10 MeV 5–10 cm 25–80 µm Identical to ionized 
He nucleus 
Negatron (β–) 5.48x10-4 amu; –1 0–4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV 
Positron (β+) 5.48x10-4 amu; +1 0-4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV except for sign of 
charge 
Neutron 1.0086 amu; 0 0–15 MeV b b Free half-life: 16 
939.55 MeV min 
X ray (e.m.  – 0 5 keV–100 keV b b Photon from 
photon) transition of an 
electron between 
atomic orbits 
Gamma (p) – 0 10 keV–3 MeV b b Photon from 
nuclear(e.m.  photon) 
transformation 
a The rest mass (in amu) has an energy equivalent in MeV that is obtained using the equation E=mc2, where 1 amu = 932 MeV. 
b Path lengths are not applicable to x- and gamma rays since their intensities decrease exponentially; path lengths in solid tissue 
are variable, depending on particle energy, electron density of material, and other factors. 
 amu = atomic mass unit; e.m. = electromagnetic; MeV = Megaelectron Volts 
The specific activity is a measure of activity, and is defined as the activity of a radionuclide per mass of 
that radionuclide. This activity is usually expressed in curies per gram and may be calculated by 
curies/gram = 1.3x108 / (Trad) (atomic weight)  or 
[3.577 x 105 x mass(g)] / [Trad  x atomic weight] 
where Trad is the radiological half-life in days. 
In the case of radioactive materials contained in living organisms, an additional consideration is made for 
the reduction in observed activity due to regular processes of elimination of the respective chemical or 
biochemical substance from the organism.  This introduces a rate constant called the biological half-life 
(Tbiol) which is the time required for biological processes to eliminate one-half of the activity. This time 
is virtually the same for both stable and radioactive isotopes of any given element. 
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Under such conditions the time required for a radioactive element to be halved as a result of the combined 
action of radioactive decay and biological elimination is the effective clearance half-time: 
Teff = (Tbiol x Trad) / (Tbiol + Trad). 
Table D-2 presents representative effective half-lives of particular interest. 
Table D-2. Half-Lives of Some Radionuclides in Adult Body Organs 
Half-lifea 












Iodine 131 Thyroid 8 d 80 d 7.3 d 
Strontium 90 Bone 28 y 50 y 18 y 
Plutonium 239 Bone surface 24,400 y 50 y 50 y 
Lung 24,400 y 500 d 474 d 
Cobalt 60 Whole body 5.3 y 99.5 d 95 d 
Iron 55 Spleen 2.7 y 600 d 388 d 
Iron 59 Spleen 45.1 d 600 d 42 d 
Manganese 54 Liver 303 d 25 d 23 d 
Cesium 137 Whole body 30 y 70 d 70 d 
ad = days, y = years
bMixed in body water as tritiated water 
D.2.3 Interaction of Radiation with Matter 
Both ionizing and nonionizing radiation will interact with materials; that is, radiation will lose kinetic 
energy to any solid, liquid or gas through which it passes by a variety of mechanisms.  The transfer of 
energy to a medium by either electromagnetic or particulate radiation may be sufficient to cause 
formation of ions. This process is called ionization.  Compared to other types of radiation that may be 
absorbed, such as ultraviolet radiation, ionizing radiation deposits a relatively large amount of energy into 
a small volume. 
The method by which incident radiation interacts with the medium to cause ionization may be direct or 
indirect. Electromagnetic radiations (x rays and gamma photons) are indirectly ionizing; that is, they give 
up their energy in various interactions with cellular molecules, and the energy is then utilized to produce a 
fast-moving charged particle such as an electron.  It is the electron that then may react with a target 
molecule.  This particle is called a “primary ionizing particle.  Charged particles, in contrast, strike the 
tissue or medium and directly react with target molecules, such as oxygen or water.  These particulate 
radiations are directly ionizing radiations.  Examples of directly ionizing particles include alpha and beta 
particles. Indirectly ionizing radiations are always more penetrating than directly ionizing particulate 
radiations. 
Mass, charge, and velocity of a particle, as well as the electron density of the material with which it 
interacts, all affect the rate at which ionization occurs.  The higher the charge of the particle and the lower 
the velocity, the greater the propensity to cause ionization.  Heavy, highly charged particles, such as alpha 
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particles, lose energy rapidly with distance and, therefore, do not penetrate deeply.  The result of these 
interaction processes is a gradual slowing down of any incident particle until it is brought to rest or 
"stopped" at the end of its range. 
D.2.4 Characteristics of Emitted Radiation 
D.2.4.1 Alpha Emission.    In alpha emission, an alpha particle consisting of two protons and two 
neutrons is emitted with a resulting decrease in the atomic mass number by four and reduction of the 
atomic number of two, thereby changing the parent to a different element.  The alpha particle is identical 
to a helium nucleus consisting of two neutrons and two protons.  It results from the radioactive decay of 
some heavy elements such as uranium, plutonium, radium, thorium, and radon.  The alpha particles 
emitted by a given radionuclide have the same energy and intensity combination.  Most of the alpha 
particles that are likely to be found have energies in the range of about 4 to 8 MeV, depending on the 
isotope from which they came. 
The alpha particle has an electrical charge of +2.  Because of this double positive charge and their size, 
alpha particles have great ionizing power and, thus, lose their kinetic energy quickly.  This results in very 
little penetrating power. In fact, an alpha particle cannot penetrate a sheet of paper.  The range of an 
alpha particle (the distance the charged particle travels from the point of origin to its resting point) is 
about 4 cm in air, which decreases considerably to a few micrometers in tissue.  These properties cause 
alpha emitters to be hazardous only if there is internal contamination (i.e., if the radionuclide is inside the 
body). 
D.2.4.2 Beta Emission. A beta particle (&) is a high-velocity electron ejected from a disintegrating 
nucleus. The particle may be either a negatively charged electron, termed a negatron (&-) or a positively 
charged electron, termed a positron (&+).  Although the precise definition of "beta emission" refers to 
both &- and &+, common usage of the term generally applies only to the negative particle, as distinguished 
from the positron emission, which refers to the &+ particle. 
D.2.4.2.1 Beta Negative Emission.  Beta particle (&-) emission is another process by which a 
radionuclide, with a neutron excess achieves stability.  Beta particle emission decreases the number of 
neutrons by one and increases the number of protons by one, while the atomic mass number remains 
unchanged.1  This transformation results in the formation of a different element.  The energy spectrum of 
beta particle emission ranges from a certain maximum down to zero with the mean energy of the 
spectrum being about one-third of the maximum.  The range of betas is much less in tissue than in air.  
Beta negative emitting radionuclides can cause injury to the skin and superficial body tissues, but mostly 
present an internal contamination hazard. 
D.2.4.2.2 Positron Emission.    In cases in which there are too many protons in the nucleus, positron 
emission may occur.  In this case a proton may be thought of as being converted into a neutron, and a 
positron (&+) is emitted.1  This increases the number of neutrons by one, decreases the number of protons 
by one, and again leaves the atomic mass number unchanged.  The gamma radiation resulting from the 
annihilation (see glossary) of the positron makes all positron emitting isotopes more of an external 
radiation hazard than pure & emitters of equal energy. 
D.2.4.2.3 Gamma Emission.    Radioactive decay by alpha, beta, or positron emission, or electron 
capture often leaves some of the energy resulting from these changes in the nucleus.  As a result, the 
nucleus is raised to an excited level.  None of these excited nuclei can remain in this high-energy state.  
Nuclei release this energy returning to ground state or to the lowest possible stable energy level.  The 
1 Neutrinos also accompany negative beta particles and positron emissions 
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energy released is in the form of gamma radiation (high energy photons) and has an energy equal to the 
change in the energy state of the nucleus.  Gamma and x rays behave similarly but differ in their origin; 
gamma emissions originate in the nucleus while x rays originate in the orbital electron structure or from 
rapidly changing the velocity of an electron (e.g., as occurs when shielding high energy beta particles or 
stopping the electron beam in an x ray tube). 
D.3 ESTIMATION OF ENERGY DEPOSITION IN HUMAN TISSUES 
Two forms of potential radiation exposures can result: internal and external.  The term exposure denotes 
physical interaction of the radiation emitted from the radioactive material with cells and tissues of the 
human body.  An exposure can be "acute" or "chronic" depending on how long an individual or organ is 
exposed to the radiation.  Internal exposures occur when radionuclides, which have entered the body (e.g., 
through the inhalation, ingestion, or dermal pathways), undergo radioactive decay resulting in the 
deposition of energy to internal organs.  External exposures occur when radiation enters the body directly 
from sources located outside the body, such as radiation emitters from radionuclides on ground surfaces, 
dissolved in water, or dispersed in the air.  In general, external exposures are from material emitting 
gamma radiation, which readily penetrate the skin and internal organs.  Beta and alpha radiation from 
external sources are far less penetrating and deposit their energy primarily on the skin's outer layer.  
Consequently, their contribution to the absorbed dose of the total body dose, compared to that deposited 
by gamma rays, may be negligible. 
Characterizing the radiation dose to persons as a result of exposure to radiation is a complex issue.  It is 
difficult to: (1) measure internally the amount of energy actually transferred to an organic material and to 
correlate any observed effects with this energy deposition; and (2) account for and predict secondary 
processes, such as collision effects or biologically triggered effects, that are an indirect consequence of 
the primary interaction event. 
D.3.1 Dose/Exposure Units 
D.3.1.1 Roentgen.    The roentgen (R) is a unit of x or gamma-ray exposure and is a measured by the 
amount of ionization caused in air by gamma or x radiation.  One roentgen produces 2.58x10-4 coulomb 
per kilogram of air.  In the case of gamma radiation, over the commonly encountered range of photon 
energy, the energy deposition in tissue for a dose of 1 R is about 0.0096 joules (J) /kg of tissue. 
D.3.1.2 Absorbed Dose and Absorbed Dose Rate.    The absorbed dose is defined as the energy 
imparted by radiation to a unit mass of the tissue or organ.  The unit of absorbed dose is the rad; 1 rad = 
100 erg/gram = 0.01 J/kg in any medium.  An exposure of 1 R results in a dose to soft tissue of 
approximately 0.01 J/kg. The SI unit is the gray which is equivalent to 100 rad or 1 J/kg.  Internal and 
external exposures from radiation sources are not usually instantaneous but are distributed over extended 
periods of time.  The resulting rate of change of the absorbed dose to a small volume of mass is referred 
to as the absorbed dose rate in units of rad/unit time. 
D.3.1.3 Working Levels and Working Level Months.    Working level (WL) is a measure of the 
atmospheric concentration of radon and its short-lived progeny.  One WL is defined as any combination 
of short-lived radon daughters (through polonium-214), per liter of air, that will result in the emission of 
1.3x105 MeV of alpha energy.  An activity concentration of 100 pCi radon-222/L of air, in equilibrium 
with its daughters, corresponds approximately to a potential alpha-energy concentration of 1 WL.  The 
WL unit can also be used for thoron daughters.  In this case, 1.3x105 MeV of alpha energy (1 WL) is 
released by the thoron daughters in equilibrium with 7.5 pCi thoron/L.  The potential alpha energy 
exposure of miners is commonly expressed in the unit Working Level Month (WLM).  One WLM 
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corresponds to exposure to a concentration of 1 WL for the reference period of 170 hours, or more 
generally 
WLM = concentration (WL) x exposure time (months)  (one “month” = 170 working hours). 
D.3.2 Dosimetry Models 
Dosimetry models are used to estimate the dose from internally deposited to radioactive substances.  The 
models for internal dosimetry consider the amount of radionuclides entering the body, the factors 
affecting their movement or transport through the body, distribution and retention of radionuclides in the 
body, and the energy deposited in organs and tissues from the radiation that is emitted during spontaneous 
decay processes.  The dose pattern for radioactive materials in the body may be strongly influenced by the 
route of entry of the material.  For industrial workers, inhalation of radioactive particles with pulmonary 
deposition and puncture wounds with subcutaneous deposition have been the most frequent.  The general 
population has been exposed via ingestion and inhalation of low levels of naturally occurring 
radionuclides as well as radionuclides from nuclear weapons testing. 
The models for external dosimetry consider only the photon doses (and neutron doses, where applicable) 
to organs of individuals who are immersed in air or are exposed to a contaminated object.   
D.3.2.1 Ingestion.    Ingestion of radioactive materials is most likely to occur from contaminated 
foodstuffs or water or eventual ingestion of inhaled compounds initially deposited in the lung. Ingestion 
of radioactive material may result in toxic effects as a result of either absorption of the radionuclide or 
irradiation of the gastrointestinal tract during passage through the tract, or a combination of both.  The 
fraction of a radioactive material absorbed from the gastrointestinal tract is variable, depending on the 
specific element, the physical and chemical form of the material ingested, and the diet, as well as some 
other metabolic and physiological factors.  The absorption of some elements is influenced by age, usually 
with higher absorption in the very young. 
D.3.2.2 Inhalation.    The inhalation route of exposure has long been recognized as being a major 
portal of entry for both nonradioactive and radioactive materials.  The deposition of particles within  the 
lung is largely dependent upon the size of the particles being inhaled.  After the particle is deposited, the 
retention will depend upon the physical and chemical properties of the dust and the physiological status of 
the lung.  The retention of the particle in the lung depends on the location of deposition, in addition to the 
physical and chemical properties of the particles.  The converse of pulmonary retention is pulmonary 
clearance. There are three distinct mechanisms of clearance which operate simultaneously.  Ciliary 
clearance acts only in the upper respiratory tract.  The second and third mechanisms act mainly in the 
deep respiratory tract.  These are phagocytosis and absorption.  Phagocytosis is the engulfing of foreign 
bodies by alveolar macrophages and their subsequent removal either up the ciliary "escalator" or by 
entrance into the lymphatic system.  Some inhaled soluble particles are absorbed into the blood and 
translocated to other organs and tissues. 
D.3.3 Internal Emitters 
An internal emitter is a radionuclide that is inside the body.  The absorbed dose from internally deposited 
radionuclide depends on the energy absorbed per unit mass by the irradiated tissue.  For a radionuclide 
distributed uniformly throughout an infinitely large medium, the concentration of absorbed energy must 
be equal to the concentration of energy emitted by the radionuclide.  An infinitely large medium may be 
approximated by a tissue mass whose dimensions exceed the range of the particle.  All alpha and most 
beta radiation will be absorbed in the organ (or tissue) of reference.  Gamma-emitting radionuclide 
emissions are penetrating radiation, and a substantial fraction of gamma energy may be absorbed in 
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tissue. The dose to an organ or tissue is a function of the effective retention half-time, the energy released 
in the tissue, the amount of radioactivity initially introduced, and the mass of the organ or tissue. 
D.4 BIOLOGICAL EFFECTS OF RADIATION 
When biological material is exposed to ionizing radiation, a chain of cellular events occurs as the ionizing 
particle passes through the biological material.  A number of theories have been proposed to describe the 
interaction of radiation with biologically important molecules in cells and to explain the resulting damage 
to biological systems from those interactions.  Many factors may modify the response of a living 
organism to a given dose of radiation.  Factors related to the exposure include the dose rate, the energy of 
the radiation, and the temporal pattern of the exposure.  Biological considerations include factors such as 
species, age, sex, and the portion of the body exposed.  Several excellent reviews of the biological effects 
of radiation have been published, and the reader is referred to these for a more in-depth discussion 
(Brodsky 1996; Hobbs and McClellan 1986; ICRP 1984; Mettler and Moseley 1985; Rubin and Casarett 
1968). 
D.4.1 Radiation Effects at the Cellular Level 
According to Mettler and Moseley (1985), at acute doses up to 10 rad (100 mGy), single strand breaks in 
DNA may be produced.  These single strand breaks may be repaired rapidly.  With doses in the range of 
50–500 rad (0.5–5 Gy), irreparable double-stranded DNA breaks are likely, resulting in cellular 
reproductive death after one or more divisions of the irradiated parent cell.  At large doses of radiation, 
usually greater than 500 rad (5 Gy), direct cell death before division (interphase death) may occur from 
the direct interaction of free-radicals with essential cellular macromolecules.  Morphological changes at 
the cellular level, the severity of which are dose-dependent, may also be observed. 
The sensitivity of various cell types varies. According to the Bergonie-Tribondeau law, the sensitivity of 
cell lines is directly proportional to their mitotic rate and inversely proportional to the degree of 
differentiation (Mettler and Moseley 1985).  Rubin and Casarett (1968) devised a classification system 
that categorized cells according to type, function, and mitotic activity.  The categories range from the 
most sensitive type, "vegetative intermitotic cells", found in the stem cells of the bone marrow and the 
gastrointestinal tract, to the least sensitive cell type, "fixed postmitotic cells," found in striated muscles or 
long-lived neural tissues. 
Cellular changes may result in cell death, which if extensive, may produce irreversible damage to an 
organ or tissue or may result in the death of the individual.  If the cell recovers, altered metabolism and 
function may still occur, which may be repaired or may result in the manifestation of clinical symptoms.  
These changes may also be expressed at a later time as tumors or cellular mutations, which may result in 
abnormal tissue. 
D.4.2 Radiation Effects at the Organ Level 
In most organs and tissues the injury and the underlying mechanism for that injury are complex and may 
involve a combination of events.  The extent and severity of this tissue injury are dependent upon the 
radiosensitivity of the various cell types in that organ system.  Rubin and Casarett (1968) describe and 
schematically display the events following radiation in several organ system types.  These include:  a 
rapid renewal system, such as the gastrointestinal mucosa; a slow renewal system, such as the pulmonary 
epithelium; and a nonrenewal system, such as neural or muscle tissue.  In the rapid renewal system, organ 
injury results from the direct destruction of highly radiosensitive cells, such as the stem cells in the bone 
marrow. Injury may also result from constriction of the microcirculation and from edema and 
inflammation of the basement membrane, designated as the histohematic barrier, which may progress to 
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fibrosis. In slow renewal and nonrenewal systems, the radiation may have little effect on the parenchymal 
cells, but ultimate parenchymal atrophy and death over several months result from fibrosis and occlusion 
of the microcirculation. 
D.4.3 Low Level Radiation Effects 
Cancer is the major latent harmful effect produced by ionizing radiation and the one that most people 
exposed to radiation are concerned about.  The ability of alpha, beta, and gamma radiation to produce 
cancer in virtually every tissue and organ in laboratory animals has been well-demonstrated.  The 
development of cancer is not an immediate effect.  Radiation-induced leukemia has the shortest latent 
period at about 2 years, while other radiation induced cancers, such as osteosarcoma, have latent periods 
greater than 20 years. The mechanism by which cancer is induced in living cells is complex and is a topic 
of intense study.  Exposure to ionizing radiation can produce cancer at any site within the body; however, 
some sites appear to be more common than others, such as the breast, lung, stomach, and thyroid.   
DNA is the major target molecule during exposure to ionizing radiation.  Other macromolecules, such as 
lipids and proteins, are also at risk of damage when exposed to ionizing radiation.  The genotoxicity of 
ionizing radiation is an area of intense study, as damage to the DNA is ultimately responsible for many of 
the adverse toxicological effects ascribed to ionizing radiation, including cancer.  Damage to genetic 
material is basic to developmental or teratogenic effects, as well.  However, for effects other than cancer, 
there is little evidence of human effects at low levels of exposure. 
D.5 UNITS IN RADIATION PROTECTION AND REGULATION 
D.5.1 Dose Equivalent (or Equivalent Dose) 
Dose equivalent (as measured in rem or sievert) is a special radiation protection quantity that is used for 
administrative and radiation safety purposes to express the absorbed dose in a manner which considers the 
difference in biological effectiveness of various kinds of ionizing radiation.  ICRP (1990) changed this 
term to equivalent dose, but it has not yet been adopted by the USNRC or DOE.   
The USNRC defines the dose equivalent, H, as the product of the absorbed dose, D, and the quality 
factor, Q, at the point of interest in biological tissue.  This relationship is expressed as H = D x Q.  The 
dose equivalent concept is applicable only to doses that are not great enough to produce biomedical 
effects. 
The quality factor or radiation weighting factor is a dimensionless quantity that depends in part on the 
stopping power for charged particles, and it accounts for the differences in biological effectiveness found 
among the types of radiation.  Originally relative biological effectiveness (RBE) was used rather than Q 
to define the quantity, rem, which was of use in risk assessment.  The generally accepted values for 
quality factors and radiation weighting factors for various radiation types are provided in Table D-3.  The 
dose equivalent rate is the time rate of change of the dose equivalent to organs and tissues and is 





Table D-3. Quality Factors (Q) and Absorbed Dose Equivalencies 
Type of radiation Quality factor (Q) Radiation weighting factor (wr)* 
X, gamma, or beta radiation 1 1 
Alpha particles, multiple- 20 0.05 
charged particles, fission 
fragments and heavy particles of 
unknown charge 
Neutrons (other than thermal >> 10 20 
100 keV to 2 MeV), protons, 
alpha particles, charged 
particles of unknown energy 
Neutrons of unknown energy 10 
High-energy protons 10 0.1 
Thermal neutrons 5 
*Absorbed dose in rad equal to 1 rem or the absorbed dose in gray equal to 1 sievert. 
Source: USNRC. 2004. Standards for the protection against radiation, table 1004(b).1.  10 CFR 20.1004.  U.S. Nuclear
 
Regulatory Commission, Washington, D.C. NCRP 1993. 

D.5.2 Relative Biological Effectiveness 
RBE is used to denote the experimentally determined ratio of the absorbed dose from one radiation type 
to the absorbed dose of a reference radiation required to produce an identical biologic effect under the 
same conditions. Gamma rays from cobalt-60 and 200–250 kVp x-rays have been used as reference 
standards. The term RBE has been widely used in experimental radiobiology, and the term quality factor 
(or radiation weighting factor) used in calculations of dose equivalents for radiation safety purposes 
(ICRP 1977; NCRP 1971; UNSCEAR 1982).  Any RBE value applies only to a specific biological end 
point, in a specific exposure, under specific conditions to a specific species.  There are no generally 
applicable values of RBE since RBEs are specific to a given exposure scenario. 
D.5.3 Effective Dose Equivalent (or Effective Dose) 
The absorbed dose is usually defined as the mean energy imparted per unit mass to an organ or tissue.  
This represents a simplification of the actual problem.  Normally when an individual ingests or inhales a 
radionuclide or is exposed to external radiation that enters the body (gamma), the dose is not uniform 
throughout the whole body.  The simplifying assumption is that the detriment will be the same whether 
the body is uniformly or non-uniformly irradiated.  In an attempt to compare detriment from absorbed 
dose of a limited portion of the body with the detriment from total body dose, the ICRP (1977) has 
derived a concept of effective dose equivalent.  ICRP (1990) changed this term to effective dose, but it 
has not yet been adopted by the USNRC or DOE. 
The effective dose equivalent, HE, is 
HE = (the sum of) Wt Ht 
STRONTIUM D-11 
APPENDIX D 
where Ht is the dose equivalent (or equivalent dose) in the tissue t, Wt is the tissue weighting factor in that 
tissue, which represents the estimated proportion of the stochastic risk resulting from tissue, t, to the 
stochastic risk when the whole body is uniformly irradiated for occupational exposures under certain 
conditions (ICRP 1977). Tissue weighting factors for selected tissues are listed in Table D-4. 
D.5.4 SI Units 
The ICRU (1980), ICRP (1984), and NCRP (1985) now recommend that the rad, roentgen, curie, and rem 
be replaced by the SI units: gray (Gy), Coulomb per kilogram (C/kg), Becquerel (Bq), and sievert (Sv), 
respectively. The relationship between the customary units and the international system of units (SI) for 
radiological quantities is shown in Table D-5. 
Table D-4. Tissue Weighting Factors for Calculating Effective Dose  

Equivalent and Effective Dose for Selected Tissues
 
Tissue weighting factor 
Tissue NCRP115/ ICRP60 USNRC/ICRP26 
Bladder 0.05 – 
Bone marrow 0.12 0.12 
Bone surface 0.01 0.03 
Breast 0.05 0.15 
Colon 0.12 – 
Esophagus 0.05 – 
Gonads 0.20 0.25 
Liver 0.05 – 
Lung 0.12 0.12 
Skin 0.01 – 
Stomach 0.12 – 
Thyroid 0.05 0.03 
Remainder 0.05 0.30 
Total 1.00 1.00 
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP  
NCRP115 = National Council on Radiation Protection and Measurements. 1993. Risk Estimates for Radiation Protection, 
Report 115.  Bethesda, Maryland 





Table D-5. Comparison of Common and SI Units for Radiation Quantities 
Customary 
Quantity units Definition SI units Definition 
Activity (A) curie (Ci) 3.7x1010 becquerel (Bq) s-1 
transformations s­
1 
Absorbed dose (D) rad 10-2 Jkg-1 gray (Gy) Jkg-1 
-1 -1Absorbed dose rate rad per second 10-2 Jkg-1s gray per second  Jkg-1 s
(Ď) (rad s-1) (Gy s-1) 
Dose equivalent (H) rem 10-2 Jkg-1 sievert (Sv) Jkg-1 
-1 -1Dose equivalent rate rem per second 10-2 Jkg-1s sievert per second Jkg-1 s
( ) (rem s-1) (Sv s-1) 
Effective dose rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Equivalent dose (H) rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Linear energy kiloelectron 1.602x10-10 Jm-1 kiloelectron volts 1.602x10-10 Jm-1 
transfer (LET) volts per per micrometer 
micrometer (keV µm-1) 
(keV µm-1) 
Jkg-1 = Joules per kilogram; Jkg-1s-1 = Joules per kilogram per second; Jm-1 = Joules per meter; s-1 = per second 
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